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ABSTRACT 
 
The alternative activation of macrophage populations by Interleukin-4 (IL-4) is well 
characterised. Alternatively activated macrophages (AAM) express high levels of the 
arginine converting enzyme arginase-1, and express a plethora of IL-4 driven 
molecules including the resistin like molecule alpha (RELMα) and the chitinase like 
molecule Ym1/2. Dendritic cells (DCs) are the professional antigen presenting cells 
(APC) of the immune system, responsible for the detection of invading pathogens, 
secretion of cytokines and the subsequent activation of T-cells. This thesis 
addresses whether IL-4 is able to ‘alternatively activate’ DCs both in vitro and in 
vivo, in a manner similar to that of AAM.  
 
The impact of IL-4 on DC and macrophage activation was compared and 
contrasted, and it was confirmed for the first time that IL-4 can alternatively activate 
DCs, inducing high level expression of a range of alternative activation associated 
markers including RELMα, Ym1/2, CCL24 and dectin-1, with the exception of 
arginase. DCs were significantly more capable at the in vivo priming of T-cell 
responses in the context of both Th1 and Th2 polarising antigens than similarly 
exposed macrophages, confirming their superior capacity as APC. 
 
The requirements for DC IL-4Rα expression were assessed, and IL-4 
responsiveness was found to be required for the optimal induction of Th1 
responses. Conversely, selective loss of only one facet of the IL-4 response, namely 
RELMα expression, limited the ability of IL-4 exposed DCs to induce the regulatory 
cytokine IL-10 both in vitro and in vivo. Furthermore, alternatively activated DCs 
(AADCs) were found in the spleen following 8 weeks of infection with the parasitic 
trematode Schistosoma mansoni, highlighting a role for DC alternative activation in 
a disease setting. 
 
IL-4 was shown to induce expression of the vitamin A converting enzyme aldehyde 
dehydrogenase, and the product of such activity, retinoic acid (RA), was found to 
promote the expression of RELMα in IL-4 exposed DCs. Aldehyde dehydrogenase 
activity was found to inversely correlate with DC expression of Ym1/2 and inhibition 
of RA signalling limited IL-4 driven RELMα and promoted Ym1/2.  
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The impact of various stimuli on IL-4 driven alternative activation was assessed. Toll 
like receptor ligands (LPS, CpG, P3C) and complex antigens (zymosan, P. acnes, 
SEA) were found to differentially modulate IL-4 driven RELMα and Ym1. The ability 
of P3C to completely abrogate IL-4 driven RELMα but only limit IL-4 driven Ym1 was 
shown to be dependent on TLR2, whereas the zymosan effect was TLR2 
independent.  
 
A novel role for pERK in modulating IL-4 dependent alternative activation of DCs 
was discovered.  pERK differentially modulated facets of IL-4 dependent alternative 
activation, inhibiting RELMα, promoting CCL24 and having no impact upon Ym1/2. 










Wild type bone marrow derived dendritic 
cell 
 
Gene deficient bone marrow derived 
dendritic cell 
 Plasmacytoid dendritic cell 
 
Bone marrow derived macrophage 
 




Peritoneal exudate cells  
 Spleen 
 Popliteal lymph nodes 
 
Pooled spleen and lymph nodes 
 
Liver 
	    







CFSE labeled T-lymphocytes 
	   Ovalbumin 
 FITC conjugated dextran 
 Coverslip 








12/15LOX: 12/15 (S) Lipoxygenase 
AADC: Alternatively activated DC	  
AAM: Alternatively activated macrophage	  
ADH: Alcohol dehydrogenase	  
ADRP: Adipose differentiation related protein	  
AKT: Ak Thymoma / protein kinase B 
ALDH: Aldehyde dehydrogenase 
AP1: Activator protein 1 
APC: Antigen presenting cell 
Arg1: Arginase 1 
BATF3: Basic Leucine Zipper transcription factor, ATF-like 3 
BEC: (S-(2-boronoethyl)-l-cysteine)	  
BM: Bone marrow 
BMDC: Bone marrow derived dendritic cell 
BMM: Bone marrow derived macrophage 
BTK: Bruton’s tyrosine kianse 
CARD: Caspase recruitment domain  
CCL: CC Chemokine Ligand  
CCR: CC Chemokine receptor 
CD: Complementarity Determining 
cDC: Conventional DC 
CDP: Common DC precursor 
CLR: C-type lectin Receptor 
COX: Cyclooxygenase 
CpG: CpG oligodeoxynucleotide 1826  
CRBP:Cellular retinol binding protein	  
Csf1R: Colony stimulating factor 1 receptor 
CTL: C-type lectin 
CTLA-4: Cytotoxic T-lymphocyte antigen 4 
CXCR: CXC cheomokine receptor 
DAMP: Danger associated molecular pattern 
DC-SIGN: DC specific ICAM 3 grabbing integrein 
DC: Dendritic cell 
Dectin1/Clec7a: Dendritic cell C-type lectin 1 
DNA: Deoxyribonucleic acid 
DSS: Dextran sulphate sodium  
DUSP: Dual Specificity phosphatase 
	   ix	  
dZym: Zymosan depleted of contaminating TLR2 ligands 
ELISA: Enzyme linked immunosorbent assay 
ER: Endoplasmic reticulum 
ERK: Extracellular signal related kinase 
Ets2: E twenty six 2 
FACS: Fluorescence activated cell sorting 
FLDC: FLT3L differentiated BMDC 
FLT3L: Fms Like tyrosine kinase 3 ligand 
Foxp3: Forkhead box protein 3 
g: gram 
GALT: Gut associated lymphoid tissue 
GATA: Gut associated lymphoid tissue 
GC: Germinal centre 
GM-CSF: Granulocyte macrophage-colony stimulating factor 
GMDC: GMCSF differentiated BMDC 
GMP: Granulocyte macrophage progenitor 
Grb2: Growth factor receptor-bound protein 2 
HMGB: High mobility group box protein 
ICOS: Inducible costimulator 
Id2: Inhibitor of DNA binding 2 
IELs: Intra-epithelial lymphocytes 
IFN: Interferon  
IGSF: Immunoglobulin super family 
IKKβ: IκB Kinase 
IL : Interleukin  
ILC: Innate lymphoid cell 
iNOS: Inducible nitric oxide synthase 
i.p: Intra-peritoneal 
IRAK: IL-1 receptor associated kinase 
IRF: Immune regulatory factor 
IRS: Insulin receptor substrate 
ITAM: Immunoreceptor tyrosine based activation motif 
iTreg: peripherally induced FoxP3 expressing Treg 
i.v.: Intra-venous 
JAK: Janus associated kinase 
JNK: cJun NH2 terminal kinase 
LN: Lymph Node 
LO: Lymphoid organ 
LP: Lamina propria 
	   x	  
LPS: Lipopolysaccharide 
LRAT: Lecitihin retinyl acyl transferase	  
M-CSF: Macrophage- colony stimulating factor 
M1: Classically activated macrophages 
M2: Non-classically activated macrophages 
MAdCAM1: Mucosal addressin cell adhesion molecule 1  
MAPK: Mitogen activated protein kinase 
MDP: macrophage-DC precursor 
MEK: Dual specificity mitogen activated protein kinase kinase 
MGL: Macrophage galactose CTL 
MHC: Major Histocompatibility  Complex 
MKK: MAPK kinase 
MKKK: MAPK kinase kinase 
MKPs: MAPK phosphatises 
mLN: Mesenteric lymph node 
MMP: Matrix metalloproteinase 
MR/Mrc1: Mannose Receptor 
MyD88: Myeloid differentiation factor 88 
Mφ: Macrophage 
NFκB: Nuclear factor κ B 
NLR: NOD like receptors 
NLRP3: NLR family, pyrin domain containing 3 
NO: Nitric oxide 
NOD: Nucleotide oligomerisation domain  
nTreg: natural Treg 
oC: Degrees centrigrade 
ODC: Ornithine decarboxylase 
P3C: Pam3CSK4 
Pa: Heat Killed Propionibacterium acnes 
PAMP: Pathogen associated molecular pattern 
PBS: Phosphate buffered saline 
PD-L: Programmed death Ligand 
PD: Programmed death 
pDC: Plasmacytoid DC 
pERK: Phosphorylated ERK 
PGE2: Prostaglandin E2  
PI3K: phosphoinositide 3 kinase  
PKC: Protein Kinase C 
pLN: Popliteal LN 
	   xi	  
PP: Peyers patch 
PRR: pattern recognition receptor 
qPCR: Quantitative polymerase chain reaction\ 
RA: All-trans retinoic acid 
RA: Retinoic acid	  
RALDH: Retinaldehyde dehydrogenase	  
RANK: Receptor activator of NFκB 
RAR: Retinoic acid receptor 
RARE: Retinoic acid response elements 
RBP: Retinol binding protein 
RELMα/Retnla: Resistin like molecule alpha 
RIG: Retinoic acid inducible gene  
RLR: RIG like receptors 
RNA: ribonucleic acid 
ROS/RNOS: Reactive (Nitrogen) oxygen species 
RXR: Retinoid X receptor 
SARM: Sterile-alpha and armadillo motif containing protein 
SDR: Short chain dehydrogenase reductase	  
SEA: Soluble egg antigen of Schistosoma mansoni 
SH2: Src homology domain containing 2	  
SI: Small intestinal	  
sMR: soluble MR 
SOS: Son of sevenless	  
St: Salmonella typhimurium 
STAT: Signal transducer and activator of transcription 
STRA6: Stimulated by retinoic acid 6	  
Syk: Spleen tyrosine kinase	  
TAK: TGFβ activated kinase 
TCR: T-cell receptor 
TF: Transcription factor 
Tfh: T follicular helper cell	  
TGFβ: Transforming growth factor beta 
Th: T helper cell 
Th3: TGFβ dependent, FoxP3 independent Treg 
Thio: Thioglycollate treated 
ThioM: Thioglycollate elicited macrophage 
Tip: TNFα and iNOS producing 	  
TIR: Toll IL-1R homology domain	  
TIRAP: Toll-IL-1receptor domain containing adaptor 
	   xii	  
TLR: Toll  like receptor 
TNF: Tumour necrosis factor 
TNFRSF: TNF receptor super family 
Tr1: Foxp3 independent IL-10 dependent Treg 
TRAF: TNFR associated factor 6	  
TRAM: TRIF related adaptor molecule 
Treg: T regulatory cell 
TRIF: Toll-IL-1receptor domain containing adaptor IFNβ 
TRIM: Trif related adaptor molecule 
Ts: T suppressor 
TTR: Transthyretin	  
VAD: Vitamin A deficient	  
VEGF: Vascular endothelial growth factor 
WT: Wild type 
Ym1/2: Chitinase like molecule 3 like 3 /3 like 4 
Zym: Zymosan 
	  xiii	  
Table of Contents  
Chapter 1. General Introduction 1 
1. INTRODUCTION 1 
1.1 DENDRITIC CELLS 1 
1.1.2 Differentiating DCs in vitro 4 
1.2 DC RECOGNITION OF NON-SELF AND DANGER 5 
1.2.1 Toll like receptors 6 
1.2.2 MAPK signalling 6 
1.2.3 Other PRRs 7 
1.3 DCs AS ANTIGEN PRESENTING CELLS 8 
1.3.1 Contact dependent signals between DCs and T-cells 9 
1.3.2 CD4+ T helper cell subsets 10 
1.3.3 Th2 diversity 13 
1.4 SCHISTOSOMA MANSONI INFECTION 14 
1.4.1 Immune recognition of schistosome egg antigens 15 
1.5 IMMUNE RECOGNITION OF BACTERIA 16 
1.6 MACROPHAGES AND ALTERNATIVE ACTIVATION 16 
1.6.1 Arginase 18 
1.6.2 Ym1 19 
1.6.3 Resistin like molecule alpha 20 
1.6.4 Mannose receptor 23 
1.6.5 Dectin-1 23 
1.6.6. AAM associated chemokines 24 
1.6.7 Metabolism and AAM 25 
1.6.8 Other cytokines implicated in the induction of AAM 27 
1.6.9 Alternative activation in non-macrophage populations 28 
1.7 IL-4R SIGNALLING 29 
1.7.1 IL-4 induction of DC IL-12 31 
1.8 VITAMIN A METABOLISM 32 
1.8.1 Retinoic acid signalling 34 
1.8.2 Intestinal homing 34 
1.8.3 CD103+ DCs, RA production and RA effects on T-cells 35 
1.8.4 Induction of RALDH2 in DCs 36 
	  xiv	  
1.8.5 Immune mediators implicated in induction and regulation of DC RALDH 
38 
1.8.6 Vitamin A and Th1/Th2 39 
1.8.7 Vitamin A and Schistosomiasis 40 
1.9 THESIS AIMS 42   
1.10 FIGURES 43 
Figure 1.1. Murine DC and macrophage ontogeny 43 
Figure 1.2 TLR signalling 44 
Figure 1.3. MAPK signalling 45 
Figure 1.4. Co-stimulatory/-inhibitory molecules 46 
Figure 1.5. T-helper cell subsets 47 
Figure 1.6. Diversity in molecules expressed by CAM and AAM 48 
Figure 1.7. Arginine metabolism 49 
Figure 1.8. IL-4Rα signalling 50 
Figure 1.9. Retinol metabolism 51 
Figure 1.10. DC imprinting of gut homing function in T-cells 52 
Chapter 2. Materials and Methods 53 
2.1 MICE, INFECTIONS AND IN VIVO EXPERIMENTS 53	  
2.1.1 Mice 53 
2.1.2 S. mansoni infection 53  
2.1.3 Intra-peritoneal injections 53 
2.1.4 Thioglycollate elicited peritoneal macrophages 54 
2.1.5 Sub-cutaneous injections into the feet 54 
2.2 CELL ISOLATIONS 54 
2.2.1 Innate cell isolation 54 
2.2.2 Splenic DC purification 55 
2.2.3 T-cell isolation for DC:T-cell co-culture 55 
2.3 IN VITRO BONE MARROW DIFFERENTIATION 55 
2.3.1 Bone marrow preparation 55 
2.3.2 Heat inactivation of foetal calf serum 56 
2.3.3 rGM-CSF BMDC culture 56 
2.3.4 Fms tyrosine like kinase-3 ligand BMDC culture 57 
2.3.5 rMCSF BMM culture 57 
2.4 IN VITRO STIMULATIONS 57 
2.4.1 Preparation of antigens 57  
	   xv	  
2.4.2 Prolonged stimulus 58 
2.4.3 Short term stimulus 59 
2.4.4 αCD40 stimulation 59 
2.4.5 DC:T-cell co-culture 59 
2.4.6 OT-II: DC cultures 59 
2.5 ANALYSIS TECHNIQUES 60 
2.5.1 Flow cytometry 60 
2.5.2 The aldefluor assay 61 
2.5.3 Enzyme linked immunosorbent assay (ELISA) 61 
2.5.4 Griess reaction for NO2 62 
2.5.5 Arginase activity assay 62 
2.5.6 Microscopy 63 
2.5.7 RNA isolation and qPCR 63 
2.6 MICROARRAY 64 
2.6.1 Microarray sample preparation 64 
2.6.2 Microarray post hybridization analysis 64 
2.7 STATISTICAL ANALYSIS 64 
2.8 FIGURES AND TABLES 66 
Figure 2.1 Gating strategy for FLT3L cultures 66 
Figure 2.2 Optimisation of M-CSF BMM culture 67 
Figure 2.3 IL-4 dose response to optimise BMDC alternative activation 68 
Figure 2.4 Optimisation of the timing of IL-4 treatment 69 
Figure 2.5.Golgistop does not enhance intracellular levels of RELMα or Ym1/2 
70 
Table 2.1 Flow cytometry antibodies 71 
Table 2.2 ELISA antibodies 72 
Table 2.3 qPCR primers 73 
Chapter 3. Can Dendritic Cells be Alternatively Activated? 74 
3.1 INTRODUCTION 74 
3.2 SPECIFIC AIMS 76 
3.3 RESULTS 76 
3.3.1 DC express IL-4Rα, which is downregulated following exposure to IL-4 in 
vitro 76 
3.3.2 IL-4 up-regulates DC expression of RELMα and Ym1/2 76 
3.3.3 IL-4 driven RELMα is located throughout the cytoplasm of BMDCs 77 
	  xvi	  
3.3.4 IL-4 upregulates multiple transcripts associated with AAM, but not Arg1 
77 
3.3.5. Arginase-1 is not a marker of an alternatively activated DC (AADC) 78 
3.3.6 FLT3L derived DCs do not become alternatively activated in response to 
IL-4 78  
3.3.7 Ex vivo splenic DC can be alternatively activated by IL-4 79 
3.3.8 DCs can be alternatively activated in vivo 80 
3.3.9 Markers of alternative activation are upregulated following S mansoni 
infection 81 
3.3.10 Parasitic helminth infection induces alternative activation of splenic 
DCs  82 
3.3.11 Defining a population of AAMs for direct comparison to AADCs 83 
3.3.12 BMDC and BMM are distinct cells types 83 
3.3.13 GMDC express higher levels of costimulatory molecules and secrete 
more cytokine than BMM 84 
3.3.14 GMDC are significantly better than BMM at priming both Th1 and Th2 
responses in vivo 85  
3.3.15 BMM are less competent than GMDC at polarising CD4+ T-cells 
towards Th2 in vitro 86 
3.4  SUMMARY 87 
3.5 DISCUSSION 88 
3.5.1 IL-4 and GM-CSF dose 88 
3.5.2 IL-4 down modulation of the IL-4Rα 88 
3.5.3 Differential expression of RELMα and Ym1/2 89 
3.5.4 What are the vacuoles in IL-4 treated GMDCs? 90 
3.5.5 DC arginase expression and activity 91 
3.5.6 AADC secretion of chemokines 92 
3.5.7 IL-4 Vs IL-13 in DC alternative activation 93  
3.5.8 Why aren’t FLDCs alternatively activated by IL-4? 94 
3.5.9 Comparing the alternative activation of BMM and ThioM 94 
3.5.10 APC function of BMM Vs BMDC 95 
3.6 FIGURES 97 
Figure 3.1 IL-4 stimulated BMDCs do not dramatically alter their activation 
phenotype 97 
Figure 3.2 IL-4 upregulates RELMα and Ym1/2 in BMDCs via the IL-4Rα 98 
	  xvii	  
Figure 3.3 IL-4 treated DCs produce RELMα protein throughout their 
cytoplasm 99 
Figure 3.4 IL-4 up-regulates multiple markers associated with AAM, but not 
Arg1 100 
Figure 3.5 Arginase-1 is not a marker of an alternatively activated DC (AADC) 
101 
Figure 3.6 FLDCs do not become alternatively activated in response to IL-4 
102 
Figure 3.7 IL-4 alternatively activates splenic ex vivo DCs in vitro 103 
Figure 3.8 IL-4 alternatively activates DCs in vivo 104 
Figure 3.9 Markers of alternative activation are upregulated following S. 
mansoni infection 105 
Figure 3.10 Parasitic helminth infection induces alternative activation of 
Splenic DCs 106 
Figure 3.11 BMM produce more RELMα than Ym1/2, the opposite is true of 
ThioM 107 
Figure 3.12 BMDC and BMM are different cells types 108 
Figure 3.13 GMDC express higher levels of co-stimulatory molecules and 
secrete more cytokine than BMM 109 
Figure 3.14 GMDC are significantly better than BMM at priming both Th1 and 
Th2 responses in vivo 110 
Figure 3.15 BMM are less competent than GMDC at polarising CD4+ T-cells 
towards Th2 in vitro 111 
Chapter 4. What is the Impact of IL-4 and Alternative 
Activation on DC Function? 112 
4.1 INTRODUCTION 112 
4.2 SPECIFIC AIMS 114 
4.3 RESULTS 114 
4.3.1 TLR ligation upregulates DC co-stimulatory molecule expression 114 
4.3.2 Concurrent exposure to IL-4 at the time of TLR ligation boosts IL-12 and 
reduces IL-10 secretion by DCs 114 
4.3.3 TLR agonists limit IL-4 induced alternative activation 115 
	  xviii	  
4.3.4 Complex bacterial, but not helminth antigens modulate DC co-
stimulatory molecule expression and cytokine production in a manner similar 
to defined TLR ligands 117 
4.3.5 Complex bacterial and helminth antigens modulate DC alternative 
activation in a manner similar to defined TLR ligands 117 
4.3.6 IL-4 alters the response of DCs to CD40 ligation 118 
4.3.7 IL-4Rα-/- DCs are less able to induce IFNγ and IL-17 responses 118 
4.3.8 DCs unable to respond to IL-4 are less able to support early Th2 
polarisation in vitro 119 
4.3.9 DC expression of RELMα during Th2 priming regulates IFNγ and 
promotes IL-10 and IL-13 production 120 
4.3.10 DC derived RELMα promotes IL-4 driven IL-10, and inhibits T-cell IL-4 
121 
4.3.11 rRELMα does not activate GMDCs 122 
4.3.12 WT, Il4ra-/- and Retnla-/- DCs are similarly capable at antigen uptake 
122 
4.3.13 Antigen processing and presentation is unimpaired in Il4ra-/- and Retnla-
/- DCs 123 
 4.3.14 IL-4 treatment of RELMα deficient DCs significantly alters transcription 
of more genes than IL-4 treatment of WT DC 123 
4.4 SUMMARY 127 
4.5 DISCUSSION 128 
4.5.1.TLR and bacterial modulation of DC co-stimulatory molecule expression 
128 
4.5.2 IL-4 regulation of bacterially induced DC function 128 
4.5.3 IL-4 and SEA regulation of DC function 130 
4.5.4 RELMα function 133 
4.5.5 Antigen processing and presentation by WT, Il4ra-/- and Retnla-/- DCs 136 
4.5.6 Microarray targets 136 
4.6 FIGURES AND TABLES 142 
Figure 4.1 TLR stimulated GMDCs upregulate co-stimulatory molecules 142 
Figure 4.2 IL-4 alters the cytokine profile of DCs activated by TLR ligation 143 
Figure 4.3 TLR agonists limit IL-4 driven alternative activation 144 
Figure 4.4 Complex bacterial but not helminth antigens modulate DC co-
stimulatory molecule expression and cytokine production 145 
	  xix	  
Figure 4.5 Complex bacterial and helminth antigens modulate DC alternative 
activation 146 
Figure 4.6 IL-4 alters the response of DCs following CD40 ligation 147 
Figure 4.7 Il4ra-/- DCs are less able to induce IFNγ and IL-17 responses 148 
Figure 4.8 DC expression of IL-4Rα promotes early IL-4 driven T-cell IL-4, IL-
10 and IL-13 149 
Figure 4.9 DC expression of RELMα during Th2 priming regulates IFNγ and 
promotes IL-10 and IL-13 production 150 
Figure 4.10 DC derived RELMα promotes IL-4 driven IL-10 but limits T-cell IL-
4 151 
Figure 4.11 rRELMα does not activate GMDCs 152 
Figure 4.12. WT, Il4ra-/- and Retnla-/- DCs are equally capable at antigen 
uptake 153 
Figure 4.13. Antigen processing and presentation is unimpaired in Il4ra-/- and 
Retnla-/- DCs 154 
Figure 4.14. IL-4 treatment of RELMα deficient DCs significantly alters 
transcription of more genes than IL-4 treatment of WT DC 155 
Table 4.3.1 Genes significantly down ≤0.5 fold in IL-4 treated WT and Retnla 
DC 157  
Table 4.3.2 Genes significantly down ≤0.5 fold only in IL-4 treated Retnla-/- DC 
158 
Table 4.3.3 Genes significantly up ≥ 2 fold in IL-4 treated WT and Retnla-/- DC 
159 
Table 4.3.4 Genes significantly up ≥ 2 fold only in IL-4 treated Retnla-/- DC 160 
Table 4.3.5 Genes significantly up ≥ 2 fold only in IL-4 treated WT DC 161 
Figure 4.15. Model of IL-4 and bacterial agonist mediated changes in DC 
function 162 
Figure 4.16. Models of IL-4 and helminth mediated changes in DC function 
163 
Chapter 5. How do IL-4 and Vitamin A Metabolites Alter DC 
Function? 164 
5.1 INTRODUCTION 164 
5.2 SPECIFIC AIMS 166 
5.3 RESULTS 166 
	   xx	  
5.3.1 Aldh1a2 and Ak2 are significantly upregulated in IL-4 treated DCs 166 
5.3.2 IL-4 induces Aldh1a2 expression and aldehyde dehydrogenase activity 
in GMDC and FLT3L DCs treated with GM-CSF 166 
5.3.3 Schistosoma mansoni infection does not enhance DC aldehyde 
dehydrogenase activity, but highlights a potential requirement for growth 
factors 167 
5.3.4 RA does not enhance GMDC aldehyde dehydrogenase activity in the 
absence of IL-4 168 
5.3.5 DC RALDH activity inversely correlates with expression of DC alternative 
activation markers, with the exception of Retnla 169 
Figure 5.3.6 RA and IL-4 synergise to enhance DC RELMα but do not impact 
Ym1/2 170 
5.3.7 RA does not synergise with IL-4 to enhance alternative activation in 
BMM 171 
5.3.8 RAR signalling regulates IL-4 driven DC alternative activation 171 
5.3.9 RARα signalling inhibits IL-4 driven RELMα and promotes IL-4 driven 
Ym1/2 172 
5.3.10 RAR signalling modulates IL-4 driven aldehdye dehydrogenase activity 
in GMDC 173 
5.3.11 RA and IL-4 alter DC co-stimulatory molecule and cytokine secretion 
173 
5.3.12 RA and IL-4 alter T-cell polarisation in the context of DC 174 
5.3.13 The absence of RARα alters DC co-stimulatory molecule expression 
and cytokine secretion 176 
5.3.14 The absence of RARα alters DC ability to polarise T-cell responses 177 
5.4 SUMMARY 179 
5.5 DISCUSSION 180 
5.5.1 How do RA and IL-4 alter DC phenotype? 180 
5.5.2 Why didn’t we detect enhanced RELMα secretion? 181 
5.5.3 Is DC expression of RALDH dependent upon colony stimulating factors? 
182 
5.5.4 What is the in vitro retinoid source? 183 
5.5.5 The role of RA in T-cell polarisation by DCs 184 
5.6 FIGURES AND TABLES 188 
Figure 5.1 Genes involved in metabolic pathways are significantly upregulated 
	  xxi	  
by IL-4 in WT GMDC 188 
Table 5.3.1 Metabolic pathway genes significantly increased by IL-4 in WT 
GMDC 189 
Figure 5.2 IL-4 induces Aldh1a2 expression and aldehyde dehydrogenase 
activity in GMDC and FLDCs treated with GM-CSF 190 
Figure 5.3. Schistosoma mansoni infection does not enhance DC aldefluor 
activity, but highlights a potential requirement for growth factors 191 
Figure 5.4. RA does not enhance GMDC aldefluor activity in the absence of 
IL-4 192 
Figure 5.5 IL-4 driven DC RALDH activity correlates with reduced expression 
of markers of alternative activation but not Retnla 193 
Figure 5.6 RA enhances IL-4 driven RELMα in GMDC 194 
Figure 5.7 RA does not enhance IL-4 driven RELMα in BMM 195 
Figure 5.8 RAR signalling regulates IL-4 driven DC alternative activation 196 
Figure 5.9 RARα signalling inhibits IL-4 driven RELMα and promotes IL-4 
driven Ym1/2 197 
Figure 5.10 RAR signalling modulates IL-4 driven aldehdye dehydrogenase 
activity in GMDC 198 
Figure 5.11 Retinoic acid and IL-4 alter DC co-stimulatory molecule and 
cytokine secretion 199 
Figure 5.12 RA and IL-4 alter DC APC capacity 200 
Figure 5.13 RARα alters DC co-stimulatory molecule expression and cytokine 
secretion 201 
Figure. 5.14 The absence of RARα alters DC ability to polarise T-cell 
responses 202 
Figure 5.15 The impact of IL-4 and RA signalling in DCs 203 
Chapter 6. How do IL-4 and TLR2 Signalling Pathways 
Integrate to Influence DC Activation? 204 
6.1 INTRODUCTION 204 
6.2 SPECIFIC AIMS 206 
6.3 RESULTS 206 
6.3.1 TLR2 agonists enhance IL-4 induced aldehyde dehydrogenase activity in 
GMDCs 206 
6.3.2 TLR2 agonists activate GMDCs, IL-4 regulates zymosan directed 
secretion of IL-10 and IL-12 207 
	  xxii	  
6.3.3 P3C and zymosan limit IL-4 driven RELMα and Ym1/2 to different 
extents 208 
6.3.4 Zymosan inhibits arginase and promotes iNOS in GMDC 209 
6.3.5 P3C and zymosan modulate chemokine production by IL-4 treated 
GMDCs 210 
6.3.6 IL-4 and TLR2 counter-regulate one another in GMDCs 210 
6.3.7 Tlr2 limits IL-4 driven RELMα in GMDC, and is responsible for P3C 
inhibition of alternative activation 211 
6.3.8 IL-4 inhibition of zymosan driven phospho-ERK1/2 is dependent upon 
TLR2 212 
6.3.9 IL-4 differentially modulates components of the MAPK signalling 
cascade in WT and RELMα deficient DCs 213 
6.3.10 ERK signalling inhibits IL-4 driven RELMα in GMDC 214 
6.4 SUMMARY 215 
6.5 DISCUSSION 216 
6.6.1 The TLR2 and IL-4 dependence of RALDH2 216 
6.6.2 TLR2 and IL-4 modulation of DC cytokine production 216 
6.6.3 Interactions between IL-4, TLR2 and ERK signalling 217 
6.6.4 Interactions between IL-4, RELMα and ERK 219 
6.6 FIGURES 223 
Figure 6.1 TLR2 agonists enhance IL-4 driven aldehyde dehydrogenase 
activity in GMDCs 223 
Figure 6.2 TLR2 agonists activate GMDCs, IL-4 regulates zymosan directed 
secretion of IL-10 and IL-12 224 
Figure 6.3 P3C and Zymosan limit IL-4 driven RELMα and Ym1/2 to different 
extents 225 
Figure 6.4 Zymosan inhibits arginase and promotes iNOS in GMDC 226 
Figure 6.5 P3C and zymosan modulate chemokine production by IL-4 treated 
GMDCs 227  
Figure 6.6 IL-4 and TLR2 counter-regulate one another 228 
Figure 6.7 TLR2 limits IL-4 driven RELMα in GMDC, and is responsible for 
P3C inhibition of alternative activation 229 
Figure 6.8 IL-4 inhibition of zymosan driven phospho-ERK1/2 is dependent 
upon TLR2 230 
	  xxiii	  
Figure 6.9 IL-4 differentially modulates components of the MAPK signalling 
cascade in WT and RELMα deficient DCs 231 
Figure 6.10 ERK signalling inhibits IL-4 driven RELMα in GMDC 232 
Figure 6.11 Model of how TLR2, IL-4 and RA signalling integrate in DCs 233 
Chapter 7. Concluding remarks and future directions 234 
Bibliography 237 
Appendix 1 266 
1 
Chapter 1. General Introduction 
1. INTRODUCTION 
 
“A properly functioning adaptive immune system signifies the best features of 
life. It is diverse beyond compare, tolerant without fail, and capable of behaving 
appropriately with a myriad of infections and other challenges. Dendritic cells are 
required to explain how this remarkable system is energized and directed” 
       Ralph M Steinman 1943-2011 
 
Mammals have evolved myriad mechanisms to avoid, delay and eradicate infection. 
The mammalian immune system is a complex multi-cellular machine tasked with 
blocking pathogen entry (barrier sites, skin, mucosa, antimicrobial peptides), 
detecting pathogen presence (innate immunity), responding appropriately to the 
pathogen and remembering the pathogen such that a faster, stronger, more 
targeted response can be mounted upon re-exposure (adaptive immunity).  
 
1.1 DENDRITIC CELLS 
Dendritic cells (DCs) are a vital link between the innate and adaptive 
immune system, due to their capacity for antigen uptake, migration and presentation 
of acquired antigen to activate naïve T-cells of the adaptive immune system 
(Steinman 2012). Identifications of humans with DC deficiencies and the 
posthumous award of the Nobel prize for physiology or medicine to Ralph Steinman 
for his 1978 discovery of DCs earlier this year highlights the importance of these 
cells in the maintenance of human health	   (Collin, Bigley et al. 2011). Since their 
discovery in 1978, DC were predominantly (if possibly inaccurately) defined by 
expression of the integrin CD11c and high levels of major histocompatibility complex 
(MHC) expression (Jung, Unutmaz et al. 2002; van Rijt, Jung et al. 2005; 
Geissmann, Gordon et al. 2010; Phythian-Adams, Cook et al. 2010; Steinman 
2012).  
 
However, it is now appreciated, that there are multiple distinct and 
overlapping DC subsets found in vivo (Fig. 1.1) and that can also be generated in 
vitro from bone marrow or peripheral blood precursors. The naming of DC types can 
become quite complicated due to the large number of surface markers and locations 
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used to define the various populations, in this introduction we will aim to explain the 
current understanding of murine DC subsets (Fig. 1.1) and briefly relate this to the 
equivalent human DC populations currently described. Conventional/classical DCs 
(cDC) can be defined broadly as non-lymphoid tissue or lymphoid tissue-resident. 
Both cDC types have two main functions, 1) maintenance of self tolerance and 2) 
induction of specific immune responses against invading pathogens	   (Merad and 
Manz 2009).  
 
Lymphoid tissue resident cDCs of the spleen can be classified into two 
subsets, CD4+CD8α-CD11b+ DCs and CD8α+CD4-CD11b+ (Naik 2008; Merad and 
Manz 2009).   CD8α+ DCs are specialised in antigen presentation via MHC-I 
whereas the CD4+CD8α- DCs present antigen to T-cells via MHC-II (see below 
section 1.3 DCs as APCs). CD8- DCs are the most numerous resident cDC in the 
spleen (Naik 2008). In addition to the CD8α+ and CD8α- DCs of the spleen, LNs 
contain populations of migratory DCs that enter via the afferent lymphatics, draining 
from the local tissue (Merad and Manz 2009).      
 
 Non-lymphoid tissue resident cDCs are present in most tissues in the steady 
state. Tissue resident steady state dermal, lung parenchyma, liver, kidney and 
pancreatic islet DCs can be divided based on expression of CD103, CD11b and 
CX3CR1, with CD103+ DCs being CD11b-CX3CR1-	  (Helft, Ginhoux et al. 2010). With 
the exception of the lung, CD103+ DCs represent ~20% of the steady state 
population at each tissue site	   (Merad and Manz 2009). DCs of the small intestinal 
(SI) lamina propria (LP) and peyers patch (PP) are MHC-II+CD11chi, and can also be 
separated into 3 different populations, based upon expression of CD11b, CD103 
and CX3CR1	  (Merad and Manz 2009). CD103+CD11b- DCs are found in the PP; LP 
DCs are CD103+CD11b+ or CD103-CD11b+CX3CR1+	   (Bogunovic, Ginhoux et al. 
2009; Helft, Ginhoux et al. 2010). Resident CD8+ DCs from lymphoid tissue have 
been shown to develop from a pre-cursor shared by the resident non-lymphoid 
tissue CD103+ DCs(Hashimoto, Miller et al. 2011). Both the CD8+ and 
CD103+CD11b- DC populations are dependent upon the transcription factors Batf3, 
IRF8 and Id2 (Aliberti, Schulz et al. 2003; Hacker, Kirsch et al. 2003; Hildner, 
Edelson et al. 2008; Ginhoux, Liu et al. 2009; Edelson, Wumesh et al. 2010).  
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At sites of tissue injury or microbial infection, a population of inflammatory 
DCs can develop transiently, these cells derive from circulating Ly6Chi monocytes 
and are characterised as Ly6C+CD11bhiCD11cint (Dominguez and Ardavin 2010). 
TNFα and iNOS producing (TipDCs) are an example of inflammatory DC population, 
TipDCs were found in the spleen of mice infected with Listeria monocytogenes	  
(Serbina, Salazar-Mather et al. 2003) and it has been questioned whether these are 
indeed DCs or classically activated macrophages	  (Dominguez and Ardavin 2010).  
 
Plasmacytoid DCs (pDCs), are a class of pre-DC, that develop in the bone 
marrow (BM) and blood and can circulate in a CD62L dependent manner (Naik 
2008). Upon viral activation via TLR7 and TLR9 pDCs secrete high levels of type-1 
interferon (IFN)	   (Liu 2005; Naik 2008). pDCs are more lymphocytic in appearance 
than conventional DCs (cDCs), only becoming dendritic upon activation (Liu 2005; 
Naik 2008). pDCs circulate in the blood and in the steady state can be found in the 
bone marrow, spleen, thymus, liver and LNs	  (Merad and Manz 2009). Murine pDCs 
are defined as being MHC-II+CD11b-
CD11cloB220+Ly6C/Gr1+PDCA1+SiglecH+TLR7+TLR9+, human pDCs are 
functionally closely equivalent to murine pDCs but are defined by a different set of 
surface markers, they are CD11c-BDCA2+BDCA4+IL-3R+CD4+CD45RA+ 
TLR7+TLR9+ (Merad and Manz 2009; Collin, Bigley et al. 2011).  
 
The accurate characterisation of human DCs has been hindered by the 
difficulty in isolating such cells from living subjects, and as such the circulating blood 
DCs are the best characterised, with both pDC and cDC cells having being located	  
(Merad and Manz 2009). An human equivalent of the murine CD8+ 
lymphoid/CD103+ non-lymphoid DCs has been characterised as expressing the C-
type lectin Clec9a, which was also found to be expressed on the murine DC subsets 
(Caminschi, Proietto et al. 2008; Sancho, Mourao-Sa et al. 2008; Collin, Bigley et al. 
2011). Human monocyte derived DCs are a CD14+CD11b+CX3CR1+CD209+ subset 
that secrete high levels of the proinflammatory cytokine TNFα. In humans, mutations 
in GATA binding protein 2 (GATA2) or IRF8 result in DC deficiency, surprisingly 
these deficiencies were first described in 2011	   (Dickinson, Griffin et al. 2011; 
Hambleton, Salem et al. 2011).  
 
4 
In 2012, multiple studies have begun to address the requirement for a DC 
specific marker that can be used to unequivocally say ‘this cell is a DC’. The initial 
results of high throughput transcriptional profiling and characterisation of myriad 
sorted cell  populations has been the discovery of a defining conventional DC (cDC) 
specific transcription factor zDC (Zbtb46) (Meredith, Liu et al. 2012; Meredith, Liu et 
al. 2012; Miller, Brown et al. 2012; Satpathy, Wumesh et al. 2012).  
 
1.1.2 Differentiating DCs in vitro 
Due to the scarcity of DCs in vivo (<1% of total hematopoietic cells during 
steady state at sites of immune priming	  (Merad and Manz 2009)) and the technical 
difficulties in isolation of these sensitive cells ex vivo without mechanical/enzymatic 
activation meant that a large proportion of the DC research to date had to focus on 
study of in vitro derived DCs. Granulocyte macrophage colony stimulating factor 
(GM-CSF; Csf2) is used routinely for the in vitro production of cDCs from murine 
bone marrow (GMDCs), resulting in populations that are CD11c+CD11b+MHC-
II+CD8- (Lutz, Kukutsch et al. 1999). GM-CSF is also used to differentiate DCs from 
human monocytes isolated from blood. However, in this context, IL-4 is used in 
combination with GM-CSF to differentiate human monocyte derived DCs (moDC) in 
vitro 	  (Sallusto and Lanzavecchia 1994). Interestingly, it has never been shown that 
monocytes differentiate into DCs in situ in humans	   (Collin, Bigley et al. 2011). In 
some studies, IL-4 is also used in combination with GM-CSF to differentiate murine 
GMDC, a study directly comparing murine GMDC differentiated with or without IL-4 
found that post differentiation the same number of DCs were present in either 
culture, with a slight enhancement in the level of CD11c on the cells differentiated in 
the presence of IL-4 (Sriram, Biswas et al. 2007).  
 
The CD8 negativity of murine GMDCs resulted in them being correlated with 
in vivo resident steady state CD8- cDCs	   (Naik 2008). It has been suggested that 
GMDCs have a phenotype more akin to Tip inflammatory monocyte derived DCs	  
(Serbina, Salazar-Mather et al. 2003; Xu, Zhan et al. 2007). In fact GM-CSF has 
been implicated in driving inflammatory monocyte DC populations in vivo	   (Naik, 
Metcalf et al. 2006). Earlier this year a paper was published which disputed this 
finding, claiming that GM-CSF was dispensable for inflammatory DCs, but required 
for the regulation of non-lymphoid tissue DCs	  (Greter, Helft et al. 2012). An overall 
consensus on the requirement for GM-CSF in DC development has not yet been 
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reached. However, the use of GM-CSF in vitro does result in the differentiation of a 
population of cells able to secrete high levels of cytokine, and to efficiently activate 
T-cell secretion of proinflammatory cytokines in vivo, which could be considered 
inflammatory properties.  cDC differentiated with GM-CSF from BM were confirmed 
to express the DC specific transcription factor Zbtb46 (Satpathy, Wumesh et al. 
2012) eschewing the notion that GM-CSF DCs are a type of macrophage. 
 
 Although GM-CSF was known to be important for DC differentiation in vitro 
relatively early during DC history (Inaba, Inaba et al. 1992; Inaba, Steinman et al. 
1992; Sallusto and Lanzavecchia 1994), it had also been shown that DCs were still 
present in mice lacking GM-CSF or GM-CSF receptor expression (Vremec, 
Lieschke et al. 1997). Fms like tyrosine kinase 3 ligand (Flt3L) was found to be the 
‘missing factor’ for DC development in vivo (Maraskovsky, Brasel et al. 1996; 
D'Amico and Wu 2003) and a protocol has since been developed for the in vitro 
production of BMDCs using Flt3L (FLDC) (Naik, Proietto et al. 2005). Culture with 
Flt3L produces 3 populations of DCs: a B220+ population of pDCs, a 
CD11chiCD11bloCD24hiSirpα- population that corresponds to the in vivo steady state 
CD8+ subset of cDCs, and a CD11cloCD11bhiCD24loSirpα+ population that 
corresponds with the in vivo steady state CD8- subset of cDCs	  (Naik, Proietto et al. 
2005). The use of in vitro DC populations derived from bone marrow has allowed 
the field of DC biology to advance substantially, as without such techniques the 
rarity of this specialised cell population would hinder such expansive research.  
 
1.2 DC RECOGNITION OF NON-SELF AND DANGER 
DCs express a broad range of pattern recognition receptors (PRRs) that 
enable them to recognise and respond to non-self products, known as pathogen 
associated molecular patterns (PAMPs) (Janeway 1989; Kapsenberg 2003). PRR 
are also able to sense endogenously produced danger associated molecules 
(DAMPs) such as high mobility group box 1 proteins (HMGB1), nucleic acids and 
heat shock proteins released by damaged/necrotic cells (Matzinger 2002; Nace, 
Evankovich et al. 2011) these ‘danger signals’ have also been referred to as 





1.2.1 Toll like receptors 
The toll-like receptor (TLR) family is the most well characterised PRR family, 
named for their similarity to Toll, a fungal recognition protein of Drosophila (Takeda, 
Kaisho et al. 2003) . The ten human and twelve murine TLRs recognise a broad 
range of PAMPs and DAMPs, highlighted in Fig. 1.2. TLRs are located both intra- 
and extra-cellularly. For example, TLR3, TLR7, and TLR9, which recognise nucleic 
acids, are mainly located on the endoplasmic reticulum (ER) membrane	   (Takeuchi 
and Akira 2010).  Transcriptional activation occurs following binding of ligands to 
their cognate TLRs, the activation of specific genes is dependent upon which TLRs 
are engaged, and the toll/IL-1R homology (TIR) domain containing adaptor proteins 
that are recruited	   (Jenkins and Mansell 2010) (Fig. 1.2). There are five adaptor 
molecules that can be recruited (MyD88, TRIF, TIRAP/MAL, TRAM and SARM)	  
(Jenkins and Mansell 2010). TLR signal transduction can be MyD88 dependent (all 
TLRs except TLR3) or MyD88 independent/TRIF dependent (TLR3 and TLR4) 
(Shaded region in Fig. 1.2). Following TLR ligation, MyD88 interacts with IL-1R-
associated kinase (IRAK) family members, which dissociate from MyD88 to allow 
interaction with TNFR-associated factor 6 (TRAF6). TRAF6 becomes ubiquitinated 
which leads to the phosphorylation of IκΒ Kinase (IKK)-β and MAP kinase kinase 6. 
The ultimate outcome of this is the activation of inflammatory cytokine genes either 
via NF-κB or the transcription factor complex AP-1	   (Takeuchi and Akira 2010)	  
(Jenkins and Mansell 2010). Ligation of dsRNA to TLR3 recruits the adaptor 
molecule TRIF leading the activation of IRF3 and IRF7, which then induce type-1 
interferon production. Other intracellular TLRs responding to nucleic acids can also 
induce downstream activation of IRF7 (Takeuchi and Akira 2010). 
 
1.2.2 MAPK signalling 
Downstream of various growth hormones, TLRs and cytokine receptors, 
intracellular mitogen activated protein kinases (MAPK) are activated. There are 
three main families of MAPK in immune cells: the extracellular signal-regulated 
protein kinases (ERK), the p38 MAPK, and the c-Jun NH2-terminal kinase (JNK)	  
(Zhang and Dong 2005). All of the MAPK have a Threonine-X-Tyrosine (TXY) motif, 
and phosphorlyation of both the threonine and tyrosine residues is required for their 
activation (Zhang and Dong 2005). Activation of all three MAPK families occurs via 
a triple kinase pathway, a MAPK-Kinase-Kinase (MAPKKK) activates a downstream 
MAPK-kinase (MAPKK) that then activates the target MAPK. MAPKKs are highly 
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specific for their target kinases, (Fig. 1.3)	   (Zhang and Dong 2005). GTPases such 
as Ras and the Rho family members Rac and Cdc42 are involved in transferring 
phosphate groups to mediate intracellular activation of receptors following ligand 
binding (Scita, Tenca et al. 2000; Yang, Shin et al. 2012). Following activation of 
any of the MAPK pathways, the phosphorylated MAPK enters the nucleus where it 
is able to bind to recognition sequences in DNA and regulate transcription or 
repression of target genes. Signalling by MAPKs is terminated by MAP kinase 
phosphatases (MKPs) also known as dual specificity phosphatases (DUSPS), which 
function in a complex negative regulatory network to control the duration, magnitude 
and timing of MAPK activation in response to physiological signals (Caunt and 
Keyse 2012). 
 
1.2.3 Other PRRs 
C-type lectin receptors (CLRs) are a family of carbohydrate binding lectins 
that are involved in altering gene expression downstream of pathogen products, 
either directly or by modulating TLR signalling	   (Geijtenbeek and Gringhuis 2009). 
Group I CLRs are members of the mannose receptor family, group II CLRs are 
asialoglycoprotein receptor family members such as DC-associated C-type lectin 1 
(dectin-1)(Takeuchi and Akira 2010). CLRs recognise glucan, mannose and fucose 
carbohydrate structures present in fungi, bacteria, viruses, mycobacteria and 
helminths(Takeuchi and Akira 2010). CLR signalling is transduced either via 
association with immunoreceptor tyrosine-based activation motif (ITAM) containing 
adaptor molecules or via direct kinase/phosphatase activation	  (Rogers, Slack et al. 
2005), both of which can result in activation or modulation of NF-κB	   (Geijtenbeek 
and Gringhuis 2009). CLR signalling can occur both dependent on, or independently 
of, crosstalk with other PRRs. For example, DC-specific ICAM3 grabbing integrin 
(DC-SIGN) can modulate TLR-induced gene expression but has not been shown to 
induce gene expression changes independently of other PRRs (Gringhuis, den 
Dunnen et al. 2007; Gringhuis, den Dunnen et al. 2009). Similarly to DC-SIGN, the 
group II CLR dectin-1 is able to modulate TLR signalling. However, this important 
CLR can also direct gene transcription independently of other PRRs, via the 
activation of spleen tyrosine kinase (Syk)	  (Rogers, Slack et al. 2005).   
 
Retinoic acid inducible gene-1 (RIG) like receptors (RLR) and nucleotide-
binding oligomerisation domain (NOD) like receptors (NLR) are intracellular PRRs 
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(Kawai and Akira 2009). RLRs detect RNA species present in cytoplasm (e.g. from 
viral infection) and elicit type-1 interferon production (Kawai and Akira 2009). There 
are three RLR family members RIG-1, MDA5 and LGP2; RIG-1 and MDA5 interact 
with other proteins using their caspase recruitment domain (CARD) like regions and 
sense ssRNA and other viruses	  (Kawai and Akira 2009).  The NLR family of proteins 
all contain 3 main domains: a nucleotide binding domain, a C-terminal leucine rich 
repeat for agonist binding, and an N-terminal region for homotypic protein-protein 
interactions, which enables scaffolds of proteins to form inflammasomes. There are 
multiple NLR family members including NOD-1, NOD-2 and NLRP3. The NODs are 
involved in the detection of intracellular bacterial products such as muramyl 
dipeptide (MDP)	  (Kawai and Akira 2009). NLRP3 is an important component of the 
inflammasome (Dagenais, Skeldon et al. 2011).  
 
Due to the diversity of PAMPs the number of recognised PRR families will 
undoubtedly expand over time as researchers discover new mechanisms via which 
mammaliam cells have evolved to detect both pathogens and danger.  
 
1.3 DCs AS ANTIGEN PRESENTING CELLS  
The ability to present antigen to activate naïve T-cells is one of the defining 
features of a DC. MHC are glycoprotein complexes used by cells to present 
peptides for recognition by T cells. MHC class I molecules (MHC-I) can be found on 
the surface of all nucleated cells and present peptides to CD8+ T-cells. MHC class II 
molecules (MHC-II) are expressed by DC, B cells, macrophages and particular 
types of thymic epithelial cells (Li, Gregg et al. 2005). Furthermore, in infection 
settings, MHC-II can be upregulated on other cell types including basophils 
(Perrigoue, Saenz et al. 2009; Sokol, Chu et al. 2009) and eosinophils (Shi 2004).  
 
Antigens can be found in two predominant cellular domains; free in the 
cytosol or within membrane bound vesicles (phago/endosomes). Antigens present 
within the cytosol are commonly referred to as endogenous (having been 
synthesised within the cell) while those found within vesicles are commonly called 
exogenous (having origin outside of the cell) (Cresswell 2005). In its classical form, 
processing and presentation of endogenous and exogenous antigens was perceived 
as being two separate processes leading to the presentation of endogenous 
antigens on MHC I molecules to CD8+ T-cells and exogenous antigens on MHC-II to 
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CD4+ T-cells (Cresswell 2005). Targeting of endogenous antigens to virus specific 
CD8+ T-cells would ensure that only cells definitively virally infected are killed (Heath 
and Carbone 2001). It is now appreciated that cross presentation of antigens occurs 
as DCs can present exogenous peptides on MHC-I, and cytosolic peptides on MHC-
II (Li, Gregg et al. 2005; Trombetta and Mellman 2005; Nair, Amsen et al. 2011).  
 
1.3.1 Contact dependent signals between DCs and T-cells 
DC priming of T-cell responses requires three interactions: 1) a cognate 
interaction between T-cell receptor (TCR) and peptide complexed MHC molecule; 2) 
co-stimulation provided by contact dependent interactions between molecules 
expressed on both DC and the T-cell surfaces; 3) the secretion of cytokines 
(Kapsenberg 2003).  DC express multiple surface receptors (Fig. 1.4) that enable 
them to interact with cognate receptors expressed on T-cells. Such receptors are 
generally termed ‘co-stimulatory’ or ‘co-inhibitory’ molecules, dependent upon 
whether they are required in addition to initial TCR:MHC recognition to provide 
‘signal 2’ for full activation of naïve T-cells (stimulatory) or to provide negative 
signals to T-cells to control the amplitude of an on-going immune response 
(inhibitory). Co-stimulatory/inhibitory molecules belong broadly to two protein 
families, the TNF receptor superfamily (TNFRSF) (CD40 (Caux, Massacrier et al. 
1994), OX40L (Fillatreau and Gray 2003; Jenkins, Perona-Wright et al. 2007), 
RANK (Andrew, Ruffing et al. 2001)) or the immunoglobulin superfamily (IGSF) 
(CD28 (Linsley and Ledbetter 1993), CTLA-4 (Kearney, Walunas et al. 1995), PD-1 
(Ishida, Agata et al. 1992), CD80/CD86 (Greenwald, Freeman et al. 2005), ICOS 
(Hutloff, Dittrich et al. 1999; Greenwald, Freeman et al. 2005)). Co-stimulatory 
molecules such as CD80, CD86 and CD40 (amongst others, see red text Fig. 1.4) 
are required to provide signal 2 to activate T-cells.  
 
Co-inhibitory molecules (see blue text Fig. 1.4) are not required during the 
initial phase of DC:T-cell interaction but become upregulated at a later stage.  For 
example, cytotoxic lymphocyte antigen-4 (CTLA-4) is expressed on activated T-cells 
and is able to outcompete CD28 for binding to CD80/CD86, resulting in suppression 
of T-cell activation via recruitment of phosphatases that inhibit AKT (Parry, 
Chemnitz et al. 2005). It was shown in 2011 that CTLA-4 can capture the ligands 
CD80 and CD86 from the surface of opposing cells via transendocytosis, thus 
reducing the availability of ligands for co-stimulatory binding by CD28 (Qureshi, 
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Zheng et al. 2011). Another CD28 family member, programmed cell death 1 (PD-1), 
also mediates T-cell inhibition following interaction with its ligand PD-L1  (Parry, 
Chemnitz et al. 2005). The expression of co-stimulatory or co-inhibitory receptors by 
DCs highlights their importance in the orchestration of immune responses, both at 
the initiation and resolution phase	  (Kapsenberg 2003).  
 
1.3.2 CD4+ T helper cell subsets 
The MHC-II molecules expressed by specialised antigen presenting cells 
such as DCs, are required for the activation of CD4+ T-cells, as they possess TCRs 
that are both MHC-II dependent (the TCR cannot recognise it’s cognate peptide in 
the absence of MHC-II presentation) and restricted (the TCRs will only recognise 
self MHC-II molecules). CD4+ T-cells are also called T-helper (Th) cells, on account 
of their ability to help B-cells via provision of cytokines. A fundamental 
immunological concept developed over the last 25 years is that of the counter-
regulatory nature of CD4+ T-cell populations. A seminal study published in 1986 
described for the first time the characteristic pattern of ‘lymphokine’ produced by two 
distinct groups of helper T-cell, defined as Th1 and Th2	  (Mosmann, Cherwinski et al. 
1986). Within the next 10 years, a wealth of research was undertaken looking at T-
helper cell diversity within normal and disease states	   (Abbas, Murphy et al. 1996). 
An important area of research focused on inbred strains of mice that were found to 
be either resistant (CBA) or susceptible (BALB/c) to Leishmania major infection 
based on their propensity toward Th1 (resistant) or Th2 (susceptible) immune 
responses (Reiner and Locksley 1995).  
 
In the context of a viral or bacterial initiated immune response IL-12 drives 
differentiation of a population of IFNγ secreting Th1 cells (Macatonia, Hosken et al. 
1995; Hilkens, Kalinski et al. 1997). Antigen stimulated DCs have been shown to 
polarise their microtubule organizing centre (MTOC) toward the interacting T-cell 
enabling the delivery of IL-12 to the immune synapse (region of contact between DC 
and naïve T-cell during priming) (Pulecio, Petrovic et al. 2010).  
 
Helminth infection and allergy drive the differentiation of an IL-4, IL-5, IL-9, 
IL-10 and IL-13 secreting population of Th2 cells (Pulendran and Artis 2012). 
However, the requirements for DC induction of Th2 responses remains much less 
well defined than that of IL-12 for Th1 cells	   (MacDonald and Maizels 2008). It has 
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recently been shown by our lab and others that DCs are both necessary and 
sufficient for the induction of Th2 responses in vivo (Hammad, Plantinga et al. 2010; 
Ohnmacht, Schwartz et al. 2010; Phythian-Adams, Cook et al. 2010). Nevertheless, 
the identity of the DC specific factor required for Th2 promotion and polarisation is 
still unknown, though multiple molecules have been proposed, and subsequently 
ruled out. For example, DCs do not produce IL-4	   (MacDonald and Maizels 2008), 
and IL-4 deficient DCs can capably promote Th2 polarisation both in vitro and in 
vivo	  (MacDonald and Pearce 2002). Similarly, IL-10-/- DCs are capable at inducing a 
Th2 response when transferred into wild type mice (Perona-Wright, Jenkins et al. 
2006). However, CD40/CD154 (MacDonald, Patton et al. 2002; MacDonald, Straw 
et al. 2002; Jenkins, Perona-Wright et al. 2008) has been shown to be required for 
full Th2 induction. Furthermore, OX40/OX40L interactions are required for sustained 
Th2 survival (Jenkins, Perona-Wright et al. 2007). 
  
The discovery that transcription factors Tbet (Szabo, Kim et al. 2000) and 
GATA-3 (Zheng and Flavell 1997) are necessary and sufficient to determine the 
lineage choice (Th1/Th2) made by a naïve CD4+ T-helper cells (Th0) enabled the 
two populations to be identified based on more than their cytokine profiles alone. It 
was further shown that GATA-3 and IL-12 signalling are mutually antagonistic 
(Ouyang, Ranganath et al. 1998) and that Tbet represses IL-4 and IL-5 production 
in Th2 clones (Szabo, Kim et al. 2000). These reports proved to strengthen the 
emerging paradigm that Th cells can counter-regulate one another. More recently, 
the range and diversity of known ‘Th’ cell types has expanded (Fig. 1.5) as has the 
number of cell types shown to influence Th cell differentiation. For example, most 
recently, type 2 innate lymphoid cells (ILCs) have been described to be a potent 
source of Th2 cytokines (Fallon, Ballantyne et al. 2006; Neill, Wong et al. 2010; 
Saenz, Siracusa et al. 2010; Mjosberg, Bernink et al. 2012). 
 
IL-17 secreting T-cells were associated with autoimmunity, a key factor 
leading to their discovery was the finding that autoimmune disease states thought to 
be mediated by Th1 cells were exacerbated in the absence of the Th1 cytokine IFNγ 
(Harrington, Hatton et al. 2005; Langrish, Chen et al. 2005). Th17 cells were named 
when it was realised that the IL-17 secreting cells differentiated down a separate 
lineage to Th1 or Th2 cells, and this differentiation was inhibited by IFNγ 
(Harrington, Hatton et al. 2005; Langrish, Chen et al. 2005). The defining 
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transcription factor of Th17 cells was determined as being the orphan nuclear 
receptor gamma T (RORγt) (Ivanov, McKenzie et al. 2006). IL-6 and TGFβ are 
required for differentiation of Th17 cells and IL-23 has been shown to be involved in 
their maintenance (Ivanov, McKenzie et al. 2006). 
 
The concept of immune regulation was discussed within the immunological 
community prior to the discovery that Th subsets existed. In the 1970’s research 
focused on a population of CD8+ T-suppressor (Ts) cells (Gershon and Kondo 
1970), this theory fell out of favour when the proposed components that were 
described as mediating suppression could not be isolated at the molecular level 
(Basten and Fazekas de St Groth 2008). Regulation by T-cells was thrown back into 
immunological favour in the mid 1990’s (Sakaguchi, Sakaguchi et al. 1995). It was 
noticed that ~10% of peripheral CD4+ cells in non-immunised adult mice expressed 
the IL-2Rα chain (CD25), antibody mediated depletion of CD25+ cells from CD4+ LN 
and spleen preparations prior to reconstitution of athymic (nu/nu, nude) mice 
resulted in development of spontaneous autoimmune disease (Sakaguchi, 
Sakaguchi et al. 1995). Furthermore, nu/nu animals reconstituted with CD4+CD25- 
cells were found have a heightened immune response against self and non-self 
proteins following allogeneic skin grafting, and this response could be ameliorated 
by provision of CD25+ T-cells (Sakaguchi, Sakaguchi et al. 1995). These cells 
became known as T-regulatory cells (Treg), further research highlighted the 
dependence of these cells on the expression of the transcription factor forkhead box 
protein 3 (Foxp3) (Fontenot, Gavin et al. 2003; Hori, Nomura et al. 2003). Foxp3-/- 
mice were found to have a specific deficit in thymic development of CD4+CD25+ T-
cells and over expression of Foxp3 in CD4+CD25- T-cells converted them to a 
regulatory phenotype (Fontenot, Gavin et al. 2003; Hori, Nomura et al. 2003). IL-2 
was later found to be required for maintenance of Treg homeostasis and survival in 
vivo but was not required for Treg development (Fontenot, Rasmussen et al. 2005). 
Thymically-derived Tregs are known as natural or nTregs, another subtype of Tregs 
exists known as the adaptive or inducible Tregs (iTreg), iTregs are produced de 
novo in the periphery from CD4+CD25- cells. iTregs can be Foxp3+ or Foxp3-,  the 
best characterised of the Foxp3- Tregs are the IL-10 producing Tr1 cells (Awasthi, 
Carrier et al. 2007). 
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TGF-β was initially found to be responsible for the conversion of CD4+Foxp3- T-cells 
into suppressive Foxp3+ iTregs at peripheral sites (Chen, Jin et al. 2003; Cobbold, 
Castejon et al. 2004). Foxp3+ iTregs are induced in mesenteric LNs (mLN) during 
induction of oral tolerance (Coombes, Siddiqui et al. 2007), and differentiate in the 
steady state in response to food antigens and microbiota in the lamina propria of the 
gut	   (Sun, Hall et al. 2007). A role for retinoic acid in the induction of iTregs at 
mucosal sites has been shown (Coombes, Siddiqui et al. 2007) (see section 1.8 
Vitamin A).  
 
Follicular B helper T cells (Tfh) are a population T-cells that are required for 
providing help to B-cells (Crotty 2011). Tfh secrete IL-21, are defined by expression 
of PD-1, CXCR5 and ICOS, (Vinuesa, Tangye et al. 2005) and are required for the 
formation of germinal centres (GC). Their development is dependent upon the 
transcription factor Bcl6 (Nurieva, Chung et al. 2009). IL-21 and IL-6 are both 
redundantly required for induction of Tfh phenotype (Eto, Lao et al. 2011 
) and ICOS has more recently been shown to initiate Bcl6 expression and 
drive T cells to a follicular rather than effector phenotype (Choi, Kageyama et al. 
2011).  
 
The newest reported player in the Th cell family, and something of a black 
sheep are the Th9 population of cells which differentiate in response to TGFβ and 
IL-4 and are associated with high level secretion of IL-9 (Dardalhon, Awasthi et al. 
2008; Veldhoen, Uyttenhove et al. 2008). Th9 cells have recently been associated 
with expression of the transcription factors PU.1 (Chang, Sehra et al. 2010; 
Goswami and Kaplan 2012) and IRF4 (Staudt, Bothur et al. 2010), however, in the 
absence of a ‘defining’ transcription factor it has to be questioned whether Th9 are 
in fact a separate Th subset.   
 
1.3.3 Th2 diversity 
Th2 cells were originally described as secreting IL-4, IL-5, IL-9, IL-13 and IL-
10 and expressing the transcription factor GATA3, and being STAT5 and STAT6 
dependent (Pulendran and Artis 2012). However, there is in fact marked 
heterogeneity in the profile of cytokines secreted by individual Th2 cells, originally 
shown by single cell PCR studies (Kelso, Groves et al. 1999). It is currently 
unknown whether populations of Th2 cells induced in vivo secrete all the Th2 
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associated cytokines simultaneously, or a select pattern of expression dependent 
upon the cellular and cytokine environment in which they are differentiating.    
 
1.4 SCHISTOSOMA MANSONI INFECTION 
Worldwide, more than 200 million people are chronically infected with 
parasites of the genus Schistosoma	  (Steinmann, Keiser et al. 2006). In sub-Saharan 
Africa, more than 280,000 people are estimated to die each year due to pathologies 
associated with schistosome infection (Pearce and MacDonald 2002). Following 
release from their snail intermediate host, S. mansoni cercariae initiate mammalian 
infection; after penetration of the skin and development into schistosomula, they 
migrate via the vasculature to the hepatic-portal system where they reside	   (Allen 
and Wynn 2011). Adult worms mature, pair up and, approximately 4-6 weeks after 
infection, the female begins to releases eggs	  (Wilson, Draskau et al. 1978; Wilson, 
Mentink-Kane et al. 2007). Schistosome eggs cause much of the 
pathology/morbidity associated with disease as following release, they are swept by 
the flow of blood into the liver. In immunocompetent hosts collagen rich granulomas 
develop around the tissue trapped eggs, sequestering egg products (Pearce and 
MacDonald 2002). Granulomas are composed of a mixed population of immune 
cells including CD4+ T-cells (a population on which granuloma formation is 
dependent	   (Phillips, DiConza et al. 1977)), macrophages and eosinophils	   (Pearce 
and MacDonald 2002) (Wilson, Mentink-Kane et al. 2007). The granulomatous 
response causes much of the morbidity associated with infection, as it leads to 
hepatic fibrosis and portal hypertension (Wilson, Mentink-Kane et al. 2007).  
Furthermore, granuloma encased eggs cause extensive damage as they pass from 
the vasculature into the intestines en route out of the host. The onset of egg release 
correlates with the emergence of a strong Th2 response, which peaks 
approximately 8 weeks following infection	  (Pearce and MacDonald 2002). A role for 
CD4+CD25+Foxp3+ T-cells in controlling the size of colonic granulomas in intestinal 
schistosomiasis has been shown	   (Layland, Rad et al. 2007; Turner, Jenkins et al. 
2011). LysMCreIL-4Rα-/flox mice that are unable to respond to IL-4/IL-13 in their 
neutrophil and macrophage compartments show 100% mortality following S. 
mansoni infection (Herbert, Holscher et al. 2004). The LysMCreIL-4Rα-/flox animals 
had increased systemic Th1 cytokines, liver damage and excessive gut 
inflammation, due to a failure to heal wounds quickly, which resorted in sepsis 
(Herbert, Holscher et al. 2004). Infection of WT mice depleted of neutrophils did not 
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have the same outcome, implicating AAM as a crucial cell type required for surviving 
schistosomiasis, particularly in protecting against sepsis	   (Herbert, Holscher et al. 
2004).  
 
1.4.1 Immune recognition of schistosome egg antigens 
DCs can sense, capture and process antigens derived from schistosome 
eggs (Cervi, MacDonald et al. 2004; van Liempt, van Vliet et al. 2007; Everts, 
Perona-Wright et al. 2009; Everts, Hussaarts et al. 2012). DCs pulsed with soluble 
egg antigen (SEA) from S. mansoni prime strong Th2 immune responses	  
(MacDonald, Straw et al. 2001). However, they fail to conventionally mature in 
response to SEA, retaining immature DC levels of expression of co-stimulatory 
molecules, and producing no measurable cytokines (MacDonald, Straw et al. 2001; 
Perona-Wright, Jenkins et al. 2006; van Liempt, van Vliet et al. 2007). DCs have 
been shown to take up SEA, or components of SEA, via multiple CLRs including 
DC-SIGN, MGL and MR	  (van Liempt, van Vliet et al. 2007; Everts, Hussaarts et al. 
2012). Elements of SEA have been reported to signal through various TLRs, 
including TLR3	   (Aksoy, Zouain et al. 2005), TLR2	   (van der Kleij, Latz et al. 2002)	  
(Gao, Zhang et al. 2012), and TLR4, though the requirements for MyD88, TLR2 and 
TLR4 signalling for SEA driven DC initiation of Th2 responses has been questioned	  
(Kane, Jung et al. 2008). A glycoprotein component of SEA, Omega-1 (Dunne, 
Jones et al. 1991), has been reported to be one of the factors that enables the 
initiation of Th2 responses by SEA exposed DCs	  (Everts, Perona-Wright et al. 2009; 
Steinfelder, Andersen et al. 2009; Everts, Hussaarts et al. 2012). Both recombinant 
Omega-1 and Omega-1 purified from SEA had RNAse activity and could initiate Th2 
polarisation via modulation of human and murine DCs (Everts, Perona-Wright et al. 
2009; Steinfelder, Andersen et al. 2009; Everts, Hussaarts et al. 2012). It was 
hypothesised that SEA/Omega-1 exposure may create a setting of weak TCR signal 
strength analogous to that seen with low-dose antigen (Steinfelder, Andersen et al. 
2009), which has been proposed to result in Th2 induction	   (Paul and Zhu 2010). 
Considering the usage of SEA as a Th2 polarising antigen preparation it is 
surprising that the impact that simultaneous exposure to SEA and IL-4 has on APC 





1.5 IMMUNE RECOGNITION OF BACTERIA 
In the work described in this thesis, both gram positive (Propionibacterium 
acnes; Pa) and gram negative (Salmonella typhimurium; St) bacterial species have 
been used to stimulate DCs and macrophages prior to assessment of activation 
status and ability to prime Th1 and Th17 responses following transfer in vivo. Pa is 
known to instruct immune activation via TLR2 (Kim, Ochoa et al. 2002) and in acne 
lesions where the predominant bacterial species is Pa, TLR2 and TLR4 are induced	  
(Jugeau, Tenaud et al. 2005). Furthermore, a specific role for TLR2 in mediating 
activation driven by Pa is highlighted by the finding that Pa was able to drive IL-6 
production from cells in the absence of TLR1 and TLR6, and the use of anti-TLR4 
antibodies did not block the ability of Pa to drive IL-12p40 and IL-8 secretion (Kim, 
Ochoa et al. 2002). Recognition of St by macrophages is mediated entirely via TLRs 
as BMM lacking both MyD88 and TRIF did not respond to heat killed St	   (Arpaia, 
Godec et al. 2011). TLR2, TLR4 and TLR5 mediate the majority of St recognition 
and an additional role for TLR9 was confirmed using TLR2, TLR4 and TLR9 double 
and triple knock out mouse strains	   (Arpaia, Godec et al. 2011). St flagellin is 
recognised by TLR5 (Feuillet, Medjane et al. 2006). However, murine BMM do not 
express TLR5	   (Arpaia, Godec et al. 2011). Recognition of St by the intracellular 
TLRs TLR7 or TLR3 was also suggested, as the use of BafilomycinA1 (an inhibitor 
of endosome acidification) blocked the remaining TNFα induced by St in 
TLR2xTLR4xTLR9 triple knock out cells	   (Arpaia, Godec et al. 2011). In addition to 
complex bacterial antigen such as Pa and St, defined TLR agonists are also used 
within this thesis to aid understanding of the complex interplay between PAMPs and 
PRRs.  
 
1.6 MACROPHAGES AND ALTERNATIVE ACTIVATION 
The archetypal Th2 cytokine, IL-4 has been shown to have diverse effects 
upon macrophage biology, a topic which will be discussed in detail within this 
section. Macrophages are professional phagocytes of the innate immune system 
(Murray and Wynn 2011), the majority of macrophages have their origins in 
monocytes of the haematopoietic system (see Fig. 1.1), however some macrophage 
subsets, such as Kupffer cells of the liver, have embryonic origins having developed 
at the yolk sac stage of development and persisted in the adult	   (Schulz, Gomez 
Perdiguero et al. 2012). Generation of macrophages and monocytes is dependent 
upon the growth factor receptor Csf1r (M-CSFR)	  (Geissmann, Manz et al. 2010). 
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Monocytes are released into the circulation from the bone marrow following 
development via granulocyte macrophage and macrophage DC progenitors (GMP 
to MDP to monocyte; Fig. 1.1)	   (Hashimoto, Miller et al. 2011). Monocytes 
extravasate through the endothelium to seed all tissues and replenish the pool of 
tissue resident macrophages (Murray and Wynn 2011). Macrophages are often 
distinguished from DCs by their expression of surface markers such as F4/80 
(Emr1; expressed on most murine tissue macrophages), CD11b (Itgam; expressed 
on all myeloid lineage cells including neutrophils), and CD68 (Cd68; expressed on 
all macrophages)	   (Murray and Wynn 2011). Macrophages can also be defined 
based on their location, with specialised subsets being present within different tissue 
sites. For example, alveolar macrophages in the lung (Balhara and Gounni 2012), 
and Kupffer cells of the liver (Crispe 2009) .  
 
Over the past 30 years it has become indisputable that the local cytokine 
milieu impacts the activation and phenotype of all immune cells, not just T-cells. A 
great deal of research has focused on the activation status of the macrophage, an 
important area given the roles that macrophages play in multiple disease states. 
Classically, macrophages were thought of as pro-inflammatory, antimicrobial cells, 
driven by interferon gamma (IFNγ), able to destroy harmful intracellular pathogens. 
Thus, macrophages induced within Th1 environments are referred to as ‘classically’ 
activated macrophages (CAM or M1). In contrast, those found within Th2 
environments are referred to as alternatively activated macrophages (AAM or M2) 
(Gordon and Martinez 2010). There exists a large literature detailing a myriad 
molecules associated with the phenotype and function of what is now known to be 
an extremely heterogeneous population of cells (Fig. 1.6). In an attempt to further 
classify the macrophage phenotype, Mantovani and colleagues introduced the 
nomenclature M2a, M2b or M2c (Mantovani, Sica et al. 2004). ‘M2’ designated 
these cells as being non-classically activated, with a, b, and c referring to the 
polarising signal influencing the detail of each phenotype (IL-4 and IL-13, immune 
complex, or IL-10, respectively) (Mantovani, Sica et al. 2004). It has also been 
proposed that macrophage activation is a spectrum that encompasses the three 
main areas of macrophage function: host defence, wound healing and immune 
regulation (Mosser and Edwards 2008). Thinking of macrophage heterogeneity as a 
continuous spectrum rather than a linear process (either M1 or M2) may more 
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accurately describe the wide range of macrophage phenotypes. The IL-4R 
dependent, IL-4 and IL-13 driven M2a/AAM has been investigated in great depth 
over the past 20 years, and a wealth of literature exists detailing the association of 
numerous molecules with this cell type (Fig. 1.6) and the relevance of these cells in 
both health and disease states (Loke, Nair et al. 2002; Herbert, Holscher et al. 2004; 
Ruckerl, Hessmann et al. 2006; Mylonas, Nair et al. 2009; Nair, Du et al. 2009; 
Pesce, Ramalingam et al. 2009; Pesce, Ramalingam et al. 2009; O'Brien, Lyons et 
al. 2010). In this thesis AAM have been defined as IL-4R dependent cells in line with 
the original description of this cell type	   (Stein, Keshav et al. 1992).  The main 
markers associated with AAM are discussed in more detail below. 
 
1.6.1 Arginase 
One of the defining characteristics of an IL-4 exposed macrophage is 
expression of arginase-1 (Arg1)	   (Modolell, Corraliza et al. 1995). Arginase-1 is an 
enzyme that catabolises the conversion of arginine into polyamines and proline 
(Hesse, Modolell et al. 2001), molecules that promotes cell growth, collagen 
synthesis and fibrosis. Arginase-1 is known to compete with inducible nitric oxide 
synthase (iNOS; Nos2), an IFNγ induced enzyme that controls the production of 
nitric oxide from arginine in CAM (Fig. 1.7) (Munder, Eichmann et al. 1998; Munder, 
Eichmann et al. 1999).  
 
In the past few years, the relevance of arginase in the pathology of Th2 
mediated disease states has been highlighted by a number of research groups. 
Intra-peritoneal (i.p.) sensitisation, followed by intra venous (i.v.) challenge with S. 
masoni eggs in IL-4, IL-4/IL-13 or IL-4/IL-10 doubly deficient animals showed a 
correlation between reduced arginase activity, eosinophillia and pathology (lung 
granuloma volume) (Hesse, Modolell et al. 2001). Arg-1 expression localises to 
granulomatous tissues (liver and intestines) of S. mansoni infected mice (Hesse, 
Modolell et al. 2001). Blocking ornithine decarboxylase, an enzyme responsible for 
the production of polyamines downstream of arginase-1	   (Bronte and Zanovello 
2005), resulted in enhanced fibrosis in S. mansoni infected livers (Hesse, Modolell 
et al. 2001). Leishmania infected BMM also produce arginase-1(Kropf, Fuentes et 
al. 2005), and in the context of non-healing Leishmania lesions, arginase depletes 
L-arginine from the local environment, limiting the ability of T-cells to proliferate and 
produce IFNγ (Modolell, Choi et al. 2009). Interestingly, studies using two different 
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strains of conditional macrophage specific arginase-1 deficient mice showed that 
during S. mansoni infection, mice died at an accelerated rate with enhanced liver 
fibrosis	   (Pesce, Ramalingam et al. 2009). Arg1 deficient macrophages failed to 
inhibit T-cell proliferation in vitro, in contrast to WT AAM (Pesce, Ramalingam et al. 
2009). In correlation with the study using Leishmania, this was found to be due to 
the arginase activity of WT macrophages depleting L-arginine from the culture 
medium, as restoration of CD4+ T-cell activity could be achieved by addition of 
exogenous L-arginine	  (Pesce, Ramalingam et al. 2009).  
 
Due to the discovery of arginase as an AAM associated molecule as early as 
1995	  (Modolell, Corraliza et al. 1995), there is a broader published literature on its 
immune function in disease states as compared to other more recently described 
AAM markers.  
 
1.6.2 Ym1 
A more recently described intracellular marker for murine AAMs is Ym1, a 
chitinase family member initially found to be highly transcribed in murine spleen and 
lung	  (Jin, Copeland et al. 1998). Since it has no apparent chitinase activity, Ym1 is 
often classified as a ‘chitinase-like’ molecule (Webb, McKenzie et al. 2001).	  Ym1 is 
encoded by the gene Chi3l3, a very closely related gene Chi3l4 encodes Ym2, an 
isomer of Ym1 (Webb, McKenzie et al. 2001). The protein products of Chi3l3 and 
Chi3l4 genes have 91% identity (Webb, McKenzie et al. 2001; Raes, De Baetselier 
et al. 2002) and as such are indistinguishable using antibodies. Thus, in the 
absence of a method to distinguish between these closely related molecules, protein 
studies within this thesis will refer to Ym1/2.  
 
Chi3l3 and Chi3l4 are not found in the human genome, however a family of 
human chitinases with roles in innate inflammation do exist and many have murine 
homologs, for example Acidic mammalian chitinase (AMCase/CHIA) and BRP-
39/YKL-40 (Chi3l1) (Lee, Da Silva et al. 2011).  
 
High levels of Ym1 crystals have been reported to be present in the 
bronchoalveolar lavage fluid (BALF) of inflamed and allergic murine lungs (Guo, 
Johnson et al. 2000; Webb, McKenzie et al. 2001) dependent upon IL-4R signalling 
(Webb, McKenzie et al. 2001), and in peritoneal exudate cells (PEC) in response to 
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Trichinella spiralis infection (Chang, Hung et al. 2001). Ym1 was also found to be 
highly expressed in nematode (Loke, Nair et al. 2002) and trypanosome (Raes, De 
Baetselier et al. 2002) elicited macrophages. Furthermore, such macrophage 
specific upregulation of Ym1/2 could be induced in vitro and ex vivo by IL-4 or IL-13 
(Raes, De Baetselier et al. 2002; Welch, Escoubet-Lozach et al. 2002; Nair, 
Cochrane et al. 2003). Ym1/2 was originally anticipated to function via the binding of 
chitin containing pathogens (Nair, Gallagher et al. 2005). However, the only reports 
of a functional role for Ym1/2 show that it promotes type-2 cytokine production in 
allergic mice (Cai, Kumar et al. 2009) and in response to treatment with statins 
(Arora, Chen et al. 2006). Ym1/2 was found to limit the production of IL-5 and IL-13 
by inhibiting 12/15(S) lipoxygenase (12/15LOX) (Cai, Kumar et al. 2009), a lipid 
peroxidating enzyme. Furthermore, 12/15LOX also catalyses, in an IL-4 dependent 
manner, the conversion of arachidonic and linoleic acid into activating ligands for the 
AAM associated genetic sensor of fatty acids, PPARγ (Huang, Welch et al. 1999; 
Odegaard, Ricardo-Gonzalez et al. 2007).  
 
On account of the high level secretion of Ym1/2 by AAM, we believe a role 
for Ym1/2 in Th2 immune responses is undoubted, however further work is required 
to characterise the cell-type specific function of this protein within the immune 
system. 
 
1.6.3 Resistin like molecule alpha 
Another IL-4 induced molecule produced by AAM and discovered at a similar 
time to Ym1/2 is resistin-like molecule alpha (RELMα) a cysteine rich secreted 
protein of the resistin family (Banerjee and Lazar 2001). RELMα is also known as 
‘found in inflammatory zone 1’ (FIZZ1), due to its original identification in bronchial 
epithelial cells in the context of allergic pulmonary inflammation (Holcomb, Kabakoff 
et al. 2000) and as hypoxia-induced mitogenic factor (HIMF)	  (Teng, Li et al. 2003). 
Initial reports suggested that RELMα was only expressed in the lung (Banerjee and 
Lazar 2001), tongue, mammary and white adipose tissues of mice (Steppan, Brown 
et al. 2001). The adipose tissue RELMα expression was found to associate with the 
stromal vascular fraction of WAT and was found to decrease upon high-fat diet 
feeding (Rajala, Lin et al. 2002), an outcome that has since been linked to AAM (see 
below ‘Metabolism and AAM’). In 2002 RELMα was found to be the second most 
highly upregulated transcript in nematode elicited peritoneal macrophages, second 
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only to Ym1 (Loke, Nair et al. 2002), and such expression was dependent on IL-4. In 
the same year, a similar report using Trypanosoma brucei brucei infection also 
made the correlation between AAM and expression of RELMα (Raes, De Baetselier 
et al. 2002). Since then, macrophage RELMα expression has also been shown to 
occur during other parasitic helminth infections including Brugia malayi, 
Litomosoides sigmodontis and Nippostrongylus brasiliensis (Nair, Cochrane et al. 
2003; Nair, Gallagher et al. 2005; Jenkins, Ruckerl et al. 2011; Ruckerl, Jenkins et 
al. 2012).   
 
The first reports of a functional role for RELMα did not involve work focusing 
on macrophages (Liu, Dhanasekaran et al. 2004; Wagner, Hellberg et al. 2004). 
However, the functions attributed to RELMα and the signalling cascades 
downstream of RELMα reception are nonetheless enlightening. RELMα can elicit α-
smooth muscle actin and collagen expression by myofibroblasts (Liu, Dhanasekaran 
et al. 2004). Surprisingly, given the known Th2 dependence of RELMα in AAM, 
RELMα was expressed in the lung following i.p.  lipopolysaccharide (LPS) injection 
and was also induced in the murine colon following induction of DSS-induced 
experimental colitis (Tong, Zheng et al. 2006; Munitz, Waddell et al. 2008). Munitz et 
al also showed that rRELMα causes increased expression of pro-inflammatory 
cytokines IL-6 and TNFα by bone marrow derived macrophages co-cultured with 
LPS, suggesting that RELMα may polarise a pro-, rather than anti-inflammatory 
response (Munitz, Waddell et al. 2008).  
 
A series of studies focusing on RELMα primarily in the lung revealed that it 
can be induced by hypoxia (Teng, Li et al. 2003) and that RELMα expression co-
localises with hypoxia induced factor 2α (HIF2α), but not HIF1α (Wagner, Hellberg 
et al. 2004). In correlation with upregulation during hypoxia, rRELMα is pro-
angiogenic and enhances vascular endothelial growth factor (VEGF), and monocyte 
chemotactic protein-1 expression in the lung (Teng, Li et al. 2003; Tong, Zheng et 
al. 2006; Yamaji-Kegan, Su et al. 2006). Interestingly, given the reports of AAM 
expression of RELMα, i.v. injection of rRELMα resulted in increased CD68+ 
monocyte/macrophage recruitment to the lungs (Yamaji-Kegan, Su et al. 2006). An 
aetiological consequence of RELMα presence in the lung is the induction of vascular 
remodelling associated with pulmonary hypertension (PH) (Angelini, Su et al. 2009). 
The same authors also showed that an induced model of PH (instillation of rRELMα) 
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resulted in recruitment of bone marrow derived mesenchymal-like cells to the 
pulmonary vasculature (Angelini, Su et al. 2010). A role for rRELMα in inducing 
migration of bone marrow derived cells had previously been shown to be dependent 
upon Bruton’s tyrosine kinase (BTK) signalling; using a transwell migration assay it 
was shown that rRELMα induced the migration of bone marrow cells (Su, Zhou et al. 
2007). BTK was identified as a binding partner for rRELMα in BMM and following 
treatment of BMM with rRELMα, BTK was phosphorylated within a few minutes (Su, 
Zhou et al. 2007).  
 
Multiple reports have shown that rRELMa activates the PI3K/AKT/NFκB 
signalling pathways within various cell types (Teng, Li et al. 2003; Tong, Zheng et al. 
2006; Tong, Zheng et al. 2006) and is able to mobilise intracellular calcium stores 
from smooth muscle cells (Fan, Su et al. 2009).  
 
In 2009, two reports using Retnla-/- mice demonstrated that RELMα functions 
as a negative regulator of helminth induced Th2 immunity (Nair, Du et al. 2009; 
Pesce, Ramalingam et al. 2009).	    The Nair study showed that S. mansoni egg 
challenged Retnla-/- mice secreted enhanced antigen specific IL-4, IL-5 and IL-13 
following restimulation of mediastinal LNs, which drain the site of granuloma 
formation in this model. Furthermore, when used in an in vitro OT-II culture system, 
Retnla-/- BMM stimulated enhanced IL-4 and IL-13 secretion from CD4+ T-cells. 
When rRELMα was applied to Th2 polarised T-cells, IL-5 was inhibited in a dose 
and BTK dependent manner	  (Nair, Du et al. 2009). In both reports using the Retnla-/- 
mice, IL-5 and IL-13 were impacted more significantly than IL-4. This disparity in 
regulation of Th2 cytokines fits with a report linking IL-4 signalling to the RELMα 
induced PH model, in which it was shown that in the lung, rRELMα enhanced IL-4 
production	  (Yamaji-Kegan, Su et al. 2010).   
 
Retnla has not been found in the human genome. However, the expression 
pattern of human resistin is more similar to murine RELMα than murine resistin 
(Nair, Guild et al. 2006). Thus investigating RELMα in mice may provide useful 
information about human resistin, a protein involved in insulin regulation	   (Bastard, 




1.6.4 Mannose receptor 
The inaugural AAM marker, the (macrophage) mannose receptor (Mrc1, MR, 
CD206) is a phagocytic receptor of the CLR family that mediates the binding of 
sulphated sugars (via a cysteine-rich domain), collagen (via a fibronectin type II 
domain), and mannose, fucose and N-acetyl-glucosamine containing sugars (via a 
C-type lectin domain) (Gazi and Martinez-Pomares 2009). The first report defining 
IL-4 treated macrophages as being ‘alternatively’ activated described the in vitro 
upregulation by IL-4 of the MR on peritoneal exudate macrophages (Stein, Keshav 
et al. 1992). The IL-4Rα dependence of MR expression was shown in macrophages 
recruited to granulomas in S. mansoni infection (Linehan, Coulson et al. 2003). The 
generation of anti-MR monoclonal antibodies aided the study of MR on macrophage 
populations (Martinez-Pomares, Reid et al. 2003). More recently, IL-10 has been 
shown to activate MR+Ym1+ macrophages in the absence of macrophage-specific 
IL-4Rα signalling (Dewals, Marillier et al. 2010) and also to enable the upregulation 
of MR on thioglycollate elicited macrophages (Martinez-Pomares, Reid et al. 2003). 
In the absence of MR, BMM are less able to phagocytose the excretory/secretory 
products of the invasive form of S. mansoni	  (Paveley, Aynsley et al. 2011), and DC 
uptake of the SEA component Omega-1 was recently shown to be MR dependent 
(Everts, Hussaarts et al. 2012), highlighting a role for macrophage expression of MR 
in the immune response against schistosomes.   
 
1.6.5 Dectin-1 
A second receptor associated with alternative activation is the dendritic cell 
c-type lectin (dectin-1; Clec7a), a β-glucan receptor re-discovered on macrophages 
in 2002 (Brown, Taylor et al. 2002) and associated with alternative macrophage 
activation in 2003 (Willment, Lin et al. 2003). Dectin-1 is a non-classical CLR as 
compared to classical CLRs as dectin-1 recognition of carbohydrate is metal-ion 
independent 	  (Brown 2006; Gazi, Rosas et al. 2011). IL-4 and IL-13 were shown to 
enhance the expression of this receptor on peritoneal macrophages within 4 hours, 
and dectin-1 was shown to bind zymosan, a β-glucan rich cell wall mixture from the 
yeast Saccharomyces cerevisiae	   (Di Carlo and Fiore 1958; Willment, Lin et al. 
2003). Following engagement of dectin-1, its intracellular ITAM is phosphorylated by 
Src family kinases, leading to activation of Syk kinase and downstream signalling 
events including activation of the MAPK, ERK	  (Slack, Robinson et al. 2007; Eberle 
and Dalpke 2012).  Zymosan contains a mixture of antigens (55% β-glucan, 20% 
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mannan, 15% protein, 10% lipids, inorganic materials and chitin	  (Di Carlo and Fiore 
1958) and as such is able to signal via a compelx of TLR2/TLR6 as well as dectin-1. 
However, zymosan depleted of contaminating TLR2 ligands can be used as a 
specific dectin-1 stimulus (dZym)	  (Eberle and Dalpke 2012). The binding of β-glucan 
component of zymosan to dectin-1 has since been shown to cause the shedding of 
MR into the supernatant as a soluble non-membrane bound form (sMR)	   (Gazi, 
Rosas et al. 2011). This shedding was shown to be dependent upon, MMP, Syk, 
and PI3K signalling, but did not require AKT or internalisation of the β-glucan 
particles	  (Gazi, Rosas et al. 2011).  
 
The interaction between MR and dectin-1 has the potential to modulate 
responses to extracellular pathogens, particularly in the presence of Th2 cytokines 
and a fungal pathogen because, as explained above, IL-4 has been shown to 
induce expression of both MR and dectin-1 in macrophages (Stein, Keshav et al. 
1992; Willment, Lin et al. 2003). 
 
To detect the intracellular proteins arginase, RELMα and Ym1/2 via flow 
cytometry it is necessary to permeabilise a cells membrane, thus making functional 
assays following cell sorting an impossibility. As both dectin-1 and MR are surface 
receptors, they are useful for the identification of AAM populations for use in 
functional studies.  
 
1.6.6. AAM associated chemokines 
In addition to surface receptors, novel proteins, and well characterised 
enzymes, AAM are also associated with secretion of defined chemotactant proteins 
(chemokines). IL-4 activation of macrophages has been associated with enhanced 
secretion of C-C type chemokines including CCL17 (Thymus and activation 
regulated chemokine; TARC) and CCL24 (eotaxin-2)	  (Mantovani, Sica et al. 2004).  
 
CCL17 is recognised by the chemokine receptor (CCR) 4	  (Imai, Baba et al. 
1997) which is highly expressed on Th2 cells, skin homing memory T-cells and NK 
cells	  (Andrew, Ruffing et al. 2001; Alferink, Lieberam et al. 2003; Mantovani, Sica et 
al. 2004). CCL17 expression by DCs has been shown to recruit activated and 
memory T-cells	  (Alferink, Lieberam et al. 2003) and, more recently, has been shown 
to limit regulatory T-cell expansion, resulting in enhanced atherogenesis	   (Weber, 
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Meiler et al. 2011). CCL17 is thought to be expressed only in the CD11b+CD8- DC 
subset	  (Alferink, Lieberam et al. 2003). 
 
CCL24 binds to CCR3, a receptor predominantly expressed by eosinophils	  
(Forssmann, Uguccioni et al. 1997). CCL24 was shown to be differentially induced 
by LPS and IL-4 in human monocytes and macrophages, with LPS enhancing 
secretion of this chemokine in monocytes and IL-4 enhancing secretion of CCL24 by 
macrophages	  (Watanabe, Jose et al. 2002). LPS was unable to induce macrophage 
CCL24 and likewise IL-4 could not induce monocytes to secrete CCL24	  (Watanabe, 
Jose et al. 2002). Murine CCL24 was identified as being a constitutively expressed 
eosinophil chemoattractant that could be induced in lungs following intra-tracheal 
instillation of IL-4 (Zimmermann, Hogan et al. 2000). CCL24 has been shown to be 
a potent recruiter of eosinophils in models of airway inflammation	   (Kurowska-
Stolarska, Stolarski et al. 2009). 
 
1.6.7 Metabolism and AAM 
Obesity and the associated metabolic syndrome (insulin resistance, glucose 
intolerance, dyslipidemia and hypertension) is one of the major causes of morbidity 
and mortality in recent times; 300-400,000 deaths every year in the USA are directly 
attributable to obesity (Odegaard and Chawla 2011). Multiple studies have begun to 
link the activation status of macrophage populations with their intrinsic metabolic 
capacity and that of their host organism (Olefsky and Glass 2010; Odegaard and 
Chawla 2011). Obesity is characterised by an underlying inflammatory state, with 
adipose tissue of obese individuals expressing high levels of TNFα, IL-6 and iNOS	  
(Olefsky and Glass 2010). A microarray study was undertaken to assess the 
transcriptional profile of adipose tissue taken from a spectrum of lean to severely 
obese mice; of the 100 genes most significantly correlated with increased body 
mass, 30% were transcripts characteristically expressed by macrophages 
(Weisberg, McCann et al. 2003). Weisberg and colleagues isolated fractions of 
perigonadal adipose tissue from obese mice (B6.VLepob/ob) and showed that the 
F4/80+ macrophage fraction expressed the highest levels of pro-inflammatory 
cytokines (Weisberg, McCann et al. 2003). Further work looking into adipose tissue 
macrophages (ATM) of obese versus lean animals showed that ATM of lean mice 
have AAM characteristics, expressing Chi3l3 and Arg1 (Lumeng, Bodzin et al. 
2007). As mentioned previously, the initiating factors required for alternative 
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activation are the type-2 cytokines IL-4 and IL-13 (Varin and Gordon 2009) (Section 
1.4). In 2006 it was shown that IL-4 treatment of macrophages results in a switch to 
oxidative metabolism via the upregulation of the transcriptional co-activator PGC1β 
(Vats, Mukundan et al. 2006). In contrast, CAM use a program of glycolysis	  
(Rodriguez-Prados, Traves et al. 2010). Inhibition of fatty acid oxidation in 
macrophages resulted in a decrease in IL-4 driven arginase 1, dectin-1 and MR 
showing a dependence on oxidative metabolism for alternative activation (Vats, 
Mukundan et al. 2006). These studies highlight that the availability of metabolites 
within a tissue site can have a large impact on the activation state of immune cells 
within that tissue.  
 
A requirement for the ligand-activated transcription factors, peroxisome 
proliferator-activated receptors (PPARs) in the maintenance of macrophage 
alternative activation downstream of IL-4 has been established (Odegaard, Ricardo-
Gonzalez et al. 2007; Odegaard, Ricardo-Gonzalez et al. 2008). PPARs are 
members of the nuclear receptor superfamily and are vital for controlling fatty acid 
metabolism	   (Odegaard and Chawla 2011). Mice with a macrophage/neutrophil 
specific deletion (LysMCre) of PPARγ were unable to maintain an alternatively 
activated state	   (Odegaard, Ricardo-Gonzalez et al. 2007). Furthermore, 
macrophage deficiency in PPARγ resulted in enhanced obesity and increased 
insulin resistance when compared to wild type mice fed a high fat diet, 
serendipitously highlighting a beneficial function for AAM in protecting against the 
metabolic consequences of obesity (Odegaard, Ricardo-Gonzalez et al. 2007).  
 
The most recent correlation between AAM and metabolism shows that upon 
exposure to cold environments, macrophages of the brown and white adipose tissue 
become alternatively activated	  (Nguyen, Qiu et al. 2011). In addition, these AAM are 
able to synthesise catecholamines that contribute to adaptive thermogenesis, a 
response that enables survival during cold stress (Nguyen, Qiu et al. 2011).	  	  
  
This section highlights an important biological role for AAM outwith the 
context of helminth infection and allergic disease, and show that even in the 
absence of strongly Th2 polarised environments, IL-4 signalling is essential for 
alternative activation. The availability of metabolites and changes in temperature are 
factors that will impact directly all cells of the immune system, it is going to be 
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interesting to see in future years how the results of these macrophage studies are 
applied to other cell types, for example the DCs.  
  
1.6.8 Other cytokines implicated in the induction of AAM 
Although most studies investigating AAM use the classical IL-4R 
dependence as defining this population, a few studies have investigated expression 
of AAM associated markers in response to other cytokines. One example of such is 
a study which investigated the role of IL-21 on account of the IL-21R having 
significant sequence and structural similarity to the IL-4R (Pesce, Kaviratne et al. 
2006). Using IL-21R deficient mice, Pesce et al found a correlation between the 
level of AAMs present following schistosome infection and the ability to respond to 
IL-21	  (Pesce, Kaviratne et al. 2006). Mice that could not receive an IL-21 signal had 
reduced IL-4, IL-13, RELMα, Ym1/2 and AMCase transcripts in granulomatous lung 
tissue 7 days after sensitisation (i.p.) and challenge (i.v.) with S. mansoni eggs 
(Pesce, Kaviratne et al. 2006).  This work also found that IL-21 signalling to BMM 
enhanced expression of both the IL-4R and IL-13Rα	  (Pesce, Kaviratne et al. 2006).  
 
Another cytokine that has recently been identified as being involved in Th2 
settings is IL-33. IL-33 is an IL-1 family member purported to be an apoptotic signal 
(Schmitz, Owyang et al. 2005; Luthi, Cullen et al. 2009). IL-33 signals via a receptor 
composed of ST2L and the IL-1R (Schmitz, Owyang et al. 2005). IL-33 has been 
shown to enhance the alternative activation of macrophage populations in co-
operation with IL-4 signalling	   (Kurowska-Stolarska, Stolarski et al. 2009). In 
particular IL-33 was shown to enhance IL-4Rα expression in the lung and promote 
CCL24 production from macrophages, which then recruited eosinophils and 
mediated allergic inflammation in the lung (Kurowska-Stolarska, Stolarski et al. 
2009).  
 
The TGFβ super family member Activin-A has been implicated in the 
regulation of both murine and human alternative activation. A 2006 study suggested 
that Activin-A (shown to be produced by Th2 cells) was able to induce the 
expression of Arg1 from peritoneal macrophages whilst simultaneously limiting 
iNOS expression	   (Ogawa, Funaba et al. 2006). Activin-A induces antigen-specific 
regulatory T-cells that are able to suppress Th2 effector cells in allergic disease	  
(Semitekolou, Alissafi et al. 2009), so a role in the promotion of alternatively 
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activated macrophages may not be that likely. In agreement with this, human PBMC 
derived macrophages were found to have reduced M2 characteristics when cultured 
in the presence of Activin-A	  (Sierra-Filardi, Puig-Kroger et al. 2011). 
 
These studies show that while other cytokines can support IL-4 dependent 
induction of macrophage alternative activation, expression of the IL-4R is required. 
In the next section we discuss the expression of alternative activation associated 
molecules in cells other than macrophages (1.6.9).  
 
1.6.9 Alternative activation in non-macrophage populations 
Reports of expression of macrophage associated alternative activation 
products by cells other than macrophages have been published. RELMα is 
produced at high levels by eosinophils (Nair, Du et al. 2009; Pesce, Ramalingam et 
al. 2009; Cook, Aynsley et al. 2011) and intestinal epithelial cells (Holcomb, 
Kabakoff et al. 2000; Munitz, Waddell et al. 2008).  Ym1/2 can also be produced by 
mast cells (Lee, Yook et al. 2005) and neutrophils (Harbord, Novelli et al. 2002). IL-4 
culture of BM with stem cell factor resulted in induction of BM-mast cells that 
expressed Ym1/2 however, no role for the presence of Ym1/2 in mast cells was 
described (Lee, Yook et al. 2005). Neutrophil derived Ym1 was shown to have 
functional β-N-acetylhexosaminidase activity, the authors also suggest that 
macrophage associated Ym1 is dependent in part due to their phagocytosis of short 
lived apoptotic Ym1 producing neutrophils (Harbord, Novelli et al. 2002). A confocal 
microscopy paper however disputed the presence of Ym1/2 in neutrophils in the 
skin (HogenEsch, Dunham et al. 2006). 
 
A few reports have been published in which markers associated with 
alternative activation have been shown to be induced in DCs. Arginase activity was 
induced in BMDC by the Th2 cytokines IL-4, with a synergistic increase seen when 
IL-10 was also included in the 48h culture	  (Munder, Eichmann et al. 1999). BMDCs 
were also shown to upregulate transcript for Ym1/2 and RELMα following overnight 
culture with IL-4 (Nair, Gallagher et al. 2005). Additionally, the same authors 
showed upregulation of RELMα and Ym1/2 in DCs sorted from the draining lymph 
nodes of animals implanted with the filarial nematode Brugia malayi (Nair, Gallagher 
et al. 2005). As well as these reports on the impact of IL-4 and nematodes on DC 
expression of alternative activation markers, Ym1/2 was shown to be expressed by 
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BMDCs exposed to the lipid lowering drug simvastatin and to be involved in DC 
priming of Th2 responses in vitro (Arora, Chen et al. 2006). Simvastatin promoted 
Th2 responses, but addition of anti-Ym1 antibody to simvastatin treated DC and T-
cell co-cultures abrogated the ability of these DCs to induce Th2 cytokine secretion 
from the T-cells	   (Arora, Chen et al. 2006). Arora et al showed that simvastatin 
induction of Ym1/2 was dependent upon STAT6 and IL-4Rα, but independent of IL-4 
presence (confirmed using neutralising antibodies) suggesting that the statin is able 
to utilise the IL-4Rα/STAT6 axis in DCs to upregulate Ym1/2 (Arora, Chen et al. 
2006). Ym1/2 was also confirmed to be expressed in mLN DCs from allergic mice, 
and addition of recombinant Ym1/2 in vitro to ll13-/- DC: WT T-cell co-cultures from 
OVA sensitised animals resulted in amplified IL-5 secretion by the T-cells (Cai, 
Kumar et al. 2009). The expression of these AAM associated molecules in DCs was 
shown in all previous reports to be dependent upon IL-4 signalling, a topic which is 
discussed in detail below (1.7).  
 
1.7 IL-4R SIGNALLING 
As mentioned above, a central component of alternative activation is the 
ability to respond to IL-4.  IL-4 signals via binding to heterodimeric receptor 
complexes, including the 140-kDa IL-4Rα chain which pairs with either the common 
gamma chain (first identified as a component of the IL-2 receptor) to create the type-
I IL-4R (Fig. 1.8), or the IL-13Rα1 to create the type-II IL-4R through which IL-13 
can also signal (Lutz, Schnare et al. 2002; Varin and Gordon 2009; Junttila, Creusot 
et al. 2012). T-cells were at first thought not to express the type-II IL-4R and to be 
unable to respond to IL-13 but a 2009 study reported that Th17 cells express a 
functional IL-13R (Newcomb, Zhou et al. 2009). IL-4 can be recognised by the IL-
4Rα in the absence of a secondary receptor chain, though receptor 
heterodimerisation is required for intracellular signalling (Nelms, Keegan et al. 
1999).  As neither the IL-4Rα or γc have endogenous kinase activity, receptor 
associated kinases are required to transduce the intracellular signal (Johnston, 
Kawamura et al. 1994; Witthuhn, Silvennoinen et al. 1994). Both the janus 
associated kinases 1 and 3 (JAK1/JAK3)	   (Johnston, Kawamura et al. 1994; 
Witthuhn, Silvennoinen et al. 1994) and Src kinase families (Izuhara, Yang et al. 
1993) are activated downstream of IL-4 binding. JAK3 associates with the γc of the 
type-I IL-4R (Witthuhn, Silvennoinen et al. 1994).  Five tyrosine residues become 
phosphorylated in the IL-4Rα tail, enabling the binding of signalling proteins via their 
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src homology domain 2 (SH2) regions (Varin and Gordon 2009). Signal transducer 
and activator of transcription (STAT) 6 becomes phosphorylated by the receptor 
associated kinases (Velazquez, Fellous et al. 1992; Darnell 1997), forms a dimer 
with another STAT6 molecule and enters the nucleus to change gene transcription. 
The 170-kDa phosphoprotein insulin receptor substrate (IRS2 also known as 4PS) 
was reported to be uniquely phosphorylated in response to IL-4 treatment of 
haematopoietic cell lines (Wang, Keegan et al. 1992). IRS1/2 becomes activated 
following binding to one of the phosphorylated tyrosine residues in the IL-4 bound 
IL-4Rα chain and activates downstream PI3K and MAPK pathways (Nelms, Keegan 
et al. 1999). The catalytic p110 subunit of PI3K is activated following interaction of 
the p85 subunit with IRS1/2. The lipid kinase activity of PI3K then triggers the 
transfer of phosphates from ATP to inositol in the cell membrane to produce 
phosphoinositides that act as second messengers to activate Protein Kinase C 
(PKC) and AKT (Nelms, Keegan et al. 1999) (Fig. 1.8).  
 
AKT and PKC are important for the control of cell growth, survival and 
proliferation and PI3K driven AKT has recently been shown to be required for IL-4 
driven macrophage proliferation in vivo (Ruckerl, Jenkins et al. 2012). 
Phosphorylated IRS1/2 also interacts with the adaptor protein Grb2 an adaptor 
protein that constitutively localises with the guanine nucleotide exchange factor son 
of sevenless (SOS); SOS functions to activate Ras the upstream activator of MAPK 
pathways (See Fig. 1.3 & Fig. 1.5)	   (Nelms, Keegan et al. 1999). The IL-4 driven 
activation of Ras/MAPK is proposed to be cell type specific and dependent upon the 
expression of other signalling molecules within the IL-4 treated cells (Nelms, 
Keegan et al. 1999). However, in T-cells IL-4R signalling has been shown to be 
controlled by Ras/MAPK signalling, and JNK signalling has been shown to promote 
Th1 and thus limit Th2 and also inhibit proliferation (Yamashita, Kimura et al. 1999; 
Jorritsma, Brogdon et al. 2003).  
 
IL-4 signalling downstream of the IL-4R is thus relatively complex, with the 
interaction of multiple signalling pathways. In relation to macrophage alternative 
activation, dependence upon IL-4Rα and STAT6 are the most frequently 
investigated components, however roles for other components have been 
investigated, for example AKT (Ruckerl, Jenkins et al. 2012). To date, the majority 
of research investigating the impact of IL-4 on DCs has focused upon IL-4 induced 
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changes in the secretion of T-cell polarising cytokines, a topic discussed in more 
detail in the next section (1.7.1 IL-4 induction of DC IL-12). 
 
1.7.1 IL-4 induction of DC IL-12 
IL-4R signalling to DCs has been investigated previously in studies aiming to 
determine how IL-4 can alter the polarisation of DC and influence their ability to 
promote Th1 or Th2 responses (Hochrein, O'Keeffe et al. 2000; Kalinski, Smits et al. 
2000; Biedermann, Zimmermann et al. 2001; Lutz, Schnare et al. 2002; Yao, Li et 
al. 2005; Guenova, Volz et al. 2008). Many of these studies were going on prior to 
or simultaneous with the work investigating IL-4 driven alternative activation in 
macrophages; as such the potential for molecules such as Ym1/2 and RELMα to 
influence the outcome of T-cell polarisation was not yet/only just being published. 
Thus this facet of IL-4 dependent immune changes was not investigated by the DC 
community.  
 
In their role as professional APCs, DCs excel at efficiently activating naïve T-
cells (Steinman 2012). DCs were shown in 1995 to be able to secrete IL-12 and 
preferentially polarise naïve T-cells toward a Th1 phenotye (Macatonia, Hosken et 
al. 1995). It was subsequently shown that the DC:T-cell interaction was not sufficient 
to induce IL-12 secretion by DCs and that exogenous factors such as IFNγ and 
CD40:CD40L engagement were required to promote optimal Th1 immunity (Cella, 
Scheidegger et al. 1996; Hilkens, Kalinski et al. 1997). Bioactive IL-12 is an 
heterodimeric cytokine of 70kD (IL-12p70), composed from the association of p35 
and p40 subunits (Hochrein, O'Keeffe et al. 2000). IL-12p40 can be secreted in 
excess both in vitro and in vivo as a (p40) homodimer, which is able to antagonise 
the effects of bioactive IL-12p70 by binding, without signalling, to the IL-12R in 
mouse and human (Mattner, Fischer et al. 1993; Gillessen, Carvajal et al. 1995; 
Ling, Gately et al. 1995).  
 
The role of IL-4 in altering the balance of IL-12 and IL-10 production by DCs 
has been investigated frequently in vitro (Hochrein, O'Keeffe et al. 2000; Kalinski, 
Smits et al. 2000; Lutz, Schnare et al. 2002; Yao, Li et al. 2005; Guenova, Volz et al. 
2008). IL-4 (but not IL-13) (Lutz, Schnare et al. 2002) was shown to enhance IL-
12p70 whilst inhibiting IL-12p40 secretion from PRR stimulated splenic DCs 
(Hochrein, O'Keeffe et al. 2000), CD40L stimulated human or monocyte derived 
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DCs (Kalinski, Smits et al. 2000), or IFNγ stimulated monocytes or GMDC (Bullens, 
Kasran et al. 2001; Lutz, Schnare et al. 2002). IL-4 was also shown to instruct 
resistance to L. major, and this was dependent upon induction of IL-12 in DCs 
(Biedermann, Zimmermann et al. 2001). The ability of IL-4 to enhance IL-12p70 
production from LPS stimulated splenic or GMDC was subsequently shown to be 
dependent upon inhibition of IL-10 production (Yao, Li et al. 2005). High or low dose 
IL-4 treatment of human monocyte derived DCs has been shown to alter their ability 
to promote Th1 or Th2 during in vitro culture, with 5ng/ml IL-4 resulting in DCs that 
secrete low IL-12p70 and prime naïve T-cell toward Th2, and 50ng/ml IL-4 treatment 
of DCs resulting in high IL-12p70 and Th1 induction from naïve T-cells (Guenova, 
Volz et al. 2008). Although the ability of IL-4 to limit PRR stimulation induced DC IL-
10 and promote DC IL-12p70 has been shown in vitro, the functional ability of IL-4 
stimulated DCs to prime Th1 responses in vivo has not been addressed.  As in vitro 
conditions cannot accurately represent the in vivo environment, for example in terms 
of the mixed antigenic, cytokine and cellular environment, it is important to address 
whether the impact of IL-4 on DC derived IL-12p70 also influences the outcome of 
DC T-cell polarisation in vivo.  
 
1.8 VITAMIN A METABOLISM 
In the second half of this thesis vitamin A metabolites are investigated in 
relation to their role in modulating DC priming of T cell responses in the context of 
an IL-4 rich environment. Vitamin A (retinol) is a fat-soluble nutrient	  (Hall, Grainger 
et al. 2011) that is converted to retinoic acid (RA) in a step-wise process via the 
intermediate product retinal (Fig.1.9). Retinol cannot be synthesised endogenously 
and as such it must be absorbed from the diet. Diet acquired retinol is converted by 
lecitihin retinol acyl transferases (LRAT) in	   small intestinal enterocytes into retinyl 
esters and is transported in chylomicrons through the lymph into the bloodstream 
(Blomhoff and Blomhoff 2006; Jaensson-Gyllenback, Kotarsky et al. 2011). The 
major site of retinol storage in the body is the liver (Blomhoff and Blomhoff 2006). To 
allow mobilisation of retinol around the body, retinol is bound by retinol binding 
protein (RBP) (Theodosiou, Laudet et al. 2010). Retinol can freely diffuse into cells 
prior to binding RBP, although retinol complexed to RBP (holoRBP) must be 
delivered via the novel surface receptor stimulated by retinoic acid 6 (STRA6)	  
(Bouillet, Sapin et al. 1997; Berry, Jin et al. 2011; Kawaguchi, Zhong et al. 2012). 
Following mobilisation from the liver, holo-RBP complexes with a second carrier 
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protein transthyretin (TTR), which increases the size of the complex protecting 
clearance by filtration in the kidney	   (Episkopou, Maeda et al. 1993). The 
RBP/retinol/TTR complex binds to the RBP-receptor STRA6 and retinol is delivered 
directly into the cell (Kawaguchi, Yu et al. 2007), where it is bound by either to 
cellular retinol binding protein-I (CRBP-I)	   (Kawaguchi, Zhong et al. 2012) or LRAT 
(Isken, Golczak et al. 2008; Amengual, Golczak et al. 2012). STRA6 sophisticatedly 
controls the balance of intracellular LRAT and CRBP-1 bound retinol to extracellular 
RBP-retinol (Kawaguchi, Yu et al. 2011; Berry, Croniger et al. 2012; Kawaguchi, 
Zhong et al. 2012). 	  
 
It was recently shown that in addition to mediating the uptake of retinol into 
target cells, STRA6 is able to signal (Berry, Jin et al. 2011). Transfer of extracellular 
retinol from RBP to intracellular CRBP results in the phosphorylation of STRA6 and 
the recruitment and activation of the signalling molecules JAK2 and STAT5 (Berry, 
Jin et al. 2011; Berry, O'Byrne et al. 2012). Following cellular uptake, retinol is 
converted into retinal by short chain or alcohol dehydrogenase (SDR/ADH), then 
retinal is converted to RA via retinal dehydrogenase enzymes (RALDHs;Aldh1a1, 
Aldh1a2, Aldh1a3)	  (Blomhoff and Blomhoff 2006). RALDH1 (Aldh1a1) is expressed 
in the dorsal retina of embryos and in adult epithelia tissues (Blomhoff and Blomhoff 
2006), and was found to be expressed in PP DCs, liver and weakly in peripheral 
LNs (Iwata, Hirakiyama et al. 2004). RALDH2 (Aldh1a2) is expressed in many cell 
types of both embryonic and adult tissue and is required for embryonic development 
(Niederreither, Subbarayan et al. 1999). RALDH2 is the most highly expressed 
RALDH in the mLN, specifically in mLN DCs (Iwata, Hirakiyama et al. 2004; 
Coombes, Siddiqui et al. 2007; Jaensson, Uronen-Hansson et al. 2008), and was 
initially not thought to be expressed in the spleen (Iwata, Hirakiyama et al. 2004), 
however upregulation in the spleen has since been reported, as discussed further in 
sections 1.8.4 and 1.8.5. RALDH3 (Aldh1a3) null animals die within 10h of birth due 
to nasal defects (Dupe, Matt et al. 2003). Aldh1a3 was shown to be weakly 
expressed in the mLN, PP and peripheral LNs (Iwata, Hirakiyama et al. 2004) and 
has recently been shown to be expressed in liver leukocytes during S. mansoni 





1.8.1 Retinoic acid signalling 
RA signals via binding to heterodimeric nuclear hormone receptors of the 
retinoic acid receptor (RAR) or retinoid x receptor (RXR) families, which have 3 
members in each family, α, β & γ (Chambon 2004; Blomhoff and Blomhoff 2006). All 
trans-RA has a high affinity for RARs but lower affinity for RXRs, whereas 9-cis-RA 
(9cRA), an isomer of atRA, is an high affinity RXR ligand	   (Kane 2012). Although 
studies had failed to detect 9cRA in tissues, leading to the suggestion that it did not 
have a functional in vivo role, it has since been detected in the pancreas (Kane, 
Folias et al. 2010).  
 
RARα is the dominant RAR isoform in myeloid cells	   (Nagy, Szanto et al. 
2012), though all RAR isoforms have been detected in murine splenic DCs	  
(Manicassamy, Ravindran et al. 2009). Ligand-bound RAR/RXRs associate with 
retinoic acid response elements (RARE) in the promoter regions of target genes to 
mediate their downstream effects. RAREs are composed of repeats of a core 
hexameric motif PuG(G/T)TCA (Bastien and Rochette-Egly 2004). The classical 
RARE has direct repeats spaced by 5bp, and as such is referred to as DR5 (Bastien 
and Rochette-Egly 2004).  DR5 elements are found in the promoters of RARβ 
(Bastien and Rochette-Egly 2004) and RARα (Leroy, Nakshatri et al. 1991) genes, 
suggesting that RA can modulate expression of its own receptors.   
 
1.8.2 Intestinal homing 
In order to explain how RA is generally perceived to be involved in immune 
system function, it is necessary to first explain how T-cells are recruited to intestinal 
sites (Fig. 1.10)	  (Iwata 2009). Pathogens generally enter the body at peripheral sites 
such as the skin, GI tract and lung, locations at which naïve T-cells are infrequently 
present/largely excluded (Ebert, Schaerli et al. 2005). In order for naïve T-cells to 
come into contact with APCs expressing antigen they continually circulate through 
secondary lymphatics in an attempt to locate an antigen loaded DC with whom they 
can form a cognate interaction (Randolph, Ochando et al. 2008). Naïve T-cell 
migration through the secondary lymphatics is dependent upon expression of 
CD62L (L-selectin) and CCR7: CCR7 expression allows naïve and central memory 
T-cells to enter the T-cell zones of lymphoid organs (LOs) by recognition of a 
gradient of CCL19/ELC (Ebert, Schaerli et al. 2005). Short lived effector T-cells 
result from this interaction and are released into the circulation such that they can 
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enter peripheral tissues to perform their effector function (Ebert, Schaerli et al. 
2005). Circulating effector T-cells express cellular adhesion receptors that allow 
them entry into defined tissues expressing their cognate vascular endothelial ligands	  
(Agace 2009). For entry into mucosal sites, T-cells are required to express CCR9, 
α4β7, and have low level expression of CD62L (Johansson-Lindbom, Svensson et 
al. 2003), a phenotype only thought to be generated in gut associated lymphoid 
tissue (GALT) such as the mLN (Johansson-Lindbom, Svensson et al. 2003). 
CCR9+ T-cell are able to enter the SI mucosa via interaction with the ligand CCL25 
(Svensson, Marsal et al. 2002). CCL25 is constitutively expressed by epithelial cells 
of the small intestine, and is present on the surface of intestinal vascular endothelial 
cells, where it is able to mediate the interaction of T-cells with the intestinal mucosa 
(Kunkel, Campbell et al. 2000). T-cell recognition of CCL25 induces clustering of 
α4β7 on the cell surface, resulting in enhanced affinity for its ligand MadCAM1, 
which is expressed constitutively on the vascular endothelium of the LP	   (Agace 
2009). Following entry into the intestinal LP, intraepithelial lymphocytes (IELs) 
downregulate expression of α4β7 and upregulate the integrin αEβ7 (CD103), 
allowing interaction with E-cadherin expressed on epithelial cells	   (Ericsson, 
Svensson et al. 2004).  
 
1.8.3 CD103+ DCs, RA production and RA effects on T-cells 
mLN DCs were found to be superior at inducing intestinal homing markers 
on circulating T-cells	   (Svensson, Johansson-Lindbom et al. 2008; Agace and 
Persson 2012). In particular, a DC subset that also expressed CD103 was also 
found to be able to induce CCR9 and α4β7 on CD8+ T-cells in vitro	   (Johansson-
Lindbom, Svensson et al. 2005). It was then determined using CCR7-/- mice that the 
CD103+ DCs in the mLN were migratory DCs, arriving from the LP in a CCR7 
dependent manner (Johansson-Lindbom, Svensson et al. 2005). Reports in other 
laboratories revealed that RA was also able to induce CCR9 and α4β7 expression 
by naïve αCD3/αCD28 stimulated CD4+ T-cells in vitro	   (Iwata, Hirakiyama et al. 
2004). mLN DCs were found to express Aldh1a2 (RALDH2) and produce RA by 
irreversible conversion of retinal, and this was sufficient to induce CCR9, α4β7 
expression by and gut homing in T-cells (Iwata, Hirakiyama et al. 2004). Further, the 
effect of RA was found to be dependent upon RARβ/RARα but not RXRs (Iwata, 
Hirakiyama et al. 2004).  
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CD103+ mLN and LP DCs have also been shown to promote spontaneous 
extra-thymic conversion of naïve T cells into Foxp3+ expressing regulatory T cells in 
a TGFβ and RA dependent manner (Coombes, Siddiqui et al. 2007; Sun, Hall et al. 
2007). In addition, it was again shown that CD103+ mLN DCs produced RA via their 
expression of Aldh1a2 (Coombes, Siddiqui et al. 2007). CD103+ mLN DCs were 
confirmed to be a tissue-derived population of migratory cells required for the 
presentation of orally derived antigens to both CD4+ and CD8+ T-cells, and an 
equivalent population (both functionally and phenotypically) was found in human 
mLN (Jaensson, Uronen-Hansson et al. 2008). Induction of T-cell Foxp3 by TGFβ 
and IL-2 was shown to be limited by DC provision of co-stimulation, and this could 
be overcome by using DCs deficient in CD80/86 or addition of exogenous RA to the 
cultures	  (Benson, Pino-Lagos et al. 2007). Interest in the role of RA in influencing Th 
differentiation was further enhanced by studies showing that RA was able to limit the 
conversion of Th cells toward a Th17 phenotype.  RA and other agonists of RARα 
were shown to inhibit Th17 whilst promoting Foxp3 expression	   in collaboration with 
TGFβ (Mucida, Park et al. 2007; Elias, Laurence et al. 2008). These studies were 
important for defining how the tolerogenic intestinal environment was maintained in 
the steady state, and highlighted an important role for vitamin A metabolites acting 
at the site of vitamin A acquisition. Further studies have begun to investigate what 
factors drive RALDH2 expression in DCs, an area discussed in more detail in the 
next section (1.8.4). 
 
1.8.4 Induction of RALDH2 in DCs 
Although in vitro culture of mLN DCs had been reported to result in the 
expression of CCR9 and α4β7 on co-cultured T-cells (Johansson-Lindbom, 
Svensson et al. 2003), it was only shown recently that this ability was abolished if 
retinoids were depleted from complete medium via UV-irradiation of FCS prior to 
use (Jaensson-Gyllenback, Kotarsky et al. 2011). Addition of retinal to serum free 
medium (XVIVO10) could also rescue the ability of mLN DCs to induce gut homing 
markers on T-cells (Jaensson-Gyllenback, Kotarsky et al. 2011). In accordance with 
this recent finding, previous studies have reported a role for RA in modulating DC 
ability to induce gut homing molecules in vitro (Feng, Cong et al. 2010). Inclusion of 
RA during DC differentiation resulted in DC populations that expressed CCR9 and 
expressed Aldh1a2 (Feng, Cong et al. 2010). The same study also reported BM 
expression of Aldh1a2, leading the authors to propose a model whereby RA 
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expression within BM results in the imprinting of ‘mucosal DCs’ that express CCR9 
to enable migration to GALT	   (Feng, Cong et al. 2010). PPARγ activation has also 
been implicated in the induction of RALDH2, resulting in enhanced RA signalling to 
RARα and upregulation of CD1d expression and leading to altered presentation of 
lipid antigens	  (Szatmari, Pap et al. 2006). The authors suggest that at intestinal sites 
there would be high levels of lipid traffic, which would provide a source of PPARγ 
ligands to drive RALDH2 production. However, this work was all carried out in vitro	  
(Szatmari, Pap et al. 2006).     
 
Until recently, a functional role for RA in induction of small intestine DC 
RALDH2 activity in vivo had not been shown. However, several studies have since 
found that animals kept on a VAD diet display reduced expression of Aldh1a2 and 
RALDH activity in their CD11c+ mLN cells (Yokota, Takeuchi et al. 2009), and that 
this also holds true for the CD103+ subset (Jaensson-Gyllenback, Kotarsky et al. 
2011). The ability of CD103+ DCs to metabolise retinal was shown to occur locally, 
as pre-DCs had no aldehdye dehydrogenase activity, in direct contrast to the report 
by Feng et al (Feng, Cong et al. 2010; Jaensson-Gyllenback, Kotarsky et al. 2011). 
DR5-luciferase reporter mice were used to show that CD103+ SI-LP DCs received 
an RA signal in vivo, and that the signal was higher in SI DCs than colonic CD103+ 
DCs (Jaensson-Gyllenback, Kotarsky et al. 2011). Contrary to expectation, the local 
source of retinol required to imprint RALDH2 activity in SI DCs was found to be bile 
retinoids released from the liver, and not a dietary retinol source (Jaensson-
Gyllenback, Kotarsky et al. 2011).   
	  
We will now discuss work detailing a role for DC RA production at sites other 
than the gut.  Splenic DCs were initially reported not to express Aldh1a2	  
(Johansson-Lindbom, Svensson et al. 2003; Iwata, Hirakiyama et al. 2004). 
However, a consensus is emerging that in response to certain stimuli, or on removal 
of inhibition, RALDH activity can be upregulated in splenic DCs both in vitro	  
(Manicassamy, Ravindran et al. 2009; Yokota, Takeuchi et al. 2009; Stock, Booth et 
al. 2011; Wang, Villablanca et al. 2011) and in vivo	  (Manicassamy, Ravindran et al. 
2009; Stock, Booth et al. 2011; Wang, Villablanca et al. 2011).  
 
One of the few stimuli that have been reported to induce Aldh1a2 in splenic 
DCs is signalling via TLR2. The S. cerevisiae fungal cell wall preparation, zymosan 
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was shown to induce Aldh1a2 production by splenic CD11c+ DCs (Manicassamy, 
Ravindran et al. 2009). Zymosan enhancement of DC Aldh1a2 in vitro was shown to 
be partially dependent upon TLR2, independent of dectin-1 but dependent upon 
ERK signalling	   (Manicassamy, Ravindran et al. 2009). Injection of zymosan was 
found to induce total splenic CD11c+ cell populations to increase production of 
Aldh1a2 mRNA and RALDH2 protein (assessed by western blot) (Manicassamy, 
Ravindran et al. 2009).	  The TLR4 and TLR9 agonists LPS and CpG were unable to 
induce splenic DC expression of Aldh1a2 (Manicassamy, Ravindran et al. 2009), 
highlighting that Aldh1a2 induction is linked to TLR2 signalling rather than generic 
pathogen recognition. In a more recent study, Aldh1a2 expression and RALDH 
activity was shown to be impaired in mLN but not the splenic DCs of MyD88-/- mice 
(Wang, Villablanca et al. 2011), and TLR2 was shown to be expressed by mLN, PP 
and spleen DCs (Wang, Villablanca et al. 2011). Furthermore, the TLR2 specific 
agonist P3C was shown to induce Aldh1a2 in splenic DCs, repeating the findings of 
Manicassamy et al in highlighting a role for TLR2 signalling in increasing RALDH in 
extra-intestinal DCs (Wang, Villablanca et al. 2011). Additionally, CD103+ mLN DCs 
were found to have reduced RALDH activity in TLR2-/- mice compared to WT 
animals	   (Wang, Villablanca et al. 2011). These data highlight a role for TLR2 
signalling in inducing DC expression of RALDH2, and suggest that DC expression of 
this enzyme may function in the immune response to both bacterial and fungal 
pathogens which signal via TLR2.   
 
1.8.5 Immune mediators implicated in induction and regulation of DC RALDH 
Interestingly, IL-4 has been shown to cause the induction of Aldh1a2 mRNA 
in mLN DCs resulting in the upregulation of CCR9, but not α4β7 on T-cells (Elgueta, 
Sepulveda et al. 2008). IL-4 and IL-13 were both shown to induce RALDH activity in 
BM cells following culture with FLT3L and either Th2 cytokine	   (Stock, Booth et al. 
2011).   However, an additional study reported that intestinal DCs from Il4ra-/- mice 
had normal or enhanced levels of RALDH activity (Yokota, Takeuchi et al. 2009). 
Given the reports that RA could directly drive Aldh1a2 in DCs, the literature 
available on the interaction of these two immune mediators is limited. A topic also 
underrepresented in the RA literature is evidence for macrophage expression of 
retinal converting enzymes, however this topic is beginning to be addressed 
(Broadhurst, Leung et al. 2012). Due to the sparse references available on DC 
alternative activation (Modolell, Corraliza et al. 1995; Nair, Gallagher et al. 2005; 
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Arora, Chen et al. 2006; Cai, Kumar et al. 2009), and the limited interest (so far) in 
macrophage vitamin A metabolism, the cross talk between IL-4 induction of 
alternative activation and retinoic acid production has not yet been addressed. We 
will begin to address the interaction between DC alternative activation and vitamin A 
metabolites/metabolism within chapter 5 of this thesis. 
 
GM-CSF has also been implicated in the acquisition of RA producing 
capacity in intestinal DCs, in combination with IL-4 (Yokota, Takeuchi et al. 2009), 
and alone in CD11c+ cells of the mLN and spleen. Interestingly RALDH activity was 
enhanced in GM-CSF treated DCs in the presence of LPS (Stock, Booth et al. 
2011). GM-CSF binds to the GM-CSFR, and deficiency in this receptor (Csf2r-/-) was 
shown to reduce CD103+CD11b+ LP DCs, the population reported to have the 
highest level of endogenous RALDH activity (Bogunovic, Ginhoux et al. 2009).  
 
Prostaglandin E2 (PGE2) has been purported to be the factor responsible for 
the low levels of RALDH activity in extra-intestinal DCs (Stock, Booth et al. 2011). 
PGE2 was shown to repress the GM-CSF dependent transcription of RALDH in 
mouse and human moDCs, in vitro via the EP-2 and EP-4 receptors respectively 
(Stock, Booth et al. 2011). Reducing PGE2 levels at steady state in vivo, via 
administration of a cyclooxygenase inhibitor indomethacin, resulted in a four to five 
fold increase in RALDH expressing splenic DCs (Stock, Booth et al. 2011), with 
stromal cells identified as being the source of the RALDH inhibitory PGE2.  
 
1.8.6 Vitamin A and Th1/Th2 
Work on Treg/Th17 induction was carried out in the steady state conditions 
and did not assess the role that RA plays in regulating Th1/Th2 balance. Prior to the 
studies investigating the role for vitamin A metabolism in DCs and Treg/Th17 
induction, animals kept on a VAD diet had been shown to have enhanced 
production of IFNγ by T-cell cultures in vitro (Carman and Hayes 1991) and in 
response to Trichinella spiralis infection in vivo (Carman, Pond et al. 1992). In 
addition, RA was found to influence the outcome of T-cell polarisation in vitro when 
added to cells under Th2 differentiation conditions, promoting the secretion of IL-4	  
(Hoag, Nashold et al. 2002). A study comparing the in vitro polarising ability of RA 
and 9cRA in a co-culture of APCs with DO11.10 TCR transgenic T-cells reported a 
role for 9cRA and RXR agonists in promoting Th2 responses in primary stimulations 
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of CD4+ T-cells	   (Stephensen, Rasooly et al. 2002). This report provides useful 
information on the capacity of RXRs to alter T-cell responses to RA, but may not be 
representative of an in vivo situation due to the relatively low level presence of 9cRA	  
(Kane 2012). Interestingly, the study by Stephensen et al found no role for primary 
exposure to RA in promoting Th2 polarisation in either secondary or tertiary 
restimulation	   (Stephensen, Rasooly et al. 2002), but did identify a role for RA in 
reducing IFNγ secretion by already polarised Th1 cells.  
 
RA acting via RARs was shown to directly suppress Th1 development and 
enhance Th2 development in a report from a different laboratory (Iwata, Eshima et 
al. 2003). In this work, RA was added to in vitro cultures of isolated T-cells in the 
absence of APCs. RA also enhanced expression of the IL-4Rα by thymocytes 
cultured under Th2 conditions (Iwata, Eshima et al. 2003), suggesting that T-cells 
exposed to RA would be more receptive to IL-4 and thus to becoming Th2. 
Additionally, RA has been shown to promote human T-cell Th2 cytokine production 
and GATA3 expression and to limit expression of T-bet and IFNγ (Dawson, Collins 
et al. 2006). A study from 2011 showed that RA signalling occurs concurrent with 
immunisation (CFA, LPS) and inflammation following allogeneic skin grafting	  (Pino-
Lagos, Guo et al. 2011). Furthermore, investigations into RA signalling in the 
inflammatory settings of Toxoplasma gondii infection and vaccination also revealed 
a broader role for RA in mediating T-cell activation via cell intrinsic RARα signalling 
(Hall, Cannons et al. 2011). Hall et al have suggested that the contrasting data 
available in the literature regarding the role for RA in mediating Treg/Th1/Th2/Th17 
responses is due to RA acting in a biphasic manner, driving T-cell activation and 
differentiation early during an immune response but regulating the response at later 
stages	   (Hall, Cannons et al. 2011). In this context, interpretation of the previous 
studies mentioned above may need re-evaluation taking timing into consideration. 
 
1.8.7 Vitamin A and Schistosomiasis 
Deficiency in dietary vitamin A, and thus reduced systemic vitamin A 
availability, is associated with increased morbidity and mortality in response to 
infectious disease (Semba 1999), and dietary supplementation with vitamin A has 
been shown to significantly reduce all-cause mortality in children (Sommer 2008). 
Serum retinol levels in school-age children have been inversely correlated with S. 
mansoni infection (Friis, Mwaniki et al. 1997). A recent study comparing the impact 
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of murine vitamin A deficiency during infection with S. mansoni or LCMV found 
enhanced numbers of Foxp3+ Tregs in the spleen and colons in control, helminth, or 
virally infected animals	  (Broadhurst, Leung et al. 2012), a result also seen in the SI 
LP of naïve animals in a separate previous study	   (Hall, Cannons et al. 2011). 
Hepatic leukocytes of S. mansoni infected VAD animals displayed significantly 
reduced intracellular CD4+ T cell IL-4, reduced secretion of IL-4 and IL-10 following 
restimulation with S. mansoni egg antigens, and decreased Il4, Il5 and Il13 mRNA, 
compared to vitamin A sufficient infected controls	   (Broadhurst, Leung et al. 2012). 
This study was the first to reveal that AAM present within liver granulomas express 
RALDH, and can be an important source of RA following schistosome infection. It 
also showed that IL-4 was able to promote Aldh1a2 induction in macrophages 
(Broadhurst, Leung et al. 2012). The role for DC RALDH2 expression in the context 
of S. mansoni is a topic that has not yet been investigated. The lack of investigation 
into DC RALDH outwith intestinal settings is perhaps due to work suggesting that 
RALDHs are not expressed in extraintestinal tissues such as the spleen, this finding 
has since been clarified by the detection of the inhibitory role of stromal cell derived 
prostaglandins	  (Stock, Booth et al. 2011). 
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1.9 THESIS AIMS 
That IL-4 can alter the activation status of macrophages is well documented. 
However, whether IL-4 has the ability to alter the activation and function of DCs in a 
similar manner is much less clear.  
 
Chapter 3 of this thesis compares the impact that IL-4 has on DCs and 
macrophages, both in vitro and in vivo, in response to exogenous IL-4 treatment and 
schistosome infection. Expression of molecules usually associated with AAM 
(arginase, RELMα, Ym1/2, dectin-1, CCL17, CCL24, MR) is systematically 
investigated in IL-4 exposed DC populations. In addition, the APC ability of BMDC 
and BMM are directly compared in vivo in response to Th1/17 (Pa, St) or Th2 (SEA) 
polarising antigens.  
 
Chapter 4 extends this theme to determine whether the capacity of DCs to 
alternatively activate (comparing WT to Il4ra-/- cells), alters their ability to prime the 
immune system in response to Th1 and Th2 antigens. Furthermore, the functional 
impact of DC expression of one specific AAM-associated molecule, RELMα, is 
investigated. An in vivo DC transfer system and in vitro assays are used to assess 
the role of RELMα deficient DCs in T-cell polarisation. A microarray study is used to 
determine the global transcriptional changes that occur in WT, IL-4Rα and RELMα 
deficient DCs. A new theme introduced in chapter 4 is the role of IL-4 in modulating 
the response of DCs to TLR stimulation, in particular the impact that IL-4 has on DC 
secretion of T-cell polarising cytokines is investigated.  
 
Chapter 5 builds on work from other laboratories and chapter 4 of this thesis, 
in which it was found that DC expression of Aldh1a2 (the retinal dehydrogenase 
enzyme) is modulated by IL-4. With the use of a panRAR inhibitor (LE540) and 
RARα deficient DCs, the relationship between RA synthesis, RA signalling and IL-4 
driven alternative activation in DCs is investigated for the first time.  
 
In chapter 6, themes taken from the previous 3 chapters are integrated with 
experiments investigating the interrelationship between TLR2 agonists (P3C, 






































Figure 1.1. Murine DC and macrophage ontogeny. This figure highlights the precursor cells, 
transcription factors (blue) and cytokines (green) known to be required for development of DC 
and macrophage populations. The granulocyte/macrophage progenitor (GMP) gives rise to 
macrophage-dendritic cell progenitor MDP, which gives rise to monocytes and the common DC 
precursors (CDP). CDPs have lost monocyte-macrophage differentiation potential and give rise 
exclusively to plasmacytoid DCs (pDCs) and pre-DCs. Pre-DCs migrate to lymphoid tissues 
where they differentiate into lymphoid tissue CD4-CD8+ and CD4+CD8- DCs and to non-
lymphoid tissue where they differentiate into CD103+CD11b- DCs and CD103+CD11b+ DCs. Flt3 
controls myeloid precursor commitment to the DC lineage as well as the differentiation of mature 
DCs in tissue. The transcription factors Batf3, Id2 and IRF8 control the differentiation of 
lymphoid tissue CD8+ DC and non-lymphoid tissues CD103+CD11b- DC. The transcription 
factors RelB, IRF2 and IRF4 control the development of CD4+ DC. Macrophage development 
from monocytes is dependent upon expression of the M-CSF/Csf1 receptor CSF1-R. Figure is 








































































Figure 1.2 TLR signalling. This figure highlights the signalling pathways downstream of the main 
TLRs. Shaded=TRIF dependent/MyD88 independent pathway. Figure is adapted from Takeuchi 
and Akira 2010. 
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Figure 1.3. MAPK signalling. This figure highlights the hierarchy of MAPK signalling, 
which functions as a triple kinase cascade. The major MAPKs families (ERK1/2, ERK5, 
p38 and JNK) are activated by dual phosphorylation on Threonine and Tyrosine 
residues by specific MKKs, which have previously been activated by MKKKs. Small 
GTPase proteins are responsible for initiating the phosphorylation cascade upstream of 
























Figure 1.4. Co-stimulatory/-inhibitory molecules. This diagram 
displays ligands and receptors expressed on DCs and T-cells that 
form the immune synapse required for the activation of naïve T-
cells. The proteins can be broadly grouped as Ig-superfamily or 
TNF/TNFR family members. Co-stimulatory (red) Co-inhibitory 














































Figure 1.5. T-helper cell subsets. This figure highlights the cytokines (blue) and transcription 
factors (orange) required for the differentiation and specification of defined CD4+ T-helper 
cell subsets. Figure is adapted from Zhou, Chong et al 2009 and Pulendran and Artis 2012.  
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Figure 1.6. Diversity in molecules expressed by CAM and AAM. Figure is 
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Figure 1.7. Arginine metabolism. This figure details the impact that Th1 and Th2 cytokines 
have on cellular metabolism of arginine, via the activation of inducible nitric oxide synthase 
(Nos2) and arginase 1 (Arg1). Th1 cyokines activate NOS2 an enzyme that converts 
arginine into reactive (nitrogen)-oxide species (ROS/RNOS), which damage cells. Th2 
cytokines drive Arg1 activity leading to the conversion of L-arginine into L-ornithine. 
Ornithine is converted by ornithine decarboxylase (ODC) into polyamines that fuel cell 
division and by ornithine aminotransferase (OAT) into L-Proline which is important for 
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Figure 1.8. IL-4Rα signalling. IL-4 binds extracellularly to the IL-4Rα causing 
heterodimerisation of this receptor with either the common gamma chain (γC) or the 
IL-13Rα (grey brackets). JAK and Src kinases are activated leading to phosphorylation of 
the intracellular tail of IL-4Rα, enabling binding of SH2 domain proteins which themselves 
become activated. STAT6 becomes phosphorylated and forms a homodimer prior to nuclear 
entry and activation of IL-4 responsive genes. IRS1/2 is able to dock at an I4R site and 
activate the downstream signaling molecules PI3K and Grb2.  
Figure is adapted from Nelms, Keegan et al 1999.  
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Figure 1.9. Retinol metabolism. This figure highlights the transport proteins, 
receptors and enzymes involved in the cellular conversion of retinol (vitamin A) into 
bioactive retinoic acid (RA). Retinol is transported bound to transthyretin (TTR) and 
the retinol binding protein (RBP), binding of RBP to the receptor stimulated by 
retinoic acid 6 (STRA6) facilitates delivery of retinol into the target cell. Retinol is 
reversibly converted into retinal by short chain/alcohol dehydrogenase (SDR/ADH). 
Retinal is irreversibly converted to retinoic acid (RA) by retinal dehydrogenases 
(RALDH). RA binds to hetero or homo-dimer nuclear hormone receptor pairings of 
retinoic acid receptor (RAR) α/β/γ and retinoid X receptor (RXR) α/β/γ that 
recognise retinoic acid response elements (RARE) in RA responsive genes. Figure 


































Figure 1.10. DC imprinting of gut homing function in T-cells. Naïve T-cells enter 
the GALT from the circulation, interact with antigen presenting DCs in the 
context of RA, upregulate expression of gut homing receptors CCR9 and 
α4β7, leave the GALT and enter the small intestinal tissue via interaction with 




Chapter 2. Materials and Methods	  
2.1 MICE, INFECTIONS AND IN VIVO EXPERIMENTS 
2.1.1 Mice 
 C57BL/6, BALB/c, Il4ra-/- (BALB/c & C57BL/6), IL-10GFP TIGR (C57BL/6), 
KN2 (C57BL/6), IL-10GFP x KN2 (C57BL/6), Ly5.1xOTII (C57BL/6), 4Get (BALB/c), 
Tlr2-/- (C57BL/6) and Retnla-/- (C57BL/6) mice were maintained under specific 
pathogen free conditions at the University of Edinburgh Animal Facilities. 
CD11ccreRARαfl/fl and littermate control bone marrow was a generous donation from 
Dr. Yasmine Belkaid, NIAID, NIH, Bethesda. All experiments were approved under a 
Project License granted by the Home Office (U.K.) and conducted in accordance 
with local guidelines. 
 
2.1.2 S. mansoni infection 
Cercariae were shed from patent S. mansoni infected B. glabrata snails by 
placing the snails in pond water under a heat lamp for 50 minutes. A sample of 
Cercariae were counted in a 1:1 dilution of Lugol’s iodine solution under a dissection 
microscope. Female C57BL/6 mice were anesthetised with 0.01ml/g of 0.25ml 
domitor and 0.19ml vetalar mixed in 2.6ml PBS (Sigma), hair was removed from 
abdomen with clippers, and animals taped to a pre-warmed heat pad to help 
maintain body temperature during the procedure. A stainless steel ring was taped 
over the shaved part of the abdomen, 80 cercariae were placed into the ring in 
200µl of pond water, with an additional 200µl of pond water added on top. Cercariae 
were allowed to penetrate for 30 minutes, following this time, steel ring and 
remaining cercariae were removed from the animals, and animals were revived by a 
sub cutaneous injection of 0.1ml of 0.04ml antisedan diluted in 0.96ml PBS (Sigma). 
Following infection animals were monitored with weights measured 3 times a week 
starting at week 5. At week 8 organs were harvested following CO2 asphyxiation.   
 
2.1.3 Intra-peritoneal injections 
 Long acting IL-4 (IL-4c): IL-4/anti-IL-4 mAb complexes (IL-4c) were prepared 
as described previously (Herbert, Yang et al. 2009; Jenkins, Ruckerl et al. 2011). 
Recombinant murine IL-4 (Peprotech) was combined with rat IgG1 anti-IL-4 mAb 
11B11 (BioXcell) at a 1:5 weight ratio (Urban, Maliszewski et al. 1995). Mice were 
injected intra-peritoneally with 50µl PBS or 0.625µg, 4µg, or 2 injections of 5µg IL-4 
complexed to 11B11 in a volume of 50µl, and peritoneal exudate cells (PEC) and 
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spleen were harvested 4 days later.  
 
2.1.4 Thioglycollate elicited peritoneal macrophages 
300-500µl of 4% BBL Brewers modified thioglycollate medium (BD Europe) 
was injected i.p. to recruit inflammatory cells to the peritoneal cavity. 4 days later 
mice were killed using CO2 asphyxiation, PEC were harvested, washed and plated 
onto 6cm petri dishes and left to adhere for 4 hours in a humidified environment, 
37oC, 5% CO2. Non-adherent cells were aspirated, 3mM EDTA (Ambion) and 10mM 
Glucose (Sigma) was added to the dishes and cells were returned to 37oC for 15 
mins, following this incubation, adherent cells were detached using mechanical 
perturbation with the centre of a 1ml syringe (BD), cells were pooled, washed to 
remove EDTA/Glucose and re-suspended in complete RPMI-1640 medium without 
additional growth factors.    
 
2.1.5 Sub-cutaneous injections into the feet 
BMDC transfer: Wild type and Il4ra-/- BALB/c BMDC or Wild type and Retnla-
/- C57BL/6 BMDC were cultured as below (section 2.3 and 2.4), with SEA, Pa or 
medium alone. 5 x 105 BMDC were injected subcutaneously into the feet of recipient 
WT BALB/c or C57BL/6 mice (2.5 x 105 per foot). 5-7 days following transfer the 
draining popliteal LNs were harvested. Single cell suspensions of LN cells (1 x 106 
cell/ml) were cultured in X-vivo 15 medium (BioWhittaker) containing 2mM L-
Glutamine and 50 mM 2-ME (Invitrogen) in 96 well plates at 37°C in a humidified 
atmosphere of 5% CO2 with or without 15 µg/ml SEA, or 1 µg/ml Pa.  Supernatants 
were harvested from the cultures after 72h and cytokine production assessed by 
ELISA. 
 
2.2 CELL ISOLATIONS 
2.2.1 Innate cell isolation  
 Single cell suspensions were prepared following protocols previously 
published by the MacDonald Laboratory (Phythian-Adams, Cook et al. 2010). 
Spleens were diced and digested at 37°C for 20 min with 1.75 Wunsch Units/ml 
Liberase TI (Roche Diagnostics) and 80 Kunitz Units/ml DNase I type VI (Sigma) in 
HBSS (Sigma) containing 50 U/ml penicillin and 50 µg/ml streptomycin (Invitrogen).  
100µl 0.1M pH 7.3 EDTA (Ambion) stop solution per ml was then added and the 
tube topped up with DMEM containing 50 U/ml penicillin and 50µg/ml streptomycin.  
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The resulting suspension was then passed through a 70µm cell strainer to obtain a 
single cell suspension, RBCs were lysed using RBC lysis buffer (Sigma) 3ml, 5 
minutes and cells counted and resuspended for use. For restimulation assays, LNs 
were disrupted without enzymatic digestion.  Single cell suspensions were prepared 
from the peritoneal cavity by flushing with 3 x 5ml PBS + 10% FCS 
(Hyclone/Sigma). RBC were lysed (as above), cells counted and resuspended for 
flow cytometric analysis.    
 
2.2.2 Splenic DC purification 
 Spleens from 5-6 naïve C57BL/6 mice were mechanically disrupted, DC 
enriched using NycoDenz density gradient separation and CD11chiB220- cDC were 
sorted from B220+CD11cmid pDC using a BD FACs Aria II. Post sort, 50,000 DCs 
were cultured overnight with 20ng/ml IL-4, prior to RNA extraction, reverse 
transcription and quantification of transcript levels using qPCR.  
 
2.2.3 T-cell isolation for DC:T-cell co-culture 
 Spleen, mesenteric, brachial and inguinal lymph nodes were pooled, crushed 
through gauze to release cells, centrifuged at 1200g for 5 minutes at room 
temperature, RBC were lysed using RBC lysis buffer (Sigma), cells were washed 
and stained with CD4-APC, PE or AlexaFluor e780 (Table 2.1), prior to sorting using 
a BD Aria-II.  
 
2.3 IN VITRO BONE MARROW DIFFERENTIATION 
2.3.1 Bone marrow preparation 
 Tibias and fibulas of the hind legs of mice were collected into ice cold PBS 
(Sigma), bones were then sterilised in 70% Ethanol (Sigma) for 3 minutes, before 
washing with PBS (Sigma), to remove all ethanol. Individual bones were selected, 
the ends of the bone were removed using a scalpel and 5ml of PBS (Sigma) was 
injected through the bone using a 5ml syringe (BD) and a 21G needle (BD), flushing 
the bone marrow into a 50 ml falcon tube (BD). Flushed bone marrow samples 
pooled from all bones collected were then disrupted by repeatedly passing through 
a 23G needle (BD). A sample of BM was mixed in a 1:1 dilution with trypan blue and 




2.3.2 Heat inactivation of fetal calf serum 
The foetal calf serum serum (FCS) used in BMDC medium was placed at 
58ºC for 50 minutes to heat inactivate it prior to use. Heat inactivation was used to 
denature the components of the complement cascade in the serum that could 
damage the cells being cultured or prepared. 
 
2.3.3 rGM-CSF BMDC culture 
Bone marrow (BM)-derived dendritic cells (DC) were prepared following 
protocols previously published from the MacDonald laboratory (MacDonald, Straw et 
al. 2001). 2x106 bone marrow cells were seeded in 10ml complete medium (RPMI-
1640 (Sigma) containing 20ng/ml rGM-CSF (Peprotech), 10% Fetal Calf Serum 
(FCS, Hyclone/Sigma), 2mM L-Glutamine (Gibco), 50 U/ml penicillin and 50 µg/ml 
streptomycin (Invitrogen)). Cells were cultured at 37oC in a humidified atmosphere 
of 5% CO2. On day 3, 10ml of complete medium was added, on days 6 and 8, 9ml 
of media was gently (to avoid undesired activation of cells) aspirated and replaced 
with 10ml of fresh complete medium, cells were harvested gently on day 10. 
Immature day 10 BMDCs were re-suspended in fresh medium containing 5ng/ml 
GM-CSF for in vitro stimulations, see below (section 2.4). 
 
Due to the nature of the feeding process and the sensitivity of GMDCs to 
movement and temperature there is variability in the basal activation status of the 
cells used in all GMDC experiments. The method to count HSCs in BM preparations 
is not precise and down to personal assessment of cell size, and as such there is 
also variability in the yield of cells after the 10 day differentiation period. Another 
confounding factor in the activation status of the DCs used is that FCS is not a 
uniform preparation due to its biological nature. To minimise the variation in GMDC 
on account of FCS (and GM-CSF), we spend a considerable amount of time batch 
testing from various companies to ensure we get comparable growth, and then bulk 
buy the FCS and GM-CSF batch that provides the highest yield, lowest activation 
status, at the lowest price, in the hope that this will last for the duration of a project. 
Unfortunately the FCS stock had to be renewed toward the end of my PhD, and as 
such the activation status in some experiments may be slightly different to the basal 
activation in others. In addition I have found over the course of my PhD that the 
more people sharing an incubator in which DCs are grown, the lower the yield of 
cells achieved, which suggests that the increased frequency that the doors are 
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being opened is creating vibrations within the incubator and fluctuations in 
temperature.     
 
2.3.4 Fms tyrosine like kinase-3 ligand BMDC culture 
FL-DCs were cultured essentially as in (Naik, Proietto et al. 2005), flushed 
BM was RBC lysed and 1.5 x 105 /ml bone marrow cells were re-suspended in 
complete FLT3 medium (as above with the addition of 50mM 2-Mercapto ethanol 
(Invitrogen), omission of GM-CSF and addition of 200ng/ml rFLT3L (Peprotech)). 
Flasks were cultured at 37oC in a humidified atmosphere of 5% CO2 for 8 days 
without feeding. On day 8 cells were harvested, and re-suspended in fresh medium 
containing 50ng/ml FLT3L for in vitro stimulations, see below. For analysis, FL-DC 
were gated based on expression of B220 and CD11c (pDC=B220+CD11cint, 
cDC=B220-CD11c+), representative gating strategy is shown in Fig. 2.1. 
 
2.3.5 rMCSF BMM culture 
Optimisation was carried out to increase macrophage 
(F4/80hiCD11bhiCD11c-) yield from culture wells, cells were harvested on days 4, 5, 
6, 7, and 8. Feeding on days 4 and 6, and unfed wells were compared (Fig. 2.2). 
Following optimisation the following protocol was used routinely: 1 x 106 bone 
marrow cells were seeded in 6 well tissue culture plates in 4ml of complete 
macrophage medium (as for GM-CSF DCs but with 20ng/ml rM-CSF (Peprotech) 
replacing GM-CSF) at 37oC in a humidified environment of 5% CO2. On days 4 and 
6, 2ml of medium was aspirated and replaced with 2ml of pre-warmed complete 
macrophage medium. On day 7 all medium was aspirated, 2ml of pre-warmed PBS 
(Sigma) containing 3mM EDTA (Ambion) and 10mM Glucose (Sigma) was added to 
the wells and cells were returned to 37oC for 15 mins, following this incubation, 
adherent cells were detached using mechanical perturbation with the plunger from a 
1ml syringe (BD) cells were pooled, washed to remove EDTA/Glucose and re-
suspended in complete medium without M-CSF.    
 
2.4 IN VITRO STIMULATIONS 
2.4.1 Preparation of antigens 
Propionibacterium acnes (Pa) is an anaerobic bacterium and was grown by 
the lab of Professor Ian R Poxton (Microbial Pathogenicity Research Laboratory, 
University of Edinburgh) before being heat-killed and stored under sterile conditions 
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at 4ºC. The heat-killed P. acnes was aliquoted and the concentration of protein per 
ml was determined for each aliquot using a Bradford (coomassie) protein assay and 
a known BSA standard. 
 
Attenuated Salmonella typhimurium strain SL3261 was supplied by Dr. 
Maurice Gallagher (University of Edinburgh) was heat-killed and stored under sterile 
conditions at 4ºC prior to use. The heat-killed S. typhimurium was aliquoted and the 
concentration of protein per ml was determined for each aliquot using a Bradford 
(coomassie) protein assay and a known BSA standard. 
 
Endotoxin-free soluble egg antigen (SEA) from S. mansoni was prepared in-
house as previously described (MacDonald et al., 2001). The stored eggs were 
thawed and transferred to a Tenbroeck 7 ml tissue grinder to which 5 ml sterile PBS 
was added.The eggs were then carefully homogenised using a twisting and grinding 
motion. After ~20 rotations, egg disruption was checked. This was repeated ~15 
times on ice until 95% of the eggs were disrupted. The homogenate was transferred 
to a 15 ml tube and spun at 2800 xg for 15 minutes at 4ºC. The supernatants were 
transferred to 1 ml micro-centrifuge tubes and spun at 16,000 xg for 10 minutes. 
The pooled supernatants were filter sterilised through a 0.45 µm filter. The SEA 
protein concentration was determined using a Bradford (coomassie) protein assay 
and a known BSA standard. The SEA was aliquoted and stored at at -80ºC. 
 
2.4.2 Prolonged stimulus 
Cells were stimulated with or without rIL-4 (2ng/ml, 20 ng/ml, 200ng/ml; 
Peprotech) to optimise alternative activation (Fig. 2.3). Following optimisation, 
20ng/ml rIL-4 was used for all other experiments. A 6h and 18h IL-4 stimulation time 
was assessed (Fig. 2.4). The 18h incubation was used for most experiments as 
RELMα and Ym1/2 proteins were only detected in the culture supernatant at the 
18hr time point (Fig. 2.4A) and intracellular RELMα and Ym1/2 staining was similar 
or enhanced at 18hr (Fig. 2.4B+C).  
  
In selected experiments, recombinant murine Interleukin 13 (rIL-13, 20ng/ml 
Peprotech), recombinant resistin like molecule alpha (rRELMα, 20ng/ml, Peprotech), 
endotoxin-free soluble egg antigen (SEA, 25µg/ml, prepared in-house), heat killed 
P. acnes (Pa, 10µg/ml), heat killed S. typhimurium, (St, 5µg/ml), Lipopolysaccharide 
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(LPS, 250ng/ml, Sigma). CpG oligodeoxynucleotide 1826 (ODN 1826, 5µg/ml, 
InvivoGen) or N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-
seryl-[S]-lysyl-[S]-lysyl-[S]-lysyl-[S]-lysine x 3 HCl (Pam3CSK4 (P3C), 250ng/ml, 
InvivoGen), Zymosan ((Zym)100µg/ml, Sigma). U0126 (10µM, Sigma), Phorbol 12, 
13-dibutyrate (PdBU; 100nM, Sigma), all-trans retinoic acid (RA, 20nM, 10µM, 
reconstituted in DMSO, Sigma), LE540 (10µM Wako) or the arginase inhibitor (S-(2-
boronoethyl)-l-cysteine) (BEC, 1µM, 10µM, 100µM; Cayman Chemical) were 
included in the post differentiation cultures. For initial RA experiments, control wells 
were stimulated with media containing DMSO. The TLR agonists chosen and 
concentrations used were based on previous studies (Hochrein, O'Keeffe et al. 
2000; Kane, Cervi et al. 2004; Guenova, Volz et al. 2008; Manicassamy, Ravindran 
et al. 2009).  
 
2.4.3 Short term stimulus 
 In order to assess phosphorylation of the kinase ERK, cells were surface 
stained with antibodies against CD11c and MHC-II (eBioscience) cultured for 15 
minutes at 37oC in the presence of media or the ERK inhibitor U0126, prior to 
addition of antigens (as listed above) for 15 minutes.    
 
2.4.4 αCD40 stimulation 
 To assess any further activation triggered by the ligation of CD40, BMDC were 
harvested after stimulation, washed, and re-plated at 4 x 106 DC/ml in a volume of 
200µl in a 96 well tissue culture plate, for a further 24 h in the presence or absence 
of 20µg/ml of an agonistic anti-CD40 Ab(Perona-Wright, Jenkins et al. 2009) (clone 
FGK.45) or an isotype control (clone Mac-1) both produced in house.           
 
2.4.5 DC:T-cell co-culture 
 50,000 IL10-eGFP-CD4+, IL-4eGFP-CD4+, KN2 CD4+ or IL-10eGFP-xKN2 
CD4+ T-cells were cultured in 96 well plates for 3-4d with 2,500 WT, Il4ra-/- or Retnla-
/- GMDCs, 1µg/ml anti-CD3 (produced in house) and with or without IL-4 (20 ng/ml, 
Peprotech) and Retinoic acid (10µm, Sigma).  
 
2.4.6 OT-II: DC cultures 
 For CFSE dilution assays CD4+ OT-II TCR Transgenic T-cells were purified 
from spleen and LN using CD4+ Dynabeads (Invitrogen) following the 
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manufacturer’s protocol. T-cells were labelled with 5µM CFSE (Invitrogen) for 15 
mins at 37oC, excess CFSE was allowed to leach from the cells prior to culture with 
5 x 104 WT, Retnla-/- or Il4ra-/- BMDCs in the presence of 0.01µg/ml OVA323-339 or 
5µg/ml OVA protein (Sigma) which had been endotoxin depleted in-house. Cultures 
were incubated at 37oC for 4 days prior to assessment of CFSE dilution by flow 
cytometry. 
 
2.5 ANALYSIS TECHNIQUES 
2.5.1 Flow cytometry 
 For initial intracellular staining of BMDC, GolgiStop (1µl/ml, BD) was added to 
cells for 6 hours prior to RELMα and Ym1/2 staining to increase the intracellular 
protein levels. For subsequent RELMα and Ym1/2 staining, golgistop was not used 
as it was found to reduce rather than enhance RELMα detection (Fig. 2.5). For 
innate cell staining panels, cells isolated from the spleen and peritoneal cavity were 
stained directly ex vivo. Following FcR-Block using αCD16/CD32 (2.4G2, produced 
in house), cells were surface stained using combinations of the following mAb 
conjugations listed in Table 2.1.  
 
 For intracellular staining, cells were fixed in 1% formaldehyde, permeabilised 
using Cytoperm (BD PharMingen) and innate and BM derived cells were stained 
with anti-RELMα, and anti-Ym1/2-biotin followed by incubation with Alexa 488–
conjugated Zenon anti–rabbit antibody and Streptavidin-APC or –PerCP/Cy5.5 (See 
Table 2.1).  
 
 To assess antigen uptake, 2 x 105 BMDCs were incubated with 200µg of FITC 
conjugated dextran (Sigma) for 30 minutes at 37oC or on ice prior to acquisition.  
 
 For analysis of phospho-ERK, pre surface stained samples were fixed 
immediately following activation using 1% formaldehye, cells were transferred to a 
96 well FACs plate, washed and permeabilised with 90% Methanol (Sigma) for 30 
minutes on ice up to 12h at -20oC, following the pERK antibody manufacturers 
protocol. Permeabilised cells were washed in PBS +1%BSA (Sigma), prior to 
staining for 1h on ice with anti Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
(197G2) Rabbit mAb (Cell Signalling Technology); bound Rabbit antibody was then 
detected using Anti-Rabbit IgG (H+L)F(ab’)2- Alex Fluor 488 (Invitrogen).  
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Samples were acquired using a FACS LSR II or FACS Canto II flow cytometer using 
BD FACS Diva software and analyzed with FlowJo v.9 software (Tree Star, Inc.). 
 
2.5.2 The aldefluor assay  
 Following surface staining, cells were washed, resuspended in aldefluor assay 
buffer (Stemcell Technologies) containing (0.25µl of 300µΜ stock, final 
concentration/well =3µM) of activated aldefluor substrate, and incubated at 37oC for 
30 minutes. Control samples had 3µl of the aldehyde dehydrogenase inhibitor 
diethyl aminobenzaldehyde (DEAB, 1.5mM stock = 90µM/well) added prior to the 30 
minute incubation. The activated aldefluor substrate contains a 
bodipyaminoacetaldehyde subtrate (BAAA) that diffuses into cells, and is converted 
by active aldehyde dehydrogenases to bodipyaminoacetate (BAA) which fluoresces, 
BAA cannot diffuse from the cells. Samples were washed following incubation in ice 
cold Aldefluor assay buffer (which contains ABC transporter inhibitors to block BAA 
active transport from the cells) 3 x, prior to sample acquisition using a a FACS LSR 
II or FACS Canto II flow cytometer, with analysis of aldefluor activity in the FITC 
channel, using BD FACS Diva software and analysis with FlowJo v.9 software (Tree 
Star, Inc.). 
 
2.5.3 Enzyme linked immunosorbent assay (ELISA) 
 Cytokine ELISAs were performed on culture supernatants using paired mAb 
(See Table 2.2) purified in house, purchased from eBioscience or BD Pharmingen, 
and recombinant cytokine standards purchased from PeproTech. TNFα, CCL24, 
CCL17 and Ym1 ELISAs were perfomed using DuoSet ELISA development kits 
(R&D systems). RELMα ELISAs were performed using products purchased from 
PeproTech. As Ym1/2 is the predominant protein in lavage fluid from litomosoides 
sigmodontis infected animals, this was used as a standard for ECL-F (Ym1/2) 
ELISA. Primary/capture antibodies were coated onto 96 well plates (NUNC) in a 
volume of 50µl in PBS overnight at room temperature (TNFα, Ym1/ECLF/CCL24) or 
4oC (RELMα, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-12p70, IL-13, IL-5, IL-4, IL-17, 
CCL17, CCL24) or for 3 hours at 37oC (all). Plates were blocked using 10% NCS or 
FCS/PBS for >1 hour. Supernatants and doubling dilutions of recombinant protein 
standards were added to 96 well plates in a volume of 50µl, in duplicate where 
possible, single wells were used in situations where supernatant or plate space was 
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limiting.  Secondary/detection antibodies were added in a volume of 50µl in 10% 
NCS/PBS, and allowed to bind for 1h at 37oC (IL-10), 1h at room temperature (IL-
12p40, IL-12p70, IL-6) or 2h at room temperature (CCL17, CCL24, Ym1/2, RELMa, 
TNFα). Streptavidin-peroxidase was added to plates in a volume of 50µl and 
incubated at 37oC for 30 minutes. 100µl of the colorimetric substrate of peroxidase, 
TMB (Sigma), was added to each well, following development of blue colour, 
reaction was stopped by addition of 0.18M H2SO4 acid (Sigma). Between steps, 
plates were washed using PBS 0.05% Tween-20 (Sigma).  
 
2.5.4 Griess reaction for NO2  
 NO2 levels within supernatants following in vitro cell culture were assessed 
using the Griess reaction	   (Tsikas 2007). Solution A: Sulfanilamide (1%)(Sigma 
S9251) in 2.5% H3PO4 (Phosphoric acid, Sigma) and Solution B: 
Napthylethylenediamine dihydrochloride (0.1%)(Sigma N9125) in 2.5% H3PO4 
(Phosphoric acid, Sigma) were prepared and mixed 1:1 immediately before use in 
the assay. 50µl of supernatant was placed in duplicate (where possible) into well of 
a 96 well plate, a standard curve of doubling dilutions of NaNO2 was made in media 
with a top concentration of 1mM, 50µl of the mixed A:B solutions was added to each 
sample and standard well, absorbance was read at 570nm using a microplate 
spectrophotometer.   
 
2.5.5 Arginase activity assay 
Arginase activity was measured following a protocol previously published by 
the Allen Laboratory (Mylonas, Nair et al. 2009). Briefly, 1.5 x 105 BMDC/BMM were 
lysed with 100µl of 0.1% Triton X-100, following a 30 min incubation at room 
temperature, 100µl of 25mM Tris-HCL (pH 7.2) and 20µl of 10mM MnCl2 were 
added and the enzyme was activated by heating to 56oC for 10 min. L-Arginine 
hydrolysis was conducted by incubating 10µl of this lysate with 10µl of 0.5M L-
arginine (pH 9.7) at 37 oC for 30-120 min. The reaction was stopped using 80µl 
H2SO4 (96%)/H3PO4 (85%)/H2O (1/3/7 v/v/v). 4µl of 9% isonitrosopropiophenone 
(Sigma) was then added followed by heating to 95oC for 30 min. Reactions were 
conducted in 200 µl PCR tubes, and incubations carried out using a PCR block. 50 
µl of each sample was transferred to a 96 well plate for measurement at 570nm 
using a microplate spectrophotometer. A standard curve of urea was used to 
determine sample concentration. One unit of arginase enzyme activity is defined as 
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the amount of enzyme that catalyzed the formation of 1µmol of urea per minute at 
37 oC.  
 
2.5.6 Microscopy 
 50,000 day 10 GM-CSF DCs were cultured overnight with or without 20ng/ml 
IL-4 in 24 well plates (Corning Incorporated) containing 22mm coverslips. Media 
was aspirated, adherent cells were washed with PBS (Sigma) and then fixed at 4oC 
in 4% formaldehyde (Sigma) for 30 minutes. Formaldehyde was aspirated, cells 
were washed with PBS, and incubated at room temperature in 50mM Glycine to 
quench the formaldehyde. Glycine was aspirated, cells were washed with PBS and 
permeabilised at room temperature in 0.1% TritonX100 (Sigma) for 6 minutes. Cells 
were washed in PBS and then blocked with PBS containing 10%FCS (Sigma) and 
2% Bovine Serum Albumin (BSA, Sigma) for 2 hours. Block was aspirated and cells 
were incubated at 4oC overnight with BODIPY-FL Phallacidin (Invitrogen) to label F-
actin and enable visualization of DC architecture, rabbit anti-murine RELMα 
(Peprotech) or polyconal rabbit IgG (produced in house). Primary stain was 
aspirated, cells were washed with PBS and counterstained with Zenon anti-rabbit 
alexa-fluor 546 (Invitrogen) for 45 minutes at room temperature. Secondary 
antibodies were aspirated, cells were washed with PBS, coverslips were dried and 
mounted onto 4 well slides using Prolong gold anti-fade mounting media (Invitrogen) 
containing 1µg/ml 4',6-diamidino-2-phenylindole (DAPI; Invitrogen). Images were 
acquired as bidirectional Z-stacks (0.25µM series) using an inverted Leica confocal 
laser scanning microscope SP5C, using a 63x oil objective, 700Hz, 1024 x 1024 
image, 3 frame average. Images were analysed using Volocity (Perkin Elmer).  
 
2.5.7 RNA isolation and qPCR 
RNA was recovered from cells following suspension in the phenol-based 
product TRIzol (Invitrogen). Phase separation of DNA/protein and RNA was 
performed using Chloroform. RNA was precipitated using 2-propanol, visualisation 
of RNA pellet was enhanced by addition of glycogen (Ambion) during precipitation. 
75% ethanol was used to wash RNA, prior to air drying and resuspension in RNAse 
free DEPC water (Ambion). 0.1-0.25µg RNA was used for the synthesis of cDNA 
using Superscript-III and oligo-dT (Invitrogen). Relative quantification was performed 
by qPCR analysis using the Roche Light Cycler 480, with LightCycler SYBR Green I 
master mix (Roche). Five serial 1:4 dilutions of a positive control sample of cDNA 
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were used to create standard curves. Expression was normalised to the 
housekeeping genes (genes expressed constitutively for the maintenance of cellular 
function) hypoxanthine-guanine phosphoribosyltransferase (Hprt) or glyceraldehyde 
3-phosphate dehydrogenase Gapdh. For primers used see Table 2.3.   
 
2.6 MICROARRAY  
2.6.1 Microarray sample preparation 
3 biological replicates of GM-CSF BMDCs were set up for each strain 
(C57BL/6, Retnla-/- and Il4ra-/-). RNA was isolated using Purelink RNA mini 
extraction kit (Ambion), following manufacturers protocol with on-column DNAse 
treatment. Samples were then checked for RNA quantity and quality (260/230 ratio) 
on a nanodrop spectrophotemeter (ThermoScientific) before biotin end labeling and 
amplification was performed using illumina total prep RNA amplification kit 
(Ambion).  End-labelled cRNA was shipped to the Wellcome trust clinical research 
facility genetics core, Western General Hospital, Edinburgh. cRNA quality was 
assessed using an Agilent 2100 bioanalyser, samples were condensed where 
needed and hybridized to Illumina Mouse WG6_V2_0_R3_11278593_A arrays. 
 
2.6.2 Microarray post hybridisation analysis 
Subsequent analysis of microarray data was carried out by Al Ivens (CIIE 
bioinformatics core support). All 18 arrays were quality control analysed using the 
arrayQualityMetrics package in Bioconductor (Kauffmann and Huber 2010). Data 
were transformed using a variance stabilisation transformation prior to normalisation 
across all arrays using robust spline normalisation. Linear modeling was used to 
compare 6 data sets (1. IL-4 WT relative to medium WT 2. IL-4 Retnla-/- relative to 
medium Retnla-/- 3. IL-4 Il4ra-/- relative to medium Il4ra-/- 4. Medium Il4ra-/- relative to 
medium Retnla-/- 5. Medium Il4ra-/- relative to medium WT 6. Medium Retnla-/- 
relative to Medium WT). p= Adj. p significance values were assessed using 
Bayesian analysis, corrected using Benjamini & Hochberg method for multiple 
testing (Al Ivens, CIIE Bioinformatics support). 
 
2.7 STATISTICAL ANALYSIS 
 Statistical analyses were carried out using GraphPad Prism 5 software.  
Student’s T tests and one-way analysis of variance were employed to determine 
significant differences between sample groups. In situations where only two 
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replicate wells or individual animals were used, statistical tests are not valid and as 






















Figure 2.1 Gating strategy for FLT3L cultures. Bone marrow was 
cultured for 8 days with FLT3L prior to staining for B220 and CD11c, 
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A.	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D.	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B.	  
Figure 2.2 Optimisation of M-CSF BMM culture. Bone marrow 
was cultured in the presence of 20ng/ml rMCSF for the number 
of days indicated, either with (fed) or without (unfed) media 
replacement. Cultures were assessed for cell number (A), NO 
production (B), F4/80 (C), CD11c (D) and CD11b (E) 











































































































































































































































































































































































































































































































































































































































































































































































Figure 2.3 IL-4 dose response to optimise BMDC alternative activation. GMDC were 
cultured overnight with 2, 20 or 200ng/ml rIL-4, intracellular expression of RELMα and 
Ym1/2 was determined by flow cytometry (A+B) and the arginase activity assay was 
carried out (C). Optimisation was carried out once, error bars represent SEM of triplicate 




















Figure 2.4 Optimisation of the timing of IL-4 treatment. GMDC 
were cultured with 20ng/ml IL-4 for 6h or 18h, prior to analysis 
of RELMα and Ym1/2 secretion (A) and intracellular expression 
(B+C). Optimisation was carried out once, data points 



























+ Golgistop - Golgistop A.	  
B.	  
Figure 2.5. Golgistop does not enhance intracellular levels of RELMα or Ym1/2. GMDC or 
BMM (differentiated with L929 supernatant) were cultured for 12h with medium or IL-4 
prior to addition or not of 1µl/ml of Golgistop (BD) for the final six hours. RELMα and 
Ym1/2 expression was determined by flow cytometry (A+B). Bars represent mean of 
triplicate culture wells. 
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Table 2.1 Flow antibody clones, manufacturer and titrations 
Antigen Name Clone Isotype Host Conjugate Titration Manufacturer 
Live/Dead Aqua Aqua Invitrogen 
huCD2 S5.5 IgG2a Mouse PE 1/200 Invitrogen 
CD4 RM4-5 IgG2a k Rat APC/eFluor780 or PE or 
AlexaFluor647 
1/800 eBioscience 
CD8 53-6.7 IgG2a k Rat PE/Cy7 1/800 Biolegend 
CD11b  M1/70 IgG2b k Rat PE/APC/eFluor780 1/600 Biolegend 
CD11c N418 IgG Ar Ham Alexa-647/PE/APC/
eFluor780 
1/200 eBioscience 
CD19 1D3 IgG2a, k Rat Alexa-700/PE 1/200 Biolegend 
CD40 3/23 IgG2a k Rat PE 1/200 BD Pharmingen 
CD45R (B220)  RA3-6B2 IgG2a, k Rat APC/eFluor780 1/400 eBioscience 
CD80 16-10A1 IgG2 k Ar Ham PerCP/Cy5.5 1/200 BD Pharmingen 
CD86 GL-1 IgG2a, k Rat Alexa-700/AlexaFluor488 1/200 BD Pharmingen 
CD124 (IL-4Rα) mIL4R-m1 IgG2a k Rat Bio 1/50 BD Pharmingen 
Chi3l3/ECF-L Polyclonal IgG Goat Bio 1/50 R&D 
Dectin-1 2A11 IgG2b, k Rat AlexaFluor647 1/50 AbD Serotech 
F4/80 BM8 IgG2a Rat PeCy7 1/400 Biolegend 
Gr1 (Ly6G+6C) RB6-8C5 IgG2b k Rat PerCP/Cy5.5 1/200 BD Pharmingen 
MHC class II (I-A/I-E) M5114 IgG2b, k Rat PerCP/Cy5.5 1/1600 eBioscience 
MHC class II (I-A/I-E) M5115 IgG2b, k Rat Alexa-450 1/800 eBioscience 
MR MR5D3 IgG2a, k Rat PE 1/25 AbD Serotech 
NK1.1 PK136 IgG2a k Mouse APC_BV570 1/200 BD Pharmingen 
RELMα Polyclonal IgG Rabbit 1/100 Peprotech 
Siglec F E50-2440 IgG2a, k Rat PE 1/200 BD Pharmingen 
Streptavidin APC/PerCP/Cy5.5 1/2500 eBioscience 
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Table 2.2 ELISA Antibodies 
Specificity Conjugation Clone Host Usage Conc. Manufacturer 
Primary Antibody (Purified) 
IL-4 Purified 11B11 Rat 2ug/ml Homegrown 
IL-5 Purified TRFK5 Rat 2ug/ml Homegrown 
IL-6 Purified MP5-20F3 Rat 2ug/ml Homegrown 
IL-10 Purified JES16-E3 Rat 1ug/ml eBioscience 
IL-12p40 Purified C15.6 Rat 2ug/ml eBioscience 
IL-12p70 Purified 9A5 Rat 2ug/ml BD 
IL-13 Purified ebio13A Rat 2ug/ml eBioscience 
IL-17 Purified TC11-18H10 Rat 0.5ug/ml BD 
IFN-gamma Purified R4-6A2 Rat 2ug/ml Homegrown 
TNF-alpha Purified Duoset DY410 0.8ug/ml R&D 
Ym1/2/Chi3l3/ECF-L Purified Duoset DY2446 1ug/ml R&D 
RELMα Purified 500-P214 Goat 0.5ug/ml Peprotech 
CCL24/Eotaxin-2 Purified Duoset DY528 2ug/ml R&D 
CCL17/TARC Purified Duoset DY529 2ug/ml R&D 
Recombinant Standard 
IL-4 Recombinant 20ng/ml Peprotech 
IL-5 Recombinant 20ng/ml BD 
IL-6 Recombinant 20ng/ml Peprotech 
IL-10 Recombinant 50ng/ml BD Pharmingen 
IL-12 Recombinant 20ng/ml Peprotech 
IL-13 Recombinant 50ng/ml Peprotech 
IL-17 Recombinant 20ng/ml eBioscience 
IFN-gamma Recombinant 50ng/ml Peprotech 
TNF-alpha Recombinant 4000pg/ml R&D 
Ym1/2 Pleural lavage 50ng/ml Homegrown (Allen) 
RELMα Recombinant 400ng/ml Peprotech 
CCL24 Recombinant 60ng/ml R&D 
CCL17 Recombinant 50ng/ml R&D 
Secondary Antibody (Biotinylated) 
IL-4 Biotin BVD6-24G2 Rat 0.25ug/ml BD 
IL-5 Biotin TRFK4 Rat 0.3ug/ml eBioscience 
IL-6 Biotin MP5-32C11 Rat 0.5ug/ml eBioscience 
IL-10 Biotin SXC-1 Rat 0.2ug/ml BD 
IL-12/IL-23p40 Biotin C17.8 Rat 0.2ug/ml eBioscience 
IL-13 Biotin Polyclonal Sera Rabbit 0.1ug/ml Peprotech 
IL-17 Biotin TC11-8H4.1 Rat 0.25ug/ml BD 
IFN-gamma Biotin XMG1.2 Rat 0.2ug/ml BD 
TNF-alpha Biotin Duoset DY410 0.15ug/ml R&D 
Ym1/2/Chi3l3/ECL-F Biotin Duoset 0.2ug/ml R&D 
RELMα Biotin 500-P214-Bt Rabbit 0.125ug/ml Peprotech 
CCL24/Eotaxin-2 Biotin Duoset DY528 0.05ug/ml R&D 
CCL17/TARC Biotin Duoset DY529 0.2ug/ml R&D 
72 
73 
Table 2.3 qPCR primers used 
Gene name Fwd/Rev Sequence TM oC 
Arg1 Fwd GTCTGTGGGGAAAGCCAAT 59 
Rev GCTTCCAACTGCCAGACTGT 60 
Retnla Fwd TATGAACAGATGGGCCTCCT 59 
Rev GGCAGTTGCAAGTATCTCCAC 59 
Il4ra Fwd GAGTGGAGTCCTAGCATCACG 59 
Rev GGATGCAGAGGCAGGAGAT 60 
Mrc1 Fwd TCATTGGAAGATCCACTCTGG 60 
Rev CAGCGCTTGTGATCTTCATTATAG 61 
Chi3l3 Fwd GAACACTGAGCTAAAAACTCTCCTG 60 
Rev GACCATGGCACTGAACGAG 60 
Il27ra  Fwd AGTTCCGGTACAAGGAATGC 59 
Rev ACAGGAGTCAGCCCATCTGT 59 
Clec7a Fwd ATGGTTCTGGGAGGATGGAT 60 
Rev GCTTTCCTGGGGAGCTGTAT 60 
Stat6 Fwd TCTCCACGAGCTTCACATTG 59 
Rev GACCACCAAGGGCAGAGAC 60 
Nos2 Fwd CTTTGCCACGGACGAGAC 60 
Rev TCATTGTACTCTGAGGGCTGAC 59 
Ccl17 Fwd TGCTTCTGGGGACTTTTCTG 60 
Rev GAATGGCCCCTTTGAAGTAA 59 
Ccl22 Fwd TCTTGCTGTGGCAATTCAGA 60 
Rev GAGGGTGACGGATGTAGTCC 59 
Ccl24 Fwd GCAGCATCTGTCCCAAGG 60 
Rev GCAGCTTGGGGTCAGTACA 59 
Pparg Fwd GGGGGTGATATGTTTGAACTTG 60 
Rev GAAAGACAACGGACAAATCACC 60 
Aldh1a2 Fwd CATGGTATCCTCCGCAATG 59 
Rev GCGCATTTAAGGCATTGTAAC 59 
Gmcsf Fwd GCATGTAGAGGCCATCAAAGA 60 
Rev CGGGTCTGCACACATGTTA 59 
Mcsf Fwd CAACAGCTTTGCTAAGTGCTCTA 59 
Rev CACTGCTAGGGGTGGCTTTA 60 
Flt3l Fwd CCTAGGATGCGAGCCTTGT 58 
Rev TGTTTTGGTTCCCAACTCG 47 
Tlr2 Fwd GGGGCTTCACTTCTCTGCTT 60 
Rev AGCATCCTCTGAGATTTGACG 59 
Hprt Fwd TCCTCCTCAGACCGCTTTT 60 
Rev CCTGGTTCATCATCGCTAATC 60 
Gapdh Fwd AATGTGTCCGTCGTGGATCT 60 
Rev CCCAGCTCTCCCCATACATA 59 
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Chapter 3. Can Dendritic Cells be Alternatively Activated? 
 
3.1 INTRODUCTION 
DCs bridge the innate and adaptive immune systems, and are responsible 
for the activation of T-cells via presentation of antigen on their surface MHC 
molecules (Kapsenberg 2003; Steinman 2012). DCs are often defined by their 
surface expression of the integrin CD11c (Phythian-Adams, Cook et al. 2010; 
Murray and Wynn 2011), although a functional role for this marker is rarely detailed. 
DC and macrophages arise from a common bone marrow resident precursor (Naik 
2008; Hashimoto, Miller et al. 2011), and share expression of many phenotypic 
markers (Murray and Wynn 2011) leading to contention within the field as to the role 
of the DC compared to the macrophage (Hume 2008; Geissmann, Gordon et al. 
2010).  The recent discovery of DC specific transcription factors such as Batf3	  
(Hildner, Edelson et al. 2008) and Zbtb46 (Meredith, Liu et al. 2012; Satpathy, 
Wumesh et al. 2012) has begun to facilitate accurate naming of DC versus 
macrophage subsets.  
 
Alternatively activated macrophages (AAM) are a well characterised cell 
population whose ‘alternative’ activation status is induced following signalling 
through the IL-4Rα (Gordon 2003; Gordon and Martinez 2010). In contrast to their 
pro-inflammatory counterparts, the classically activated macrophage (CAM), AAM 
are a more regulatory cell population (Taylor, Harris et al. 2006). AAM are involved 
in the ‘fast and dirty’ repair of wounds	  (Allen and Wynn 2011), for example following 
infection with parasitic worms. AAM both cause disease pathology and mediate 
survival during infection with Th2 inducing pathogens such as the trematode S. 
mansoni (Herbert, Holscher et al. 2004). AAM are induced in non-infectious disease 
states during cancer, asthma and allergy, and in non-disease settings in the adipose 
tissue of lean animals (Lumeng, Bodzin et al. 2007). The mRNA expression profile 
of an AAM is much different to that of a CAM, for example, AAM express high levels 
Ym1/2 (Chi3l3) and RELMα (Retnla) transcripts that are not associated with IFNγ 
stimulated CAM (Loke, Nair et al. 2002; Nair, Gallagher et al. 2005; Mantovani, Sica 
et al. 2007; Gordon and Martinez 2010; Thomas, Ruckerl et al. 2012).  
 
Although the impact of IL-4 on DC has been investigated previously	  
(Hochrein, O'Keeffe et al. 2000)	  (Kalinski, Smits et al. 2000)	  (King, Mueller Hoenger 
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et al. 2001; Lutz, Schnare et al. 2002; Webb, Cai et al. 2007; Liao, Schones et al. 
2008), the ability of IL-4 treated DCs to express many of the molecules associated 
with AAM has not been addressed fully	  (Nair, Gallagher et al. 2005; Cai, Kumar et 
al. 2009). Given the dramatically different functional outcome of alternative vs. 
classical activation in macrophages (Varin and Gordon 2009; Gordon and Martinez 
2010; Murray and Wynn 2011), we reasoned that it is important to understand the 
extent to which DCs can also be alternatively activated.  
 
In the work detailed in this chapter, we have carefully characterised the 
ability of DCs to become ‘alternatively activated’ in response to the canonical Th2 
cytokine IL-4.  The relevance of these experiments has been addressed by 
investigating the presence of alternatively activated DCs during murine infection with 
the parasitic helminth S. mansoni. Finally, we have compared the similarities and 
differences in how DCs and macrophages become alternatively activated, to provide 
information to guide subsequent work (chapter 4) addressing the function of some 
key alternative activation products on DC function.     
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3.2 SPECIFIC AIMS 
1. To characterise the impact of IL-4 on activation of DCs in vitro and in vivo  
2. To determine whether DCs express molecules associated with AAM in 
response to infection with S. mansoni.  
3. To compare the influence of IL-4 on activation of DCs and macrophages, 
both in vitro and in vivo.  
 
3.3 RESULTS  
3.3.1. DCs express IL-4Rα, which is downregulated following exposure to IL-4 
in vitro 
Initially we decided to investigate the impact of IL-4 on a defined population 
of in vitro generated cells, GMDC. To determine what impact IL-4 has on the basal 
activation status of bone marrow derived DC, changes in expression of well 
characterised co-stimulatory molecules and the IL-4Rα were assessed by flow 
cytometry. GM-CSF derived DC expressed the IL-4Rα (Fig. 3.1B), in addition we 
revealed the novel finding that DC expression of IL-4Rα was reduced following 
culture with IL-4 (Fig. 3.1B). Signalling via IL-4Rα resulted in a slight but significant 
reduction in fluorescence intensity of CD80 and MHC-II in the CD11c+ population, 
however no significant difference was found upon addition of IL-4 to surface 
expression of CD86 or CD40 (Fig. 3.1C). We next assessed whether IL-4 altered 
the basal secretion of cytokine following overnight culture, IL-4 significantly reduced 
the secretion of both IL-12p40 and IL-6 (Fig. 3.1D). We also assessed TNFα, IL-10 
and IL-12p70 secretion all of which were most consistently not detected in the 
absence of stimulation. Having confirmed that in our hands GMDC are able to 
respond to IL-4, we next assessed whether IL-4 was able to induce expression of 
AAM markers within GMDCs. 
  
3.3.2. IL-4 upregulates DC expression of RELMα and Ym1/2 
In order to assess the impact that IL-4 has on DC activation, we investigated 
whether two of the major molecules associated with alternative activation of 
macrophage populations (RELMα and Ym1/2) were upregulated in GMDC 
populations following culture with IL-4 (Fig. 3.2A). Intracellular staining for both 
RELMα and Ym1/2 was carried out simultaneously using a protocol developed in 
the Allen Laboratory, University of Edinburgh. Addition of IL-4 strongly enhanced 
intracellular expression of both RELMα and Ym1/2 single and double positive cells 
77 
(Fig 3.2B&C). Unstimulated GMDCs secreted high levels of RELMα and Ym1/2 into 
the culture supernatant and this was increased upon addition of IL-4 (Fig. 3.2D). 
Growing DCs from bone marrow deficient in expression of the IL-4Rα confirmed that 
increased expression of these alternative activation markers was dependent upon 
signalling through this receptor (Fig. 3.2B-D). Interestingly, IL-4Rα-/- DCs had a 
reduced basal level of Ym1/2 production  (p=0.0001; ICS and secretion) compared 
to WT cells.  However, RELMα expression in IL-4Rα-/- was comparable to WT (Fig. 
3.2B-D) suggesting a possible disparity in the requirement for IL-4 signalling in the 
induction of these alternative activation products. As IL-4 has now been confirmed 
to induce intracellular expression and secretion of AAM associated molecules, we 
were interested to determine the localisation of these molecules within individual 
cells.  
 
3.3.3. IL-4 driven RELMα is located throughout the cytoplasm of BMDCs  
We decided to use fluorescence and confocal microscopy to determine the 
expression pattern of the resistin like molecule RELMα within IL-4 treated GMDCs 
(Fig. 3.3A). A phalloidin toxin based stain for filamentous actin enabled the 
visualisation of the DC cytoskeleton. RELMα was detectable within medium 
GMDCs, however expression was increased upon addition of IL-4 to the overnight 
cultures. RELMα protein was detected throughout the cytoplasm of the IL-4 treated 
GMDCs, spreading out along the extended dendrites, whereas it was less prominent 
within the dendrites of medium DCs (Fig. 3.3B). Areas with the appearance of 
vacuoles were detected within the IL-4 treated samples, and this was most easily 
visualised when contrasted to the strongly positive RELMα staining.  
 
3.3.4 IL-4 upregulates multiple transcripts associated with AAM, but not Arg1 
Having found that both RELMα and Ym1/2 proteins were increased in 
GMDC on addition of IL-4 we wanted to confirm that this was due to increased 
mRNA transcript being produced within the cells and not due to a change in post-
transcriptional regulation. IL-4 upregulated mRNA for both RELMα and Ym1/2 in 
GMDC (Fig. 3.4B). Following on from this finding, it seemed reasonable that other 
markers associated with AAM may also be transcriptionally regulated by IL-4 in 
DCs. Interestingly, the transcript for arginase-1, an enzyme whose expression is 
often used as a defining marker of an AAM (Gordon and Martinez 2010), was not 
significantly increased by IL-4 (Fig. 3.4C). Correspondingly, there was no significant 
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difference in the expression of inducible nitric oxide synthase (Nos2) at the mRNA 
level between medium and IL-4 treated GMDC (Fig. 3.4C). iNOS and arginase are 
known to counter regulate one another (Fig. 1.7) and in AAM arginase expression is 
enhanced by IL-4 (Modolell, Corraliza et al. 1995; Munder, Eichmann et al. 1999). 
Both Arg1 and Nos2 transcripts were at a high basal level in the medium samples 
(Fig. 3.4C). The chemokines CCL17 and CCL24 are both expressed by AAM 
(Mantovani, Sica et al. 2004), and it was found that both mRNA and secreted 
protein was enhanced in DC populations on addition of IL-4 (Fig. 3.4D&E). CCL24 
was highly significantly upregulated by IL-4 perhaps due to it being expressed at a 
much lower level in the medium GMDCs than many of the other markers tested (Fig. 
3.4E).  Various scavenger receptors and C-type Lectin family members have been 
associated with AAM. The macrophage mannose receptor (Mrc1, CD206/MR) was 
significantly upregulated by IL-4 at the level of transcript, but no shift in surface 
protein expression was detected (Fig. 3.4F). Dendritic cell C-type lectin-1 (Clec7a, 
Dectin-1) was significantly enhanced in DC upon addition of IL-4 at the level of both 
mRNA and protein (Fig. 3.4G). Other markers (Il27ra, Pparg, Stat6, Ccl22) that have 
been linked to AAM were not found to be consistently upregulated to a significant 
level in GMDC (Fig. 3.4H).     
 
3.3.5. Arginase-1 is not a marker of an alternatively activated DC (AADC) 
To further probe the Arg1 qPCR result an arginase assay was performed to 
assess whether IL-4 treatment of GMDCs resulted in an enhanced conversion of 
arginine to urea. There was no significant difference in arginase activity between 
medium and IL-4 treated DCs (Fig. 3.5B). To confirm the lack of a role for arginase-
1, GMDCs were treated with an arginase inhibitor (BEC). No impact upon GMDC 
arginase activity was seen on addition of varying doses (1, 10, 100µM) of BEC to 
the overnight culture, with or without IL-4. The lack of impact found upon addition of 
BEC could suggest that the inhibitor was non-functional. Having confirmed that with 
the exception of arginase upregulation, GMDCs can alternatively activate in 
response to IL-4 we decided to confirm whether IL-4 could also alternatively activate 
FLDCs. 
 
3.3.6 FLT3L derived DCs do not become alternatively activated in response to 
IL-4 
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There are two growth factors used for the in vitro differentiation of murine 
DCs from bone marrow: GM-CSF and FLT3L. The majority of BMDC work carried 
out previously within the MacDonald Laboratory used GM-CSF, which enables the 
differentiation of high numbers of a homogenous population of conventional CD11c+ 
DCs. FLT3L differentiates BM into a heterogenous population of conventional 
CD11c+B220- and CD11cmidB220+ plasmacytoid DC (cDC/pDC). FLT3L generated 
DCs (FLDC) have been reported to better represent in vivo steady state DCs, 
compared to the more inflammatory GMDC (Xu, Zhan et al. 2007; Naik 2008). In 
order to determine whether FL-DC could be alternatively activated in a comparable 
manner to GMDC, the two types of BMDC were generated using either GM-CSF or 
FLT3L. Following differentiation, cells were cultured overnight with IL-4 or IL-13 and 
intracellular RELMα and Ym1/2 staining was performed (Fig. 3.6A). The IL-4 related 
cytokine IL-13 was capable of inducing comparable percentages of RELMα and 
Ym1/2 in GMDC as IL-4 (Fig. 3.6B&C). It was very clear that both IL-4 and IL-13 
failed to upregulate comparable levels of RELMα or Ym1/2 in either pDC or cDC 
from FLT3L cultures to those seen in GMDC (Fig. 3.6B&D). This failure was unlikely 
to be due to an inability to detect IL-4, as both cDC and pDC expressed IL-4Rα (Fig. 
3.6E), with expression being lower on pDC than cDC.  
 
3.3.7 Ex vivo splenic DC can be alternatively activated by IL-4  
To determine whether splenic cDCs respond to IL-4 similarly to GMDCs or 
FLT3L DCs, we enriched DC from naïve wild type mice using density gradient 
centrifugation and magnetic beads, then sorted cDCs (CD11c+B220-) from pDCs 
(CD11cintB220hi) using FACS (Fig. 3.7A). The enriched DC population was sorted 
based on size, width and surface expression of CD11c and B220 (Fig. 3.7B&C). 
Quantitative real time PCR (qPCR) was used to assess the level of expression of 
alternative activation markers following overnight culture of the sorted splenic cDCs 
with IL-4. Reassuringly, cDC expressed the IL-4Rα and presence of IL-4 caused 
down regulation of this transcript, as was shown previously following IL-4 treatment 
of GMDC (Fig. 3.7D). Due to low cell numbers achieved following FACS, alternative 
activation status following IL-4 treatment was only determined by qPCR and not by 
flow cytometry. A strong upregulation of RELMα mRNA expression was detected 
upon addition of IL-4 to splenic cDC, whereas there was no increase in Chi3l3 
transcript (Fig. 3.7E). Clec7a and Ccl24, markers of alternative activation that we 
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found to be enhanced by IL-4 in GMDC populations, were also enhanced by IL-4 
addition to splenic cDC (Fig. 3.7F).  
 
3.3.8 DCs can be alternatively activated in vivo.  
Having confirmed that GMDCs could be alternatively activated in vitro and 
splenic DCs ex vivo following culture with IL-4 (Fig. 3.7), we next sought to 
determine whether we could directly isolate alternatively activated DCs from mice 
exposed to IL-4 in vivo.  Although recombinant cytokines have a short half-life when 
injected in vivo, it has been shown previously that mixing rIL-4 with anti-IL-4 mAb 
(IL-4 complex; IL-4c) prior to injection enables the slow release of cytokine, 
increasing its half life of activity for 2-3 days	  (Finkelman, Madden et al. 1993). Based 
on previous studies (Finkelman, Madden et al. 1993) we chose to inject mice i.p. 
with either PBS vehicle control or a 1:5 weight to weight mixture of IL-4 and 11B11 
antibody. Animals were given either one (Fig. 3.8A-C) or two (Fig. 3.8D-F) doses of 
IL-4c. Four days following injection of IL4c or vehicle, peritoneal exudate cells (PEC) 
(Fig. 3.8A) and splenocytes (Fig. 3.8D) were isolated. Flow cytometry was then 
used to stringently define DC (F4/80-FSCloCD11chiMHC-IIhi) and macrophage 
(F4/80+FSCint/hiMHC-IIint/lo) populations following prior gating to exclude 
granulocytes, monocytes and B cells based on cell size, Gr1 and CD19 expression 
(Fig. 3.8B). We have recently shown that IL-4c induces macrophage proliferation in 
the peritoneal cavity and at distant tissue sites (Jenkins, Ruckerl et al. 2011). In 
contrast to the expected enhanced macrophage numbers, IL-4c did not significantly 
increase the numbers of DCs within the cavity (Fig. 3.8B). In order to determine the 
alternative activation status of the cavity DC and macrophage populations, PEC 
were intracellularly stained for RELMα and Ym1/2. As expected, IL-4c significantly 
upregulated both RELMα and Ym1/2 within the peritoneal macrophage population, 
in a dose dependent manner (Fig. 3.8C). Interestingly, the peritoneal DC population 
displayed strong IL-4 induced upregulation of RELMα within a large percentage of 
the population, whereas Ym1/2 expression was restricted to a smaller proportion of 
cells and only in animals that had been injected with a higher concentration of IL-4c. 
To address whether the impact of IL-4 on alternative activation of DCs was a 
localised effect, we also isolated splenocytes from IL-4c injected animals and 
assessed the levels of RELMα and Ym1/2 by intracellular staining and flow 
cytometry (Fig. 3.8D). IL-4c injection i.p. clearly alternatively activated splenic DCs, 
indicating that this effect was not restricted to the site of injection alone (Fig. 
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3.8E&F). IL-4c elicited splenic AADC expressed significantly enhanced levels of 
both RELMα and Ym1/2 compared to PBS elicited control cells and, similar to PEC, 
the percentage of Ym1/2+ cells was considerably lower than that of RELMα+ (Fig. 
3.8F).       
 
3.3.9 Markers of alternative activation are upregulated following S mansoni 
infection.  
Having confirmed the ability of recombinant IL-4 to alternatively activate DCs 
in the peritoneal cavity and the spleen, we wanted to assess whether DC alternative 
activation was also a feature of relevant infection settings wherein IL-4 is the 
predominant cytokine. We chose to assess alternative activation status of DCs from 
Schistosoma mansoni infected animals that display a robust Th2 response following 
release of the egg stage of the parasite life cyle (Pearce and MacDonald 2002; 
Phythian-Adams, Cook et al. 2010). In order to assess global changes in levels of 
alternative activation following S. mansoni infection, cDNA samples were used from 
a time course infection that had previously been carried out in the MacDonald 
laboratory (Rachel Lundie). Tissue samples from sites of immune priming, egg 
recruitment and transit (spleen, liver and gut) were collected at time points relevant 
for S. mansoni infection. Samples were collected 4 weeks following infection prior to 
egg release, 6 weeks following infection as egg release begins, 8 weeks following 
infection as the Th2 response peaks and 12 weeks post infection as the Th2 
response begins to decline	   (Pearce and MacDonald 2002). qPCR for markers of 
alternative activation Arg1 (Fig. 3.9B), Retnla (Fig. 3.9C) and Chi3l3 (Fig. 3.9D) 
were carried out.  The liver was the tissue that had the most significant change in 
levels of alternative activation markers during infection, with significantly reduced 
Arg1, and significantly upregulated Retnla and Chi3l3 (Fig. 3.9B-D). Highest levels 
of expression of both Retnla and Chi3l3 were detected at week 8 in the liver, 
corresponding to the peak of Th2 activity in this model of infection (Pearce and 
MacDonald 2002). Interestingly, Chi3l3 was down regulated in the liver between 
weeks 8 and 12 of infection (Fig. 3.9D). The inhibition of Arg1 in the liver upon 
infection could be due to an alteration in the cellular architecture of the liver as 
arginase activity is known to be highly abundant within the liver	   (Cai, Kumar et al. 
2009). The global expression of alternative activation markers within the spleen was 
much more varied than the liver; the only significant upregulation of any of the 
markers assessed in the spleen was Chi3l3 at week 6 of infection (Fig.3.9B-D).  
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Retnla was significantly upregulated in gut tissue from week 6 of infection and Arg1 
from week 8, and a trend for infection-induced expression at this tissue site was 
apparent at later time points, though this did not reach significance, Chi3l3 
expression was not assessed in the gut (Fig. 3.9B&C). During the course of S. 
mansoni infection, the damage induced by the granulomatous response in the liver 
increases due to the increased egg burden, as such increased expression of AAM 
related markers in this tissue makes sense due to their proposed role in wound 
healing	   (Allen and Wynn 2011). Likewise, intestinal damage will occur later in 
infection as the eggs traffic out of the intestines, and infection induced levels of Arg1 
and Retnla were highest in the gut following 8 weeks of infection (Fig. 3.9B&C). 
Infection induced changes in AAM markers in the spleen were most apparent at the 
earlier time points assessed as the switch from a mixed Th1/Th2 to more 
pronounced Th2 response is occuring	  (Pearce and MacDonald 2002). It is important 
to keep in mind when assessing this data set that there are multiple cell types able 
to express Arg1, Retnla and Chi3l3 in the liver, spleen and gut. Infection induced 
changes in individual cell types can still occur but be masked by the unchanged or 
reduced levels of expression within the other cells within the mixed population used 
to create the cDNA of interest.  
 
3.3.10 Parasitic helminth infection induces alternative activation of splenic 
DCs.  
As mentioned above, the lack of splenic global transcript increase seen for 
alternative activation markers upon infection with S. mansoni does not rule out the 
possibility that DCs present in this immune organ are alternatively activated. 
Furthermore, the ability of recombinant IL-4 delivered intra-peritoneally to 
alternatively activate DCs in the spleen (Fig. 3.8E&F) shows that these cells can be 
alternatively activated. In order to determine if S. mansoni can induce AADCs, we 
chose to focus on splenic DCs isolated from animals at 8 weeks post infection with 
S. mansoni, the time around which the peak of the Th2 response occurs (Pearce 
and MacDonald 2002).  Spleens were harvested from mice at this 8 week timepoint, 
and intracellular staining was used to determine RELMα and Ym1/2 expression (Fig. 
3.10A) within the MHC-II+CD11chi DC population of individual spleens (Fig. 3.10B).  
RELMα was significantly upregulated in DCs by S. mansoni infection, whereas 
Ym1/2 was actually significantly decreased compared to naïve controls (Fig. 
3.10B&C). This finding was not totally unexpected given that addition of IL-4 to 
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splenic DCs ex vivo did not enhance Chi3l3 expression (Fig. 3.7E), and that 
upregulation of Ym1/2 in splenic DCs was much lower than RELMα when IL-4c was 
injected into the peritoneal cavity (Fig. 3.8E&F). 
 
3.3.11 Defining a population of AAMs for direct comparison to AADCs.  
Having identified that AADC can be induced by IL-4 in vitro and in vivo, and 
found during helminth infection, we then wanted to compare some of the aspects of 
their alternative activation to AAM.  DCs and macrophages isolated from the 
spleens of infected animals would be the ideal populations to carry out competence 
assays to compare the functional capacity of AAM and AADC side by side. 
However, isolation of DC populations is technically difficult and extremely expensive 
to achieve due to their rarity. As a compromise, we chose to compare macrophages 
to GMDC differentiated from bone marrow, a method which provides a readily 
available supply of defined cells in the quantities required for our assays (Lutz, 
Kukutsch et al. 1999). In order to allow a direct comparison between AADC and 
AAM it was necessary to first define a population of macrophages to compare 
GMDCs with. Two commonly used types of experimental macrophage are 1) those 
generated in vitro from bone marrow using macrophage-colony stimulating factor 
(M-CSF) or 2) isolated ex vivo following intra-peritoneal injection of an sterile 
inflammation inducing medium (thioglycollate). BMM and ThioM both expressed 
F4/80, CD11b and CD11c on their surface (Fig. 3.11B). ThioM displayed higher 
expression of F4/80 and CD11b than BMM, and addition of IL-4 during overnight 
culture resulted in upregulation of CD11c on both BMM and ThioM (Fig. 3.11C). IL-4 
induced production of RELMα and Ym1/2 was then assessed by ICS and ELISA 
and, as expected, the two proteins were significantly upregulated by IL-4 in both 
macrophage populations (Fig. 3.11D&E). Interestingly, there was a disparity in the 
expression of these hallmark proteins of alternative activation between the 
macrophage types, with BMM producing more RELMα than the ThioM and ThioM 
producing more Ym1/2 (Fig. 3.11D&E). Since both BMM and ThioM could be 
alternatively activated in our hands in response to IL-4, and BMM can be generated 
in large numbers from few mice, we decided to focus on use of BMM in our DC 
comparison studies. 
 
3.3.12 BMDC and BMM are distinct cells types.  
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In general, there is broad agreement in the field that most DC and 
macrophages represent quite distinct myeloid cell types	   (Hashimoto, Miller et al. 
2011). However, in some tissues or inflammatory conditions, it can sometimes be 
difficult to distinguish DCs and macrophages based on surface marker expression 
alone, allowing a small but vocal minority to continue to raise discussion as to the 
delineation of DC and macrophage populations in general	   (Hume 2008)	  
(Geissmann, Gordon et al. 2010). In experiments carried out prior to the 
identifiaction of the DC specific transcription factor zDC	   (Meredith, Liu et al. 2012)	  
(Satpathy, Wumesh et al. 2012) we decided to compare the surface phenotypes of 
BMM and GMDC differentiated in vitro (Fig. 3.12A). GMDC expressed very little 
F4/80 and high levels of CD11c (Fig. 3.12B). BMM expressed significantly higher 
levels of F4/80, comparable levels of CD11b and significantly reduced CD11c 
compared with GMDC (Fig. 3.12B). Thus, the levels of expression of the expected 
defining markers CD11c and F4/80 clearly distinguish BMMs from GMDCs. In the 
experiment shown, the GMDC expressed comparable levels of MHC-II to the BMM, 
however this was found to vary between experiments (Fig. 3.12B) and as no antigen 
was included in the culture such variability is dependent upon how activated the 
cells have become during the differentiation process. As AAM are known to express 
enhanced arginase activity in the presence of IL-4, we direclty compared their 
phenotype with IL-4 treated GMDC (Fig. 3.12C), which we have shown do not 
upregulate Arg1 transcript (Fig. 3.4C) or arginase activity (Fig. 3.5) in response to 
IL-4. The basal arginase activity of GMDC was significantly higher than that of BMM 
and although addition of IL-4 enhanced arginase activity in the BMM this did not 
reach the basal level of activity present within GMDC (Fig. 3.12D). This result lends 
credence to the theory that GMDC express such a high level of arginase that the 
amount of BEC inhibitor added was not sufficient to inhibit the activity (Fig. 3.5C).  
 
3.3.13 GMDC express higher levels of co-stimulatory molecules and secrete 
more cytokine than BMM.  
A defining feature of DCs that helps to distinguish them from macrophages is 
their ability to migrate to the secondary lymphatics and efficiently activate naïve T 
cells	  (Geissmann, Gordon et al. 2010).  Adoptive transfer of GMDCs stimulated with 
either heat killed bacteria (gram positive P. acnes/ gram negative S. typhimurium) or 
soluble egg antigens (SEA) from S. mansoni efficiently primes Th1 or Th2 immune 
responses in lymph nodes draining the site of injection (MacDonald, Straw et al. 
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2001; Perona-Wright, Jenkins et al. 2009). We differentiated GMDC and BMM from 
C57BL/6 bone marrow and stimulated them overnight with media, P. acnes, S. 
typhimurium or SEA, prior to quality control assessment by ELISA and flow 
cytometry (Fig. 3.13A) Surface phenotyping by flow cytometry showed that pre-
transfer GMDC expressed higher levels of the co-stimulatory molecules MHC-II, 
CD80 and CD86 than BMM (Fig. 3.13B). Bacterial antigens elicited the highest 
levels of expression of all three markers of APC activation by GMDC, whereas the 
only evident shift in BMM surface expression was in CD80 following stimulation with 
S. typhimurium (Fig. 3.13B). Correspondingly, the only cytokines secreted by BMM 
pre-transfer at levels comparable to GMDC was also in response to stimulation by 
S. typhimurium (Fig. 3.13.C; IL-10 & TNFα). The Th1 & Th17 polarising cytokines IL-
12p70, IL-12p40 and IL-6 were secreted in much larger amounts by GMDC than 
BMM in response to bacterial stimuli (Fig. 3.13C). BMM all produced comparable 
levels of the anti-microbial molecule nitric oxide in response to S. typhimurium as 
GMDC (Fig. 3.13D). 
 
3.3.14 GMDC are significantly better than BMM at priming both Th1 and Th2 
responses in vivo.  
Following overnight culture with either SEA, P. acnes (Pa) or S. typhimurium 
(St) GMDCs were phenotyped (Fig. 3.13) and equal numbers of GMDC or BMM 
were injected subcutaneously into the top of the feet of naïve WT recipients. 7 days 
later the draining popliteal lymph nodes (pLN) were harvested, cells isolated and 
restimulated with the priming antigens for 72 hours in order to elicit a recall cytokine 
response from any T-cells present (Fig. 3.14A). Following transfer, SEA pulsed 
GMDC primed significantly higher levels of SEA specific IL-4, IL-5, IL-13, IL-10 and 
IFNγ than SEA pulsed BMM that elicited very little SEA specific Th2 cytokine (Fig. 
3.14B).  BMM were slightly more capable at priming Th1 responses than Th2, with 
detectable levels of P. acnes specific IFNγ and S. typhimurium specific IL-10 being 
induced (Fig. 3.14C) however these levels were significantly reduced in comparison 
to the GMDC response. The inability of bacterially stimulated BMM to polarise Th1 
and Th17 responses with the same magnitude as bacterially stimulated GMDCs is 
potentially due to the inability of these cells to secrete comparable quantities of the 
Th1 polarising cytokine IL-12 and the Th17 polarising cytokine IL-6 pre-transfer (Fig. 
3.13C & see Fig. 1.5). 
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3.3.15 BMM are less competent than GMDC at polarising CD4+ T-cells towards 
Th2 in vitro.  
The adoptive transfer experiments show that BMM are much less capable 
than GMDCs at induction of adaptive responses in vivo, and it is possible that the 
impaired ability is largely due to the well-documented poor migratory ability of 
macrophages (Niess, Brand et al. 2005; Bogunovic, Ginhoux et al. 2009; 
Geissmann, Gordon et al. 2010). To be able to compare the basic APC capacity of 
the GMDCs and the BMM, we used an in vitro culture system to remove migratory 
capacity from the equation. We sorted CD4+IL-10GFP- T-cells from the spleen and 
LNs of HuCD2xIL-10GFP mice. Upon transcription of Il10 mRNA, cells from this 
strain of mouse express green fluorescent protein. Additionally, when IL-4 protein is 
translated, human-CD2 is expressed on their cell surface	  (Mohrs, Wakil et al. 2005), 
enabling the detection and identification of cells that are either singly or doubly 
positive for these cytokines. We stimulated the sorted T-cells for 4 days using anti-
CD3 (αCD3) (a requirement of this polyclonal T cell system to enable cytokine 
secretion) and determined if there was induction of IL-4 protein or IL-10 mRNA on 
addition of IL-4 when GMDC or BMM were included in the culture (Fig. 3.15A). IL-4 
was added to this system to determine whether the impact of IL-4 on DCs was 
instructive in their ability to modulate T-cell cytokine secretion.  In the absence of 
αCD3 or an antigen presenting cell, the T-cells did not proliferate. GMDC supported 
enhanced blasting when compared to BMM, as assessed by cell pellet size at day 4 
and time taken to acquire similar numbers of T-cells by flow cytometry. Addition of 
IL-4 resulted in significant increases in percentage expression of huCD2 (IL-4 
protein) and GFP (IL-10 mRNA) within the CD4 population by day 4, in the presence 
of either GMDC or BMM (Fig. 3.15B&C). However,  the percentage induction within 
the GMDC culture wells was significantly higher than in the BMM wells (Fig. 3.15C). 
ELISA data confirmed that BMM were less capable at inducing T-cell cytokine 
secretion in response to IL-4 (Fig. 3.15D). It is not possible to assess accurately 
using this experimental design to what extent the IL-4 is acting directly on the T-cell 
or via the DC/BMM.  However, this shows that, as expected given their limited 
surface activation phenotype, BMM have a basic APC ability and are much less 
capable than GMDCs in this regard.  Further, these in vitro data suggest that the 
more dramatically imparied APC ability of BMM in the adoptive transfer experiments 
(Fig. 3.14) may be largely down to their poor migratory capacity.
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3.4  SUMMARY 
• IL-4 can trigger a profile of ‘alternative activation’ in DCs similar, but not 
identical, to that of macrophages, both in vitro (Fig. 3.2), ex vivo (Fig. 3.7) 
and in vivo (Fig. 3.8). For example, DC arginase activity was not enhanced 
by IL-4 treatment (Fig. 3.5).  
• Global expression levels of Retnla and Chi3l3 in whole tissue following S. 
mansoni infection do not correlate with DC alternative activation (Fig. 3.9).  
• Alternative activation of splenic DCs is a feature of infection with the parastiic 
helminth S. mansoni (Fig. 3.10) 
• BMDCs, BMM and ThioM are phenotypically different cell populations (Fig. 
3.11-3.15) 
• BMDCs are more efficient at priming Th1, Th2 and Th17 immune responses 





3.5.1 IL-4 and GM-CSF dose 
A previous study had found that overnight culture of splenic DCs with a 
higher concentration of IL-4 (100ng/ml) resulted in moderate downregulation of 
CD80 (B7.1 in this study) and significant upregulation of CD86 (B7.2 in this study), 
and that these changes were reversed by addition of anti-IL-4 antibody (11B11) to 
the culture well	  (King, Mueller Hoenger et al. 2001). A second study that included IL-
4 in the culture during differentiation of GMDCs found no impact of IL-4 presence on 
DC expression of MHC-II or B7.2 (Lutz, Schnare et al. 2002) when the cells were 
differentiated using high dose GM-CSF (200U/ml). It is possible that the dose of IL-4 
used impacts the ability of IL-4 to alter the activation status of GMDCs. As shown in 
the materials and methods (Fig. 2.3), changes in the concentration of IL-4 that DCs 
are exposed to can impact DC phenotype. In particular, we focussed on a 
concentration of IL-4 at which alternative activation was most evident. The Lutz 
paper investigated the changes in maturation status of GMDCs cultured in the 
presence of different concentrations of both IL-4 and GM-CSF	  (Lutz, Schnare et al. 
2002). It would be interesting to assess the alternative activation status of DCs 
differentiated in the presence of IL-4.  We would hypothesise that this would result in 
a much increased basal level of alternative activation, such that addition of 
exogenous IL-4 following differentiation may no longer result in significant 
enhancement of the alternatively activated state.  
 
3.5.2 IL-4 down modulation of the IL-4Rα 
We confirmed, as had been reported previously (Lutz, Schnare et al. 2002) 
that GMDCs express the IL-4Rα (Fig. 3.1). In addition, we have reported the novel 
finding that IL-4 presence results in reduced detection of this receptor on the surface 
of GMDCs (Fig. 3.1). It is possible that IL-4 binding to the IL-4Rα may be blocking 
the binding of the IL-4Rα antibody to its epitope. To address this possibility, a 
different IL-4Rα antibody clone could have been used that targets an epitope 
outwith the IL-4 recognition domain. An alternative and more interesting possibility is 
that IL-4 binding may initiate a negative feedback loop to increase internalisation of 
it’s receptor via phagocytosis. However, some of our data actually suggests that IL-4 
may mediate a reduction in the expression of the IL-4Rα at the level of transcription, 
as splenic DCs cultured overnight with IL-4 had a trend for reduced Il4ra transcript 
when compared to cells cultured overnight with medium alone (Fig. 3.7D). This 
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observation was not statistically significant, so to clarify this issue, repeat 
experiments would be required.  
 
3.5.3 Differential expression of RELMα and Ym1/2 
We found that overnight culture with 20ng/ml IL-4 was able to upregulate the 
high level expression of both RELMα and Ym1/2 in GMDCs (Fig. 3.2). Interestingly, 
although the intracellular expression of Ym1/2 was ablated in IL-4Rα deficient 
GMDCs a low level of Ym1/2 was detectable in the supernatant (Fig. 3.2D). The 
same basal level of RELMα expression was maintained in IL-4Rα deficient cells 
prior to the addition of IL-4, as was detected in WT cells. This intracellular protein 
data suggests that RELMα expression can be maintained in GMDCs in the absence 
of a basal signal through the IL-4Rα.  As GM-CSF is a potent stimulus to DCs, and 
5ng/ml is included in the overnight cultures with IL-4, it is possible that this may be 
resulting in IL-4R independent RELMα production. A useful experiment to assess 
this would be to directly compare GMDCs stimulated overnight with IL-4 with and 
without GM-CSF. Further, exposure of the GMDCs to a dose curve of both would 
likely be the most informative, given the findings of Lutz et al., as discussed in 
section 3.5.2.  
 
In addition to characterising the response of GMDCs to IL-4 in vitro, we also 
looked at DC populations ex vivo and their ability to alternatively activate.  Ex vivo 
culture of FACS sorted CD11c+ splenic DCs with IL-4 resulted in enhanced 
expression of Retnla, but not Chi3l3 (Fig. 3.7E). DCs isolated from the peritoneal 
cavity following IL-4c treatment only expressed detectable intracellular Ym1/2 when 
a higher concentration (4µg) of IL-4 was injected (Fig. 3.8C). Although splenic DCs 
were capable of expressing intracellular Ym1/2 in response to IL-4, the population of 
cells expressing Ym1/2 was clearly more minor than those expressing RELMα (Fig. 
3.8E). This apparently poor ability of DCs to express Ym1/2 in response to IL-4c in 
vivo, at least relative to GMDCs in vitro, may be due to dose, as mice received two 
injections of IL-4c prior to spleen harvest. Macrophages isolated from PEC following 
injection of IL-4c were able to express both RELMα and Ym1/2 at high levels even 
at the lower concentrations of IL-4 (Fig. 3.8C), suggesting that these cells in vivo are 
more sensitive to IL-4 than the F4/80- DC population. In accord with the qPCR data 
following overnight incubation of splenic DCs with IL-4 (Fig. 3.7), splenic DCs 
isolated following 8 weeks of S. mansoni infection also failed to dramatically 
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upregulate Ym1/2 in response to this Th2 cytokine dominated infection. It is possible 
that the level of IL-4 present in the spleen following infection is not sufficient to 
induce Ym1/2 expression in DCs. For example previous studies from the 
MacDonald laboratory have shown that, upon restimulation with SEA, 2 million 
splenocytes produce in the region of 100pg/ml IL-4 over 72h (Jenkins, Perona-
Wright et al. 2008). An additional possibility is that the IL-4 level is sufficient to 
induce Ym1/2, but that S. mansoni worm or egg secretions may actively interfere 
with Ym1/2 upregulation in DCs.  
 
A less pleasing thought for a DC laboratory such as ours, is that GMDCs 
may be more closely related to in vivo macrophage populations, and that high level 
expression of Ym1/2 as well as RELMα in GMDCs in response to IL-4 proves to 
highlight this fact. However, as shown in later experiments, GMDCs have enhanced 
APC activity as compared to BMM and are able to migrate to sites of naïve T-cell 
priming (as assessed by antigen-specific restimulation assays following DC transfer 
Fig. 3.14). Both migration and activation of naïve T-cell are characteristics of DCs	  
(Geissmann, Gordon et al. 2010; Steinman 2012). Furthermore, the recent papers 
identifying the DC specific transcription factor zDC have shown that DC 
differentiated with GM-CSF in vitro express this gene (Satpathy, Wumesh et al. 
2012), whereas BMM do not.  
 
Although GMDCs may not be identical to a defined in vivo DC subset, they 
do possess defining characteristics of DCs, and provide a useful source of DCs for 
use in assays that would otherwise be too costly both in terms of mouse usage and 
reagents for isolating DCs ex vivo.   
 
3.5.4 What are the vacuoles in IL-4 treated GMDCs? 
In Figure 3.3, we showed the intracellular expression of RELMα within IL-4 
treated GMDCs. It is possible that the regions with a vacuolar appearance are lipid 
bodies, as lipid mediators such as the PPARs are known to be involved in mediating 
nematode elicited macrophages that have an M2 like phenotype (Thomas, Ruckerl 
et al. 2012). However, an accumulation of lipid in DCs in response to IL-4 has never 
been reported previously. Further staining for markers known to induce lipid body 
formation such as adipocyte differentiation related protein (ADRP) may prove 
informative (Maya-Monteiro and Bozza 2008). An accumulation of lipid within DCs 
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may provide a fuel source for fatty acid oxidation by the DCs; as in macrophages, 
IL-4 has previously been shown drive a switch from glycolysis to fatty acid oxidation 
(Vats, Mukundan et al. 2006). 
  
3.5.5 DC arginase expression and activity 
In contrast to what has been reported previously for macrophages, which we 
have confirmed in Fig. 3.12D, IL-4 failed to consistently induce increased expression 
and activity of arginase in GMDCs (Fig. 3.4, 3.5, 3.12). In our experiments, the 
inability of the arginine analogue BEC to influence arginase activity (Fig. 3.5), is 
likely due to a failure of the BEC to inhibit arginase activity at the range of 
concentrations used. Repeating this experiment using higher doses of BEC would 
address this suspicion. Alternatively, it may be the case that GMDCs produce such 
a high basal level of arginase that the inhibitor is unable to effectively reduce 
activity. To address if this might be the case, it would be important to first ensure 
that the inhibitor was functional, for example through use of this inhibitor with BMM, 
as BMM display a lower level of arginase activity than GMDCs (Fig. 3.12).  
 
Addition of 0.2% BEC in the drinking water of mice infected with S. mansoni 
(Herbert, Orekov et al. 2010) has been shown to replicate the disease phenotype of 
animals either deficient in arginase	  (Pesce, Ramalingam et al. 2009) or deficient in 
Arg1 in their BM compartment (via use of a chimera)(Herbert, Orekov et al. 2010). 
Inhibition of arginase activity by various inhibitors has been reported to have off 
target effects, and as such use of an inhibitor may not be the best system to block 
DC expression of this enzyme for further studies(Bronte and Zanovello 2005). It 
would be interesting to determine whether the absence of GMDC expression of 
arginase alters the ability of IL-4 to enhance RELMα and Ym1/2 expression, for 
example via generation of a DC specific arginase deficient animal (eg.CD11cCreArg-
1fl/fl). Interestingly, chimeric mice with a deficiency in Arg1 in their BM compartment 
have enhanced levels of pro-inflammatory cytokines within their intestinal 
compartment following 8 weeks of S. mansoni infection compared to WT BM 
chimeras, but no difference in expression of Retnla (Herbert, Orekov et al. 2010).  
 
As mentioned above, GMDCs expressed a higher basal level of arginase 
activity than BMM in the absence of IL-4 treatment (Fig. 3.12). However, GM-CSF 
has been reported to itself be able to induce arginase activity. Incubation of BMM 
92 
with GM-CSF results in a dose dependent increase in arginase activity (Jost, Ninci 
et al. 2003; Martin, Comalada et al. 2006), and increases the upregulation of an 
arginine transporter, CAT2 (Martin, Comalada et al. 2006). Assessment of GMDC 
arginase activity immediately following differentiation, or following overnight culture 
in media not supplemented with 5ng/ml GM-CSF, may abrogate the inability of IL-4 
to enhance DC arginase activity in our studies. Interestingly, a role for the SH2 
domain containing inositol-5’ phosphatase (SHIP) in blocking IL-4 induced Arg1 has 
been reported in AAM (Weisser, McLarren et al. 2011). Assessment of the levels of 
this phosphatase within GMDC cultures could provide a potential avenue to 
understand why IL-4 is unable to enhance Arg1 expression and activity in these 
cells.  
 
The lack of enhanced IL-4 driven arginase in AADCs, highlights that these 
cells have a different function to AAM. AAM are evolutionarily very important for the 
repair of tissue damage, and as such an IL-4 driven increase in production of 
polyamines and proline, (which promote collagen deposition and tissue repair) by 
these cells is necessary for their function (Allen and Wynn 2011). DCs on the other 
hand are the prime initiators of T-cell activation (Kapsenberg 2003; Steinman 2012), 
and enhanced production of arginase by DCs may deplete this important amino acid 
from the T-cells which they are in the process of activating (Bronte and Zanovello 
2005).  
  
3.5.6 AADC secretion of chemokines  
In vivo, DC expression of chemokines and chemokine receptors is important 
not only for mediating their migration between bone marrow, sites of immune 
priming and effector function, but also for controlling DC interactions with other cells 
of the immune system (Mantovani, Sica et al. 2004). We confirmed that, like AAM, 
AADCs can secrete high levels of the eosinophil chemoattractant CCL24/eotaxin-2 
(Fig. 3.4E). It is not yet clear what the in vivo role for DC expression of this 
chemokine may be. However, eosinophils have been shown to be a potential source 
of IL-4 for the maintenance of alternative activation of macrophages in adipose 
tissue during helminth infection (Wu, Molofsky et al. 2011). So it is possible that DC 
expression of CCL24, may result in the propagation of a Th2 response via the 
recruitment of IL-4 secreting cells. IL-4 also significantly increased DC expression of 
CCL17 (Fig. 3.4D). A recent report suggests that DC derived CCL17 is able to limit 
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T-regulatory cell induction in atherosclerotic lesions	   (Weber, Meiler et al. 2011). In 
this study, transwell migration assays were also carried out that showed reduced 
CD4+ T-cell migration towards BMDCs deficient in CCL17, suggesting that CCL17 
may function to increase CD4+ T-cell accumulation at sites of an ongoing immune 
response (Weber, Meiler et al. 2011).    
 
3.5.7 IL-4 Vs. IL-13 in DC alternative activation  
IL-4 can signal via the type-I IL-4R, whereas IL-13 can signal via the type-II 
IL-4Rα (a combination of IL-4Rα and IL-13Rα1)	   (Nelms, Keegan et al. 1999). 
Genetic ablation of IL-4Rα thus blocks signalling by both IL-4 and IL-13. We found 
that IL-13 induced comparable levels of alternative activation in GMDCs to IL-4 (Fig. 
3.6C). IL-13 has also been shown to induce comparable alternative activation in 
macrophage populations (Doyle, Herbein et al. 1994; Van den Bossche, Bogaert et 
al. 2009). As IL-13 was found to induce comparable levels of alternative activation 
within DCs, we decided to focus only on IL-4, to remove the complexity of dual IL-4 
and IL-13 signalling. A separate study on IL-13 induction of AADCs would be 
interesting and would most likely highlight functional differences between the 
phenotype of DCs induced by these different Th2 cytokines.    
 
A recent study in human monocytes/macrophages has shown that different 
Jaks and STATs are activated downstream of IL-4 and IL-13 signalling 
(Bhattacharjee, Shukla et al. 2012). IL-4 was found to preferentially recruit Jak1 to 
regulate STAT3 and STAT6, and IL-13 both Jak2 and Tyk2, which then activated 
STAT3, and STAT1 and STAT6 respectively (Bhattacharjee, Shukla et al. 2012). A 
thorough characterisation of Jak/STAT usage within IL-4 and IL-13 treated DCs 
would likely provide useful information about the mechanism(s) by which these two 
cytokines mediate programmes of alternative activation. Such signalling studies 
would also be a good starting point to investigate the differential expression of 
RELMα and Ym1/2 within different DC populations, for example to determine if 
FLDCs activate specific JAK/STAT combinations downstream of IL-4 binding, or if 
GMDCs deficient in components of the IL-4R signalling machinery alternatively 
activate in a different way. Studies into Jak/STAT usage may also provide 
information as to why RELMα and Ym1/2 are upregulated with different magnitudes 
in response to the same concentration of IL-4 both in vitro and in vivo and in 
different cells types (ie DCs vs. macrophages) (Fig. 3.2, 3.6, 3.7, 3.8, 3.10, 3.11). As 
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discussed in the introduction, other Th2 related cytokines IL-21 (Pesce, Kaviratne et 
al. 2006), IL-33 (Kurowska-Stolarska, Stolarski et al. 2009) and Activin A (Ogawa, 
Funaba et al. 2006) have been implicated in modulating AAM activation, similar 
investigations into the impact of these cytokine on DC activation status should also 
be carried out.  
  
3.5.8 Why aren’t FLDCs alternatively activated by IL-4? 
FLDCs have been described as being the equivalent of ‘steady state’ splenic 
DCs (Naik, Proietto et al. 2005). It was somewhat surprising, given their expression 
of IL-4Rα (Fig. 3.6), that they were unable to express RELMα or Ym1/2 in response 
to IL-4 (Fig. 3.6D), when overnight culture of splenic DCs from naïve mice (also 
described as ‘steady state’ DCs) with IL-4 did induce RELMα expression.  
 
It is possible that FLDCs simply require an additional signal to allow their 
alternative activation. This signal is not IL-13, as addition of this cytokine also failed 
to induce RELMα or Ym1/2 in either the pDCs or cDCs from the FLDC culture (Fig. 
3.6B&D). A possibility is that the absence of GM-CSF within this system is the 
reason that FLDCs are unable to alternatively activate, a simple experiment to 
assess this would be the addition of exogenous GM-CSF to the overnight culture of 
FLDC +IL-4. Alternatively, the pDCs present within the mixed FLDC cultures could 
inhibit the alternative activation of the cDCs. It may be informative to sort pDC and 
cDC populations prior to culture with IL-4 and phenotyping for alternative activation.   
 
A further possible explanation for the ability of splenic DCs to alternatively 
activate, when FLDCs cannot, could be that isolation of splenic DCs ex vivo results 
in their low level activation, which may be sufficient to license them for alternative 
activation.  
 
It is also interesting to note that permeabilisation of FLDCs substantially 
altered their size and granularity as detected by flow cytometry (Fig. 3.6). It is 
possible that use of a different method to permeabilise these cells may enable better 
detection of intracellular proteins.  
 
3.5.9 Comparing the alternative activation of BMM and ThioM 
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Thioglycollate medium is a mixture of proteins, sugars and sodium 
thioglycollate (Li, Baviello et al. 1997) which induces ‘sterile’ inflammation and 
recruitment of monocytes to the peritoneal cavity (Gallily and Feldman 1967). IL-4 
was able to induce higher levels of RELMα protein from M-CSF stimulated BMM 
than from ThioM, which had a preponderance of Ym1/2 expression (Fig. 3.11). It is 
possible that such thioglycollate recruitment results in macrophages with a more 
inflammatory phenotype, and Ym1 has been reported previously to promote rather 
than limit T-cell cytokine secretion	  (Cai, Kumar et al. 2009). It is also possible that 
the ThioM population contains cells with a more neutrophilic phenotype, as injection 
with thioglycollate initially recruits an influx of neutrophils to the peritoneal cavity 
(Kuhn, Godshall et al. 2001) and the ThioM expressed higher levels of CD11b than 
BMM (Fig. 3.11B). Additionally neutrophils have been reported to express high 
levels of Ym1/2	  (Harbord, Novelli et al. 2002). These findings prove to highlight that 
BMM and ThioM are not necessarily comparable cell populations.   
 
3.5.10 APC function of BMM vs. BMDC 
BMDCs were more efficient at priming of Th1, Th2 and Th17 immune 
responses following transfer into WT recipients than BMM (Fig. 3.14). Assessment 
of cytokine production prior to transfer highlighted that bacterially stimulated BMM 
secreted much lower levels of IL-12p70 and IL-6 than BMDCs stimulated with the 
same amounts of the same antigens (Fig. 3.13C). Upon transfer, Pa or St stimulated 
BMM induced pLN T-cells to secrete low level IFNγ and very low level IL-17, as may 
have been predicted by their failure to secrete significant amounts of the Th1 and 
Th17 polarising cytokines IL-12p70 and IL-6 (Fig. 3.13). BMM did secrete IL-10 in 
response to overnight culture with St (Fig. 3.13C) and, following transfer, St BMM 
induced higher levels of T-cell IL-10 than Pa BMM, which did not secrete detectable 
IL-10 pre transfer (Fig. 3.14C). Furthermore BMM also failed to upregulate high level 
expression of MHC-II and co-stimulatory molecules in response to antigen challenge 
prior to transfer (Fig. 3.13B), suggesting that these cells would be less competent at 
providing signal 2 to activate naïve T-cells.  
 
SEA pulsed BMM failed to induce any detectable recall response in the dLN 
following transfer into WT recipients (Fig. 3.14B). It is likely that SEA activated BMM 
fail to migrate to the LN following transfer. In order to assess whether this may the 
cause of the reduced priming ability of BMM, a cell tracking experiment could be 
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undertaken using congenic BM or fluorescently labelled cells, such as those from 
dsRed animals	  (Vintersten, Monetti et al. 2004).    
 
The results we gained from in vitro co-culture experiments suggest that 
failure to migrate to the sites of immune priming are not the only reason why BMM 
are unable to effectively prime Th2 responses. BMM still induced lower levels of IL-
4, IL-13 and IL-10 from T-cells than equivalent numbers of DCs, in the presence of 
the Th2 polarising cytokine IL-4 (Fig. 3.15). This result supports the idea that 
BMDCs are able to supply factor(s) that BMM cannot to support T-cell activation and 
polarisation. Co-stimulation may be one factor that is missing, or cytokine 
production, and further work to address what these factors may be would be 
interesting. IL-2 has been implicated in supporting DC induction of T-cell IL-4 
secretion (Cote-Sierra, Foucras et al. 2004)	   (Mandron, Aries et al. 2006) and IL-2 
secretion by DCs has been reported	   (Granucci, Vizzardelli et al. 2001). So, it is 
possible that DCs provide IL-2 to support T-cell induction of IL-4, and that 
macrophages do not. However, preliminary experiments in our laboratory have so 
far failed to detect IL-2 secretion by GMDCs, following  2 hours of culture with IL-4. 
 
Chapter 3 of this thesis has compared the impact that IL-4 has on DCs and 
macrophages, both in vitro and in vivo, in response to exogenous IL-4 treatment and 
schistosome infection. Expression of molecules usually associated with AAM 
RELMα, Ym1/2, dectin-1, CCL17, CCL24 and MR were found to be upregulated in 
IL-4 exposed DC populations, whereas arginase was not. In addition, the APC 
ability of BMDC and BMM were directly compared in vivo with BMM being found to 
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Figure 3.1. IL-4 stimulated BMDCs do not dramatically alter their activation 
phenotype. WT BMDCs were stimulated overnight with 20ng/ml IL-4 and their 
expression of the IL-4Rα, CD80, CD86, CD40 and MHC-II was assessed by flow 
cytometry (A-B). Shaded=isotype control, black line=media, grey line=+IL-4. 
Geometric mean fluorescence intensity (MFI) of marker expression by CD11c+ cells 
(C) and cytokine secretion was assessed by ELISA (D). Data representative of >5 
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Figure 3.2. IL-4 upregulates RELMα and Ym1/2 in BMDCs via the IL-4Rα. 
Overnight culture of BMDCs with IL-4 induces increased intracellular RELMα and 
Ym1/2  (A&B) and secretion (C), that depends upon IL-4Rα expression (D). Data 






































Figure 3.3. IL-4 treated DCs produce RELMα protein throughout their 
cytoplasm. GMDC were cultured overnight with or without 20ng/ml IL-4 in wells 
containing coverslips (A). Expression of the alternative activation associated 
molecule RELMα (pink) was assessed by confocal microscopy (B). The 
nucleus of the cells are stained using DAPI (blue) and DC structure is 
visualized using phallacidin staining for filamentous actin (green). An isotype 



























Figure 3.4. IL-4 upregulates multiple markers associated with AAM, but not Arg1. 
Overnight culture of GMDCs with IL-4 (A) upregulated Retnla and Chi3l3 (B), but did 
not enhance Arg1 or Nos2 (C) Chemokines (D+E) and C-type lectins (F+G) were 
upregulated by IL-4 at both transcript and protein level. Other markers associated 
with macrophage alternative activation were not upregulated by IL-4 in GMDCs (H). 
Black= media, Grey = +IL-4, shaded =isotype. Data shown are representative of 3-5 




± rIL-4  
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C. 
Figure 3.5 Arginase-1 is not a marker of an AADC. GMDC were treated overnight 
with IL-4 and units of Arginase activity were quantified (A+B) The Arginase inhibitor 
BEC was unable to limit DC Arginase activity at a range of doses (0-100μM) (C). 
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Flow cytometry 
A. 
Figure 3.6 FLDCs do not become alternatively activated in response to IL-4. Bone marrow 
derived DCs were differentiated in the presence of GM-CSF (GMDC) or FLT3L (FLDC) prior to 
overnight culture with IL-4 or IL-13 (A-D) RELMα and Ym1/2 were significantly up-regulated by 
IL-4 and IL-13 in GMDCs (B+C), neither IL-4 or IL-13 upregulated pDC or cDC expression of 
RELMα or Ym1/2 in FLDC cultures (D). Both cDC and pDC from FLDC cultures express the 
IL-4Rα (E) shaded=isotype control, black line=media, grey line=+IL-4. Data shown are 
representative of 3 independent experiments carried out in triplicate *=P<0.05, **P<0.01, 
***P<0.001.  
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Figure 3.7. IL-4 alternatively activates splenic ex vivo DCs in vitro. Following 
enrichment for DC populations, splenic cDCs (CD11chiB220-) from naïve mice were 
separated from pDCs (B220+CD11cmid) (B-C) and cultured overnight in the presence 
of 20ng/ml IL-4. IL-4 increased mRNA expression of alternative activation markers 
(D-F). Data representative of 2 experiments, 3-4 replicate wells per group, 
a.u.=arbitrary units, N.D.= not detected.  
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Figure 3.8  IL-4 alternatively activates DCs in vivo. C57BL/6 animals were injected 
i.p. with 50μl PBS or IL-4c (0.6 or 4μg), peritoneal exudate cells (PEC) were 
harvested 4 days later (A). Relative abundance of Macrophage (MΦ) and DC 
populations in peritoneal exudate cells (PEC) from PBS or IL-4c treated mice was 
assessed by flow cytometry (B). MΦ and DC populations as defined in (B) stained 
for intracellular expression of RELMα and Ym1/2 (C). Splenic DCs (MHC-II+ 
CD11chi) from PBS or IL-4c treated mice (2 x 5 µg, d0 and d2) were harvested at d4 
and stained for intracellular expression of RELMα and Ym1/2 (D-F). Data are 
representative of 5 (B-C) or 3 (D-F) independent experiments, graphs show % 
expression for individual mice. FMO = Fluorescence minus one control. Error bars 
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Figure 3.9 Markers of alternative activation are upregulated following S .mansoni 
infection. Whole tissue sections from Liver, Spleen, and Gut of S. mansoni infected 
mice were harvested at 4, 6, 8 and 12 weeks post infection, RNA was extracted, 
reverse transcribed and qPCR was carried out (A) to detect Arg1 (B), Retnla (C) 
and Chi3l3 (D). Data are representative of 2 experiments, error bars represent SEM 
of 5-8 mice per group. *=P<0.05, **P<0.01, ***P<0.001. 
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Figure 3.10. Parasitic helminth infection induces alternative activation of Splenic 
DCs. Splenic DCs (MHC-II+CD11chi) from naïve and S. mansoni (Schisto) infected 
mice were stained for intracellular expression of RELMα and Ym1/2 (A-C). Data is 
representative of 3-6 independent experiments, graphs show % expression for 
individual mice, 5-8 per group. *=P<0.05 **= P<0.01.  
A.  
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Figure 3.11 BMM produce more RELMα than Ym1/2, the opposite is true of ThioM. BM 
derived macrophages were differentiated in vitro with M-CSF (BMM) or elicited from the 
peritoneal cavity following injection of Thioglycollate (ThioM), cells were cultured overnight with 
IL-4 or media (A). Surface expression of F4/80, CD11b and CD11c was quantified by flow 
cytometry (B+C) and alternative activation by intracelluar RELMα and Ym1/2 staining and 
ELISA (D+E). Data is representative of 2 independent experiments carried out in triplicate. 
*=P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.   107 
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Figure 3.12 BMDC and BMM are different cells types. BM was differentiated with 
either GM-CSF (BMDC) or M-CSF (BMM) and expression of surface markers was 
assessed via flow cytometry (A&B) Following overnight culture with IL-4 an Arginase 
activity assay was carried out (C&D). Data is representative of 3 (B) or 1 (C&D) 
independent experiments, carried out in triplicate **P<0.01.  
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Figure 3.13 GMDC express higher levels of co-stimulatory molecules and secrete 
more cytokine than BMM. WT BMM or BMDCs were cultured overnight in medium 
alone (M), SEA (S), P. acnes (Pa) or S. typhimurium (St), prior to transfer into naïve 
recipients (A) Co-stimulatory molecule expression (B), cytokine secretion (C) and 
nitric oxide production (D) was assessed pre transfer. Data are representative of 2 
independent experiments, with single culture wells.  
A. 
C57BL/6 BMDC  
or BMM  
+ Med, SEA, Pa, St 
QC: ELISA, Flow 
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Figure 3.14 GMDC are significantly better than BMM at priming both Th1 and Th2 responses in 
vivo . WT BMM or BMDCs were cultured overnight in medium alone (M), SEA, P. acnes (Pa) or 
S. typhimurium (St), and injected subcutaneously into WT mice, 7d later pLN were harvested, 
cells restimulated for 72h with M, SEA, Pa or St and cytokine secretion was assessed by ELISA 
(A). Cytokines produced following restimulation with S (B), Pa or St (C) was assessed by ELISA. 
Data is  representative of one independent experiment, error bars = SEM of 3-5 mice per group, 
*=P<0.05 **= P<0.01. 
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Figure 3.15 BMM are less competent than GMDC at polarising CD4+ T-cells towards Th2 in 
vitro. CD4+ cells sorted from KN2xIL-10eGFP mice (IL-4/IL-10 dual reporters) were cultured for 
4 days with GMDCs or BMM and agonistic anti-CD3 antibody with or without IL-4 (A). Cells 
were assessed for IL-4 protein production and IL-10 mRNA production by flow cytometry (B+C) 
and cytokine secretion by ELISA (D). Data are representative of 2 experiments, error bars 
represent SEM of 3- 5 replicate wells per group, *=P<0.05 **= P<0.01 ****P<0.0001. 
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Chapter 4. What is the Impact of IL-4 and Alternative 
Activation on DC Function? 
 
4.1 INTRODUCTION 
Having confirmed that DCs can be alternatively activated both in vitro, ex 
vivo and in vivo we wanted to determine how such alternative activation might alter 
the ability of DCs to respond to antigenic stimuli, and to function as APCs.  
 
DCs are professional antigen presenting cells, able to migrate and activate 
naïve T-cells (Geissmann, Gordon et al. 2010; Steinman 2012), as shown in the 
previous chapter, GMDC are able to do this efficiently, whereas BMM were less 
capable (Fig. 3.14&3.15). In their role as APCs, DC expression of cell polarising 
factors such as cytokines and chemokines is very important in determining not only 
the outcome of T-cell priming but also in defining the amplitude and duration of an 
ongoing immune response. We showed in chapter 3 of this thesis that in response 
to the Th2 cytokine IL-4, DC isolated from the spleen or peritoneal cavity and 
differentiated from bone marrow are able to produce high levels of RELMα, and in 
situations of high dose IL-4, the chitinase like molecule Ym1/2. RELMα production 
by macrophages has previously been suggested to function to limit Th2 cytokine 
production (Nair, Du et al. 2009; Pesce, Ramalingam et al. 2009), as animals 
deficient in Retnla had enhanced T-cell production of IL-4, IL-5 and IL-13 in S. 
mansoni egg induced models of pulmonary granuloma. However other studies have 
shown that rRELMα can increase IL-4 expression in the mouse lung and the authors 
propose that RELMα can act as an amplifier of Th2 cytokines (Yamaji-Kegan, Su et 
al. 2010). DC production of Ym1/2 has been reported to enhance Th2 cytokine 
secretion (Arora, Chen et al. 2006; Cai, Kumar et al. 2009).  
 
The contrasting and potentially confusing roles for these alternative 
activation products in modulating the immune response warrant further 
investigation. The reports investigating RELMα do not investigate expression of this 
protein in DCs, we feel that this is an area that needs to be addressed more fully, on 
account of the high level of RELMα that was detected in all IL-4 exposed DC 
populations assessed in chapter 3, and given the importance of DCs in directing the 
immune response (Steinman 2012).   
113 
In a normal in vivo situation, where a DC is continually sampling the 
environment, it is likely to come into contact with a mixed antigenic and cytokine 
milieu. Unless an animal has come upon their very first pathogenic antigen, the 
activation of DCs in response to antigen is going to occur in the context of an 
already established immune environment. For example, in places in which helminth 
infection is endemic, such as schistosomiasis in sub-saharan Africa (Wilson, 
Mentink-Kane et al. 2007), young children (who have not yet developed immunity to 
this parasite) are likely to have an ongoing Th2 polarised immune response, should 
they come into contact with a Th1 driving antigen, such as a bacterial or viral 
infection, they need to be able to mount an appropriate response (Kamal and El 
Sayed Khalifa 2006). Thus, it is important to investigate how DCs deal with 
simultaneous exposure to Th1 polarising antigen in the context of Th2 cytokines 
such as IL-4. 
 
In the work detailed in this chapter, we aimed to build upon some older 
reports in the literature that had identified some aspects of the impact of IL-4 on DC 
cytokine production in vitro. Although one theme emerged from these studies – 
somewhat surprisingly, IL-4 enhancement of DC IL-12p70 production – the authors 
of this earlier work only speculated on what this might mean functionally	  (Hochrein, 
O'Keeffe et al. 2000; Kalinski, Smits et al. 2000; Guenova, Volz et al. 2008). The 
intention of the work presented in this chapter was to more deeply interrogate the 
role for DC IL-4 responsiveness in the activation of both Th2 and Th1 immune 
responses, a facet of DC function that had not been exhaustively investigated in 
vivo (Hochrein, O'Keeffe et al. 2000; Biedermann, Zimmermann et al. 2001; King, 
Mueller Hoenger et al. 2001). To complement such studies, experiments were also 
carried out to identify the impact of IL-4 on the response of DC to antigen exposure, 
as well as investigate the involvement of specific products of AADCs, produced 
downstream of IL-4R engagement, in naïve T-cell priming.  
As AADC have not previously been carefully characterised, the functional 
significance of DC alternative activation with regard to immune system priming has 
not been investigated fully. Two previous publications have investigated the role of 
DC expression of Ym1/2 in the promotion of Th2 responses in the context of allergy 
(Cai, Kumar et al. 2009)	  and following treatment with a statin (Arora, Chen et al. 
2006). However a functional role for RELMα in DCs has not previously been 
addressed.  
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4.2 SPECIFIC AIMS 
1. To determine to what extent IL-4 alters the response of DC to polarisng 
antigenic stimuli.  
2. To investigate the broad requirements for DC IL-4 responsiveness in 
their ability to prime both Th1 and Th2 responses. 
3. To identify the specific role for DC expression of the alternative activation 
associated molecule RELMα in their ability to polarise CD4+ T cells. 
 
4.3 RESULTS 
4.3.1 TLR ligation upregulates DC co-stimulatory molecule expression  
We wanted to further investigate the impact of IL-4 on DC function, to assess 
whether the presence of IL-4 is able to modulate the ability of DCs to perform their 
function as APCs, and whether IL-4 is able to modulate the response of DCs to 
antigen preparations from pathogens. To do this, we initially chose to assess the 
changes in DC phenotype upon exposure to well defined TLR ligands (CpG/TLR9 or 
LPS/TLR4) in combination with IL-4. In their role as professional APC, the 
expression of co-stimulatory molecules and secretion of T-cell polarising cytokines 
are major functional requirements of a DC, at least in the case of Th1 and Th17 
polarisation	  (Ouyang, Ranganath et al. 1998; Kapsenberg 2003; Harrington, Hatton 
et al. 2005; Zhou, Chong et al. 2009). DCs were cultured overnight in the presence 
of the bacterial TLR ligands CpG and LPS with and without addition of IL-4 and co-
stimulatory molecule expression was assessed by flow cytometry (Fig. 4.1A). TLR9 
or TLR4 ligation did not significantly enhance expression of MHC-II above the 
medium control samples (Fig. 4.1B&C) but did significantly increase expression of 
CD80, CD86 and CD40 (Fig. 4.1B&D-F). As shown in Fig. 3.1, IL-4 significantly 
decreased CD80 expression on control DCs (Fig. 4.1D), but the impact of IL-4 on 
MHC-II was not significant in this experiment (Fig. 4.1C), unlike in Fig. 3.1. The only 
influence that IL-4 had on the ability of TLR ligation to upregulate CD80, CD86 and 
CD40, was a subtle but significant enhancement of the ability of LPS to upregulate 
CD86 (Fig. 4.1E). 
 
4.3.2 Concurrent exposure to IL-4 at the time of TLR ligation boosts IL-12 and 
reduces IL-10 secretion by DCs 
It has been previously reported that concurrent IL-4 and LPS or CpG 
treatment of murine splenic DCs ex vivo results in enhanced production of bioactive 
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IL-12 heterodimers (IL-12p70) and reduced antagonistic IL-12p40 homodimers 
(Mattner, Fischer et al. 1993) suggesting that the Th2 polarising cytokine IL-4 is 
involved in a negative feedback loop whereby its presence increases the levels of 
the Th1 promoting cytokine IL-12p70 (Hochrein, O'Keeffe et al. 2000). Such a 
feedback mechanism would make sense in a co-infection setting, as would often 
occur in nature, in which a host is exposed to a Th1 polarising infection such as a 
bacterium in the context of an ongoing Th2 response, for example to a helminth. To 
ascertain whether, in our hands, GMDCs also respond to LPS/CpG and IL-4 in a 
similar manner to that reported for splenic DCs (Hochrein, O'Keeffe et al. 2000), we 
cultured GMDCs overnight in the presence of IL-4 and either LPS or CpG and 
collected the supernatants for ELISA analysis (Fig. 4.2A). The addition of IL-4 to the 
cultures significantly enhanced IL-12p70 secretion in response to CpG and LPS 
above the levels elicited by either antigen in the absence of IL-4 (Fig. 4.2B). As was 
previously reported for splenic DCs, IL-4 addition significantly impaired DC secretion 
of IL-12p40 in response to the TLR9 agonist CpG, whereas only a trend towards 
decreased secretion was apparent in the case of LPS and IL-4 (Fig. 4.2C). The LPS 
and CpG induced secretion of the regulatory cytokine IL-10 was decreased by the 
addition of IL-4 (Fig. 4.2D), lending further credence to the idea that, when in the 
presence of a strong bacterial stimulus such as LPS or CpG, IL-4 functions to 
promote a Th1 polarising environment (Kalinski, Smits et al. 2000). The pro-
inflammatory cytokines TNFα and IL-6 were not significantly affected by the 
presence of IL-4 at the time of either TLR9 or TLR4 ligation (Fig. 4.2E).  
 
4.3.3 TLR agonists limit IL-4 induced alternative activation 
Having confirmed in chapter 3 that IL-4 was able to alternatively activate 
DCs, and in Fig. 4.2 that TLR ligation concurrent with IL-4 treatment modulated 
conventional DC cytokine production, we thought it would be prudent to investigate 
the impact that TLR ligation has on IL-4 induction of AADC, given the immune 
modulatory functions previously reported for RELMα (Yamaji-Kegan, Su et al. 2006; 
Nair, Du et al. 2009; Pesce, Ramalingam et al. 2009; Yamaji-Kegan, Su et al. 2010) 
and Ym1/2 (Arora, Chen et al. 2006; Cai, Kumar et al. 2009). In order to determine 
the impact of TLR9 or TLR4 ligation on IL-4 driven GMDC alternative activation, we 
detected RELMα and Ym1/2 protein by intracellular staining and ELISA following 
overnight culture with the defined ligands CpG and LPS, alone or with the addition 
of IL-4 (Fig. 4.3A). TLR9 ligation with CpG DNA was able to significantly reduce IL-4 
116 
driven RELMα and Ym1/2 protein, however, this inhibition was not as complete as 
that seen with LPS, as substantial amounts of intracellular protein were still 
upregulated by IL-4 even in the presence of CpG (Fig. 4.3B-D).  The presence of 
LPS dramatically abrogated IL-4 induced RELMα both within the DCs (Fig. 4.3B&C) 
and secreted by the DCs over the 18 hour time point (Fig. 4.3D). However, LPS did 
not completely impede basal secretion of RELMα as ~0.5ng/ml was detectable 
within the supernatant in both the media and LPS treatment groups (Fig. 4.3D). LPS 
also abrogated intracellular IL-4 driven Ym1/2 protein (Fig. 4.3B&C), although 
~0.1µg/ml of IL-4 driven Ym1/2 was detectable by ELISA (Fig. 4.3D).  
 
To assess more broadly the activation status of DCs following either LPS+IL-
4 or CpG+IL-4 treatment, qPCR was carried out on a panel of alternative activation 
associated markers (Fig. 4.3E&F). Shown as arbitrary units relative to the 
housekeeping gene Hprt, inclusion of all genes on the same axis allows a global 
view of the activation state of the DCs. The addition of CpG (E; striped bars) or LPS 
(F; striped bars) reduced transcript levels of Retnla below the basal level for media 
only. IL-4 driven Chi3l3 transcripts were decreased by the presence of both 
agonists. However, in a similar pattern to protein production, an IL-4 driven 
response was still apparent. As shown in chapter 3 (Fig. 3.4) Arg1 was not 
enhanced by IL-4 and neither CpG nor LPS significantly affected the transcript for 
this arginine converting enzyme (Fig. 4.3E). Nos2, which encodes the enzyme 
iNOS, competes with arginase for the shared substrate arginine (Modolell, Corraliza 
et al. 1995). As expected, Nos2 mRNA expression was stimulated by either TLR 
agonist (Fig. 4.3E&F), and this was not significantly altered by the addition of IL-4. 
Expression of the CLR Mrc1 (MR) was almost completely abrogated by the 
presence of LPS or CpG even in the presence of IL-4, whereas Clec7a (Dectin-1), 
though reduced by the presence of CpG, was still significantly upregulated by 
addition of IL-4 (Fig. 4.3E), however IL-4 was unable to overcome the LPS inhibition 
of Clec7a (Fig. 4.3F). Neither LPS nor CpG significantly altered IL-4 induced 
upregulation of the eosinophil attractant Ccl24 (Eotaxin2). Interestingly, expression 
of both Ccl17 and Ccl22 (MDC) was highest when CpG and IL-4 were 
simultaneously provided to the DCs; in macrophages a similar outcome has 
previously been shown in a microarray analysis of BMM or ThioM primed by IL-4 for 
18h and then stimulated with LPS (Major, Fletcher et al. 2002; El Chartouni and 
Rehli 2010) however in this work, addition of LPS and IL-4 simultaneously did not 
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significantly upregulate Ccl17 or Ccl22 over the level induced by either stimulus 
alone (Fig. 4.3E).  The data in this figure prove to highlight that similar to the ability 
of IL-4 to modulate TLR driven cytokine production in Fig. 4.2, TLR ligation can 
modulate IL-4 driven responses in DCs.  
 
4.3.4 Complex bacterial, but not helminth antigens modulate DC co-
stimulatory molecule expression and cytokine production in a manner similar 
to defined TLR ligands  
In order to determine whether the response of GMDCs to defined TLR 
ligands could be mirrored with complex antigens more akin to what the innate 
immune system encounters in reality, we compared the effects of culturing DCs with 
both IL-4 and the Th1 polarising gram positive bacterium P. acnes (Pa) or the Th2 
polarising soluble egg antigen (SEA) from S. mansoni (Fig. 4.3A). Following 
overnight culture with Pa, DCs significantly upregulated expression of MHC-II, CD86 
and CD40, and IL-4 did not alter such upregulation (Fig. 4.4B&C). As previously 
reported (MacDonald, Straw et al. 2001), SEA did not significantly increase DC 
expression of MHC-II, CD80, CD86 or CD40 and inclusion of IL-4 in the culture did 
not change this outcome (Fig. 4.4B&C). Pa strongly induced GMDC secretion of IL-
12p70 and IL-10 following overnight culture (Fig. 4.4D) and addition of IL-4 to the 
culture significantly enhanced secretion of IL-12p70 while reducing secretion of IL-
10. As previously reported SEA did not stimulate GMDC to secrete the T-cell 
polarising cytokines IL-12 and IL-10 (MacDonald, Straw et al. 2001), and the 
inclusion of IL-4 did not alter this (Fig. 4.4D).  
 
4.3.5 Complex bacterial and helminth antigens modulate DC alternative 
activation in a manner similar to defined TLR ligands  
The secretion (Fig. 4.5B), intracellular production (Fig. 4.5C) and 
transcription (Fig. 4.5D) of alternative activation products by IL-4 and antigen 
exposed DCs was also assessed. Pa was found to abrogate secretion of both IL-4 
induced RELMα and Ym1/2 whereas SEA displayed little inhibitory impact in this 
regard upon Ym1/2, but significantly inhibited IL-4 driven RELMα (Fig. 4.5B-D). The 
differential inhibition of SEA on RELMα production compared to Ym1/2 suggests 
that a component of this antigenic mix is able to modulate the IL-4R signalling 
pathway after the point at which induction of RELMα and Ym1/2 diverges.  
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4.3.6 IL-4 alters the response of DCs to CD40 ligation 
Having determined that IL-4 alters the production of both alternative 
activation markers and T-cell polarising cytokines, we decided to investigate how 
such changes may alter the interaction of DCs with T-cells, both in terms of changes 
to the DC themselves and to the polarisation of the T-cells. To initially assess this, 
we chose to ligate the co-stimulatory molecule CD40 on the DC surface using 
agonistic monoclonal antibodies (Jenkins, Perona-Wright et al. 2007). DCs express 
CD40 and interact with CD154 on the surface of T-cells. This interaction enhances 
DC cytokine production, an important mechanism in the induction of Th1, Th2 and 
Th17 responses (Elgueta, Benson et al. 2009; Perona-Wright, Jenkins et al. 2009). 
GMDCs were cultured overnight with medium, Pa or SEA in the presence or 
absence of IL-4, then washed and re-cultured with anti-CD40 antibody for a further 
24 hours. Anti-CD40 ligation of DC following treatment with Pa enhanced secretion 
of IL-12, IL-10 and IL-6 compared to cells treated with an isotype control antibody 
that did not ligate CD40 (Fig. 4.6B). Pre-culture with Pa and IL-4 resulted in 
enhanced IL-12p40, IL-12p70 and IL-6 secretion following αCD40 treatment when 
compared to Pa treatment alone (Fig. 4.6B). There was also a trend for reduced IL-
10, however this did not reach significance. Neither RELMα or Ym1/2 secretion by 
the DCs was altered by αCD40 ligation (Fig. 4.6C).  Interestingly, the DCs continued 
to secrete both RELMα and Ym1/2 following removal of IL-4 from the culture 
supernatant (Fig. 4.6C). Prolonged secretion of alternative activation products in the 
absence of IL-4 stimulus suggests that DCs in vivo would be able to migrate away 
from the proximal site of IL-4 exposure to alter the immune response at distal 
tissues or LNs.  
 
4.3.7 IL-4Rα-/- DCs are less able to induce IFNγ and IL-17 responses  
Having determined that DC exposure to IL-4 triggers production or 
expression of a wide range of molecules, and alters their response following CD40 
ligation, we next wanted to ascertain what impact IL-4 signalling to DCs had on their 
ability to polarise either Th1 or Th2 immune responses. As presented in chapter 3, 
Pa and SEA pulsed DCs efficiently prime Th1/Th17 and Th2 responses, 
respectively, following adoptive transfer in vivo (Fig. 3.14). We initially hoped to 
determine whether culture with IL-4 prior to transfer would alter the resultant 
immune response in the dLN of recipient mice.  However, there was a lot of 
variation in the immune response following transfer of IL-4 treated DCs, suggesting 
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that the impact of IL-4 in vitro may be too transient to detect a consistent impact of 
this exposure on DC function in vivo. As an alternative approach to the question of 
how IL-4 alters DC APC function, we instead chose to assess the polarising ability 
of DCs unable to receive an IL-4 signal following transfer in vivo. IL-4 signals via the 
IL-4Rα, so we used Il4ra-/- bone marrow to generate GMDCs and compared their 
ability to prime T-cell responses with DCs grown from WT bone marrow.  WT or IL-
4Rα deficient GMDCs were cultured overnight with media, Pa or SEA. DCs were 
then transferred into the feet of WT naïve recipients, the pre-transfer supernatants 
were assessed by ELISA; following transfer cells were left for 7 days, the draining 
popliteal LN were harvested, and the cells re-stimulated for 72h (Fig. 4.7A). Prior to 
transfer, Pa stimulated IL-4Rα deficient DCs had significantly increased IL-12p40 
and significantly reduced IL-10 secretion but had no difference in the levels of Pa 
induced pro-inflammatory molecules IL-12p70, NO, TNFα or IL-6 (Fig. 4.7B). 
Interestingly, upon transfer, the Pa stimulated IL-4Rα deficient DCs were less 
capable of priming IL-17 and IFNγ T-cell responses than their WT counterparts (Fig. 
4.7C), suggesting that in a WT situation, receipt of an IL-4 signal in the context of a 
bacterial pathogen drives a feedback loop to enhance Th1/Th17 cytokine 
production, even in the absence of high levels of Th2 cytokine. It was interesting to 
note that Pa pulsed DCs also induced IL-13 production upon restimulation, however 
no significant difference in IL-13 was found between WT and IL-4Rα deficient cells 
(Fig. 4.7C).  IL-4Rα deficient DCs were also significantly less competent at inducing 
SEA driven IL-10 and IFNγ than their WT counterparts but had no defect in 
induction of the Th2 cytokines IL-4 or IL-13. This data shows that IL-4Rα  
expression by DCs is not an absolute requirement for Th2 induction in response to 
helminth antigen.  Moreover, it reveals that IL-4 responsiveness is necessary for 
optimal DC polarisation of T cells in Th2 or Th1/17 settings via fine-tuning of IL-10, 
IL-17 and IFNγ production (Fig. 4.7C&D).  
 
4.3.8 DCs unable to respond to IL-4 are less able to support early Th2 
polarisation in vitro 
The DC transfer model provides an important readout of in vivo priming 
ability. However, following transfer it is hard to determine which precise cell types 
are involved. As a more reductionist and controllable complementary approach, we 
set up in vitro DC:T-cell co-culture assays incorporating huCD2 (IL-4) reporter T-
cells and DCs either sufficient or deficient in IL-4Rα expression, to determine if the 
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DC response to IL-4 changed their capacity to polarise T-cells. Anti-CD3 was used 
to stimulate T-cells in the presence of DCs, with or without addition of exogenous 
recombinant IL-4 (Fig. 4.8A), this method was modified from a study in which TGFβ 
was used (in place of IL-4) to convert αCD3 stimulated CD4+FoxP3- T-cells (in place 
of huCD2 reporters) to a Treg phenotype in the presence of DCs	  (Travis, Reizis et 
al. 2007). Following 3 days of culture, IL-4 induced increased expression of huCD2 
by reporter T-cells cultured in the presence of WT DCs (Fig. 4.8B&C). By day 3 of 
culture, there was a significantly reduced induction of huCD2 (IL-4 protein) in T cells 
cultured with DCs lacking IL-4Rα expression (Fig. 4.8B&C). This reduced Th2 
polarisation was also evidenced by reduced IL-10 and IL-13 protein secretion (Fig. 
4.8D). There was no significant difference in the levels of IFNγ secreted by any of 
the groups (Fig. 4.8E), however, the level of IFNγ was very low as there was no 
antigenic stimulus to promote IFNγ cytokine secretion, unlike in the SEA/Pa 
stimulated Il4ra-/- transfer (Fig. 4.7). This system allows conclusions to be drawn as 
to the direct versus indirect effects of IL-4 on T-cell activation. In the absence of DC 
IL-4Rα expression, recombinant IL-4 is able to induce IL-4 protein expression by T-
cells, though at a reduced level. In conclusion, early IL-4 driven Th2 polarisation is 
partially dependent upon provision of an unknown signal provided by IL-4 
responsive DCs. IL-4 signalling to the IL-4Rα changes the gene expression profile of 
DCs in multiple ways, including (but not limited to) the initiation of a programme of 
alternative activation, we were interested to determine what signal was being 
produced by IL-4 responsive DCs to induce Th2 polarisation and whether alternative 
activation products played a role in such DC dependent T-cell polarisation. 
 
4.3.9 DC expression of RELMα during Th2 priming regulates IFNγ and 
promotes IL-10 and IL-13 production 
Using IL-4Rα deficient cells enabled us to determine the global changes that 
occur in the absence of complete IL-4 signalling, one facet of which is alternative 
activation. As we were predominantly interested in the functional impact of DC 
alternative activation rather than the large scale changes that occur following IL-4 
treatment, we decided to use cells deficient in one dominant aspect of the 
alternative activation profile, RELMα (Fig. 3.2-4&3.7-10). We adoptively transferred 
WT or Retnla-/- GMDCs into WT recipients, and assesed their ability to prime 
Th1/Th17 (Pa) or Th2 (SEA) immune responses (Fig. 4.9A). In contrast to the result 
found with IL-4Rα deficient DCs, there was no defect in Th1/Th17 induction 
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following transfer of Pa pulsed Retnla-/- DCs (Fig. 4.9B). There was, however, a 
significant role for DC derived RELMα in the induction of IL-10 and IL-13 and in the 
regulation of IFNγ in the context of the Th2 polarising antigen SEA (Fig. 4.9C). IL-10 
and IL-13 were both significantly reduced when the priming DCs could not produce 
RELMα, whereas IFNγ was enhanced. We saw a different outcome in terms of 
immune response induction and polarisation when the priming DC could not 
become alternatively activated on account of having no IL-4Rα (decreased Pa 
specific IL-17 and IFNγ, decreased SEA specific IL-10 and IFNγ) than when the 
DCs were deficient only in RELMα (decreased SEA specific IL-10, IL-13 and 
enhanced IFNγ). These experiments suggest that IL-4 causes greater changes to 
the functional antigen presenting and T-cell polarising capability of a DC than 
induction of RELMα expression.  
 
4.3.10 DC derived RELMα promotes IL-4 driven IL-10, and inhibits T-cell IL-4  
In order to investigate specifically whether DC alternative activation was 
involved in supporting Th2 polarisation, αCD3 stimulated T-cell co-cultures were set 
up using DCs deficient in expression of the alternative activation related molecule 
RELMα (Fig. 4.10A). When DCs were unable to produce RELMα, a significantly 
increased level of CD4+ T-cell huCD2 (IL-4) expression was detected (Fig. 
4.10B&C). This result suggests that RELMα usually functions to limit the induction of 
T-cell IL-4. Due to the addition of exogenous rIL-4 to the culture wells it was not 
possible to assess IL-4 secretion. However, the production of IL-13 was measured 
in the culture supernatants by ELISA (Fig. 4.10D). In contrast to increased IL-4 
protein production (huCD2), IL-13 secretion was reduced in the presence of RELMα 
deficient DCs (Fig. 4.10D). IL-10 was initially reported as being a Th2 cytokine, was 
later associated with Tregs and most recently has been shown to have broad 
associations with many cells of the immune system (Saraiva and O'Garra 2010). We 
wondered whether the reduction in IL-4 driven IL-13 was mediated via altered 
induction of IL-10. A surprisingly clear reduction in the levels of IL-4 driven IL-10 
(GFP Fig. 4.10E&F) and protein (Fig. 4.10G) was found when DCs were unable to 
produce RELMα, confirming a role for RELMα in promoting T-cell IL-10. This data 
recapitulates the findings from the Retnla-/- GMDC transfer (Fig. 4.9) where it was 
found that DCs deficient in RELMα failed to promote optimal Th2 responses, with 
reduced IL-10 and IL-13, and enhanced IFNγ. In this system, in the absence of 
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antigen or Th1 polarising cytokine, there was no difference in the secretion of IFNγ 
by T-cells exposed to WT or Retnla-/- DCs (Fig. 4.10H). 
 
4.3.11 rRELMα does not activate GMDCs  
We next aimed to ascertain whether RELMα could be acting in an autocrine 
manner to change DC function within the context of a WT DC transfer or T-cell co-
culture. In order to assess this we cultured GMDC with recombinant RELMα in the 
presence or absence of IL-4 overnight and phenotyped the cells to determine if 
there were changes in IL-4Rα expression (Fig. 4.11B), co-stimulatory marker 
expression (Fig. 4.11C), RELMα or Ym1/2 production (Fig. 4.11D), or cytokine 
secretion (Fig. 4.11E). There were no significant differences detected between the 
rRELMα treated and control wells for any of the parameters tested. No IL-12p70 or 
IL-10 were secreted by the cells in response to rRELMα, and no significant 
difference was apparent in those cytokines which were detected (CCL24, TNFα, IL-
12p40, NO). This lack of impact of recombinant RELMα on DC activation phenotype 
suggests that RELMα may directly influence the T-cells. Alternatively, RELMα may 
affect a parameter of DC activation that we did not measure in these experiments.  
 
4.3.12 WT, Il4ra-/- and Retnla-/- DCs are similarly capable at antigen uptake 
To determine whether altered function of the IL-4Rα and RELMα deficient 
DCs was the cause of their impaired ability to prime T-cell response in vitro and in 
vivo, we first assessed whether the cells were equally competent at antigen uptake 
as WT DCs. The rationale behind this approach was that, if DCs are less capable at 
taking up antigen, then they would be less able to process and present components 
of that antigen to T-cells. We undertook a simple assay to assess 
endocytic/pinocytic activity	   (Steinman, Mellman et al. 1983), whereby WT, IL-4Rα 
deficient or RELMα deficient GMDCs were incubated with fluorescently labelled 
dextran at 37oC for 30 minutes, followed by analysis of fluorescence by flow 
cytometry to determine uptake as compared to control samples incubated on ice to 
stop biological processes (Fig. 4.12A). There was no major difference in the ability 
of either type of genetically deficient DC to uptake FITC conjugated Dextran when 
compared to WT cells (Fig. 4.12B&C), however IL-4Rα deficient cells had a 
significantly increased % of FITC positive cells and gMFI than did WT cells, and 
although a similar percentage of RELMα deficient cells had taken up FITC-dextran, 
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the gMFI data would suggest that each cell had pinocytosed less dextran than the 
WT cells (Fig. 4.12C).  
 
4.3.13 Antigen processing and presentation is unimpaired in Il4ra-/- and Retnla-
/- DCs 
Although antigen uptake was intact in the IL-4Rα and RELMα deficient DCs, 
we next wanted to determine whether altered antigen processing or presenting 
function might be the cause of their impaired ability to prime T-cell response in vitro 
and in vivo. We assessed whether the IL-4Rα and RELMα deficient DCs were 
equally competent at processing and presentation of antigen (Fig. 4.13) to 
ovalbumin specifc (OT-II) TCR transgenic CD4+ T cells (Barnden, Allison et al. 
1998) in vitro.  To assess antigen presentation ability, OT-II T-cells labelled with the 
intracellular dye CFSE were first cultured with WT, Il4ra-/- or Retnla-/- DCs, in the 
presence of ovalbumin peptide (Fig. 4.13A). CFSE can not diffuse out of cells, and 
as such gets diluted at each round of cell division	   (Hawkins, Hommel et al. 2007). 
CFSE dilution was assessed by flow cytometry following 4d of culture; using peptide 
rather than whole ovalbumin protein allowed determination of the ability of a cell to 
present the ovalbumin peptide to T-cells outwith the requirements to first process 
the antigen. There was no deficit in the ability of the DCs to present pOVA resulting 
in T-cell proliferation. In fact, Il4ra-/- and Retnla-/- deficient DCs induced enhanced T-
cell proliferation compared to the control WT cells (Fig. 4.13B). Next, in order to 
assess whether there was a defect in the ability of the DCs to process antigen prior 
to presentation to T-cells, whole OVA protein was used instead of pOVA in an 
otherwise identical assay (Fig. 4.13C). There was no deficit in ability to drive T-cell 
proliferation. Indeed, similar to what was observed with the addition of peptide (Fig. 
4.13B), Il4ra-/- and Retnla-/- DCs also induced significantly enhanced T-cell 
proliferation compared to WT cells when cultured with whole OVA protein (Fig. 
4.13C). This enhanced proliferation was consistent with expectation, given the 
reduced IL-10 levels evident following transfer of Il4ra-/- (Fig. 4. 7) or Retnla-/- (Fig. 
4.9) DCs in vivo, and in T-cell co-culture assays in vitro (Fig. 4.8 & Fig. 4.10).  
 
 4.3.14 IL-4 treatment of RELMα deficient DCs significantly alters transcription 
of more genes than IL-4 treatment of WT DC  
In an attempt to determine the gene(s) responsible for the changes in T-cell 
polarising ability of Retnla-/- DC compared to WT DC, Illumina whole genome 
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expression profiling was undertaken. This system allows determination of 
transcription changes within cell populations by biotion labelling of total cellular 
cRNA prior to hybridisation to standard mouse reference genome chips which (in 
this study) contained probes for 45,281 transcripts. In this microarray, we chose to 
assess the impact of IL-4 treatment on WT and Retnla-/- GMDC, with Il4ra-/- GMDC 
serving as a control population. In order to enhance the statistical power of the data 
produced by gene expression profiling, we used 3 biological rather than technical 
replicates per genotype tested. GM-CSF was used to differentiate DCs from bone 
marrow harvested from 3 individual mice per genotype (9 mice total). GMDCs were 
stimulated with IL-4 for 6 hours, then counted, and equal numbers per biological 
replicate were used to produce pooled RNA, which was converted to biotin-labelled 
complementary RNA. Quality control (flow cytometry, ELISA) was carried out on 
aliquots of cells not used for RNA extraction (Fig. 4.14B-E). The biotin labelled 
cRNA samples were transferred to the Clinical Research Facility at the Western 
General Hospital, Edinburgh, for chip hybridisation and sample normalisation (Fig. 
4.12A). Il4ra-/- DCs did not express the IL-4Rα (Fig. 4.14B&C), Retnla-/- DCs 
expressed slightly reduced levels of IL-4Rα compared to WT cells and 6 hours of IL-
4 treatment downregulated the IL-4Rα (Fig. 4.14B&C) to a similar extent to 18h of 
IL-4 treatment (as shown previously  in Fig. 3.1). With regard to co-stimulatory 
marker expression, all three genotypes of DC were fairly comparable, with the only 
significant difference being enhanced CD40 expression on Retnla-/- DCs and a trend 
for reduced CD80 when DCs were unable to produce RELMα or respond to IL-4 
(Fig. 4.14B&C). Retnla-/- DCs were unable to produce RELMα but produced 
comparable levels of intracellular Ym1/2 in response to IL-4 (Fig. 4.14D&E). IL-4 
failed to upregulate RELMα or Ym1/2 in Il4ra-/- DCs (Fig. 4.14D&E), unfortunately 
the on plate standard failed for the Ym1/2 ELISA, and as all of the supernatant had 
been used, this ELISA could not be repeated, as such OD values have been plotted. 
Following hybridisation, QC analysis was carried out by Al Ivens (CIIE, 
bioinformatics support) using the arrayQualityMetrics package in BioConductor 
(Kauffmann and Huber 2010). One of the IL-4 treated Il4ra-/- samples failed the QC 
analysis, this sample had a low concentration of RNA following initial extraction, and 
had to be concentrated prior to chip hybridisation, and unfortunately failed to 
hybridise correctly.  Due to this failure, the IL-4Ra data set was excluded from 
further analysis. Although statistical significance could not be assessed in this group 
125 
due to the low sample number (n=2), no genes were changed by IL-4 treatment of 
the IL-4Rα deficient DCs, as expected.  
 
Following IL-4 treatment of WT DCs, 109 genes were significantly changed 
(up or down regulated) (p<0.05). Interestingly, 308 genes were significantly altered 
by IL-4 treatment of Retnla-/- DCs, 199 more genes than were changed by IL-4 
treatment of WT DCs; 79 of the IL-4 induced gene changes were shared by WT and 
RELMα deficient cells (Fig. 4.14F). In order to reduce the size of the gene lists, 
stringent fold change cut offs of ≤0.5 and ≥2 were chosen, such that IL-4 treatment 
must reduce the expression of a gene of interest by at least 50% or conversely 
enhance gene expression by 100% or more. Using these cutoffs reduced the 
number of significant genes of interest to 53, genes are listed in tables in order of 
significance with most significant first.  
 
Only Thbs1 (Thrombospondin-1, a glycoprotein involved in cell adhesion) 
was down regulated by IL-4 in both DC strains (Table 4.3.1, Fig. 4.14G). IL-4 
treatment of Retnla-/- DCs (Table 4.3.2) significantly downregulated an additional 14 
genes. The most significantly down regulated gene was Il1rn (interleukin 1 receptor 
antagonist p=0.0025). Of the 14 downregulated genes, the two with the lowest fold 
change (and thus most reduced by IL-4 treatment) were Tlr2 (Toll like receptor 2) 
and Clec4e (C-type lectin domain family 4, member e; also known as Mincle).   
 
21 genes were significantly increased by 2 fold or greater following IL-4 
treatment of  WT DCs. Of these, 18 were also upregulated in Retnla-/- DCs (Table 
4.3.3), and an additional 17 genes were upregulated by IL-4 only in Retnla-/- DCs 
(Table 4.3.4) (Fig. 4.14H).  
 
Only 3 genes were upregulated by IL-4 in WT DCs that were not upregulated 
in Retnla-/- DCs, indicating that these genes potentially require RELMα to be present 
for their expression. Retnla itself was one of these genes, the other 2 being Hfe 
(Hemochromatosis) and Apol7c (Apolipoprotein 7c) (Table 4.3.5).   
 
Of the 18 genes upregulated by IL-4 in both WT and Retnla-/- DCs (Table 
4.3.3) the eosinophil chemoattractnat Ccl24 (also known as Eotaxin-2) was both the 
most significantly upregulated gene and also had the highest fold change (16), 
126 
Chi3l3 (Ym1) and Chi3l4 (Ym2) also had a high fold change (≥4), these changes 
had already been identified by qPCR, ELISA and flow cytometry (chapter 3). 
 
The most significantly upregulated gene >2FC in Retnla-/- DCs was Edn1 
(Endothelin 1)(Table 4.3.4), although this gene was also significantly upregulated in 
IL-4 treated WT DCs, but did not reach the 2FC cut off. As IL-4 treatment 
significantly enhanced more genes in Retnla-/- deficient cells than in WT cells, this 
suggests that RELMα may normally act to inhibit, either directly or indirectly, the 






• IL-4 enhanced IL-12p70 and reduced IL-10 secretion from DCs stimulated 
with bacteria or bacterial products (LPS, CpG, heat killed P. acnes) (Fig. 4.2, 
Fig. 4.4). 
• Markers of IL-4 driven alternative activation were not uniformly down 
regulated by TLR ligation (Fig. 4.3 & Fig. 4.5). 
• Helminth antigens did not modulate IL-4 driven Ym1/2, but did modulate IL-4 
induced RELMα (Fig. 4.5).  
• Pre-culture with IL-4 enhanced DC cytokine production following CD40 
ligation (Fig. 4.6). 
• DC RELMα and Ym1/2 secretion was maintained for at least 24h following 
removal of IL-4 (Fig. 4.6).  
• Il4ra-/- DCs were less capable of priming mixed Th1/Th17 responses against 
P. acnes, and induced reduced SEA specific IL-10 and IFNγ (Fig. 4.7 & Fig. 
4.8). This was not due to a defect in antigen uptake (Fig. 4.12), processing 
or presentation (Fig. 4.13).  
• Retnla-/- DCs were less capable of priming some aspects of the Th2 
response: SEA specific IL-10 and IL-13 were reduced, but IFNγ was 
enhanced (Fig. 4.9 & Fig. 4.10). This was not due to a defect in antigen 
uptake (Fig. 4.12), processing or presentation (Fig. 4.13). 
• IL-4 significantly increased expression of more genes in Retnla-/- DCs than in 
WT DCs (Fig. 4.14):  hence RELMα may act to some extent as a feedback 






4.5.1.TLR and bacterial modulation of DC co-stimulatory molecule expression 
We showed in Fig. 4.1 that TLR9 or TLR4 ligation with the specific agonists 
CpG or LPS significantly enhanced expression DC expression of the co-stimulatory 
molecules CD80, CD86 and CD40, as has been reported previously (Dearman, 
Cumberbatch et al. 2009). Also as reported previously for LPS, there was no 
significant increase in the level of MHC-II expression following overnight culture 
(Dearman, Cumberbatch et al. 2009), though this is in contrast with an earlier report	  
(MacDonald, Straw et al. 2001). The ability of exogenous PRR stimuli to activate 
GMDCs is dependent upon the basal level of expression of the marker of interest. 
For example, if DCs have become activated during differentiation, the ability to 
enhance MHC-II expression further may be compromised, which might explain the 
differences between the studies. IL-4 is able to downregulate the basal level of DC 
CD80 expression (Fig. 3.1, 4.1D). Interestingly, in the presence of strong TLR 
ligation, IL-4 no longer limits CD80 expression (Fig. 4.1D). However, IL-4 does 
instead promote CD86 (Fig. 4.1E). The IL-4 mediated reduction in any of the 
conditions, though significant, is only a minor alteration in the absolute level of 
expression, so may not make any biological difference to the ability of the DCs to 
activate T-cells. In contrast to the LPS and CpG enhancement of CD80, CD86, and 
CD40 but not MHC-II, Pa enhanced MHC-II, CD86 and CD40 expression but not 
CD80 (Fig. 4.4B&C). Indeed, the more subtle induction of CD80 by Pa than LPS 
was published previously (MacDonald, Straw et al. 2001). IL-4 did not cause any 
alteration in the amount of MHC-II, CD80, CD86 or CD40 upregulated on DCs in 
response to stimulation with Pa.    
 
4.5.2 IL-4 regulation of bacterially induced DC function 
We also confirmed results from previous studies (Hochrein, O'Keeffe et al. 
2000; MacDonald, Straw et al. 2001) showing that LPS, CpG and Pa enhanced DC 
secretion of T-cell polarising cytokines IL-12p70, IL-12p40, IL-10, TNFα and IL-6 
(Fig. 4.2 & 4.4D). Furthermore, we confirmed in Fig. 4.2, that IL-4 enhances the 
secretion of IL-12p70, and decreases secretion of IL-10 (Yao, Li et al. 2005) and IL-
12p40 (Hochrein, O'Keeffe et al. 2000) during TLR ligation with LPS or CpG. We 
add to the findings of these previous studies by showing that IL-4 mediates the 
same cytokine changes in IL-12p70 and IL-10 in cells stimulated with the more 
complex antigen preparation of P. acnes (Fig. 4.4). 
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If a DC is exposed to Th1 inducing pathogen and Th2 cytokine at the same 
time, it makes sense that the cytokine (in our study, IL-4) should help to enable a 
Th1 response to develop (e.g. enhancing IL-12p70) as Th1 pathogens are likely to 
be more immediately life threatening (Allen and Wynn 2011). This raises interesting 
questions about flexibility and stability of the impact of IL-4 on DC function.  One 
theory is that later, once the immediate Th1 threat has been dealt with, the DC 
would be competent to drive a Th2 response. To test this theory, following culture of 
a DC with LPS or Pa and IL-4, we could wash the cells then re-expose the DC to IL-
4 only and assess the cytokines that are secreted, and the ability of those DCs to 
support naïve Th differentiation.  
 
Prior to in vivo transfer it was found that Pa stimulated Il4ra-/- DC secreted 
significantly enhanced levels of IL-12p40 and reduced levels of IL-10, but had no 
increase in IL-12p70, NO, TNFα or IL-6 (Fig. 4.7B). IL-4 has previously been shown 
to inhibit the secretion of (p40)2 homodimers from TLR stimulated DCs (Hochrein, 
O'Keeffe et al. 2000). (p40)2 has been shown to function as an antagonist of both 
mouse and human IL-12p70 signalling (Mattner, Fischer et al. 1993; Gillessen, 
Carvajal et al. 1995; Ling, Gately et al. 1995). The ability of IL-4 to mediate 
enhanced IL-12p70, (via relieving the antagonism of (p40)2), was suggested to 
result in a feedback mechanism whereby IL-4 was able to promote a Th1 response 
(Hochrein, O'Keeffe et al. 2000). Although we did not determine whether the IL-
12p40 that we detected prior to DC transfer was of a (p40)2 conformation, it is 
possible that, as it was produced from Il4ra-/- DC at such high levels, it was in the 
antagonistic form. Further evidence that the DC derived IL-12p40 was functioning in 
an antagonistic role in vivo is highlighted by the significantly reduced level of IFNγ 
that was primed upon transfer of Pa stimulated Il4ra-/- DCs (Fig. 4.7C).  
 
Interestingly, IL-4 has been reported to inhibit IL-10 secretion from LPS/CpG 
stimulated DCs, which results in an enhancement of IL-12p70, an outcome which 
enables the polarisation of a Th1 type response in vitro (Yao, Li et al. 2005; 
Guenova, Volz et al. 2008). As such, the finding that Pa pulsed IL-4Rα deficient 
cells produced less IL-10 than WT DCs (Fig. 4.7B) is at first surprising. However, it 
has to be remembered that there is no detectable or exogenous IL-4 within this 
system pre-transfer. As Pa stimulated IL-4Rα deficient DCs were less capable of 
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priming IL-17 and IFNγ T-cell responses than their WT counterparts (Fig. 4.7C), this 
suggests that in a WT situation, receipt of an IL-4 signal in the context of a bacterial 
pathogen drives a feedback loop to enhance Th1/Th17 cytokine production (Fig. 
4.15). 
 
A question that should be addressed in relation to the transfer of Pa 
stimulated DCs in vivo is: what is the source of IL-4 (or IL-13) in this setting? No IL-4 
was detected upon restimulation of LNs following Pa DC transfer, though a small 
amount of IL-13 was measured (Fig. 4.7C). Thus, IL-13 may be the factor that is 
influencing the outcome of Th1/Th17 polarisation by bacterially stimulated WT or 
Il4ra-/- DCs.  
 
4.5.3 IL-4 and SEA regulation of DC function  
As shown in previous studies, SEA caused no obvious maturation of DCs 
(MacDonald, Straw et al. 2001) in terms of MHC-II, co-stimulatory molecule or IL-10 
and IL-12p70 expression/secretion, and this was the case irrespective of IL-4 
presence (Fig. 4.4).  
 
The ability of SEA pulsed DCs to induce potent Th2 responses following 
transfer in vivo has been reported previously	   (MacDonald, Straw et al. 2001; 
Perona-Wright, Jenkins et al. 2006; MacDonald and Maizels 2008). We extended 
the use of this transfer system to address how the ability of the polarising DC to 
respond to IL-4 alters the ensuing immune response. DCs that could not receive an 
IL-4 signal (Il4ra-/-), primed less IL-10 and IFNγ, following restimulation of pLN cells 
with SEA (Fig. 4.7D). In this system, SEA delivery via the transferred DCs induces 
an IL-4 rich environment. S. mansoni eggs and the soluble antigens released from 
them activate mast cells and induce IL-4 production from eosinophils (Sabin, Kopf et 
al. 1996), and SEA exposure results in purified human basophil secretion of IL-4	  
(Falcone, Dahinden et al. 1996; Haisch, Schramm et al. 2001). However, in the 
absence of mast cells or eosinophils, S. mansoni eggs can induce normal Th2 
responses, and it has been suggested that the main source of IL-4 is in fact the 
CD4+ T-cells	   (Pearce, C et al. 2004). An alternative source of IL-4 in Th2 settings 
are the innate lymphoid cells (ILCs) (Mjosberg, Bernink et al. 2012), a cell 
populations whose importance in the DC dependent induction of Th2 responses has 
yet to be investigated comprehensively. 
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Based on our data (Fig. 4.7D), we propose that the IL-4 induced following 
DC presentation of components of SEA in vivo then feeds back to signal to the 
priming DC, altering the magnitude of the resultant effector response. The concept 
that IL-4 can drive enhanced DC secretion of IL-12p70 and reduced IL-12p40 and 
IL-10 (as discussed above), provides a possible explanation for the reduced 
induction of SEA-specific IFNγ by IL-4Rα-/- DCs (Fig. 4.7C). No cytokines were 
induced by SEA prior to DC transfer (Fig. 4.7B), but this does not preclude the 
possibility that in vivo derived signals will promote SEA-DC cytokine secretion 
following transfer.  
 
A study has addressed a related question, of how DCs that produce IL-4 
may modulate priming of Th cell responses	  (Kaneko, Wang et al. 2003). Since DCs 
do not themselves produce IL-4 (MacDonald and Maizels 2008). This study used an 
adenoviral transduction system to create IL-4 secreting DCs, which they then 
trasferred in vivo, and restimulated draining LN cells 7 days later with γ-irradiated 
splenocytes (Kaneko, Wang et al. 2003). IL-4 secreting DCs promoted enhanced 
levels IL-4, IL-10 and IFNγ than control DCs (Kaneko, Wang et al. 2003). This data 
indicates that DC IL-4 acting in an autocrine manner is able to promote IFNγ and IL-
10 expression by T-cells, confirming our finding of reduced IFNγ and IL-10 in the 
absence of DC IL-4R signalling. Kaneko et al confirmed that in response to CD40 
ligation or LPS treatment, the IL-4 producing DCs also secreted more IL-12p70 
(Kaneko, Wang et al. 2003) than control cells, highlighting a role for the secreted IL-
4 in promoting Th1 responses (Hochrein, O'Keeffe et al. 2000; Kalinski, Smits et al. 
2000; Yao, Li et al. 2005). Indeed, the in vivo signal that mediates altered SEA-DC 
cytokine production may be partly due to CD40 ligation, as this has previously been 
shown to be required for Th2 induction by SEA pulsed DCs transferred in vivo	  
(MacDonald, Straw et al. 2002). DC CD40 expression was shown not to be required 
for induction of Th1 responses by Pa stimulated DCs (MacDonald, Straw et al. 
2002), and in vitro ligation of CD40 did not alter DC cytokine secretion in response 
to SEA (Fig. 4.6). Nevertheless, in vivo CD40 stimulation may be required for the 
induction of Th1 cytokines (enhanced IFNγ) in the context of the Th2 polarising 
antigen SEA.  
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The ability of SEA to partially inhibit IL-4 dependent RELMα production by 
DCs (Fig. 4.5) was a little surprising given previous reports showing that SEA does 
very little to modulate detectable changes in DC activation	  (Perona-Wright, Jenkins 
et al. 2006). DC derived RELMα promotes SEA (and IL-4) dependent T-cell IL-10 
and IL-13, but limits IFNγ in vivo (Fig. 4.9) as well as IL-4 in vitro (Fig. 4.10). SEA 
interference with RELMα production (Fig. 4.5) may be a factor contributing to the 
lack of significant difference seen in IL-4 or IL-13 priming by WT and IL-4Rα-/- DCs 
following their in vivo transfer (Fig. 4.7D).  The differences observed in the in vitro 
DC:T-cell co-cultures, in which significant enhancement of IL-4 (Fig. 4.8B&C) and 
reduction of IL-13 was found when DCs lacked IL-4Rα (Fig. 4.8D) (See Fig. 4.16), 
could in part be due to the absence of SEA in the in vitro assay.    
 
Given this complexity, we have attempted to put together working models of 
how IL-4 responsiveness and RELMα production may alter the ability of DCs to 
polarise CD4+ T cell cytokine production in vitro and in vivo, in the presence and 
absence of helminth antigen (Fig. 4.16). Based on our data, we would propose that, 
in the absence of helminth antigen, a DC IL-4Rα dependent factor (labelled ‘A’) may 
be primarily responsible for the promotion of T-cell IL-4 in vitro (Fig. 4.16A). 
Similarly, as illustrated in Fig. 4.16B, an SEA dependent factor ‘B’ may be 
responsible for the stringent promotion of T-cell IL-4 in vivo. 
 
Although IL-10 and IFNγ were significantly decreased following transfer of 
SEA pulsed Il4ra-/- DCs, as compared to WT SEA DCs, IL-4 was not significantly 
reduced, suggesting that an IL-4R independent signal is promoting T-cell IL-4 in this 
setting (Fig. 4.7D). Furthermore, in contrast to what was seen in vitro (Fig. 4.10B), 
Retnla-/- DCs were not found to promote elevated IL-4 in vivo following transfer (Fig. 
4.9C), suggesting that the SEA driven factor A may override or bypass the ability of 
RELMα to control DC IL-4 induction.  
 
Factors A and B may be the same molecule, induced via two separate 
pathways (IL-4/SEA), or separate molecules, indeed, molecules A and B may also 
counter-regulate one another or synergise with each other. To try and identify Th2 
polarising molecules expressed by DCs, a microarray, deep sequencing or 
proteomic screen comparing WT DCs +IL-4, WT DCs +SEA, and Il4ra-/- DC +SEA 
could be undertaken. We would hypothesis that, if a single DC molecule is 
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responsible for promoting T-cell IL-4 downstream of IL-4R and SEA receptor 
signalling, then it would be enhanced by both IL-4 and SEA in WT DCs, and by SEA 
in the absence of IL-4R signalling.  
 
This leads into the question of which receptor is signalling downstream of 
SEA recognition? The lacto-N-fucopentaose III (LNFPIII) moiety of SEA has been 
shown to bind to DCs via DC-SIGN, a molecule that has been associated with IL-4 
driven AAM	  (Relloso, Puig-Kroger et al. 2002; Martinez, Helming et al. 2009). Thus 
IL-4 may upregulate expression of CLRs such as DC-SIGN on DCs, enabling a 
more efficient interaction with SEA components, leading to an altered induction of 
RELMα. Although DC-SIGN was not addressed in this work, we did investigate the 
impact of IL-4 on DC expression of a different CLR, MR. MR is another molecule 
associated with both the uptake of the SEA component omega-1 and in vivo priming 
of Th2 by DCs (Everts, Hussaarts et al. 2012).  MR is also enhanced by IL-4 in AAM 
(Stein, Keshav et al. 1992), and found to be significantly increased at the transcript 
level in AADCs (Fig. 3.4F). An investigation into the ability of SEA to limit IL-4 driven 
RELMα in Mrc1-/- DCs would be a good starting point to investigate whether SEA 
inhibition of RELMα is dependent upon this uptake receptor. Alternatively, anti-MR 
antibodies could be used to block this receptor in WT DCs.  
 
Signalling molecules downstream of TLRs should also be considered, as 
TLR recognition of SEA components has been reported previously (van der Kleij, 
Latz et al. 2002; Aksoy, Zouain et al. 2005; Gao, Zhang et al. 2012). Another layer 
of complexity that could be particularly relevant here may also be provided by the 
recent identification of cross-talk between TLR and CLR signalling, an aspect of DC 
activation that has not yet been investigated in the context of Th2 induction and 
development (Geijtenbeek and Gringhuis 2009). 
 
4.5.4 RELMα function 
Previous studies using global RELMα deficient animals have suggested that, 
globally, RELMα functions as a negative regulator of Th2 responses (Nair, Du et al. 
2009; Pesce, Ramalingam et al. 2009). In our study investigating the function of 
RELMα specifically in DCs, we found that RELMα limited T-cell IL-4 in vitro (Fig. 
4.10) but promoted T-cell IL-10 and IL-13 both in vitro and in vivo (Figs. 4.9 & 4.10).  
These findings suggests that the role of RELMα in the immune system varies in a 
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context and timing dependent manner; DC secretion during T-cell priming 
influencing responses differently to RELMα produced more generally by other cell 
types at other timepoints of immune development. Using an S. mansoni lung 
granuloma model, Pesce et al found that there was enhanced expression of IL-4, IL-
5 and IL-13 mRNA in global Retnla-/- mice, and T-cells secreted elevated IL-4 and 
IL-5. This contrasts our results in which we show that DC RELMα differentially 
modulates IL-4 and IL-13 (Fig. 4.10).  In the liver during S. mansoni  infection 
eosinophils were found to be the main source of Retnla, and animals globally 
deficient in Retnla had enhanced liver granuloma volume by 12 weeks post infection 
(Pesce, Ramalingam et al. 2009).    
 
Neither of the published reports of RELMα deficiency in settings of helminth 
infection have described a role for RELMα in the modulation of IL-10, which is a 
novel aspect of our work (Figs. 4.9 & 4.10) (Nair, Du et al. 2009; Pesce, 
Ramalingam et al. 2009). Addition of rRELMα during LPS stimulation of BMM was 
found to enhance the production of the pro-inflammatory cytokines IL-6 and TNFα, 
whilst inhibiting LPS induced IL-10 (Munitz, Waddell et al. 2008). Thus the ability of 
RELMα to modulate IL-10 also appears to be cell type and context dependent, with 
rRELMα being able to limit IL-10 in BMM in the context of a Th1 stimulus, but 
absence of RELMα in GMDCs reducing their ability to promote T-cell IL-10 secretion 
in the context of Th2 polarising antigen (Fig. 4.9) or cytokine (Fig. 4.10). In 
agreement with Fig. 4.11, in which it was shown that treatment of GMDCs with 
rRELMα alone did not alter their co-stimulatory molecule or cytokine secretion, 
Munitz et al, also found rRELMα was unable to modulate IL-10, IL-6 and TNFα 
production from BMM in the absence of LPS (Munitz, Waddell et al. 2008). The 
modulation of BMM by rRELMα (Munitz, Waddell et al. 2008) underscores the ability 
of AAM/AADC derived RELMα to function in an autocrine manner. In future work to 
help better delineate the different impact of RELMα on macrophages vs. DCs, the 
addition of exogenous rRELMα to GMDCs should be repeated in the presence of 
LPS or other defined TLR ligands, as was carried out in the BMM study (Munitz, 
Waddell et al. 2008).  
 
The 2008 study from Munitz et al (Munitz, Waddell et al. 2008) also reported 
that DSS colitis was reduced in Retnla-/- animals, so it is perhaps surprising that no 
similar role for RELMα in modulation of gut inflammation and pathology during 
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schistosomiasis was identified in the Pesce study (Pesce, Ramalingam et al. 2009). 
Another study has previously shown that LysMCreIL-4Rαfl/- animals that lack AAM 
display reduced survival following S. mansoni infection, linked to enhanced gut 
pathology, breakdown of barrier function and sepsis	  (Herbert, Holscher et al. 2004). 
In this study, in the absence of AAM, there was impaired intestinal wound healing, 
which was suggested to be reason for increased death. However, the LysMCreIL-
4Rαfl/- animals would likely also have reduced RELMα at the site of intestinal 
damage, and thus less amplification of LPS driven IL-6 and TNFα, as shown in the 
DSS colitis model (Munitz, Waddell et al. 2008). Thus, the reduction or absence of 
RELMα production by the IL-4Rα deficient macrophage populations simultaneously 
exposed to gut bacteria and their products could have been beneficial in the Herbert 
schistosome infection study. To assess more precisely the role of macrophage 
derived RELMα in gut pathology during S. mansoni infection the use of 
LysMCreRetnla-/fl animals would be most informative. In the absence of such mice, 
providing exogenous rRELMα intestinally during S. mansoni infection of LysMCreIL-
4Rαfl/- animals, could determine the contribution of RELMα in mediating intestinal 
inflammation.  
 
The clear role for DC expression of RELMα in limiting T-cell IL-10 shown in 
Figs. 4.9 & 4.10 suggests that, in response to IL-4, RELMα deficient DCs are either 
producing a factor that directly inhibits T-cell IL-10, or not producing a factor that IL-
4 treated WT cells produce to support T-cell IL-10 production. Alternatively, the 
factor could be acting indirectly on T cells by modulating other aspects of DC APC 
function. It is possible that RELMα itself is the factor, and/or Retnla-/- DCs may 
differentially express other T-cell/DC polarising factors. The identity of the RELMα 
receptor has not yet been determined, although BTK has been proposed as a 
binding partner (Su, Zhou et al. 2007; Nair, Du et al. 2009). Identification of a 
presumably, surface bound receptor for RELMα and generation of a mouse strain 
deficient in expression of the receptor would enable future experiments to determine 
the relative importance of DC Vs T-cell responsiveness to RELMα.  In the absence 
of such information, we undertook a microarray study to investigate which molecules 
may be differentially transcribed in WT vs. Retnla-/- DCs in response to IL-4 
treatment (Fig. 4.12), as discussed below in section 4.5.6. “Microarray targets”. 
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 One fascinating feature of alternative activation of the GMDCs was that they 
continued to secrete RELMα and Ym1/2 up to 36 hours after removal of IL-4 from in 
vitro culture (Fig. 4.6C), clearly showing that the impact of IL-4 on DC alternative 
activation is not transient. The maintained expression of these AA markers suggests 
that, in the context of an immune response, a DC could become alternatively 
activated in the peripheral tissues and influence effector responses there, but also 
still be able to secrete RELMα and Ym1/2 following migration to the secondary 
lymphatics and so during T cell priming.  
 
4.5.5 Antigen processing and presentation by WT, Il4ra-/- and Retnla-/- DCs  
In order to control for the possibility that IL-4Rα and/or RELMα deficient DCs 
had an altered ability to acquire and present antigen to T-cells, compared to WT 
DCs, we undertook antigen uptake and presentation assays (Figs. 4.12 & 4.13). A 
similar percentage of the GMDC population was able to pinocytose FITC conjugated 
dextran in the absence of RΕLΜα, though the per cell uptake may have been 
slightly lower than WT cells. In contrast IL-4Rα deficient DCs had significantly 
enhanced uptake at both the population and per cell level. The functional outcome 
of this finding is unclear, however increased uptake of antigen may result in 
enhanced processing and presentation of antigen which may in turn provide a 
stronger signal for T-cell proliferation. Importantly, the altered ability of Il4ra-/- or 
Retnla-/- DCs to polarise T-cell responses following in vivo transfer was not due to a 
fundamental inability to take up antigen.  
 
Additionally, using the model antigen ovalbumin, we showed that both IL-
4Rα and RELMα deficient DCs are better at driving the proliferation of OVA specific 
TCR transgenic T-cells (Fig. 4.13), highlighting that the altered cytokine induction 
following DC transfer (Figs. 4.7 & 4.9) is not due to a fundamental inability of these 
DCs to efficiently process and present antigen. The enhanced proliferation induced 
by IL-4Rα deficient DCs is in keeping with the increased signal strength idea 
proposed in the previous paragraph, as Il4ra-/- GMDCs pinocytosed higher levels of 
FITC-Dextran (Fig. 4.12).   
  
4.5.6 Microarray targets 
Having realised the complexity of the impact of IL-4 on DC activation, we 
took a more broad approach to attempt to assess the major mRNA changes within 
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AADCs. This approach has revealed a number of genes regulated by IL-4 that could 
have an important functional role in DCs, and with potential to be the focus of new 
studies out-with the scope of this thesis. As is the caveat with all assays measuring 
transcript levels, the results of this microarray analysis do not necessarily correlate 
with changes in protein production. However, many of the targets found to be 
upregulated by IL-4 at the transcript level (Table 4.3.3) had already been previously 
validated at the level of protein in WT DCs in chapter 3 of this thesis, for example 
RELMα, Ym1/2, and CCL24 (Figs. 3.2 & 3.4). 
 
The only gene to be reduced by more than 50% by IL-4 treatment of both 
WT and RELMα deficient DCs was Thbs1, a gene that encodes Thrombospondin-
1/TSP1, a protein known to be involved in cell adhesion (Lynch, Maillet et al. 2012) 
and previously reported to negatively regulate human monocyte derived DC 
cytokine production (Doyen, Rubio et al. 2003). IL-10, TGFβ and PGE2 were 
previously shown to enhance human moDC secretion of TSP1, furthermore, TSP1 
was proposed to mediate DC exhaustion (Doyen, Rubio et al. 2003). Recombinant 
TSP1 could be used in our studies to investigate whether in the context of TLR 
ligation and IL-4 treatment, this molecule is involved in the modulation of T-cell 
polarising cytokine secretion by DCs. In relation to the role of Thbs1 in cell 
adhesion, it would be interesting to investigate whether reduction in Thbs1 by IL-4 
has any impact upon the duration or strength of interaction between DCs and T-
cells. An assay to determine the length of DC:T-cell interactions with and without IL-
4 presence could be carried out with collaborators (Fagerholm Laboratory) in 
Dundee, who use shear flow cell adhesion assays to assess such interactions 
(MacPherson, Lek et al. 2011)  
 
As described in the results (Table 4.3.2), the gene most significantly down 
regulated by IL-4 treatment of Retnla-/- DCs was Il1rn (interleukin 1 receptor 
antagonist, IL-1RA, p=0.0025), a gene whose down-regulation by IL-4 in                                                                                   
macrophages has previously been reported to be dependent upon the transcription 
factor IRF4 (El Chartouni, Schwarzfischer et al. 2010). Il1rn was also significantly 
down regulated following IL-4 treatment of WT DCs, but did not reach the 50% 
reduction in expression that was used as a cut off during this analysis (Adj p 
value=0.026, FC=0.54). IL-1RA potently suppresses the effects of the 
proinflammatory cytokine IL-1. Interestingly, Ilrn-/- animals have been shown to have 
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exacerbated Th2 cytokine production, which was associated with decreased DC IL-
12 production in a non-helminth model of liver granuloma (Iizasa, Yoneyama et al. 
2005).  Furthermore, reduced DC IL-12p40 was also seen during cutaneous 
leishmaniasis in IL-1RA deficient animals (Kautz-Neu, Kostka et al. 2011). 
Decreased Il1rn expression in Retnla-/- DCs following IL-4 treatment may indicate a 
mechanism via which these cells are more capable at supporting T-cell IL-4 
production than their WT counterparts, which maintain higher levels of expression of 
Il1rn (Fig. 4.8B&C). 
 
Several PRRs were also identified as being differentially expressed in 
AADCs.  The importance of TLR2 in the regulation of IL-4  treated DCs is the focus 
of Chapter 6 and will not be discussed in detail here. Mincle (Clec4e) was identified 
as a C-type lectin induced in macrophages by proinflammatory stimuli (LPS, IFNγ, 
TNFα, IL-6) (Matsumoto, Tanaka et al. 1999) and so its downregulation by IL-4 is 
not that surprising. Mincle functions as a danger receptor, recognising dead cells, 
damaged self and pathogen products from mycobacteria and fungus	   (Miyake, 
Ishikawa et al. 2010). IL-4 dependent downregulation of Mincle in DCs has not been 
reported previously.   
 
Of the three genes upregulated greater than 100% by IL-4 treatment of WT 
but not Retnla-/- DCs (Table 4.3.5), one was Retnla, one (Apol7c) has an unknown 
function and the third was Hfe. Hfe encodes haemochromatosis, a protein involved 
in the regulation of iron transport (Evstatiev and Gasche 2011). Specifically, it 
interacts with and controls the activity of transferrin receptors. Classical versus 
alternative activation has previoulsy been reported to impact the iron handling ability 
of MCSF derived BMM (Corna, Campana et al. 2010). IFNγ exposed M1 cells were 
shown to have a sealed intracellular pool of iron, whereas IL-4 exposed M2 cells 
were poised for iron release and uptake allowing recycling of any available iron. The 
same study also found that in conditions of iron limitation, M2 cells had reduced 
expession of CD86 and MHC-II, whereas M1 cells maintained the same levels of 
costimulatory molecule expression. Hfe was significantly upregulated by IL-4 in 
RELMα deficient cells but the fold change did not meet the 2 fold cut off. Altered iron 
metabolism in DCs in the context of IL-4 and a pathogen (such as a bacteria) could 
influence the outcome of immune activation and host survival, as iron retention can 
be used as a mechanism to deplete iron from invading pathogens (Gaetano, 
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Massimo et al. 2010). Upregulation of the transferrin receptor c (Tfrc) by IL-4 in both 
WT and Retnla-/- DCs (Table 4.3.3) confirmed a role for IL-4 in altering DC iron 
metabolism. 
 
Another gene dramatically altered in DCs by IL-4 was Aldh1a2, which 
encodes the retinal dehydrogenase enzyme RALDH2, and is involved in the 
conversion of retinal to RA	   (Blomhoff and Blomhoff 2006). There is already a 
substantial literature on the possible role of RA in DC activation and function, which 
prompted us to more fully address this observation, and Aldh1a2 is the focus of 
Chapter 5 of this thesis.  
 
Other upegulated genes with relevance to this thesis include Irf4, the 
interferon response factor originally shown to be required for homeostasis in B and 
T cells (Mittrucker, Matsuyama et al. 1997) and more recently shown to be the 
transcription factor required for GMDC differentiation (Lehtonen, Veckman et al. 
2005).  Irf4 is a component of the T regulatory cell transcriptional machinery (Zheng, 
Chaudhry et al. 2009) and is thought to be required for alternative macrophage 
activation (El Chartouni, Schwarzfischer et al. 2010; Satoh, Takeuchi et al. 2010).. 
As Il1rn is known to be regulated by expression of Irf4 (El Chartouni, Schwarzfischer 
et al. 2010), it is possible that the significant downregulation of Il1rn detected 
following IL-4 treatment of GMDCs, was due to the upregulation of this trasncription 
factor. A time course approach could be used to determine the dynamics of Il1rn 
and Irf4 transcription following IL-4 treatment.    
 
In terms of chemokine receptors, there was also a very significant 
upregulation by IL-4 of Cxcr2 (also known as IL8RB)	  (Murphy and Tiffany 1991), a 
receptor known to be involved in neutrophil egress (Day and Link 2012). Only one 
previous report confirms Th2 cytokine induction of CXCR2 in human monocyte 
derived DCs (Bonecchi, Facchetti et al. 2000). Induction of CXCR2 expression by 
IL-4 or IL-13 in the study by Bonecchi et al was found to enable cells to respond to 
IL-8 as assessed by chemotaxis and release of oxygen radicals (Bonecchi, 
Facchetti et al. 2000). The authors speculate that IL-4 and IL-13 in vivo can reorient 
the action of IL-8 from neutrophils to monocyte derived cells via the upregulation of 
CXCR2 (Bonecchi, Facchetti et al. 2000).  
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Flt1 (FMS- related tyrosine kinase 1; Also known as VEGFR1) a receptor for 
the angiogenic factor vascular endothelial growth factor (VEGF) was upregulated by 
IL-4 with a fold change >3 (Table 4.3.3). Flt1 has previously been shown to be 
expressed by monocyte derived DCs differentiated in the presence of GM-CSF and 
IL-4 (Fernandez Pujol, Lucibello et al. 2001). Soluble Flt1 can also act as a decoy 
receptor, binding VEGF without signalling (Xie, Fan et al. 2009). Conceivably, this 
could alter the ability of DCs to respond to VEGF in a Th2 cytokine setting.  It was 
interesting that Flt1 was also upregulated in Retnla-/- DCs, as RELMα has been 
described to enhance VEGF expression in the lung	   (Teng, Li et al. 2003; Tong, 
Zheng et al. 2006; Yamaji-Kegan, Su et al. 2006).  
 
Edn1 is significantly upregulated by IL-4 in WT and Retnla-/- DCs (Tables 
4.3.3 & 4.3.4), although in WT cells the upregulation did not reach the 2FC cut off 
(FC=1.88, P=0.00063). Edn1 is a vasoconstrictive molecule, and the expression of 
endothelin receptors by human DCs is associated with maturation (Guruli, Pflug et 
al. 2004). Further, blockade of certain aspects of endothelin-1 signalling (ETA) 
results in reduced IL-12 production by DCs, whereas blockade of ETB results in 
enhanced DC survival (Guruli, Pflug et al. 2004). Interestingly, Edn1 secretion by 
DCs has been linked to TLR2 and TLR4 agonists (Spirig, Potapova et al. 2009). 
RELMα acting under it’s pseudonym HIMF, has also been shown to have 
vasoconstrictive action in the lung	  (Teng, Li et al. 2003). The potential for regulation 
of angiogenesis and vasodilation/vasoconstriction previously reported for various 
genes upregulated in GMDCs in response to IL-4, this should prove an exciting area 
for continued study.  
 
Aqp3 (Aquaporin 3) was significantly upregulated within WT and Retnla-/- 
DCs in the presence of IL-4. Aquaporin 3 is a membrane water transport protein, 
that is permeable to water, urea, glycerol and was more recently shown to mediate 
uptake of H2O2 (Miller, Dickinson et al. 2010). Aquaporins play a role in maintaining 
the fluid balance of a cell, and are particularly important in immature DCs which 
constitutively take up fluid via macropinocytosis (de Baey and Lanzavecchia 2000). 
Aqp3 has previously been shown to be expressed by immature DC and become 
downregulated following maturation; DCs in the De Baey study were differentiated 
from monocytes using GMCSF and IL-4. However, the authors noted that IL-4 was 
not required for the moDC expression of Aqp3 and that macrophages did not 
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express this protein (de Baey and Lanzavecchia 2000). A report from 2012 has 
further highlighted the importance of Aqp3 in the immune system by showing a 
requirement for aqauporin 3 mediated uptake of H2O2 in chemokine mediated 
migration of T-cells (Hara-Chikuma, Chikuma et al. 2012).  
 
Finally, the transcription factor Batf3 was – somewhat surprisingly – 
significantly induced by IL-4 in Retnla-/- DCs (but not induced at all in WT DCs), a 
result that has not previously been reported. Batf3 is responsible for the 
development of CD8α+ DCs in vivo, a subset required for the cross presentation of 
antigens	  (Hildner, Edelson et al. 2008). It is not apparent as to why Batf3 would be 
upregulated by IL-4 or why this molecule may be reguated by RELMα. Batf3 has 
potential to be the factor that alters the priming capacity of RELMα deficient DCs, 
and analysis of the impact of IL-4 on Batf3-/- DCs, or the impact of rRELMα on WT 
DC Batf3 expression could shed light on this matter.  
 
As is inherent to transcriptomic approaches used to characterise cell 
populations, a large numer of possibly interesting candidate genes has been 
generated, in this instance with regard to AADC induction and function. In depth 
analysis of the available literature on each potential target gene will enable the most 
relevant target genes to be chosen for further interrogation. In this thesis, based 
upon the large body of literature available on DC vitamin A metabolism (section 1.8), 
we chose to interrogate further the role of Aldh1a2 in IL-4 exposed DCs.   


















Figure 4.1 TLR stimulated GMDCs upregulate co-stimulatory molecules. WT 
GMDCs were stimulated overnight with 5μg/ml CpG or 250ng/ml LPS and their 
expression of MHC-II, CD80, CD86 and CD40 was assessed by flow cytometry (B). 
Shaded=isotype control, black line=media, grey line=CpG, blue line = LPS. 
Geometric mean fluorescence intensity (MFI) of MHC-II (C), CD80 (D), CD86 (E), 
and CD40 (F) by CD11c+ cells following overnight culture with or without CpG, LPS 
and IL-4. Data is representative of 3 experiments (MHC-II), or 1 experiment (CD80, 















Figure 4.2 IL-4 alters the cytokine profile of DCs activated by TLR ligation. GMDCs 
were cultured overnight in the presence of 5μg/ml CpG 1826 or 250ng/ml LPS with 
or without 20ng/ml IL-4 (A), their secretion of T-cell polarising cytokines was 
assessed by ELISA (B-E). Error bars represent SEM of triplicate wells, data is 




































Figure 4.3 TLR agonists limit IL-4 driven alternative activation. GMDCs were cultured overnight in 
the presence of 5μg/ml CpG or 250ng/ml LPS with or without 20ng/ml IL-4 (A), alternative 
activation status was assessed by intracellular RELMα & Ym1/2 staining (B+C), ELISA (D) or 
qPCR analysis of alternative activation associated genes (E+F). Graphs in C show percentage 
positive populations, error bars represent SEM of triplicate wells. The medium control presented in 
part E are the same as those presented in part F, CpG  (E) and LPS (F) stimulations were carried 
out within the same experiment but have been separated to improve clarity. Bars in parts E+F 
Black= Medium, Grey= +IL-4, Striped=+TLR ligand. Data is representative of 4 (A-C) or 2 (E+F) 








18 h Flow cytometry 
ELISA 
Figure 4.4 Complex bacterial but not helminth antigens modulate DC co-stimulatory molecule 
expression and cytokine production. GMDCs were cultured overnight in the presence of 10μg/ml P. 
acnes or 25μg/ml SEA with or without 20ng/ml IL-4 (A), co-stimulatory molecule expression (B+C) 
and secretion of IL-12p70 and IL-10 was assessed by ELISA (D). Graphs in C show mean 
fluorescence intensity. Error bars represent SEM of triplicate wells, data is representative of >3 
independent experiments *=P<0.05 **= P<0.01 ***=P<0.001.  
D. 










































Figure 4.5 Complex bacterial and helminth antigens modulate DC alternative activation. GMDCs 
were cultured overnight in the presence of 10μg/ml P. acnes or 25μg/ml SEA with or without 20ng/
ml IL-4 (A), alternative activation status was assessed by ELISA (B), intracellular RELMα & Ym1/2 
staining (C) and qPCR (D). Graphs in C show percentage positive populations, error bars represent 
SEM of triplicate wells, data is representative of >3 independent experiments, a.u.=arbitrary units 










Med 24 h 
ELISA 
Figure 4.6 IL-4 alters the response of DCs following CD40 ligation. 
GMDCs cultured overnight with IL-4 and Pa or SEA were washed and 
re-cultured with agonistic anti-CD40 (black bars) or control antibody 
(white bars) for a further 24h (A). Cytokine (B) and RELMα and 
Ym1/2 (C) secretion was assessed by ELISA. Data representative of 3 
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Figure 4.7  Il4ra-/- DCs are less able to induce IFNγ and IL-17 responses. WT or Il4ra-/- 
BMDCs were cultured overnight in medium alone (M), with Pa or SEA, harvested and injected 
subcutaneously into WT mice, 7 days later the draining pLN were harvested, cells restimulated 
for 72h with Pa or SEA and cytokine secretion was assessed by ELISA (A). Cytokine secretion 
was assessed pre transfer (B). Cytokines produced following restimulation with Pa (C) or SEA 
(D) was assessed by ELISA. Data are representative of 5 independent experiments, error bars 
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Figure 4.8 DC expression of IL-4Rα promotes early IL-4 driven T-cell IL-4, IL-10 and IL-13. 
CD4+ cells sorted from KN2 IL-4 reporter mice were cultured for 3 days with WT or Il4ra-/- 
GMDCs and agonistic anti-CD3 antibody with or without IL-4 (A). Cells were assessed for IL-4 
protein production by flow cytometry (B+C) and cytokine secretion by ELISA (D+E). Data are 
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Figure 4.9 DC expression of RELMα during Th2 priming regulates IFNγ and promotes 
IL-10 and IL-13 production. WT or Retnla/- BMDCs were cultured overnight in medium 
alone (M), Pa or SEA and injected subcutaneously into WT mice, 5-7d later pLN were 
harvested, cells restimulated for 72h (A) with Pa (B) or SEA (C) and cytokine secretion 
assessed by ELISA.. Data representative of 2 (B) or 4 (C) experiments, error bars = SEM 
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Figure 4.10 DC derived RELMα promotes IL-4 driven IL-10 but limits T-cell IL-4. CD4+ 
cells sorted from KN2 IL-4 reporter mice (B+C), or IL-10eGFP--CD4+ cells (E+F), were 
cultured for 4 days with WT or Retnla-/- BMDCs and agonistic anti-CD3 antibody with or 
without IL-4 (A) and assessed for IL-4 protein production or IL-10 mRNA expression by 
flow cytometry (B+C,E+F) and cytokine secretion by ELISA (D,G-H) Data is representative 
of 2 (B+C, E+F) or 4 (D,G-H) experiments, error bars = SEM of 4-5 replicate wells per 




























18 h Flow cytometry 
ELISA 
Figure 4.11 rRELMα does not activate GMDCs. GMDCs were cultured overnight in the 
presence of 20ng/ml rRELMα with or without 20ng/ml IL-4 (Α). Εxpression of IL-4Rα 
was confirmed by surface staining (Β), changes in levels of expression of MHC-II and 
CD86 were determined by flow cytometry (C). The alternative activation status of the cells 
was assessed by intracellular RELMα & Ym1/2 staining (D), and cytokine secretion was 
assessed by ELISA (E). Graphs in D show percentage positive populations, bars in D 
represent mean of triplicate wells, data is representative of 2 (E) or 3(B-D) independent 













or	   Flow 
cytometry 
Figure 4.12. WT, Il4ra-/- and Retnla-/- DCs are equally capable at antigen uptake. WT, 
Il4ra-/- or Retnla-/- BMDCs were incubated with FITC conjugated dextran at 37°C and 
antigen uptake assessed by flow cytometry (A-C). Shaded=0°C, Black line=37°C. Data is 
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Figure 4.13. Antigen processing and presentation is unimpaired in Il4ra-/- and Retnla-/- 
DCs. WT, Il4ra-/- or Retnla-/- GMDCs were cultured for 4d with CFSE labelled OT-II Tg T-
cells in the presence of OVA peptide (B) or protein (C) and the ability to stimulate 
proliferation was assessed by flow cytometric analysis of CFSE dilution (A). Shaded=no 
peptide/protein, Black line=0.01μg/ml OVA peptide (A) or 5μg/ml OVA protein (B). Data 
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Figure 4.14. IL-4 treatment of RELMα deficient DCs significantly alters transcription of more 
genes than IL-4 treatment of WT DC. WT, Il4ra-/- or Retnla-/- GM-DCs were cultured for 6h with 
IL-4, cells were assessed for activation status by flow cytometry and ELISA (B-E), RNA was 
extracted and an illumina microarray carried out, genes significantly changed upon IL-4 were 
assessed (F-H) Data is from one microarray experiment, 3 biological replicates per genotype 
*=P<0.05 **= P<0.01 ***=P<0.001 ****=P<0.0001. 
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Figure 4.14 continued 
Significantly	  decreased	  with	  fold	  change	  ≤0.5	  upon	  IL-­‐4	  treatment	  
WT	  	   Retnla-­‐/-­‐	  
Significantly	  changed	  upon	  IL-­‐4	  treatment	  
WT	  	   Retnla-­‐/-­‐	  
F.	  
G.	  
WT	  	   Retnla-­‐/-­‐	  
Significantly	  increased	  with	  fold	  change	  ≥	  2	  upon	  IL-­‐4	  treatment	  
H.	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Table	  4.3.1	  Genes	  significantly	  down	  ≤0.5	  fold	  in	  IL-­‐4	  treated	  WT	  and	  Retnla-­‐/-­‐DC	  
Symbol	   Synonym	   Name	   Puta/ve	  func/on	   FC	  
Thbs1	   TSP-­‐1	   thrombospondin	  1	   Cell	  adhesion	   0.31	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Table	  4.3.2	  Genes	  significantly	  down	  ≤0.5	  fold	  only	  in	  IL-­‐4	  treated	  Retnla-­‐/-­‐DC	  	  
Symbol	   Synonym	   Name	   Puta/ve	  func/on	   FC	  
Il1rn	   IL-­‐1ra	   interleukin	  1	  receptor	  antagonist	   Inhibits	  IL-­‐1	  signalling	   0.44	  
Dusp6	   MKP3	   dual	  specificity	  phosphatase	  6	   Nega[ve	  regulator	  of	  ERK1/2	   0.50	  
Pilra	   FDF03	  
paired	  immunoglobin-­‐like	  type	  2	  receptor	  
alpha	  
Inhibitory	  receptor,	  
phosphatase	  recruitment	   0.47	  
Lpcat2	   AYTL1	   lysophospha[dylcholine	  acyltransferase	  2	  
Synthesis	  of	  PAF	  &	  
Glycerophospholipid	  precusors	   0.41	  
Clec4d	   Mpcl	   C-­‐type	  lec[n	  domain	  family	  4,	  member	  d	  
Phagocy[c	  receptor,	  	  
Ac[vates	  Syk	  kinase	   0.35	  
Arhgef3	   GEF3	  
Rho	  guanine	  nucleo[de	  exchange	  factor	  
(GEF)	  3	  
Guaning	  exchange,	  regula[on	  
of	  iron	  uptake	   0.38	  
LOC638301	  




Tlr2	   TLR2	   toll-­‐like	  receptor	  2	   Lipopep[de	  recogni[on	   0.29	  
Pilra	   FDF03	  
paired	  immunoglobin-­‐like	  type	  2	  receptor	  
alpha	  
Inhibitory	  receptor,	  
phosphatase	  recruitment	   0.50	  
Klhl6	   KLHL6	   kelch-­‐like	  6	  (Drosophila)	   BCR	  signal	  transduc[on	   0.47	  
Rsad2	   Viperin	  
radical	  S-­‐adenosyl	  methionine	  domain	  
containing	  2	  
moDC	  induc[on	  of	  Th2	  
IFN	  inducible	   0.44	  
Serpinb2	   PAI-­‐2	  
serine	  (or	  cysteine)	  pep[dase	  inhibitor,	  
clade	  B,	  member	  2	  
Suppression	  of	  Th1,	  promo[on	  
of	  Th2	   0.38	  
Fpr2	   Fprl1	   formyl	  pep[de	  receptor	  2	  
Leukocyte	  (CD11c+)	  
recruitment/	  migra[on	   0.35	  
Pid1	   PID1	  




Clec4e	   Mincle	   C-­‐type	  lec[n	  domain	  family	  4,	  member	  e	  
CTL/mycobacterium	  +	  necro[c	  
self	  recogni[on	   0.29	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Table	  4.3.3	  Genes	  significantly	  up	  ≥	  2	  fold	  in	  IL-­‐4	  treated	  WT	  and	  Retnla-­‐/-­‐	  DC	  	  
Symbol	   Synonym?	   Name	   Puta/ve	  func/on	   FC	  
Ccl24	   Eotaxin-­‐2	   chemokine	  (C-­‐C	  mo[f)	  ligand	  24	   Eosinophil	  recruiment	   16	  
Cxcr2	   IL8RB	   chemokine	  (C-­‐X-­‐C	  mo[f)	  receptor	  2	  
IL-­‐8R	  
Neutrophil	  recruitment	   3.48	  
Aqp3	   GIL	   aquaporin	  3	  
Pinocytosis	  cell	  volume	  
control	   3.25	  
Rnf19b	   Ibrdc3	   ring	  finger	  protein	  19B	   E3	  ubiqui[n	  ligase	   2.14	  
Casp6	   MCH2	   caspase	  6	   Apoptosis	   3.25	  
Ms4a6d	   ?	  
membrane-­‐spanning	  4-­‐domains,	  subfamily	  
A,	  member	  6D	   Unknown	   2.64	  
Hemk1	   ?	   HemK	  methyltransferase	  family	  member	  1	   Unknown	   2.14	  
Pim3	   ?	   proviral	  integra[on	  site	  3	   Cell	  prolifera[on	  	   2.46	  
Aldh1a2	   RALDH2	  
aldehyde	  dehydrogenase	  family	  1,	  
subfamily	  A2	  
Conversion	  of	  Re[nal	  to	  
Re[noic	  Acid	  (RA)	   2.64	  
Tfrc	   TfR1	   transferrin	  receptor	   Iron	  homeostasis	   2.14	  
Pdlim1	   CLP-­‐36	   PDZ	  and	  LIM	  domain	  1	  (elfin)	   Unknown	   3.03	  
Ak2	   ADK2	   adenylate	  kinase	  2	   Mitochondrial	  component	   2.14	  
Gm8221	   ?	   apolipoprotein	  L,	  3-­‐like	  pseudogene	   Unknown	   2	  
Myo1e	   MYO1C	   myosin	  IE	  
Molecular	  motor,	  Clathrin	  
mediated	  endocytosis	   2.83	  
Chi3l4	   Ym2	   chi[nase	  3-­‐like	  4	   Th2	  promo[on?	   4.29	  
Irf4	   IRF4	   interferon	  regulatory	  factor	  4	   TF,	  DC	  development	   2.14	  
Chi3l3	   Ym1	   chi[nase	  3-­‐like	  3	   Th2	  promo[on?	   4	  
Flt1	   VEGFR1	   FMS-­‐like	  tyrosine	  kinase	  1	   Clearance	  of	  VEGF	   3.48	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Table	  4.3.4	  Genes	  significantly	  up	  ≥	  2	  fold	  only	  in	  IL-­‐4	  treated	  Retnla-­‐/-­‐DC	  	  
Symbol	   Synonym?	   Name	   Puta/ve	  func/on?	   FC	  
Edn1	   ET1	   endothelin	  1	   Vascular	  homeostasis	   2.30	  
Plekhf1	   LAPF	  
pleckstrin	  homology	  domain	  containing,	  family	  F	  
(with	  FYVE	  domain)	  member	  1	   Apoptosis	   2.14	  
Hist1h1c	   H1c	   histone	  cluster	  1,	  H1c	  
Chroma[n	  
compac[on	   2	  
Sema4b	   SEMAC	   semaphorin	  4B	  
Nega[ve	  regula[on	  
basophil	  Th2	   2.46	  
Mgll	   MagL	   monoglyceride	  lipase	  
FFA	  release	  from	  
lipids	   2.83	  
BaZ3	   BATF3	   basic	  leucine	  zipper	  transcrip[on	  factor,	  ATF-­‐like	  3	  
TF,	  CD8+	  DC	  
development	   2.64	  
Rufy4	   ?	   RUN	  and	  FYVE	  domain	  containing	  4	   Unknown	   2.30	  
Btbd11	   Unknown	   BTB	  (POZ)	  domain	  containing	  11	   Unknown	   2.64	  
AZ3	   ATF3	   ac[va[ng	  transcrip[on	  factor	  3	  
Regula[on	  of	  immune	  
&	  metabolic	  func[on	   2.64	  
Prps1	   ARTS	   phosphoribosyl	  pyrophosphate	  synthetase	  1	   Purine	  metabolism	   2.14	  
Cdh1	   E-­‐cadherin	   cadherin	  1	  
Cell	  adhesion,	  
epithelial.	   2.64	  
Lad1	   LadA	   ladinin	  
Epithelial	  aoachment	  
to	  mesenchyme	   2.00	  
Tgm2	   TG2/TGC	   transglutaminase	  2,	  C	  polypep[de	   Protein	  crosslinking	   2.14	  
AZ5	   ATF5	   ac[va[ng	  transcrip[on	  factor	  5	   TF	   2	  
Sdc4	   SDC4	   syndecan	  4	  
Proteoglycan	  receptor	  
Ac[vates	  PKC	   3.03	  
Serpina3g	   Spi2A	  




from	  apoptosis	   2.46	  
Plau	   ATF,	  URK	   plasminogen	  ac[vator,	  urokinase	   Degrada[on	  of	  ECM	   2.14	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Table	  4.3.5	  Genes	  significantly	  up	  ≥	  2	  fold	  only	  in	  IL-­‐4	  treated	  WT	  DC	  	  
Symbol	   Synonym	   Name	   Puta/ve	  func/on	   FC	  
Hfe	   HLA-­‐H	   hemochromatosis	   Iron	  homeostasis,	  regula[on	  of	  Transferrin	  Rs	   2.14	  
Retnla	   RELMα	   resis[n	  like	  molecule	  alpha	   Regula[on	  of	  Th2	   3.73	  
Apol7c	   ?	   apolipoprotein	  L	  7c	   Unknown	   2.83	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Figure 4.15. Model of IL-4 and bacterial agonist mediated changes in 
DC function.  In the presence of Pa and IL-4, DCs increase IL-12p70 
and decrease IL-10 secretion, which in vivo results in enhanced IFNγ 
and IL-17 production, confirmed using Il4ra-/- DC transfer (Fig. 4.7C).  
T 







Figure 4.16. Models of IL-4 and helminth mediated changes in DC function. 
(A) In vitro IL-4 treatment of DCs promotes RELMα production (Fig. 3.2), RELMα leads to 
enhanced priming of T-cell IL-10 and IL-13, and reduced IL-4 (Fig. 4.10), IL-4Rα 
dependent factor ‘A’ promotes T-cell IL-4 (Fig. 4.8C).  
(B) In vivo SEA pulsed DCs polarise a Th2 response via unknown factor ‘B’, IL-4 from T-
cells and other innate cell sources signal to DCs via IL-4Rα, promoting RELMα. 
RELMαinhibits IL-4 and promotes IL-10 and IL-13 (Fig. 4.10). However, SEA inhibits IL-4 
driven DC RELMα(Fig. 4.5), releasing the RELMα dependent inhibition of T-cell IL-4 and 
promotion of IL-13 by WT DCs, thus limiting the impact of IL-4Rα deficiency following 
SEA DC transfer (Fig. 4.7) in which no significant difference in priming of IL-4 or IL-13 is 
found between WT and Il4ra-/- DCs, in contrast to the in vitro DC:T-cell co-culture (Fig. 
4.8), in which no SEA is present.  
A. 
B. 
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At the end of chapter 4 (Table 4.3.3) results of the IL-4 DC microarray 
highlighted that one of the genes significantly upregulated greater than 2 fold in both 
WT and Retnla-/- DCs was Aldh1a2, a gene that encodes the retinal dehydrogenase 
enzyme RALDH2 (Zhao, McCaffery et al. 1996). RALDH2 converts retinal to retinoic 
acid, a bioactive metabolite with important roles in the immune system (see section 
1.8). We decided to interrogate further the relationship between IL-4 and vitamin A 
metabolism in DCs. 
 
The importance of dietary vitamin A (retinol) in health is now well 
established, with multiple studies showing significantly reduced all-cause mortality in 
children 6 months to 5 years of age following dietary supplementation (Sommer 
2008).  The specific impact of vitamin A signalling within the immune system has 
begun to be elucidated during the past decade (Iwata, Hirakiyama et al. 2004; 
Coombes, Siddiqui et al. 2007; Hall, Grainger et al. 2011; Jaensson-Gyllenback, 
Kotarsky et al. 2011; Broadhurst, Leung et al. 2012).  
 
Recent work has highlighted a role for retinoic acid (RA), the transcriptionally 
active metabolite of vitamin A, in the development and promotion of CD4+ T-cell 
responses (Hall, Cannons et al. 2011; Pino-Lagos, Guo et al. 2011). It had 
previously been shown that RA expression by gut associated lymphoid tissue 
(GALT) DCs imprints intestinal specificity on T-cells via the upregulation of homing 
receptors α4β7 and CCR9	  (Iwata, Hirakiyama et al. 2004; Benson, Pino-Lagos et al. 
2007). Furthermore, CD103+ gut resident steady state DCs have been shown to 
express Aldh1a2 (RALDH2) (Coombes, Siddiqui et al. 2007), which encodes an 
aldehyde dehydrogenase enzyme responsible for the conversion of retinal into 
retinoic acid (Duester 2000). DC expression of RALDH2 was shown to promote 
extra-thymic conversion of naïve T cells into Foxp3+ regulatory T cells in a TGF-β 
and RA dependent manner (Coombes, Siddiqui et al. 2007; Sun, Hall et al. 2007).   
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Interestingly, it is becoming clear that vitamin A signalling is required for T 
helper cell function outwith the promotion of Foxp3 expression (Hall, Cannons et al. 
2011; Pino-Lagos, Guo et al. 2011). A requirement for RA in the elicitation of the 
proinflammatory CD4+ T-cell response to Toxoplasma gondii infection	   (Hall, 
Cannons et al. 2011) has been shown, as has a role for RA in mediating T-cell 
migration and effector function following allogeneic skin graft	  (Pino-Lagos, Guo et al. 
2011).   However, the impact of vitamin A metabolism on the immune system in the 
context of Th2 settings is underrepresented within the literature.  
 
CD11c+ DCs are both necessary and sufficient for the induction of Th2 
responses in models of helminth infection (Phythian-Adams, Cook et al. 2010; 
Smith, Hochweller et al.). The archetypal Th2 cytokine IL-4 has been shown to 
promote DC expression of Aldh1a2 (Elgueta, Sepulveda et al. 2008; Yokota, 
Takeuchi et al. 2009; Stock, Booth et al. 2011). As we have shown in previous 
chapters that IL-4 stimulates the alternative activation of DCs, we sought to 
determine whether IL-4 also regulates DC vitamin A metabolism and the impact of 
the vitamin A metabolite RA on DC APC function.  
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5.2 SPECIFIC AIMS:  
1. To confirm the role of IL-4 in modulating vitamin A metabolism within DCs. 
2. To understand the interactions that occur between signalling pathways 
involved in alternative activation and vitamin A metabolism. 
3. To dissect the impact of retinoic acid and IL-4 on DC function.  
 
5.3 RESULTS 
5.3.1 Aldh1a2 and Ak2 are significantly upregulated in IL-4 treated DCs  
KEGG (Kyoto Encyclopedia of Genes and Genomes;	  
http://www.genome.jp/kegg/) is a database resource that assists in the 
understanding of biological functions, by compiling associations onto which high 
throughput genomic information can be mapped. The KEGG PATHWAY is a 
collection of manually drawn pathway maps representing the current knowledge of 
molecular interactions and reaction networks for various biological pathways. 
Analysis of IL-4 treated WT DC illumina expression array data (as carried out in Fig. 
4.14) found that the KEGG pathway with which the IL-4 treated WT DC sample data 
had the highest number of associations was metabolic pathways, with which 14 
significantly altered genes were associated (Fig. 5.1A&B). In order to determine 
genes that may have more prominent roles in modulating cellular function following 
treatment with IL-4, we chose to use a 2 fold change cut off, ensuring that only 
transcripts which were doubled in response to IL-4 were being investigated at this 
stage. When using the stringent 2FC cutoff, only 2 metabolic genes remained: Ak2 
(adenylate kinase 2) a mitochondrial protein, and Aldh1a2 (Aldehdye 
dehydrogenase 1a2) (Fig. 5.1 and Table 5.3.1).  
 
5.3.2 IL-4 induces Aldh1a2 expression and aldehyde dehydrogenase activity in 
GMDC and FLT3L DCs treated with GM-CSF 
IL-4 has previously been shown to induce enhanced metabolism of retinal to 
retinoic acid in DC via upregulation of the aldehyde dehydrogenase RALDH2 
(Elgueta, Sepulveda et al. 2008; Yokota, Takeuchi et al. 2009); we were interested 
to relate this role for IL-4 to the role we had described in chapters 3 and 4. In 
chapter 3 it was shown that IL-4 increased expression of alternative activation 
associated molecules (including RELMα and Ym1/2) in DC both in vitro, in vivo and 
ex vivo. In chapter 4 DC derived RELMα was shown to be required for induction of 
T-cell IL-10 and regulation of T-cell IL-4.  Using GMDCs, we first confirmed that, in 
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agreement with published data	  (Elgueta, Sepulveda et al. 2008; Yokota, Takeuchi et 
al. 2009; Stock, Booth et al. 2011), IL-4 enhanced Aldh1a2 transcript and aldehyde 
dehydrogenase activity in DCs. Overnight culture with IL-4 resulted in significant 
upregulation of Aldh1a2 message in GMDCs compared to media only controls (Fig. 
5.2A&B). In addition, we confirmed that the enhanced Aldh1a2 transcript level 
correlated with increased aldehyde dehydrogenase (ALDH) activity using the 
aldefluor assay (Fig. 5.2C). This assay utilizes a BODIPY-conjugated aldehyde 
substrate allowing a fluorescent readout of ALDH activity in individual cells (Stock, 
Booth et al. 2011; Broadhurst, Leung et al. 2012). Activity levels were compared to 
control DCs that had been exposed to a specific inhibitor of ALDH, 
diethylaminobenzaldehyde (DEAB) (Fig. 5.2C). In contrast to GMDCs, DCs 
generated using FLT3L did not have enhanced aldefluor activity when cultured with 
IL-4 (Fig. 5.2D&E). However, overnight culture of FLDCs with GM-CSF and IL-4 did 
increase their aldefluor activity (Fig. 5.2D&E), as has been reported previously 
(Yokota, Takeuchi et al. 2009). This highlights a requirement for colony stimulating 
factors for DC retinoic acid production. As FLT3L DCs do not become alternatively 
activated in our hands (Fig. 3.6) we did not further pursue this angle of research as 
our aim was to compare the impact of IL-4 on DC alternative activation to their 
metabolism of vitamin A.  
 
5.3.3. Schistosoma mansoni infection does not enhance DC aldehyde 
dehydrogenase activity, but highlights a potential requirement for growth 
factors 
As CD11c+ DCs are known to be required for mounting Th2 responses to the 
parasite Schistosoma mansoni	  (Phythian-Adams, Cook et al. 2010), we investigated 
whether DCs from the spleens of schistosome infected mice were able to synthesise 
retinoic acid via the action of aldehyde dehydrogenases. Splenic DCs isolated from 
animals at the peak of the Th2 response, 8 weeks post infection with S. mansoni 
(Fig. 5.3A) were defined by flow cytometry as being live singlets that were 
SSCmidGr1-CD19-CD11c+ (Fig 5.3B&C); the % of CD11c+ cells in the spleen was 
reduced following infection, while the total number of DCs was increased in the 
spleens of infected animals due to infection dependent splenomegaly (Fig. 5.3D). As 
expected, the CD11c+ cells had higher levels of MHC-II than CD11c- cells (Fig. 
5.3E). Within the gated DC population, there was a significant reduction in the % of 
aldefluor positive cells and the geometric mean fluorescence intensity of aldefluor 
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activity was also significantly reduced (Fig. 5.3F), however due to the increased size 
of the spleen during infection, there was no significant difference in the total number 
of aldefluor+CD11c+ cells in each spleen between naïve and infected animals (Fig. 
5.3G). We were initially surprised by the reduced expression of ALDH activity in the 
CD11c compartment due to the high levels of IL-4 known to be induced by 8 weeks 
following infection with this helminth	  (Jenkins, Perona-Wright et al. 2008). Due to the 
results shown in Fig. 5.2 we wondered whether the levels of colony stimulating 
factors were changed in the spleen during S. mansoni infection and if this could be 
responsible for the altered aldehyde dehydrogenase activity in infection. To assess 
this we performed qPCR on RNA extracted from naïve or S. mansoni (S.m.) infected 
spleens (Fig. 5.3H-J). We first confirmed that Il4 was expressed at a high level in the 
spleen during infection, and were not surprised to find that, in keeping with data for 
GMDCs (Fig. 3.1), during infection where there is high level IL-4 that Il4ra was down 
regulated (Fig. 5.3H). We next assessed the transcript levels of the colony 
stimulating factors Gmcsf and Mcsf (Fig. 5.3.I). Though not significant, there was a 
trend for a reduction in the level of Gmcsf, and a significant reduction in Mcsf during 
infection (Fig. 5.3I). We then assessed the level of the DC differentiation factor Flt3l, 
which was also found to be significantly decreased in the spleen after 8 weeks of 
infection with S. mansoni (Fig. 5.3J).    
 
5.3.4. RA does not enhance GMDC aldehyde dehydrogenase activity in the 
absence of IL-4 
Having confirmed that IL-4 was able to induce enhanced BMDC RALDH 
activity (Fig. 5.2), we asked whether the product of RALDH2 activity (RA) could 
regulate its own induction within GMDCs.  The presence of RAREs in the genes of 
RA receptors has been shown, suggesting that RA can modulate the ability of cells 
to receive an RA signal (Leroy, Nakshatri et al. 1991; Bastien and Rochette-Egly 
2004). To assess this point, we first tested whether exogenous all-trans retinoic acid 
(RA) was able to enhance DC RALDH activity, as has been published previously 
(Feng, Cong et al. 2010; Jaensson-Gyllenback, Kotarsky et al. 2011; Stock, Booth 
et al. 2011). We were surprised to find that overnight culture with RA alone did not 
enhance RALDH activity in GMDCs (Fig. 5.4A&B). In order to determine whether 
this disparity was due to the dose of RA, or timing of exposure, we replicated the 
experimental conditions used in the Jaensson-Gyllenbäck 2011 report, namely 
using 20nM RA for a longer time period (39h). This also failed to induce a higher 
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percentage of aldeflour positive cells with RA (Fig. 5.4C).  We do not know why we 
were unable to repeat the finding of Jaensson-Gyllenbäck et al. However, we 
propose that the disparity may due to the differentiation stage of the cells used 
within the assay. Our study used GMDC following 10 days of differentiation, 
whereas Jaensson-Gyllenbäck et al used cells differentiated for only 6 days. 
Cultures differentiated for this length of time will still contain non-DC populations 
(Lutz, Kukutsch et al. 1999), which may well display different responses to RA. 
Additional reports detailing the ability of RA to induce RALDH activity in BMDC also 
used DCs differentiated for less than 10 days (Feng, Cong et al. 2010; Stock, Booth 
et al. 2011). Furthermore, RA was included in the culture during differentiation rather 
than being added as an additional stimulus post-differentiation, making it hard to 
directly compare their findings with those in our study (Feng, Cong et al. 2010; 
Stock, Booth et al. 2011).  
 
We next assessed the impact of combined RA and IL-4 treatment on GMDC 
ALDH activity (Fig. 5.4D). Overnight culture in combination with RA enhanced the 
levels of RALDH activity within the BMDC culture further than the enhancement 
seen on addition of 20ng/ml IL-4 alone (Fig. 5.4E), a finding we believe not to have 
been reported previously in the literature.  
 
5.3.5 DC RALDH activity inversely correlates with expression of DC alternative 
activation markers, with the exception of Retnla 
As IL-4 is known to have diverse effects upon DCs (Hochrein, O'Keeffe et al. 
2000) (Sriram, Biswas et al. 2007; Cook, Jones et al. 2012)(Chapters 3 & 4 of this 
thesis) we sought to determine whether the ability of DCs to alternatively activate 
was changed as a consequence of enhanced RALDH activity. GMDCs were 
cultured overnight in the presence of media alone or media supplemented with 
20ng/ml IL-4, surface stained for CD11c and FACS was used to separate the cells 
into three populations (negative, low, high) based on aldefluor activity, as compared 
to a DEAB control (Fig. 5.5A&B). RNA was extracted from each population, 
converted to cDNA and expression of Aldh1a2 (RALDH2), Chi3l3 (Ym1/2), Mrc1 
(MR), Pparg (PPARγ), Retnla (RELMα) and Ccl24 (CCL24) assessed by 
quantitative PCR (Fig. 5.5C-G). High level aldefluor activity correlated with 
significantly enhanced Aldh1a2 transcript (Fig. 5.5C), implicating RALDH2 as the 
enzyme responsible for the IL-4 enhanced aldefluor activity. As would be predicted 
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from the results presented in chapter 3 (Fig. 3.4), IL-4 significantly enhanced 
expression of Chi3l3, Mrc1, Ccl24 and Retnla, but not Pparg (Fig. 5.5C-F). 
Surprisingly, DC RALDH activity inversely correlated with Ym1/2 expression, with 
aldefluor negative cells having significantly more Chi3l3 mRNA than aldefluor high 
cells (Fig. 5.4D). This inverse relationship between high level aldefluor and low level 
mRNA expression was also the case for MR and PPARγ (Fig. 5.4D&E). Strikingly, 
however, this pattern was not observed with RELMα, where no significant difference 
in Retnla transcript levels was found between any of the IL-4 exposed sorted 
populations (Fig. 5.4F). Although there was a trend for a correlation between Ccl24 
transcript and aldefluor activity, this did not reach significance (Fig. 5.5G). This data 
highlights again a disparity in the regulation of RELMα as compared to other 
alternative activation related proteins such as Ym1/2, and adds in the additional 
complexity of a role for vitamin A metabolism, or RA signalling in modulating 
response downstream of the IL-4Rα in DCs. 
 
5.3.6 RA and IL-4 synergise to enhance DC RELMα but do not impact Ym1/2  
Having shown that Aldh1a2 expression levels and ALDH activity correspond 
with decreased mRNA expression of alternative activation markers, with the 
exception of Retnla, we hypothesised that such a disparity may be due to the 
product of RALDH activity (retinoic acid, RA) acting endogenously to promote 
Retnla message and thus increase DC RELMα production and/or secretion. To test 
this hypothesis, we exposed GMDCs to exogenous RA in the presence of IL-4 and 
assessed the induction of Retnla and Chi3l3 message and intracellular and secreted 
protein production (Fig. 5.6A). The addition of RA alone had no significant impact on 
DC expression of the alternative activation markers RELMα or Ym1/2 (Fig. 5.6B-F).  
However, following overnight culture in the presence of both RA and IL-4, a 
significantly higher proportion of BMDCs expressed RELMα protein than cells 
exposed to IL-4 alone, whereas exogenous RA did not alter DC expression of 
Ym1/2 (Fig. 5.6B&C). These protein expression profiles were mirrored at the 
transcript level, with combined RA and IL-4 treatment significantly enhancing Retnla 
but not Chi3l3 (Fig. 5.6D). Confusingly, there was no comparable significant 
increase in the quantity of secreted RELMα detected by ELISA in the presence of 
combined RA and IL-4 treatment (Fig. 5.6E), and no change was seen in the 
secreted levels of Ym1/2 (plotted as absorbance due to on plate standard failure) 
(Fig. 5.6E).  
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5.3.7 RA does not synergise with IL-4 to enhance alternative activation in BMM 
As macrophage alternative activation has been more widely investigated 
than that of DCs (Gordon and Martinez 2010), we also assessed whether M-CSF 
derived bone marrow macrophages (BMMs) responded to combined RA and IL-4 in 
the same way as BMDCs (Fig. 5.7A), by upregulating RELMα but not Ym1/2. 
Interestingly, overnight culture with combined RA and IL-4 did not significantly affect 
intracellular expression (Fig. 5.7B&C) or secretion (Fig. 5.7D) of alternative 
activation markers RELMα or Ym1/2 by BMMs (Fig. 5.7). As addition of exogenous 
RA to BMMs did not result in enhanced IL-4 driven alternative activation and taking 
into account our data showing that RA does induce enhanced DC alternative 
activation (Fig. 5.6) we propose (in line with a mechanism proposed in a recent 
study for macrophage derived RA driving DC RALDH activity (Broadhurst, Leung et 
al. 2012)) that in vivo, in the context of helminth infection, macrophage derived RA 
may act upon DCs to enhance their alternative activation. 
  
5.3.8 RAR signalling regulates IL-4 driven DC alternative activation 
Due to the enhanced RELMα production from IL-4 exposed DCs upon 
addition of RA (Fig. 5.6) we sought to determine whether the presence of RA within 
the culture media was required for IL-4 driven alternative activation. Initially we 
chose to inhibit RA signalling within GMDC cultures by using a PanRAR antagonist 
LE540. LE540 is a chemical antagonist that blocks all RAR signalling but does not 
however impact other RA receptors. We added LE540 and IL-4 simultaneously to 
GMDC cultures for 18h and assessed the alternative activation status of these cells 
by intracellular staining and ELISA (Fig. 5.8A). LE540 was able to limit the ability of 
IL-4 to drive RELMα protein within GMDCs when compared to cells that were not 
treated with the RAR antagonist and, surprisingly, LE540 was found to enhance 
intracellular IL-4 driven Ym1/2 (Fig. 5.8B&C). LE540 also significantly reduced IL-4 
driven secretion of both RELMα and the chemokine CCL24 by GMDC (Fig. 5.8D). 
Again slightly confusingly, although there was a trend for enhanced secretion of 
Ym1/2 in the presence of both IL-4 and LE540 this did not reach significance in any 
of the experimental repeats (Fig. 5.8E). This result highlights a potential disconnect 
between intracelluar RELMα and Ym1/2 production and secretion, similar to that 
seen in Fig. 5.6C&E, where enhanced intracellular RELMα was not detected at the 
level of secretion. The impact of LE540 on IL-4 induced RELMα in this experimental 
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set up was both more significant and more reproducible than any impact upon 
Ym1/2. The ability of LE540 to differentially modulate the secretion of RELMα as 
compared to Ym1/2 suggests that the point at which RA signalling intersects the 
intracellular cascade downstream of IL-4 binding to the IL-4Rα may be after the 
point at which the pathways leading to RELMα and Ym1/2 have diverged, enabling 
an inhibition of IL-4 driven RELMα but not Ym1/2.  
 
5.3.9 RARα signalling inhibits IL-4 driven RELMα and promotes IL-4 driven 
Ym1/2 
As antagonising all RAR signalling significantly reduced some components 
of IL-4 driven DC alternative activation (RELMα/CCL24) whilst promoting others 
(Ym1/2) (Fig. 5.8) we sought to determine the relative contribution of one of the 3 
retinoic acid receptors (Blomhoff and Blomhoff 2006), RARα. RARα was chosen for 
our studies as it is the most commonly expressed RAR in the myeloid compartment 
(Nagy, Szanto et al. 2012), and the effects of RA in DCs have previously been 
attributed to this receptor (Iwata, Hirakiyama et al. 2004). RARα was also chosen as 
two reports from 2011 had shown that this receptor mediates broad regulation of T-
cell polarisation (Hall, Cannons et al. 2011; Pino-Lagos, Guo et al. 2011).  
 
GMDCs with a specific defect in expression of RARα were differentiated 
from CD11cCreRARαfl/fl bone marrow and the ability of IL-4 to alternatively activate 
these cells was compared with GMDCs differentiated from littermate control BM 
(CD11cWtRARafl/-) that was able to express the RARα (Fig. 5.9A). In stark contrast to 
blocking all RAR signalling (Fig. 5.8), blocking signalling only through RARα resulted 
in a significant enhancement of IL-4 driven RELMα and a significant reduction in 
Ym1/2 (Fig. 5.9B&C). Both the enhancement of RELMα and the reduction in Ym1/2 
were also seen basally in the absence of IL-4 signalling, with CD11cCreRARαfl/fl 
GMDCs displaying significantly more intracellular RELMα than CD11cWtRARafl/- cells 
(Fig. 5.9B; top left compared to bottom left panels). The same trend for increased 
RELMα and reduced Ym1/2 was also apparent at the level of secreted protein both 
in the absence and presence of IL-4 (Fig. 5.9D).  These results suggest that RARα 
may function as a regulatory receptor, to limit the impact of RA at least in the 
presence of IL-4, as addition of exogenous RA (Fig. 5.6) or absence of the RARα 
(Fig. 5.9) caused the same change in IL-4 driven DC derived RELMα. This result is 
in contrast to the inhibition of IL-4 driven RELMα seen when all RAR signalling was 
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inhibited with LE540 (Fig. 5.8), suggesting that signalling via the other RARs (β and 
γ) may promote IL-4 driven RELMα. This data suggests that the cumulative effect of 
RA signalling via various RARs in one cell is not equivalent to the outcome of RA 
signalling via individual RARs. The cumulative outcome of blocking signalling via all 
RARs (Fig. 5.8) induced the opposite response following IL-4 treatment as removing 
signalling via RARα (Fig. 5.9), suggesting that RARα may constrain the response 
induced following binding to other RARs.   
 
5.3.10 RAR signalling modulates IL-4 driven aldehdye dehydrogenase activity 
in GMDC 
Although addition of exogenous retinoic acid was not found to induce 
aldehyde dehydrogenase activity in our hands (Fig. 5.4), we decided that, as 
inhibition of RA signalling altered IL-4 driven DC alternative activation, we should 
confirm or exclude a role for RA signalling in GMDC aldehyde dehydrogenase 
activity. GMDCs were cultured overnight in the presence of the panRAR antagonist 
LE540 with and without IL-4 (Fig. 5.10A). Addition of IL-4 upregulated aldefluor 
activity, and such upregulation was impaired in the presence of LE540 (Fig. 5.10B). 
To provide more firm evidence that RA signalling regulates IL-4 dependent 
production of retinoic acid (via RALDH2 activity), we chose to assess the aldefluor 
activity of IL-4 treated CD11cWtRarafl/- or CD11cCreRarafl/fl DCs which cannot signal 
via RARα (Fig. 5.10C). CD11cCreRarafl/fl GMDC displayed a much higher basal level 
of aldefluor activity when compared to CD11cWtRarafl/- controls, and this significantly 
higher level of activity could be further enhanced by addition of IL-4 (Fig. 5.10D).  
The finding that RARα deficient cells have enhanced basal aldefluor activity (Fig. 
5.10) and lower basal levels of Ym1/2 protein when compared to control cells (Fig. 
5.9) helps to confirm the existence of an inverse relationship between DC Aldh1a2 
and Chi3l3 a novel result discussed earlier in this chapter (Fig. 5.5). This data 
further highlights a regulatory role for RARα, this time in modulating the ability of IL-
4 to induce aldehyde dehydrogenase activity.  
 
5.3.11 RA and IL-4 alter DC co-stimulatory molecule and cytokine secretion 
Having determined that changing the ability of DCs to respond to RA altered 
their alternative activation status, and having previously shown that DC expression 
of both the IL-4Rα and RELMα changes the ability of a DC to polarise T-cell 
responses (Chapter 4 and (Cook, Jones et al. 2012)) we sought to determine how 
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concurrent exposure of DCs to RA and IL-4 affects their ability to activate T-cells 
(Fig. 5.11). As DC expression of MHC, co-stimulatory molecules and production of 
cytokine are major factors in their ability to prime T-cell responses, we determined 
DC surface phenotype and cytokine production following culture with IL-4 and RA 
(Fig. 5.11A). Inclusion of RA in the overnight culture did not significantly alter the % 
of CD11c+ DCs nor the gMFI of CD11c (Fig. 5.11B).  In the presence of both IL-4 
and RA the surface expression of CD40 was significantly decreased compared to 
IL-4 treatment alone (Fig. 5.11C). RA had no further impact on CD80 or MHC-II than 
IL-4 alone (Fig. 5.11C), unfortunately the antibody for CD86 was not available for 
inclusion in the staining panels at the time these experiments were carried out. As 
shown in Fig. 3.1, IL-4 reduced the basal secretion of IL-6 and IL-12p40 by GMDCs 
(Fig. 5.11D) Culture of GMDC with RA resulted in enhanced basal secretion of the 
pro-inflammatory cytokine IL-6, in the absence of antigenic stimulation and this 
enhancement was abrogated in the presence of IL-4 (Fig. 5.11D). As reported 
previously, RA decreased DC secretion of IL-12p40 (Wada, Hisamatsu et al. 2009) 
(Fig. 5.11D). However, in the absence of antigenic stimulation, the amount of 
cytokine produced in all conditions was very low and no IL-10 or IL-12p70 was 
detected.   
 
5.3.12 RA and IL-4 alter T-cell polarisation in the context of DC 
The cytokine data from Fig. 5.11 suggest that RA and IL-4 exposed DCs 
may be less capable of polarising a Th1 response or a Th2 response (reduced 
CD40 (MacDonald, Straw et al. 2002)). The reduced IL-12p40 found in the 
presence of RA and IL-4 may result in reduced availability of IL-12p40 to form 
bioactive IL-12p70 heterodimers, or could be construed to result in decreased levels 
of IL-12p40 homodimers which have been shown to limit the action of IL-12p70 
(Hochrein, O'Keeffe et al. 2000). Thus the impact of RA and IL-4 on DC polarisation 
of T-cells could not be predicted from this data alone. Previous studies have shown 
that RA can influence T-cell polarisation, by promoting IL-4 secretion under Th2 
conditions (Hoag, Nashold et al. 2002; Iwata, Eshima et al. 2003), or not promoting 
IL-4, but limiting IFNγ from already polarised Th1 cells, (Stephensen, Rasooly et al. 
2002). Given the contrasting reports on RA and IL-4 regulation of T-cell polarisation 
by DCs and as a result of our finding of reduced CD40 and IL-12p40 expression we 
decided to carry out a polarisation assay to determine whether DC exposure to RA 
and IL-4 can modulate T-cell cytokine production. As RA and IL-4 were shown to 
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enhance DC RELMα production (Fig. 5.6), and Retnla-/- DCs supported reduced IL-
10 secretion both following in vivo transfer post SEA exposure (Fig. 4.9) and in vitro 
in co-culture with polyclonally stimulated T-cells (Fig. 4.10) we investigated the 
induction of T-cell IL-10 by DCs exposed to RA in combination with IL-4.  
 
To investigate the role of RA and IL-4 in T cell polarisation we undertook in 
vitro DC:T-cell co-culture assays incorporating 4Get (IL-4GFP (Mohrs, Shinkai et al. 
2001)) or TIGR (IL-10eGFP (Kamanaka, Kim et al. 2006)) reporter T-cells and WT 
GMDCs. This experiment allowed us to determine if DC exposed to RA and IL-4 had 
an altered capacity to polarise polyclonally activated T-cells. αCD3 was used to 
stimulate FACS GFP negative T-cells (not currently expressing IL-4 or IL-10) in the 
presence of DC, with or without IL-4 and RA, for 4 days (Fig. 5.12A). Following 
culture, as previously presented (Fig. 3.13), addition of IL-4 alone enabled DC 
induction of enhanced CD4+T-cell IL-10, as assessed by GFP expression and IL-10 
protein secretion (Fig. 5.12B&D). IL-10 was increased further by concurrent addition 
of RA (Fig. 5.12B&D). The presence of RA within the culture wells reduced 
transcription of Il4 mRNA in CD4+ T-cells as assessed by GFP expression (Fig. 
5.12C). Due to the addition of exogenous recombinant IL-4 in this experimental 
system, it was not possible to accurately measure DC induced T-cell IL-4 secretion, 
however IL-13 was measured and found to accurately represent the IL-4GFP result, 
with significantly reduced IL-13 secretion in the presence of RA and IL-4 as 
compared to IL-4 alone (Fig. 5.12E). Very low levels of IFNγ were detected in the 
supernatant, and none was detected in the presence of RA regardless of IL-4 
presence (Fig. 5.12F). 
 
We have previously shown that DC derived RELMα not only promotes CD4+ 
T-cell IL-10 but also limits T-cell IL-4 (Fig. 4.10 &(Cook, Jones et al. 2012)). Thus, in 
addition to the observed changes in cytokine and co-stimulatory molecule 
expression (Fig. 5.11), the altered T-cell response could be in part due to the 
enhanced RELMα produced within DCs in the presence RA and IL-4 (Fig. 5.6). 
However, given the inability to detect increased RELMα by ELISA in Fig. 5.6, the 
impact of enhanced RELMα would have to be indirect via RELMα modulation of 
another cell intrinsic factor which then alters DC APC function .To confirm a role for 
RELMα in the RA and IL-4 dependent induction of T-cell IL-10, this experiment will 
have to be repeated with the use of RELMα deficient DCs.  
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5.3.13 The absence of RARα alters DC co-stimulatory molecule expression 
and cytokine secretion 
Having revealed a role for exogenous RA in the ability of IL-4 treated 
GMDCs to activate and polarise T-cell responses (Fig. 5.12), and having determined 
that blocking all RAR receptors differentially alters AADC phenotype (Fig. 5.8) 
compared to blocking only RARα (Fig. 5.9), we next decided to address what the 
absence of RARα would do to DC APC function in the context of IL-4.  
 
We initially chose to interrogate the phenotype of RARα deficient GMDCs 
more thoroughly than previously (where we only assessed their ability to 
alternatively activate (Fig. 5.9)) to ensure that these cells differentiate comparably to 
WT DCs. CD11cWtRarafl/- or CD11cCreRarafl/fl GMDC were cultured overnight with IL-
4 and expression of surface markers and cytokine secretion were assessed (Fig. 
5.13A). Following overnight culture, CD11cCreRARαfl/fl DCs appeared to have a 
reduced percentage of CD11c+ cells/population and reduced per cell expression (as 
assessed by gMFI) this could not be confirmed statistically due to the low sample 
number for the medium controls (Fig. 5.13B), interestingly, following culture with IL-4 
there was no significant difference in the expression of CD11c between RARα 
deficient and control DCs (Fig. 5.13B).   
 
As shown in Fig. 3.1, control CD11cWTRarafl/- DCs also had reduced 
expression of MHC-II and CD80 following culture with IL-4, however significance 
could not be assessed as only 2 samples were available for the medium control 
population (Fig. 5.13C).  CD11cCreRarafl/fl GMDC had lower basal level co-
stimulatory molecule expression than control CD11cWtRarafl/- GMDCs, and IL-4 did 
not alter this response, however due to there only being 2 control wells, statistical 
significance between control and RARα deficient cells is not included on the graphs 
(Fig. 5.13C); the lack of impact of IL-4 on co-stimulatory molecule expression in 
CD11cCreRarafl/fl DCs in contrast to the control cells may be due to a much reduced 
level of IL-4Rα being expressed by RARα deficient cells, even in the absence of IL-4 
(Fig. 5.13D). CD11cCreRarafl/fl GMDCs did however respond to IL-4, as shown by 
altered cytokine secretion (Fig. 5.13E), suggesting that the reduced levels of IL-4Rα 
present were still functional, or that the receptor may only have been down 
regulated in the latter stages of the 18 hour culture. A time course experiment 
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assessing the expression of IL-4Rα at early time points post culture would be 
informative to address these possibilities.  
 
CD11cCreRarafl/fl DC also displayed enhanced basal IL-6 secretion and 
reduced IL-12p40 compared to control cells that were able to express RARα (Fig. 
5.13E). This result was very similar to the result following culture of WT DCs with 
RA in Fig. 5.11, in which addition of RA resulted in enhanced IL-6 and reduced IL-
12p40 secretion.  The addition of RA (Fig. 5.6) or removal of RARα (Fig. 5.9C) also 
induced the same response from IL-4 treated cells in terms their expression of 
RELMα and Ym1/2, in which both addition of RA or removal of DC RARα enhanced 
RELMα but inhibited Ym1/2. The enhanced IL-6 and reduced IL-12p40 upon 
addition of RA (Fig. 5.11) or removal RARα (Fig. 5.13E) again suggests that in DCs, 
in the presence of IL-4, RARα functions as a regulatory receptor, to limit the impact 
of RA.  
 
5.3.14 The absence of RARα alters DC ability to polarise T-cell responses 
In order to assess the role of DC RARα in activating T-cell responses, we 
undertook in vitro DC:T-cell co-culture assays similar to those described above (Fig 
5.11), but this time incorporating reporter T-cells from KN2 (IL-4huCD2) x TIGR (IL-
10eGFP) (Mohrs, Wakil et al. 2005; Kamanaka, Kim et al. 2006) animals. These T-
cells report both IL-4 protein synthesis (rather than Il4 transcription as in 4Get 
animals) and IL-10 transcription within the same cells, reducing the number of 
assays required to acquire comparable information as using T-cells that report 
individual cytokine synthesis. CD11cCreRarafl/fl GMDC were used to determine if DC 
expression of RARα altered the capacity of IL-4 exposed DCs to polarise 
polyclonally activated T-cells. αCD3 was used to stimulate flow sorted CD4+GFP 
negative T-cells (not currently expressing IL-10) in the presence of CD11cCreRarafl/fl 
or control CD11cWtRarafl/- DC, with or without IL-4, for 3 days (Fig. 5.14A). When 
DCs were RAR-sufficient (CD11cWtRarafl/-), IL-4 was able to induce high levels of T-
cell IL-4 and IL-10, as assessed by anti-huCD2 staining and GFP expression, 
respectively (Fig. 5.14B). When DCs were RARα deficient (CD11cCreRarafl/fl), IL-4 
was able to induce higher levels of T-cell IL-4, but reduced levels of T-cell IL-10, as 
compared to control cultures with RARα sufficient cells (Fig 5.14B). RARα deficient 
GMDC also supported reduced IL-4 driven T-cell IL-10 and IL-13 protein secretion, 
but did not influence T-cell IFNγ secretion, in this experimental system (Fig 5.14C).  
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Given the comparable results in terms of RELMα induction and cytokine 
secretion following culture of DCs with RA and IL-4 (Fig. 5.6, 5.11) or in the absence 
of DC RARα expression in the presence of IL-4 (Fig. 5.9, 5.12), the lack of similiarity 
in T-cell cytokine induction following addition of RA or removal of RARα was 
surprising (Fig. 5.12 Vs. Fig. 5.14). Addition of exogenous RA, which can signal 
through multiple RARs (Blomhoff and Blomhoff 2006), supported enhanced T-cell 
IL-10 and reduced T-cell IL-4 and IL-13 (Fig. 5.12), whereas removal of RA 
signalling via RARα resulted in reduced IL-10 and IL-13 induction and enhanced IL-





• IL-4 significantly upregulated 14 genes within the KEGG metabolic pathway 
(Fig. 5.1 and Table 5.3.1): of these only 2 were upregulated greater than 2 
fold in WT GMDCS. 
• IL-4 significantly upregulates Aldh1a2 mRNA, and enhances aldehyde 
dehydrogenase activity, in GMDCs, as assessed by use of the aldefluor 
assay (Fig. 5.2). 
• Schistosoma mansoni infection results in the down regulation of aldehyde 
dehydrogenase activity within splenic CD11c+ populations, when compared 
to uninfected controls (Fig. 5.3). 
• Retinoic acid alone does not promote enhanced aldehyde dehydrogenase 
activity in GMDCs, but does synergise with IL-4 to drive higher aldefluor 
activity (Fig. 5.4).  
• Aldefluor activity correlates with Aldh1a2 transcript in GMDCs (Fig. 5.5.C) 
• Aldh1a2 inversely correlates with some facets of alternative activation, but 
not Retnla (Fig. 5.5). 
• Retinoic acid and IL-4 synergise to promote RELMα in GMDCs, but not in M-
CSF derived BMM (Fig. 5.6 & Fig. 5.7). 
• Blocking all RAR signalling results in reduced IL-4 driven RELMα in GMDCs, 
and elevated IL-4 driven Ym1/2 (Fig. 5.8), confirming a role for RA signalling 
in promoting DC RELMα (Fig. 5.6). 
• The RA receptor alpha is a regulatory receptor that constrains RELMα 
production whilst promoting Ym1/2 (Fig. 5.9). 
• RA and IL-4 change the ability of DCs polarise T-cell responses by altering 
co-stimulatory molecule expression (Fig. 5.11A), cytokine secretion (Fig 
5.11B) and RELMα production (Fig. 5.6 and Fig. 5.11H).  
• RA exposed, IL-4 stimulated, DCs induce increased T-cell IL-10 and reduced 
T-cell IL-4 upon co-culture in vitro (Fig. 5.12).  
• Signalling via RARα in GMDCs promotes T-cell IL-10 and IL-13 and limits T-




5.5.1 How do RA and IL-4 alter DC activation? 
As presented in a proposed model (Fig. 5.15), attempting to summarise 
some of the key results detailed in this chapter, we have found that RA modulates 
IL-4 driven DC alternative activation (Fig. 5.5 (1)), with RA promoting IL-4 
dependent RELMα, as shown by exogenous addition of RA (Fig. 5.6) and blocking 
of all RAR receptors, resulting in decreased RELMα (Fig. 5.8). Signalling through 
the RARα was found to inhibit RELMα production, even in the absence of IL-4, as 
DCs unable to signal via RARα displayed higher levels of IL-4 dependent and IL-4 
independent RELMα (Fig. 5.9). In contrast, RA signalling via all RARs did not 
significantly alter IL-4 driven Ym1/2 when exogenous RA was added to the cells 
(Fig. 5.6), but a subtle yet significant increase in IL-4 driven Ym1/2 was found when 
panRAR signalling was blocked using LE540 (Fig. 5.8). Interestingly, removing only 
the RARα from DCs significantly reduced expression of Ym1/2 (Fig. 5.9). These 
data suggest that RA signalling via RARα promotes Ym1/2 and this counteracts the 
inhibitory impact of RA signalling via the other RARs, resulting in no significant 
change overall upon addition of exogenous RA to GMDCs (Fig. 5.6).  
 
Work in this chapter has shown that IL-4 promotes DC expression of 
Aldh1a2, resulting in enhanced RALDH2 activity (Fig. 5.15 (2)), as has previously 
been reported (Elgueta, Sepulveda et al. 2008; Yokota, Takeuchi et al. 2009; Stock, 
Booth et al. 2011) (Figs. 5.2B & C). GM-CSF was also shown to promote aldehyde 
dehydrogenase activity in FLDCs (Fig. 5.2E), as previously reported (Yokota, 
Takeuchi et al. 2009). RA signalling via all RARs promoted IL-4 driven RALDH 
activity, but not IL-4 independent RALDH, as shown in Fig. 5.4 and confirmed in Fig. 
5.10B, as inclusion of the panRAR inhibitor LE540 impaired the ability of IL-4 to 
upregulate aldefluor activity, but did not inhibit basal RALDH2 (Fig. 5.10B). 
Conversely, interfering with signalling via RARα alone enhanced both IL-4 
dependent and IL-4 independent RALDH2 (Fig. 5.10D). The finding that RA does 
not promote RALDH2 in our system is in contrast to previous reports (Feng, Cong et 
al. 2010; Jaensson-Gyllenback, Kotarsky et al. 2011), a difference that we believe 
must be dependent upon the source, differentiation and activation status of the DCs 
under investigation.  
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 Cumulative RA signalling following addition of exogenous RA promotes IL-6 
and inhibits IL-12p40 (Fig. 5.11D; Fig. 5.15 (3)). A similar cytokine profile was 
evident with RARα deficient DCs, indicating that, although cumulative RA signalling 
promotes IL-6 and inhibits IL-12p40, (Fig. 5.11D), RARα signalling alone in fact 
does the exact opposite of this, limiting pro-inflammatory IL-6 and promoting IL-
12p40 (Fig. 5.13E). In contrast, signalling via RARα is required for DC surface 
marker activation, as in the absence of this receptor, there are much lower basal 
levels of MHC-II and co-stimulatory molecules (Fig. 5.13B&C; Fig 5.15 (4)).  
 
This data would therefore suggest an overall role for RA in boosting pro-
inflammatory cytokine production in the context of GMDCs, and a specific role for 
RARα in limiting these cumulative effects of RA signalling through all the RARs on 
cytokine production.  Indeed, this may be a direct inhibition of RA signalling via the 
other RARs, a theory which would require further experimentation to confirm.   
Further, our data would suggest that although RARα signalling limits some aspects 
of GMDC cytokine production, it promotes GMDC surface molecule expression.  
This dual role for RARα in GMDCs suggests, once again, that the impact of RA on 
DC function in general will be determined by context, location and the balance of 
signalling via the other RARs. 
 
5.5.2 Why didn’t we detect enhanced RELMα secretion? 
An issue that we did not address fully in this chapter was the inability to 
detect secreted RELMα from GMDCs following culture with RA and IL-4, in contrast 
to the high levels detected intracellularly by flow cytometry and at the level of 
transcript (Fig. 5.6). An explanation for this is not really apparent, unless some 
influence of the combination of RA and IL-4 on the cells is modulating their ability to 
secrete protein, RELMα in particular. If this was the case, and RA is somehow 
blocking RELMα egress, it might be the case that RA does not in fact promote IL-4 
driven RELMα but rather causes an accumulation of the IL-4 induced protein within 
the cells. However, this is contradicted by the upregulation of Retnla mRNA in the 
presence of RA and IL-4 (Fig. 5.6D). To try and address this issue, a time course 
could be carried out to assess the levels of RELMα intracellularly and secreted in 




5.5.3 Is DC expression of RALDH dependent upon colony stimulating factors? 
We found that FLDC bulk cultures (including both cDC and pDCs) did not 
increase expression Aldh1a2 in response to IL-4, unless we added in exogenous 
GM-CSF (Fig. 5.2). The dependence of FLDC on GM-CSF for RALDH activity had 
already been reported by Yokota et al who initially described a role for IL-4 in driving 
DC expression of Aldh1a2	   (Yokota, Takeuchi et al. 2009). Indeed, in the Yokota 
study mice deficient in the signalling partner for the GM-CSFR Beta-c, (through 
which IL-3 and IL-5 also signal) were found to have reduced aldehyde 
dehydrogenase activity in mLN and PP DCs.  
 
Intestinal sites are well documented as having high levels of DC RALDH 
activity in the steady state (Iwata, Hirakiyama et al. 2004; Coombes, Siddiqui et al. 
2007)	  (Sun, Hall et al. 2007). Furthermore, we have highlighted a potential role for 
growth factors in the induction of RALDH during infection, as we found reduced 
levels of aldehyde dehydrogenase in splenic DCs following schistosome infection, at 
a time when high levels of IL-4 were present. In these experiments, reduced DC 
aldefluor activity correlated with significantly reduced total splenic mRNA for Mcsf 
and Flt3l (Fig. 5.3). As transcript does not always directly correlate with protein 
levels, in future work it would be necessary to assess the protein levels of these 
factors in the spleen during infection. Additionally, a study to more closely 
interrogate the DC phenotype in the spleen both in naïve settings and during 
infection would be advised, given reports that splenic DCs cannot metabolise retinol 
unless they are released from the inhibitory effects of prostaglandins (Stock, Booth 
et al. 2011). Now that the number and quality of fluorochromes available to use 
simultaneously during flow cytometry has increased and the technology available to 
detect multiple fluorochromes has advanced, it should be possible to include more 
markers than were available at the time of this study, to more thoroughly assess the 
in vivo DC subsets that have both RA producing capacity and are alternatively 
activated (as investigated in chapter 3).  
It is possible that colony stimulating factors are not responsible for limiting 
aldehyde dehydrogenase activity in DCs during S. mansoni infection. One possibility 
is that the parasite itself may release factors which block aldehyde dehydrogenase 
activity. For example, prostaglandins have previously been reported to restrain 
aldehyde dehydrogenase activity	   (Stock, Booth et al. 2011), and S. mansoni is 
known to express prostaglandin homologues (Fusco, Salafsky et al. 1985; 
183 
Ramaswamy, Kumar et al. 2000). Indeed S. mansoni cercarial prostaglandins, and 
the induction of host PGE2 and IL-10 by cercarial secretions, are required for the 
regulation of the inflammatory immune response in the skin, to expediate parasite 
migration (Ramaswamy, Kumar et al. 2000). Thus there is potential at sites of worm 
transit, and potentially from worm secretions, for local production of prostaglandins 
which may then restrain DC Aldh1a2 induction (Stock, Booth et al. 2011).  
To further complicate matters, the parasites also encode their own retinol 
converting enzymes (as is predicted by homology to human RALDHs) that may 
either increase RA in infection settings or, as has actually been suggested in 
humans	  (Friis, Mwaniki et al. 1997), result in a depletion of vitamin A from the host 
and thus reduce the substrate for DC RALDH.   
As the liver is a storage organ for retinol, and a major site of pathology 
during schistosomiasis, this may be the most relevant site for investigating the 
impact of schistosomes on retinol metabolism. Indeed, it was recently shown that 
macrophages in the livers of S. mansoni infected mice express enhanced levels of 
RALDH enzymes compared to their uninfected counterparts (Broadhurst, Leung et 
al. 2012).  
 
5.5.4 What is the in vitro retinoid source?  
One issue not addressed in this chapter is the source of the vitamin A 
metabolites in vitro that are converted by DCs in order for the detection of aldefluor 
activity. As we can detect aldefluor activity without the addition of exogenous retinol 
or retinal, this suggests that the media we use (RPMI-1640, Sigma, supplemented 
with 10% FCS) is supplying these to the GMDCs. In order to control for the levels of 
natural retinoids in the FCS there are a few different approaches that we could take: 
1) irradiate the FCS to destroy any endogenous vitamin A metabolites 2) use a 
different type of media which does not depend on FCS for protein supply, for 
example XVIVO medium. Both of these approaches have been used previously to 
address how mLN DCs in vitro are able to induce CCR9 expression on co-cultured 
T-cells (Jaensson-Gyllenback, Kotarsky et al. 2011). 3) Alternatively, we could try 
and quantify the level of endogenous retinoids within the media that we use, or that 
is taken up by each DC (Kawaguchi, Yu et al. 2007) using high pressure liquid 
chromatography (HPLC). In the proposed experiments in which we remove retinoids 
from our media, we would have to control for DC phenotype, as RA has been 
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suggested to be involved in normal DC development (Szatmari, Pap et al. 2006; 
Wang, Villablanca et al. 2011). As the previous studies isolated mLN DCs following 
their natural differentiation in the presence of the in vivo cytokine/growth factor 
milieu, prior to depletion of retinoids from their culture medium, it may be possible to 
differentiate the DCs for 10 days in the presence of FCS, and modify the retinoid 
level only for the overnight incubation with our antigens/cytokines of choice (e.g. IL-
4). These approaches would also enable us to determine whether vitamin A is 
required for the ability of IL-4 to trigger alternative activation within our system.  
 
The absence of signalling via RARα alone during the in vitro differentiation of 
CD11cCreRARaflfl bone marrow, as compared to blocking all RAR activity only at the 
time of exposure of fully differentiated DCs to IL-4 with addition of the panRAR 
antagonist LE540, are hard systems to compare experimentally. However the 
development of a retinoid free system for differentiating DCs, would help address 
this issue. 
 
5.5.5 The role of RA in T-cell polarisation by DCs 
In the work detailed in this chapter, we have shown that addition of 
exogenous RA or removal of RARα signalling both resulted in the same measured 
changes to DC cytokine secretion (Figs. 5.11D & 5.13E), with enhanced IL-6 
secretion and decreased IL-12p40. Addition of IL-4 at the same time as RA (Fig. 
5.11D) or treatment of RARα deficient DCs with IL-4 (Fig. 5.13E) decreased IL-6 
secretion more in line with the levels secreted in medium control cells. Similarly, IL-4 
addition also reduced DC IL-12p40 secretion such that the lowest levels of IL-12p40 
were induced in the presence of RA and IL-4 (Fig. 5.11D) or IL-4 in the absence of 
DC RARα signalling (Fig. 5.13E).  An RA analog has previously been shown to 
reduce LPS induced IL-12p40 secretion by human monocyte derived DCs 
differentiated in the presence of GM-CSF and IL-4 (Wada, Hisamatsu et al. 2009). 
IL-4 in the steady state significantly reduces IL-6 secretion in GMDCs, (first shown 
in Fig. 3.1D).  
 
IL-4 reduction of basal levels of DC IL-6, in the absence of antigen, is 
potentially a mechanism to help ensure that in the presence of Th2 cytokines 
(potentially in steady state) that a Th17 response is not induced, as IL-6 in 
combination with TGFβ is known to polarise T-cell IL-17 secretion	   (Harrington, 
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Hatton et al. 2005). It is a little surprising that RA induces the upregulation of IL-6 
secretion by GMDCs, as intestinal associated DC provision of RA via RALDH 
activity is known to promote TGFβ dependent Treg induction whilst limiting the IL-6 
and TGFβ dependent induction of IL-17	   (Mucida, Park et al. 2007). However, RA 
induction of IL-6 from pig monocyte derived DCs has previously been shown 
(Saurer, McCullough et al. 2007). In further work it would be interesting to 
characterise the secretion of TGFβ by RA and IL-4 exposed GMDCs, particularly in 
light of their high levels of aldehyde dehydrogenase activity (Fig. 5.4E).   
The contrasting roles for exogenous RA vs. DC deficiency in RARα in 
supporting IL-4 dependent T-cell cytokine production (Figs. 5.12 & 5.14), in spite of 
inducing a similar activation phenotype in DCs with respect to RELMα production 
(Figs. 5.6 & 5.9), CD11c, MHC-II and co-stimulatory molecule expression as well as 
cytokine secretion (Figs. 5.11 & 5.13), can be explained in several ways: 1) The 
enhanced T-cell IL-10 and reduced IL-4 in the RA+IL-4 DC:T-cell co-cultures is a 
result of high levels of exogenous RA acting directly on the T-cells within the culture, 
and not necessarily via alteration of DC phenotype. 2) Alternatively, the differential 
T-cell polarisation results could suggest a cumulative role for RA signalling in DCs to 
limit Th2 responses and promote regulation, and a dominant role for RARα in this 
process. 3) As IL-4 is able to directly induce T-cell IL-4, and CD11cCreRarafl/fl GMDC 
had reduced levels of IL-4Rα following overnight culture compared to control 
GMDCs (Fig 5.12C), this would suggest that there may be more IL-4 free in the 
culture well in the presence of CD11cCreRarafl/fl GMDCs, which could explain the 
higher levels of huCD2. However, we have shown previously that IL-4 is able to 
induce high levels of IL-10 from T-cells cultured with WT DCs (Figs. 4.8 & 4.10), and 
this was not enhanced in the absence of RARα expression (Fig. 5.14).  
 
CD11cCreRarafl/fl GMDCs had reduced levels of IL-12p40 secretion following 
overnight culture than control GMDCs (Fig. 5.13), suggesting that these DCs may 
also produce less bioactive IL-12p70 (though this was below detection limit in these 
experiments) and so could be less efficient at polarising Th1 type responses. 
However, there was no difference in the levels of IFNγ detected within the DC:T-cell 
co-culture supernatants, regardless of RARα expression. It should be noted that this 
polyclonal system was optimised to address Th2 induction, and there was no 
antigenic stimulus within this assay. To properly assess the influence of DC RARα 
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expression on their ability to modulate Th1 induction, a system using a bacterial 
stimulus or IL-12 addition could be used.    
 
In future studies it will be necessary to determine whether RA and IL-4 
exposed DC:T-cell co-culture assays result in increased T cell Foxp3 expression, 
and what the role for RARα may be in this system.  Given that RA and IL-4 increase 
the activity of DC aldehyde dehydrogenases (Fig. 5.4E), and that upon co-culture 
with T-cells they induce increased secretion of IL-10, we would predict that they 
would be able to induce a regulatory phenotype within the T-cell population. Indeed 
RALDH2 positive macrophage populations elicited following injection of 
Thioglycollate and IL-4 i.p. when used in co-culture were recently shown to induce a 
regulatory T cell phenotype, that was dependent upon RA production by the 
Thio+IL-4 macrophage population (Broadhurst, Leung et al. 2012).  
 
In addition we should determine whether RA and IL-4 exposed GMDCs 
induce T-cell upregulation of intestinal homing markers such as the integrin α4β7 
and the chemokine receptor CCR9, as has previously been reported for GALT 
CD103+ DCs (Iwata, Hirakiyama et al. 2004; Johansson-Lindbom, Svensson et al. 
2005; Coombes, Siddiqui et al. 2007; Sun, Hall et al. 2007).  
 
To develop this area of research further, it will be important to relate the 
results achieved using GMDCs to in vivo DC populations. To initially address this, 
we propose to use injection of exogenous IL-4c i.p. (as in Fig. 3.8) in combination 
with and without RA, into control and CD11cCreRARαfl/fl animals, followed by 
assessment of DC alternative activation status and aldehyde dehydrogenase 
activity. To relate this to a more physiological induction of a Th2 type response, 
helminth antigens such as SEA or S. mansoni eggs themselves could be used in 
place of IL-4c.  
 
In this chapter we showed for the first time an interaction between RA and 
IL-4 within DCs resulting in enhancement of both aldehyde dehydrogenase activity 
and RELMα production. Furthermore, a differential requirement for RARs in 
directing responses downstream of IL-4 and RA binding was revealed, with RARα 
constraining RELMα, but promoting Ym1/2. We concluded by showing that addition 
of exogenous RA or removal of DC RARα resulted in altered DC APC function, with 
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addition of RA inducing T-cell IL-10 and limiting IL-4, and removal of DC RARα 
limiting T-cell IL-10 and promoting T-cell IL-4.     
Total	  number	  of	  genes	  
significantly	  upregulated	  in	  IL-­‐4	  
treated	  WT	  DCs	  involved	  in	  
Metabolic	  Pathways	  as	  
determined	  by	  KEGG	  (Blue)	  
Number	  of	  genes	  significantly	  
upregulated	  >2FC	  in	  	  
IL-­‐4	  treated	  WT	  DC	  (Yellow)	  
A. 
Number	  of	  genes	  involved	  in	  
metabolic	  pathways	  that	  
were	  upregulated	  >2FC	  in	  
IL-­‐4	  treated	  WT	  DC	  (Brown)	  
B. 
Figure 5.1 Genes involved in metabolic pathways are significantly upregulated by IL-4 in WT 
GMDC. C57BL/6 WT GMDCs were cultured with IL-4 for 6 hours, RNA was extracted and an 
illumina microarray carried out, KEGG pathway analysis was carried out highlighting metabolic 
pathways (KEGG pathway mmu:01100, (A)) as the most altered upon IL-4 treatment (B; blue) 
with 14 genes significantly changed (highlighted in red in A), of these 14 genes only 2 (B; 
overlap/brown) were significantly upregulated with a FC greater than 2 (B;Yellow).  Data is from 
the same microarray experiment, as shown in Fig 4.12.  
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Table	  5.3.1	  Metabolic	  pathway	  genes	  significantly	  increased	  by	  IL-­‐4	  in	  WT	  GMDC	  
Symbol	   Synonym	   Name	   Puta/ve	  func/on	   FC	  
Aldh1a2	   RALDH2	   aldehyde	  dehydrogenase	  family	  1,	  subfamily	  A2	  
Conversion	  of	  ReUnal	  
to	  RA	   2.64	  
Ak2	   ADK2	   adenylate	  kinase	  2	  
Mitochondrial	  
component	   2.14	  
Prps1	   ARTS	   phosphoribosyl	  pyrophosphate	  synthetase	  1	   Purine	  metabolism	   1.91	  
Mgll	   MagL	   monoglyceride	  lipase	   FFA	  release	  from	  lipids	   1.88	  
Xdh	   XDH	   xanthine	  dehydrogenase	   Purine	  metabolism	   1.65	  
S23b	   SIMP	  
STT3,	  subunit	  of	  the	  oligosaccharyltransferase	  complex,	  
homolog	  B	  
Post-­‐translaUonal	  N-­‐
glycosylaUon	   1.58	  
Ptgs1	   COX1	   prostaglandin-­‐endoperoxide	  synthase	  1	  
ConsUtuUve	  
prostaglandin	  
synthesis	   1.56	  
P6p	   PFK-­‐C	   phosphofructokinase,	  platelet	   Glycolysis	   1.44	  
Mpi	   PMI	   mannose	  phosphate	  isomerase	  
Frustose-­‐6P	  
producUon	  for	  
glycolysis	   1.42	  
Pla2g12a	   sPLA2	   phospholipase	  A2,	  group	  XIIA	  
Arachidonic	  acid	  
release	  from	  
phospholipids	   1.39	  
Aldh3a1	   aldehyde	  dehydrogenase	  family	  3,	  subfamily	  A1	   B-­‐cell	  development	   1.26	  




UDP-­‐Gal:betaGlcNAc	  beta	  1,3-­‐galactosyltransferase,	  
polypepUde	  4	   Unknown	   1.16	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Figure 5.2 IL-4 induces Aldh1a2 expression and aldehyde dehydrogenase activity in GMDC and 
FLDCs treated with GM-CSF. GMDC (A-C) and FLDC (D+E) were cultured overnight with IL-4 
and GM-CSF and aldehyde dehydrogenase activity was assessed (aldefluor activity). Data is 
representative of 5(A+B) or 1(E) independent experiments, error bars represent triplicate culture 
wells, a.u.= arbitrary units as compared to Hprt expression. **= P<0.01 ***P<0.001.  
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Figure 5.3. Schistosoma mansoni infection does not enhance DC aldefluor activity, but highlights 
a potential requirement for growth factors. Spleens were harvested from naïve or S.mansoni 
infected animals 8 weeks post infection, spleens were digested, RBC lysed and surface stained 
(A+B) prior to assessment of CD11c (C) and MHC-II (D) expression and aldefluor activity (E). In 
B+C Naïve=3 pooled spleens per symbol, S.m.= individual infected spleen samples. RNA was 
extracted from whole spleens prior to qPCR analysis of Il4 and Il4ra (F), Gmcsf, Mcsf (G) and 
Flt3l (H) expression, Data is representative of 2 independent experiments, a.u.=arbitrary units 
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Figure 5.4. RA does not enhance GMDC aldefluor activity in the absence of IL-4. GMDCs were 
cultured overnight with or without 10μM RA (A) or for 39h with or without 20nM RA (C) or 
overnight with 10μM RA and 20ng/ml IL-4 (D+E) and aldehyde dehydrogenase activity was 
assessed (aldefluor assay). Data is representative of 5(B+E) or 1(C) independent experiments, 
error bars represent triplicate culture wells. *=P<0.05. 
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Figure 5.5 IL-4 driven DC RALDH activity correlates with reduced expression of markers of 
alternative activation but not Retnla. Following overnight culture with IL-4, GMDC populations 
were flow sorted based upon Aldefluor activity (A+B) and qPCR was used to assess expression 
of Aldh1a2 (C) Chi3l3, Mrc1 (D), Pparg (E), Retnla (F) and Ccl24 (G) within aldefluor negative, 
low or high expressing populations. Data is representative of 4-5 independent experiments, error 
bars represent triplicate culture wells, a.u.= arbitrary units as compared to Hprt expression. 
*=P<0.05 **= P<0.01.  
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Figure 5.6 RA enhances IL-4 driven RELMα in GMDC. GMDC were cultured 
overnight with or without 20ng/ml IL-4 and 10μM RA (A). Production of 
intracellular RELMα and Ym1/2 protein (B+C) Retnla and Chi3l3 transcript 
(D) and secreted protein (E) were assessed via intracellular staining (B+C), 
qPCR (D), and ELISA (E). Data is representative of 3 independent 
experiments, error bars represent triplicate culture wells, a.u.= arbitrary units 
as compared to Hprt expression. *=P<0.05, ****P<0.0001  
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Figure 5.7 RA does not enhance IL-4 driven RELMα in BMM. BMM were 
cultured overnight with or without 20ng/ml IL-4 and 10μM RA. Production of 
RELMα and Ym1/2 protein was assessed via intracellular staining (B+C) 
and ELISA (D). Data is representative of 2 independent experiments, error 
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Figure 5.8 RAR signalling regulates IL-4 driven DC alternative activation. GMDC were 
cultured overnight with or without 20ng/ml IL-4 and the PanRAR antagonist LE540 
(10μM) (A).  RELMα and Ym1/2 protein production was assessed by intracellular 
staining (B+C). RELMα, CCL24 and Ym1/2 secretion was assessed by ELISA (D+E). 
Data is representative of 3 independent experiments, error bars represent triplicate culture 



























18 h Flow cytometry 
ELISA  Control or  
CD11cCreRARαfl/fl  
Figure 5.9 RARα signalling inhibits IL-4 driven RELMα and promotes IL-4 driven Ym1/2. 
CD11cWtRarafl/- or CD11cCreRarafl/fl GMDC were cultured overnight with or without 20ng/ml 
IL-4 (A) RELMα and Ym1/2 protein production was assessed by intracellular staining (B
+C) and ELISA (D). Data is representative of 1 independent experiment, error bars 































18 h Aldefluor assay 
Flow cytometry 
Figure 5.10 RAR signalling modulates IL-4 driven aldehdye dehydrogenase activity in 
GMDC. WT (A+B) or CD11cWtRarafl/- and CD11cCreRarafl/fl GMDC (C+D) were cultured 
overnight with or without IL-4 and LE540 (A+B only), aldefluor activity was assessed by 
flow cytometry (B+D). Data is representative of 3 independent experiments (A+B) or one 
independent experiment (C+D), error bars represent triplicate culture wells. *=P<0.05, **= 
P<0.01.  
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Figure 5.11 RA and IL-4 alter DC co-stimulatory molecule and cytokine 
secretion. GMDC were cultured overnight with or without IL-4 and RA (A); 
CD11c expression (B), co-stimulatory molecule and MHC-II expression 
(C) and cytokine secretion (D) were assessed. Data is representative of 5 
independent experiments, N=3 replicate wells per condition. *=P<0.05 **= 
P<0.01 ***P<0.001 ****P<0.0001. 
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Figure 5.12 RA and IL-4 alter DC APC capacity. IL-10eGFP-CD4+ or 4Get-CD4+ T-cells, 
were cultured for 3 days with WT GMDCs, anti-CD3 mAb, with or without 20ng/ml IL-4, 
and 10μM RA (A) and assessed for IL-10 or IL-4 mRNA expression by flow cytometry (B
+C) and IL-10 (D), IL-13 (E) and IFNγ (F) secretion by ELISA. Data is representative of 2 
(B+C) or 4 (D-F) independent experiments, N=4-5 replicate wells per condition. *=P<0.05 




























18 h Flow cytometry 
ELISA  Control or  
CD11cCreRARαfl/fl  
Figure 5.13 RARα alters DC co-stimulatory molecule expression and cytokine secretion. 
CD11cWtRarafl/- and CD11cCreRarafl/fl GMDC were cultured overnight with or without 20ng/
ml IL-4 (A). CD11c expression (B), co-stimulatory molecule expression (C) and IL-4Rα 
expression (D) were assessed by flow cytometry. Cytokine secretion was assessed by 
ELISA (E). Data is from 1 independent experiment, N=3 replicate wells per condition. 
*=P<0.05, ***P<0.001, ****P<0.0001. 
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Figure. 5.14 The absence of RARα alters DC ability to polarise T-cell responses. 
IL-10eGFP-CD4+T-cells sorted from KN2xIL10eGFP animals, were cultured for 3 days with 
CD11cWtRarafl/- or CD11cCreRarafl/fl GMDC and anti-CD3 mAb, with or without 20ng/ml IL-4 
(A) and assessed for IL-4 protein (HuCD2) or IL-10 mRNA expression by flow cytometry (B) 
and IL-10, IL-13 and IFNγ secretion by ELISA (C). Data is representative of 1 independent 
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Figure. 5.15  The impact of IL-4 and RA signalling in DCs. This figure depicts the 
modulation of DC alternative activation (1) , RALDH2 production (2), cytokine 
secretion (3) and co-stimulatory molecule expression (4) directed by RARα (yellow 
lines), all RARs (green lines), IL-4Rα and GM-CSF (blue lines). Arrows represent 






Chapter 6. How do IL-4 and TLR2 Signalling Pathways 
Integrate to Influence DC Activation? 
 
6.1 INTRODUCTION 
In the previous chapters of this thesis we have shown that IL-4 can induce 
the alternative activation of DCs, both in vitro, in vivo and ex vivo (chapter 3), 
upregulating a similar but not identical profile to that seen in AAM (chapter 3). IL-4 
exposed GMDCs express high levels of RELMα, Ym1/2 and CCL24 (Fig. 3.2-3.4 & 
Table 4.3.3) but do not significantly upregulate arginase activity in response to IL-4 
(Fig. 3.5). In chapter 4 a microarray analysis of IL-4 treated GMDCs showed that 
multiple genes were also down regulated by IL-4, for example, TLR2 (Table 4.3.2).  
Furthermore in chapter 5 we showed that IL-4 induced DC expression of aldehyde 
dehydrogenase activity (Fig. 5.2B&C), and that the product of such enzymatic 
activity, RA, was able to synergise with IL-4 to enhance DC RELMα (Fig. 5.6) and to 
modulate IL-4 dependent T-cell polarisation (Fig. 5.12).  
 
The TLR2 ligands zymosan and Pam3CSK4 (P3C) are known to modulate 
DC IL-10 to IL-12 balance, by inducing IL-10 and impairing IL-12p70 (Agrawal, 
Agrawal et al. 2003; Dillon, Agrawal et al. 2006; Slack, Robinson et al. 2007; Wang, 
Villablanca et al. 2011). In chapter 4 of this thesis IL-4 was shown to modulate DC 
IL-10 and IL-12 production in response to the defined TLR4 and TLR9 ligands, LPS 
and CpG, inducing an opposite response to the published outcome of TLR2 ligation 
(Dillon, Agrawal et al. 2004) by enhancing secreted IL-12p70 and reducing secreted 
IL-10 (Fig. 4.2). We hypothesised that TLR2 and IL-4 signalling pathways may 
converge at the level of IL-10 and IL-12 regulation and so were interested to 
investigate how DCs would respond following exposure to both IL-4 and TLR2 
ligation simultaneously.  
 
Zymosan has also been reported to modulate vitamin A metabolism in a 
TLR2 dependent manner (Manicassamy, Ravindran et al. 2009). We and others 
(Chapter 5) (Yokota, Takeuchi et al. 2009; Stock, Booth et al. 2011; Agace and 
Persson 2012; Broadhurst, Leung et al. 2012) have reported that IL-4 can enhance 
DC aldehyde dehydrogenase activity. Furthermore, we have shown that the product 
of such enzyme activity, retinoic acid, is able to modulate IL-4 driven DC alternative 
activation by increasing IL-4 driven RELΜα (Fig. 5.6).   
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In the work detailed in this chapter we have characterised how IL-4 
influences the phenotype of DCs exposed to the synthetic triacylated lipopeptide 
P3C, a defined TLR2 ligand (Oliveira-Nascimento, Massari et al. 2012), and a mixed 
antigenic preparation of the Saccharomyces cerevisiae fungal cell wall, zymosan, 
which contains ligands recognized by multiple PRRs including TLR2	   (Di Carlo and 
Fiore 1958; Gazi, Rosas et al. 2011). We have determined the impact of TLR2 and 
IL-4R ligation on DC aldehyde dehydrogenase activity, cytokine secretion, and 
alternative activation. Using inhibitor studies and microarray analysis we have 
begun to understand the signalling pathways downstream of IL-4R and TLR2 
engagement which specifically modulate DC RELMα production, highlighting a 




6.2 SPECIFIC AIMS:  
1. To determine the relationship between TLR2 agonists, IL-4 treatment, 
RALDH activity and alternative activation of DCs. 




6.3.1 TLR2 agonists enhance IL-4 induced aldehyde dehydrogenase activity in 
GMDC 
P3C is a synthetic bacterial triacylated lipopeptide that is recognised 
immunologically by the PRR heterodimer of TLR2 and TLR1 (Oliveira-Nascimento, 
Massari et al. 2012). Zymosan is a mixed antigenic preparation of the 
Saccharomyces cerevisiae cell wall, rich in β-glucans and mannan, which are 
recognised by a combination of receptors, including the c-type lectin receptor (CLR) 
dectin-1 (Brown, Taylor et al. 2002; Taylor, Brown et al. 2002), the heterodimer 
pairing of TLR2 and TLR6 (Ozinsky, Underhill et al. 2000) and an unknown pathway 
that is Syk dependent but that is independent of dectin-1 (Rogers, Slack et al. 2005; 
Manicassamy, Ravindran et al. 2009).  
 
TLR2 agonists have previously been shown to enhance DC expression of 
Aldh1a2 (Manicassamy, Ravindran et al. 2009; Wang, Villablanca et al. 2011).  
Aldh1a2 encodes RALDH2, a retinol conversion enzyme previously confirmed as 
being induced by IL-4 (Yokota, Takeuchi et al. 2009; Stock, Booth et al. 2011; 
Agace and Persson 2012) (Fig. 5.2). We sought to determine whether IL-4 and the 
TLR2 agonists P3C and zymosan interact synergistically to enhance aldehyde 
dehydrogenase activity within DCs.  
 
GMDC were cultured for 18h with media alone, P3C, or zymosan with or 
without addition of exogenous IL-4 (Fig. 6.1A). CD11c+ cells were gated and the 
highest level of aldehyde dehydrogenase activity was induced in the presence of IL-
4 together with P3C, as assessed by use of the aldefluor assay (Fig. 6.1B&C). 
Zymosan enhanced aldefluor expression above the level induced basally (medium 
alone), and the presence of IL-4 with either P3C or zymosan resulted in a 
significantly higher percentage of CD11c+ cells expressing activity than in the 
presence of IL-4 alone (Fig. 6.1B&C). However, per CD11c+ cell expression of 
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aldefluor activity, when compared to IL-4 controls, only increased significantly in the 
presence of zymosan (Fig. 6.1D). The transcript encoding RALDH2 was significantly 
enhanced by IL-4, and by zymosan alone (Fig. 6.1D), but there was no synergistic 
increase in Aldh1a2 mRNA expression in the presence of P3C, or a combination of 
IL-4 and either TLR2 agonist. This could suggest that the regulation of enzyme 
activity may not be via de novo transcription, or that the time point at which the cells 
were sampled did not correlate with the point at which a change in transcript levels 
for Aldh1a2 occurred, a time course could be carried out to test this possibility.  
 
6.3.2 TLR2 agonists activate GMDCs, IL-4 regulates zymosan directed 
secretion of IL-10 and IL-12 
To competently activate T-cells, DC must express co-stimulatory molecules 
and secrete cytokines. We were interested to assess how either TLR2 agonist was 
able to modulate DC activation status, and whether this was altered by the presence 
of IL-4. GMDC were cultured for 18h with either media alone, P3C or zymosan with 
or without addition of exogenous IL-4, and surface expression of co-stimulatory 
markers was assessed by flow cytometry (Fig. 6.2B). Zymosan capably induced 
high level expression of MHC-II (Fig. 6.2C), CD86 (Fig. 6.2D), CD80 and CD40 (Fig. 
6.2E). P3C enhanced expression of MHC and the co-stimulatory molecules 
assessed. However, at the concentrations of P3C used, the per cell expression of 
MHC-II (Fig. 6.2C) and CD86 (Fig. 6.2D) was much lower than that induced by 
zymosan (Fig. 6.2B-F). P3C induced more comparable expression of CD80 and 
CD40 (Fig. 6.2E). The low level induction of CD86 by P3C is in accordance with 
similar previous work carried out using human monocyte derived DCs (Agrawal, 
Agrawal et al. 2003). The surface phenotype induced by either TLR2 agonist was 
not significantly changed by the simultaneous addition of IL-4 (Fig 6.2 B-E). These 
findings are similar to those seen in Fig. 4.1 in which ligation of TLR9 and TLR4 
enhanced DC co-stimulatory molecule expression, and only a subtle impact of IL-4 
treatment on co-stimulatory molecule expression was seen, with a slight 
enhancement of LPS stimulated CD86 being apparent.  
 
In a similar manner to the ability of P3C to differentially enhance DC co-
stimulatory molecules, very low level IL-10 and no IL-12p70 was secreted by 
GMDCs cultured overnight with P3C (Fig. 6.2F). However, both TNFα and IL-6 were 
secreted in significant amounts when compared to medium only controls (Fig. 6.2G). 
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No IL-10 was detected in supernatants in which both IL-4 and P3C had been 
included in the overnight culture, whereas no impact of IL-4 was seen on the ability 
of P3C exposed DCs to secrete IL-12p70, TNFα or IL-6 (Fig. 6.2F&G). Zymosan 
induced the highest levels of all cytokines assessed (Fig. 6.2F&G). Interestingly, IL-
4 regulated the secretion of IL-10 and IL-12p70 by zymosan exposed DCs (Fig. 
6.2F) but did not significantly impact TNFα or IL-6 secretion (Fig. 6.2G). In the 
presence of IL-4, zymosan induced significantly less IL-10 and significantly more IL-
12p70 secretion than it was able to provoke alone, a similar result to that seen with 
TLR9 and TLR4 agonists in the presence of IL-4 (Fig. 4.1). The absence of secreted 
IL-12p70 from DC in the presence of P3C differs from published work using splenic 
DCs, in which similar levels of IL-12p70 were found following culture with either P3C 
or zymosan (Dillon, Agrawal et al. 2006). Interestingly, however, work from the 
same group had previously found only very low level IL-12p70 induction from human 
monocyte DCs in response to P3C	  (Agrawal, Agrawal et al. 2003). The differences 
in cytokine secretion between these studies are probably due to antigen dose, as in 
this work we used P3C at 250ng/ml, the 2003 study used P3C at 20µg/ml	  (Agrawal, 
Agrawal et al. 2003) and the 2006 study at 100µg/ml (Dillon, Agrawal et al. 2006). 
Work using anti-IL-10R and IL-10 deficient DCs has previously shown that zymosan 
induction of DC IL-10 down modulates zymosan driven DC secretion of IL-12, TNFα, 
IL-6	  (Manicassamy, Ravindran et al. 2009). 
 
6.3.3 P3C and zymosan limit IL-4 driven RELMα and Ym1/2 to different extents 
Having shown that TLR2 agonists modulate DC aldehdye dehydrogenase 
activity (Fig. 6.1), and that IL-4 differentially modulates DC responsiveness to the 
TLR2 agonists P3C and zymosan (Fig. 6.2), we next investigated whether the 
presence of P3C and zymosan modulated IL-4 induced DC alternative activation. 
GMDC were cultured for 18h with either media alone, P3C or zymosan, with or 
without addition of exogenous IL-4 and flow cytometry, ELISA and qPCR were used 
to assess RELMα and Ym1/2 expression (Fig. 6.3A). The TLR2 specific agonist 
P3C was able to completely abrogate intracellular IL-4 induced RELMα (Fig. 6.3 
B&C), RELMα secretion (Fig. 6.3D), and Retnla transcript (Fig. 6.3E), with DCs 
present in P3C + IL-4 culture wells having the same level of RELMα expression as 
control DCs cultured in medium only (Fig. 6.3 B-E). P3C did not inhibit IL-4 induced 
Ym1/2 and there was a trend for reduced intracellular Ym1/2 protein, although this 
did not reach significance (Fig. 6.3 B&C). P3C did significantly inhibit Ym1/2 
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secretion (Fig. 6.3D) and Chi3l3 transcript (Fig. 6.3E), but did not reduce expression 
to basal levels, as was evident with RELMα. Zymosan completely abrogated IL-4 
induced expression of both RELMα and Ym1/2 at the level of intracellular and 
secreted protein (Fig. 6.3 B-D) and transcript (Fig. 6.3E).  
  
The differential inhibition of RELMα and Ym1/2 expression following 
treatment with IL-4 and P3C was different to the impact seen when culturing DC 
with any other defined TLR ligand (CpG, LPS, zymosan) at the same time as IL-4, 
where the inhibition of both RELMα and Ym/12 followed roughly the same pattern 
(Fig. 4.3 & Fig. 6.3). However, a difference in inhibition of IL-4 induced RELMα but 
not Ym1/2 was also seen when the mixed helminth antigenic preparation SEA was 
used to stimulate DCs in combination with IL-4 (Fig. 4.5). This may suggest that the 
component of SEA that is responsible for RELMα inhibition may also be signalling 
via the same TLR as P3C (eg. TLR2 and the co-receptor TLR1).  
 
6.3.4 Zymosan inhibits arginase and promotes iNOS in GMDC  
To further investigate the impact of TLR2 agonists on GMDC activation, we 
assessed the regulation of arginine converting enzymes by P3C, zymosan and IL-4. 
As discussed in previous chapters, IL-4 does not enhance GMDC arginase 
expression in contrast to its ability to enhance BMM arginase (Fig. 3.12D). As 
ligation of either TLR9 or TLR4 significantly induced DC expression of Nos2 but not 
Arg1 (Fig. 4.3 E&F), we were interested to determine whether the TLR2 ligands 
would influence expression of these arginine conversion enzymes and whether 
TLR2 ligation would then alter the ability of IL-4 to drive arginase activity.  
 
GMDC were cultured for 18h with media alone, P3C or zymosan with or 
without addition of exogenous IL-4. Arginase (Arg1) and inducible nitric oxide 
synthase (Nos2) levels were assessed by qPCR and production of nitric oxide (NO) 
was determined using the Griess reaction (Fig. 6.4D). Though not significant, there 
was a trend for reduced expression of Arg1 and enhanced Nos2 in GMDC cultured 
overnight with P3C, a pattern that was not altered by presence of IL-4 (Fig. 
6.4B&C). Zymosan was able to significantly inhibit Arg1 and significantly enhance 
Nos2 expression, independently of IL-4 presence (Fig. 6.4B&C). Nitric oxide 
production detected by the Griess reaction is a direct readout of inducible nitric 
oxide synthase activity	   (Tsikas 2007). Zymosan significantly enhanced NO 
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production by GMDC as compared to medium alone controls, while IL-4 caused a 
subtle but significant reduction in the level of zymosan induced NO (Fig. 6.4D).  
 
6.3.5 P3C and zymosan modulate chemokine production by IL-4 treated 
GMDCs 
As TLR2 ligands were found to modulate AADC expression of RELMα and 
Ym1/2, we investigated whether the same ligands influenced the expression of 
chemokines that we had found to be enhanced in GMDCs exposed to IL-4 (Fig. 
3.4D&E, 4.3E&F). GMDC were cultured for 18h with either media alone, P3C or 
zymosan, with or without addition of exogenous IL-4 (Fig. 6.5A). P3C and zymosan 
both significantly reduced transcripts for Ccl17 below the basal level found in the 
presence of media alone (Fig. 6.5B). Following the addition of IL-4, neither P3C or 
Zymosan altered expression of Ccl17, levels of which were the same as in the 
presence of IL-4 alone (Fig. 6.5B). In the absence of IL-4, P3C and Zymosan had no 
impact on the transcription (Fig. 6.5C) or secretion (Fig. 6.5D) of CCL24. In the 
presence of IL-4 there was an interesting contrasting effect of P3C versus zymosan. 
With P3C, CCL24 secretion was significantly higher than following culture with IL-4 
alone, whereas zymosan significantly inhibited IL-4 driven CCL24 (Fig. 6.5D). We 
had previously found no impact of TLR9 or TLR4 ligation on the modulation of IL-4 
induced CCL24 (Fig. 4.3E&F). These data suggest that signalling via a TLR2 
agonist is more closely related to changes downstream of IL-4 signalling, than is 
signalling via TLR9 or TLR4.  
6.3.6 IL-4 and TLR2 counter-regulate one another in GMDCs 
As the data in this chapter indicated several examples of interaction between 
the different TLR2 agonists and exposure to IL-4, we decided to assess whether IL-
4 could directly regulate TLR2 expression. GMDC were cultured overnight with IL-4 
and their expression of Tlr2 was assessed by qPCR (Fig. 6.6A). Following overnight 
culture, IL-4 significantly downregulated mRNA transcript for TLR2 (Fig. 6.6B). We 
next assessed whether the presence of the IL-4Rα modulated GMDC TLR2 
expression. WT or Il4ra-/- GMDC were cultured for 6 hours with or without IL-4 and 
Tlr2 expression was assessed by qPCR (Fig. 6.6C). After only 6 hours of culture 
with IL-4, WT GMDC Tlr2 expression was not reduced (Fig. 6.6D) in contrast to the 
reduction seen by 18 hours (Fig. 6.6B). Suggesting that the inhibition of TLR2 
expression by IL-4 may not be a direct effect, and thus require alterations in a 
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cascade of transcription and translation before a decline in the levels of Tlr2 mRNA 
was apparent. Additionally, the level of Tlr2 message at 6 hours may not correlate 
with the translated protein for TLR2, an added complexity that we cannot detect 
using this qPCR system.  
IL-4Rα-/- GMDC displayed significantly enhanced basal levels of Tlr2 mRNA 
relative to WT GMDCs and, reassuringly, this was not changed by addition of IL-4 to 
the culture (Fig. 6.6D). Suggesting the presence of the IL-4Rα is required for the 
inhibition of TLR2 in the steady state in the absence of exogenous IL-4.  
As IL-4 and TLR2 ligands have been implicated in the modulation of DC 
aldehyde dehydrogenase activity	   (Manicassamy, Ravindran et al. 2009; Yokota, 
Takeuchi et al. 2009), we investigated whether aldehyde dehydrogenase activity 
level correlated with TLR2 expression. GMDCs were cultured overnight in the 
presence of media alone or media supplemented with 20ng/ml IL-4, surface stained 
for CD11c and flow sorted into three populations (negative, low, high) based on 
aldefluor activity as compared to a DEAB control (Fig. 6.6E & Fig. 5.5). RNA was 
extracted from each population, converted to cDNA and expression of Tlr2 was 
measured using quantitative PCR, normalised to the housekeeping gene Hprt (Fig. 
6.6F). Tlr2 mRNA expression inversely correlated with aldefluor activity, with 
aldefluor high cells having significantly lower Tlr2 expression (Fig. 6.6F). IL-4 was 
found to decrease Tlr2 expression (confirming the result in Fig. 6.6B) and, even in 
the presecnce of IL-4, the cells with highest aldehyde dehydrogenase activity had 
lowest Tlr2 expression (Fig. 6.6F). This suggests that a close interplay exists 
between the expression of aldehyde dehydrogenas activity and Tlr2, with IL-4 
treatment downregulating Tlr2 expression, whilst simultaneously enhancing Aldh1a2 
expression and RALDH activity as shown in Figure 5.5.   
 
6.3.7 Tlr2 limits IL-4 driven RELMα in GMDC, and is responsible for P3C 
inhibition of alternative activation 
Having shown that TLR2 ligation simultaneous with IL-4 exposure can 
synergistically enhance the ability of IL-4 to promote DC aldefluor activity (Fig. 6.1), 
but that the same agonists can also inhibit other facets of IL-4 dependent DC 
stimulation (alternative activation Fig. 6.3), we wondered whether the impact of P3C 
and zymosan upon alternative activation was mediated via TLR2.  In order to 
confirm a role for TLR2 in mediating the inhibitory effect of P3C and zymosan on IL-
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4 induced RELMα and Ym1/2 (Fig. 6.3), we assessed the impact of the TLR2 
agonists and IL-4 on GMDC deficient in TLR2 expression. WT or Tlr2-/- GMDCs 
were cultured overnight in the presence of medium, P3C or zymosan with or without 
the addition of IL-4 (Fig. 6.7A). In the absence of TLR2, GMDC expressed higher 
intracellular levels of IL-4 induced RELMα but no significant change in IL-4 induced 
Ym1/2 (Fig. 6.7B-D). The ability of P3C to inhibit IL-4 driven RELMα and Ym1/2 was 
entirely dependent upon TLR2 expression, as P3C did not limit IL-4 driven 
intracellular expression or secretion of either alternative activation marker in the 
absence of TLR2 (Fig. 6.7B-D). Surprisingly, the zymosan inhibition of IL-4 driven 
DC alternative activation was independent of TLR2, as zymosan addition resulted in 
abrogation of both RELMα and Ym1/2 in the Tlr2-/- GMDCs at the level of both 
intracellular and secreted protein (Fig. 6.7 B-D). As zymosan can signal via the CLR 
dectin-1 as well as TLR2 (Brown 2006), it is possible that dectin-1 is responsible for 
the ability of zymosan to inhibit IL-4 driven alternative activation. 
 
6.3.8 IL-4 inhibition of zymosan driven phospho-ERK1/2 is dependent upon 
TLR2 
Previous studies have highlighted that the mitogen activated protein kinase 
(MAPK) signalling cascade is activated downstream of TLR2 signalling, with 
phosphorylation of the extracellular signal regulated kinases (ERK1/2; MAPK3/1) 
being a frequently reported outcome (Dillon, Agrawal et al. 2004; Dillon, Agrawal et 
al. 2006; Slack, Robinson et al. 2007; Adhikary, Sun et al. 2008; Manicassamy, 
Ravindran et al. 2009; Wang, Villablanca et al. 2011). We aimed to investigate 
whether in our hands, ERK phosphorylation was a downstream outcome of P3C and 
zymosan binding, and to what extent IL-4 was able to impact such signalling events. 
Phosphorylation of ERK occurs within a much shorter time frame than the 18 hour 
overnight culture used as standard in our assay so, in order to assay these early 
signalling events, a 15 minute time point was assessed. GMDCs were surface 
stained for CD11c prior to 15 minute incubation with either P3C, zymosan or the 
phorbol ester PdBU (which acts as a positive control for ERK activation) in the 
presence or absence of IL-4. Following culture, cells were harvested, fixed and 
permeabilised prior to staining with an anti-pERK antibody (Fig. 6.8A). To provide a 
control for the absence of ERK activation, the MEK1/2 inhibitor (MEK1/2 is the 
kinase upstream of ERK1/2) U0126 was used to treat control GMDCs prior to 
addition of the antigen and IL-4 combinations. Experiments were only considered to 
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have worked if addition of the inhibitor U0126 was able to limit all phosphorylation 
induced by PdBU. IL-4 alone did not induce ERK1/2 activation in DCs (Fig. 6.8), 
P3C induced a small but significant increase in ERK phosphorylation and zymosan 
induced dramatic activation of ERK, equal to the level of phosphorylation seen with 
the positive PdBU treated control wells (Fig. 6.8B&C).  Interestingly, IL-4 clearly 
interfered with zymosan induced ERK activation and this inhibition was not evident 
in TLR2-/- DCs (Fig. 6.8.B&C). Furthermore IL-4 was able to inhibit P3C induced 
ERK phosphorylation in WT DCs (Fig. 6.8).  In this section we have shown that both 
TLR2 ligation and IL-4 integrate at the level of ERK phosphorylation, as IL-4 is able 
to limit pERK induced in response to either P3C or zymosan, surprisingly, this 
inhibition is dependent upon TLR2, while zymosan induction of pERK is 
independent of TLR2.   
 
6.3.9 IL-4 differentially modulates components of the MAPK signalling 
cascade in WT and RELMα deficient DCs 
Having identified a role for the MAPK signalling pathway in IL-4 modulation 
of the GMDC response to TLR2 ligation, we next decided to re-assess our 
microarray data from WT and RELMα deficient DCs carried out in earlier chapters 
(Fig. 4.14, Fig. 5.1), this time specifically focussing on signalling pathways. Our 
initial analyses (chapter 4, section 14) had only investigated genes significantly 
changed (P <0.05) within a high fold change threshold (>2FC enhancement or 
reduced by more than 0.5FC). In this new signalling focused analysis of the data, all 
genes significantly changed by IL-4 treatment (P<0.05) were assessed for 
involvement in signalling pathways. 26 genes that encode components of signalling 
pathways or proteins that directly interact with such pathways were found to be 
significantly upregulated by IL-4 within either WT or RELMα deficient DCs (Fig. 6.9). 
Interestingly, 17 of these signalling genes were only changed by IL-4 in cells 
deficient in RELMα, with 10 of the 17 known to interact with or regulate the MAPK 
signalling pathway.    
 
The bias toward RELMα dependence in regulation of MAPK signalling gave 
our first indication that the differential regulation of IL-4 dependent RELMα as 
compared to Ym1/2 downstream of PRR (SEA, Fig. 4.5), TLR2 (P3C, Fig. 6.3) and 
RA (Fig. 5.5 & 5.6) signalling may be dependent upon components of this pathway. 
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6.3.10 ERK signalling inhibits IL-4 driven RELMα in GMDC 
Having determined that IL-4 can regulate pERK signalling within DCs 
following TLR2 ligation (Fig. 6.8), that the TLR2 agonist P3C can phosphorylate 
ERK and abrogate IL-4 driven RELMα production in DC (Fig. 6.3 & 6.7) and that 
RELMα is involved in regulating the IL-4 induced MAPK signalling capacity of DCs 
(Fig. 6.9) we hypothesised that DC expression of alternative activation markers may 
be dependent upon ERK signalling. To test this, GMDCs were cultured in the 
presence or absence of the MEK inhibitor U0126, prior to addition of IL-4 (Fig. 
6.10A). GMDC alternative activation status was then assessed by ELISA and qPCR. 
In the presence of U0126, IL-4 exposed GMDCs secreted significantly enhanced 
levels of RELMα protein when compared to IL-4 exposed cells in the absence of 
inhibitor (Fig. 6.10B). This elevated RELMα secretion correlated with significantly 
increased Retnla transcript (Fig. 6.10B), suggesting that baseline ERK signalling is 
responsible for inhibiting IL-4 induced RELMα. In contrast to RELMα, Ym1/2 was 
not significantly increased on addition of U0126 (Fig. 6.10C), with a trend for 
reduction at both the protein and transcript level. Similarly, IL-4 induced CCL24 was 
significantly inhibited by the addition of U0126, highlighting a dependence on ERK 
signalling for IL-4 upregulation of this chemokine (Fig. 6.10D). This result suggests 
that ERK signalling is directly involved in DC alternative activation, being particularly 
responsible for controlling the expression levels of various IL-4 induced gene 




• IL-4 synergises with TLR2 agonists P3C and zymosan to enhance GMDC 
aldehyde dehydrogenase activity (Fig. 6.1). 
• IL-4 modulates zymosan dependent IL-10 and IL-12p70 secretion by 
GMDCs but does not  alter zymosan induced TNFα or IL-6 (Fig. 6.2F&G). 
• IL-4 does not alter P3C induction of cytokine secretion by GMDCs (Fig. 
6.2F&G). 
• P3C abrogates IL-4 induced RELMα, but only partially inhibits Ym1/2 in 
GMDCs (Fig. 6.3). 
• Zymosan significantly inhibits IL-4 induced RELMα and Ym1/2 in GMDCs 
(Fig. 6.3). 
• Zymosan inhibits Arg1 but promotes Nos2 and nitric oxide production in 
GMDCs (Fig. 6.4). 
• P3C and IL-4 synergise to enhance CCL24, whereas zymosan inhibits IL-4 
driven CCL24, in GMDCs (Fig. 6.5D). 
• IL-4 downregulates Tlr2 expression in GMDCs, and Tlr2 expression 
inversely correlates with aldefluor activity: cells with higher aldefluor activity 
have lower levels of Tlr2 expression (Fig. 6.6). 
• P3C abrogation of IL-4 induced RELMα and Ym1/2 in GMDCs is dependent 
upon TLR2, whereas zymosan inhibition of IL-4 induced RELMα and Ym1/2 
is independent of TLR2 (Fig. 6.7B-D). 
• P3C and zymosan induce intracellular phosphorylation of ERK1/2 in 
GMDCs: P3C activation of ERK1/2 is TLR2 dependent whereas zymosan 
activation of ERK1/2 is independent of TLR2 (Fig. 6.8C). 
• IL-4 inhibits only TLR2 dependent P3C and zymosan induction of pERK1/2 
in GMDCs (Fig. 6.8D). 
• IL-4 significantly alters multiple components of the MAPK signalling pathway 
in GMDCs, particularly in Retnla-/- deficient cells (Fig. 6.9). 
• ERK signalling differentially affects different aspects of GMDCs alternative 
activation: IL-4 induced RELMα is inhibited by ERK signalling (Fig. 6.10B), 




6.6.1 The TLR2 and IL-4 dependence of RALDH2  
In the work described in this chapter, we found that inclusion of IL-4 and 
either a defined agonist of TLR2 (P3C) or an antigenic mixture containing TLR2 
ligands (zymosan) resulted in the greatest induction of aldefluor activity within 
GMDCs. This result indicates a synergistic interaction between TLR2 ligation and IL-
4 signalling in the control of DC RA synthesis (Figs. 6.1 & 6.11).  
 
Zymosan induction of Aldh1a2 has previously been shown to be partially 
dependent upon TLR2 expression in splenic DCs, as TLR2 deficiency significantly 
decreased zymosan dependent Aldh1a2 transcription but did not totally abrogate 
the response to the level seen in medium control treated DCs (Manicassamy, 
Ravindran et al. 2009). The remaining induction (independent of TLR2) was found to 
also be independent of zymosan signalling via dectin-1, and the authors proposed 
that the rest of the response to zymosan was dependent upon signalling mediated 
via unidentified Syk dependent receptor although this data was not published 
(Manicassamy, Ravindran et al. 2009). As we have shown that RA and IL-4 
synergise to enhance DC Aldh1a2 (Fig. 5.4E), elevated TLR2 and IL-4 dependent 
aldehyde dehydrogenase activity may result in a feed-forward loop via production of 
RA to promote even more enhancement of RALDH activity (Fig. 6.11).  To 
determine the relative contributions of TLR2, dectin-1 and IL-4Rα signalling in 
RALDH activity, DCs deficient in Tlr2, Clec7a and Il4ra should be compared with 
regard to their aldefluor activity both basally and in the presence of IL-4 and TLR2 
agonists.  
 
6.6.2 TLR2 and IL-4 modulation of DC cytokine production 
P3C has previously been shown to induce much higher levels of pERK than 
LPS, and the enhancement of ERK signalling was shown to alter the ability of these 
TLR agonists to induce the cytokines IL-10 and IL-12 (Agrawal, Agrawal et al. 2003; 
Dillon, Agrawal et al. 2004). Deficiency in ERK1 in DCs, or inhibition of ERK 
signalling using the upstream inhibitor of MEK1/2 U0126, resulted in increased 
secretion IL-12p70 and reduced secretion of IL-10 by LPS or P3C stimulated DCs  
(Dillon, Agrawal et al. 2004).  In later work, the same authors also assessed the 
impact of zymosan on both murine and human monocyte derived DC cytokine 
secretion (Dillon, Agrawal et al. 2006), finding that zymosan acting via TLR2 and 
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dectin-1 resulted in increased secretion of IL-10 and reduced IL-12p70, as 
compared to LPS stimulation (Dillon, Agrawal et al. 2006). The zymosan induction of 
IL-10 could be inhibited in a U0126 dependent manner, and blocking of dectin-1 β-
glucan recognition of zymosan using laminarin during stimulation of Tlr2-/- DCs 
totally abrogated phosphorylation of ERK (Dillon, Agrawal et al. 2006).  More recent 
studies in human monocyte derived DCs have highlighted a role for DC expression 
of cyclooxygenase-2 in response to zymosan resulting in autocrine prostaglandin 
E2, which enhanced Il10 transcription  (Alvarez, Municio et al. 2009). This recent 
work may be particularly relevant to our results, given the 2011 paper from Stock et 
al which found that PGE2 limited the induction of DC Aldh1a2 at extra-intestinal sites	  
(Stock, Booth et al. 2011). Taking these two studies together, the expression of 
COX2 in response to zymosan may result in a feedback loop to inhibit further 
induction of Aldh1a2.  
  
We propose that the IL-4 dependent inhibition of pERK seen following 
culture with zymosan (Fig. 6.8) is responsible for the reduced IL-10 and enhanced 
IL-12p70 detected in the supernatant following overnight culture with both zymosan 
and IL-4 (Fig. 6.2F). In addition, if P3C was used at higher dose, we predict that the 
same outcome (enhanced IL-12p70 and reduced IL-10 following the addition of IL-4) 
would result.  Moreover, we would anticipate that DCs expressing elevated levels of 
IL-12p70 and reduced IL-10 would be prone to polarise naïve T-cells towards a Th1 
type phenotype, as shown in summary Figure 6.11.  
 
6.6.3 Interactions between IL-4, TLR2 and ERK signalling  
 We highlighted in Fig. 6.6 that IL-4 is able to down modulate transcription of 
Tlr2 by 18h in murine GMDCs and that, in the absence of IL-4Rα there was an 
enhanced level of Tlr2 in GMDCs. The ability of IL-4 to modulate Tlr2 expression 
has previously been reported in human monocytes (Staege, Schaffner et al. 2000) 
and human monocyte derived DCs (Krutzik, Ochoa et al. 2003). It was also shown 
by Staege et al that IL-4 down regulated monocyte expression of TLR4 following 
24h of culture. IL-4 modulation of TLR4 may be an important mechanism in 
modulating the DC response to LPS, which we showed in chapter 4.  For this 
reason, the levels of TLR4 following LPS and IL-4 treatment of GMDCs should be 
assessed and related to this previous work (Staege, Schaffner et al. 2000). No 
apparent role for IL-10 or GM-CSF in down regulating TLR2 was found in the study 
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by Krutzik et al, which is an important result as TLR2 ligation promotes DC IL-10 
secretion (Dillon, Agrawal et al. 2004; Dillon, Agrawal et al. 2006; Alvarez, Municio 
et al. 2009) (Fig. 6.2E).  
 
Furthermore, DCs with the highest level of aldefluor activity (which also had 
the highest level of Aldh1a2 transcript (Fig. 5.5)) were found to have the lowest 
expression level of Tlr2 (Fig. 6.6F). TLR2 agonists were shown to promote RALDH 
activity in GMDCs (Fig. 6.1 and discussed above), as has been reported previously 
by Manicassamy et al (Manicassamy, Ravindran et al. 2009). The ability of RA to 
down modulate monocyte TLR2 expression has also been shown previously (Liu, 
Krutzik et al. 2005).  As enhanced aldehyde dehydrogenase activity should result in 
enhanced RA, this may account for the low level Tlr2 found in cells with highest 
aldefluor activity (Fig. 6.6F), with RA acting in an autocrine manner.  In the report by 
Liu et al, the authors failed to locate any RAR binding elements in the TLR2 
upstream region, suggesting that the transcriptional regulation of TLR2 by RA is 
indirect	   (Liu, Krutzik et al. 2005). It would be interesting to assess within sorted 
populations of aldefluor negative, low and high activity, the level of ERK activity, 
although this would be technically difficult since post sort levels may have declined 
such that this activity would be undetectable.    
 
Our work investigating TLR2 modulation of IL-4 dependent DC alternative 
activation has shown that P3C inhibited RELMα and Ym1/2 in DCs in a TLR2 
dependent manner whereas zymosan limited DC alternative activation in a TLR2 
independent manner (Fig. 6.7). Thus, the zymosan inhibition of IL-4 induced RELMα 
must occur via a receptor other than TLR2. As zymosan can signal via the CLR 
dectin-1	  	  (Brown, Taylor et al. 2002) it is possible that dectin-1 is responsible for the 
ability of zymosan to inhibit IL-4 driven alternative activation. In order to test this, the 
soluble β-glucan laminarin could be used to block signalling through dectin-1 in WT 
GMDCs. Alternatively, GMDCs could be grown from bone marrow derived from 
Clec7a-/- mice, and these then compared to similarly stimulated WT cells. However, 
the zymosan impact upon Aldh1a2 expression has previously been proposed to be 
independent of both TLR2 and dectin-1, but dependent upon Syk, leading the 
authors to propose a novel and currently undefined Syk dependent signalling 
pathway	   (Rogers, Slack et al. 2005). Furthermore, induction of IL-10 by zymosan 
has been shown to be dependent upon ERK signalling, but zymosan was unable to 
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activate ERK in Syk-/- GMDCs	  (Slack, Robinson et al. 2007). Signalling to ERK via 
the TLR2 agonist P3C was shown to be entirely MyD88 dependent (Slack, 
Robinson et al. 2007).  It will be important to confirm or exclude a role for Syk in the 
modulation of DC alternative activation. Syk-/- GMDCs could be used for these 
studies, or use of an inhibitor of a small molecule inhibitor of Syk, for example, 
R406, as has been used in previous GMDC studies (Ritter, Gross et al. 2010) 
 
IL-4 alone did not induce ERK1/2 phosphorylation in GMDCs (Fig. 6.8), 
which is in contrast to the previously published effect of IL-13 in lung tissue	   (Lee, 
Zhang et al. 2006). P3C induced a small but significant increase in ERK 
phosphorylation, and zymosan induced dramatic activation of ERK (Fig. 6.8), 
findings which have been reported previously (Agrawal, Agrawal et al. 2003; Dillon, 
Agrawal et al. 2004; Dillon, Agrawal et al. 2006; Alvarez, Municio et al. 2009). IL-4 
was able to significantly inhibit some, but not all, of the zymosan induced ERK 
phosphorylation (Fig. 6.8). Interestingly, given the TLR2 independence of zymosan 
modulation of DC alternative activation, the IL-4 inhibition of zymosan driven pERK 
was not evident in Tlr2-/- DCs (Fig. 6.8 B&C). This result suggests that some 
component of zymosan signalling to the DCs is acting via TLR2, even though 
zymosan inhibition of alternative activation is not (Fig. 6.7), and that IL-4 only 
inhibits TLR2 dependent pERK, not dectin-1 (or an unknown syk dependent 
receptor) induced pERK. Zymosan has previously been shown to activate ERK1/2 
signalling in both human and murine monocyte derived DCs in a TLR2 and dectin-1 
dependent manner, as shown by the use of Tlr2-/- murine DCs and blocking of 
dectin-1 with laminarin (Dillon, Agrawal et al. 2006). Furthermore zymosan depleted 
of TLR2 ligands (dZ), such that it signals only via dectin-1, has recently been 
confirmed to phosphorylate ERK in BMM (Eberle and Dalpke 2012). In our work, IL-
4 also inhibited the induction of pERK by P3C in a TLR2 dependent fashion (Fig. 
6.8). As a next step, the use of ERK deficient animals, or specific ERK inhibitors, 
would enable determination of the requirements for ERK activation in modulating the 
DC response to IL-4.  
 
6.6.4 Interactions between IL-4, RELMα and ERK 
As discussed in section 6.6.3, Tlr2-/- DCs were used to confirm that P3C 
abrogation of IL-4 induced Retnla/RELMα and P3C inhibition of Chi3l3/Ym1/2 (Fig. 
6.3) was dependent upon TLR2. No significant reduction was found between 
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medium + IL-4, or P3C + IL-4 treatment, when DCs were deficient in TLR2 (Fig. 
6.7). In addition, IL-4 was found to inhibit P3C phosphorylation of ERK (Fig. 6.8). 
Furthermore, results of microarray analysis of GMDCs exposed to IL-4 highlighted 
that many genes involved in modulating signalling cascades were significantly 
altered (up or downregulated) in Retnla-/- DCs but not in WT cells following 6 hours 
of culture with IL-4 (Fig. 6.9). For example, TLR2 was actually found to be more 
significantly reduced by IL-4 treatment of RELMα deficient cells than WT cells, a 
finding that we need to confirm with TLR2 surface staining by flow cytometry. There 
were 5 different Dusp/MKP genes significantly modulated by IL-4 treatment. Dusps 
encode dual specificity phosphatases that remove phosphate groups from MAPKs 
to inhibit their action (Caunt and Keyse 2012). DUSP6 is a specific phosphatase of 
ERK1/2 signalling (Nunes-Xavier, Tarrega et al. 2010; Zhang, Kobayashi et al. 
2010; Caunt and Keyse 2012), and has been described to function in a feedback 
loop regulated by the transcription factor encoded by Ets2 (Nunes-Xavier, Tarrega 
et al. 2010), another gene significantly downregulated by IL-4 treatment of Retnla-/- 
but not WT DCs (Fig. 6.9). The frequency of genes involved in MAPK signalling, 
specifically in the regulation of ERK1/2 signalling, that were altered significantly in 
RELMα deficient DCs (Fig. 6.9), coupled with our finding that IL-4 regulated pERK 
activation in GMDCs (Fig. 6.8), leads us to propose that ERK signalling may 
regulate RELMα and/or vice versa (Fig. 6.11).  
 
We addressed this possibility by using a specific inhibitor of MEK1/2, the 
upstream kinase of ERK1/2 (Fig. 1.3), to demonstrate that ERK1/2 differentially 
modulates alternative activation products in GMDCs (Fig. 6.10). Inhibition of ERK1/2 
by pre-culture with U0126 significantly enhanced IL-4 induced RELMα at the level of 
protein secretion and Retnla transcription (Fig. 6.10B), highlighting that ERK1/2 
activation would usually function to inhibit IL-4 induction of RELMα. In contrast, 
there was no significant change in the expression of Chi3l3 transcript or Ym1/2 (Fig. 
6.10B), a significant reduction in CCL24 protein and a trend for reduced Ccl24 
transcript (though this did not reach significance)(Fig. 6.10C).  Thus, ERK1/2 
regulates several key aspects of IL-4 dependent alternative activation in DCs (Fig. 
6.11).  
 
 This finding does not discount the possible role for other kinases in the 
regulation of DC alternative activation. For example, several studies have suggested 
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functional roles for both PI3K and AKT in modulating AAM (MacKinnon, Farnworth 
et al. 2008; Ruckerl, Jenkins et al. 2012).  It was reported that inhibition of PI3K in a 
human monocytic cell line (THP-1) resulted in abrogation of IL-4 induced alternative 
activation, as assessed by MR expression (MacKinnon, Farnworth et al. 2008). In 
the same study, inhibition of PI3K limited IL-4 phosphorylation of AKT (also known 
as PKB), but not STAT6. Furthermore, IL-4 was shown to promote activation of AKT 
(MacKinnon, Farnworth et al. 2008). Another study published in 2012 showed that 
inhibition of AKT with the inhibitor triciribine in vivo significantly reduced IL-4 induced 
peritoneal macrophage proliferation and RELMα expression, but did not significantly 
modulate Ym1/2  (Ruckerl, Jenkins et al. 2012). PI3K is activated downstream of IL-
4Rα signalling by IRS1/2, and PI3K then activates AKT (Nelms, Keegan et al. 
1999)(Fig. 1.8).  ERK can also be phosphorylated downstream of IL-4Rα, via the 
action of IRS1/2  (Fig. 1.8). Thus, IRS1/2 should be investigated with regard to the 
differential involvement of ERK in regulating DC RELMα expression in response to 
IL-4.  
 
RELMα itself has also been shown to phosphorylate AKT in pulmonary 
microvascular smooth muscle cells in a PI3K dependent manner (Teng, Li et al. 
2003). In this study, the authors also annotated the Retnla gene, finding putative 
transcription factor binding consensus sequences	   (Teng, Li et al. 2003); 6 C/EBP 
binding motifs (which had been identified as an IL-4 dependent STAT6 binding 
partner for the induction of RELMα (Fizz1) prior to the Teng report (Stutz, Pickart et 
al. 2003)), 5 NF-κB motifs, an AP-1 site in the 3’UTR, a putative IRF site and two 
GAS elements	  were located	  (Teng, Li et al. 2003). One of the GAS sites had already 
been identified as the site at which STAT6 and C/EBP regulated the IL-4 dependent 
induction of RELMα in the BMnot cell line (Stutz, Pickart et al. 2003). The number of 
binding sites available for different transcription factors within the cloned murine 
Retnla gene highlights the possible range of complex interactions that could 
regulate the transcription of this gene within mammalian cells	  (Teng, Li et al. 2003). 
Interestingly, this article did not report any RARE within the Retnla gene	  (Teng, Li et 
al. 2003), suggesting that the combined impact of RA and IL-4 on RELMα 
transcription (Fig. 5.6) will not be direct.  
 
In this chapter we revealed a disparity in the ability of TLR2 agonists to limit 
IL-4 induced alternative activation in DCs. We went on to identify a novel role for 
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pERK in modulating IL-4 dependent responses in GMDCs. pERK was found to 
differentially modulate facets of DC alternative activation, inhibiting IL-4 induction of 
RELMα, promoting IL-4 induced CCL24 and having no impact upon Ym1/2.  
Figure 6.1 TLR2 agonists enhance IL-4 driven aldehyde dehydrogenase activity in GMDCs. 
WT GMDC were cultured overnight with or without addition of 20ng/ml IL-4, Pam3Csk4 
(20ng/ml P3C) or zymosan (100μg/ml, Zym)  (A). DCs were gated as CD11c+, prior to 
assessment of both the % level of aldehyde dehydrogenase activity within the population (B
+C) and the gMFI of aldefluor activity within the total CD11c+ population (D). Expression of 
Aldh1a2 transcript was also quantified (E). Data is representative of 3 independent 
experiments, error bars represent triplicate culture wells, a.u.= arbitrary units as compared 
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Figure 6.2 TLR2 agonists activate GMDCs, IL-4 regulates Zymosan directed secretion of 
IL-10 and IL-12. WT GMDC were cultured overnight with or without addition of 20ng/ml IL-4, 
250ng/ml Pam3Csk4 (P3C) or 100μg/ml zymosan (Zym)  (A). Co-stimulatory marker 
expression (B-E) and cytokine secretion were determined (F+G). Histograms in B are 
representative plots of triplicate culture wells, black line=medium, grey line=P3C, blue=Zym, 
shaded= isotype control. Graphs in C-E show geometric mean fluorescence intensity 
(gMFI). Data is representative of 5 independent experiments, error bars represent triplicate 


































Figure 6.3 P3C and zymosan limit IL-4 driven RELMα and Ym1/2 to different extents. WT 
GMDC were cultured overnight with or without addition of 20ng/ml IL-4, 250ng/ml  
Pam3Csk4 (P3C) or 100μg/ml zymosan (Zym) (A). Intracellular protein (B+C), secreted 
protein (D) and mRNA levels of RELMα and Ym1/2 were detected by flow cytometry, ELISA 
and qPCR respectively. Data is representative of 5 independent experiments, a.u.= arbitrary 
units as compared to Hprt expression, error bars represent triplicate culture wells, *= P< 
0.05 **= P<0.01 ***P<0.001 ****P<0.0001. 
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Figure 6.4 Zymosan inhibits Arg1 and promotes iNOS in GMDC. WT GMDC 
were cultured overnight with or without addition of 20ng/ml IL-4, 250ng/ml  
Pam3Csk4 (P3C) or 100μg/ml zymosan (Zym) (A). mRNA for the arginase 
converting enzymes Arginase 1 (Arg1: B)  and iNOS (Nos2; C) were assessed 
by qPCR as was the production of NO by the cells (D). Data is representative of 
3 independent experiments, a.u.= arbitrary units as compared to Hprt 
expression, error bars represent triplicate culture wells, *= P< 0.05 **= P<0.01 
***P<0.001. 
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Figure 6.5 P3C and zymosan modulate chemokine production by IL-4 treated 
GMDCs. WT GMDC were cultured overnight with or without addition of 20ng/ml 
IL-4, 250ng/ml Pam3Csk4 (P3C) or 100μg/ml zymosan (Zym)  (A). mRNA for 
the chemokines CCL17 (Ccl17: B)  and CCL24 (Ccl24; C) were assessed by 
qPCR as was the secretion of CCL24 protein (D). Data is representative of 3 
independent experiments, a.u.= arbitrary units as compared to Hprt expression, 




18	  h	   qPCR	   or	  
±	  rIL-­‐4	  
6	  h	   qPCR	  
±	  rIL-­‐4	  











Figure 6.6 IL-4 and TLR2 counter-regulate one another. WT GMDC were cultured 
overnight with or without addition of 20ng/ml IL-4 (A). mRNA for Tlr2 was 
assessed by qPCR (B); WT or Il4ra-/- GMDC were cultured with IL-4 for 6h (C), 
expression of Tlr2 was determined by qPCR (D). Following overnight culture with 
IL-4, WT GMDC populations were flow sorted based upon aldefluor activity and 
qPCR was used to assess expression of Tlr2 within aldefluor negative, low or 
high expressing populations (F).  Data is representative of 2 independent 
experiments, a.u.= arbitrary units as compared to Hprt expression, error bars 
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Figure 6.7 TLR2 limits IL-4 driven RELMα in GMDC, and is responsible for P3C inhibition of 
alternative activation. WT or Il4ra-/- GMDC were cultured with or without addition of 20ng/ml 
IL-4, Pam3Csk4 (250ng/ml P3C) or Zymosan (100μg/ml Zym) (A). RELMα and Ym1/2 
production was assessed by intracellular staining (B+C) or ELISA (D). Data is representative 
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Figure 6.8 IL-4 inhibition of zymosan driven phospho-ERK1/2 is dependent upon TLR2.  
WT or Tlr2-/- GMDC were cultured for 15 minutes with an inhibitor or ERK1/2 signalling 
(U0126, 10μΜ) or media, prior to addition of 250ng/ml Pam3Csk4 (P3C), 100μg/ml 
zymosan (Zym) or 100nM phorbol 12, 13-dibutyrate (+ve) with or without 20ng/ml IL-4 for a 
further 15 minutes (A). Phosphorylation of ERK was determined by intracellular staining (B
+C). Data is representative of 3 independent experiments using WT GMDCs, 1 independent 
experiment using Tlr2-/- GMDCs, error bars represent triplicate culture wells, *= P< 0.05 **= 
P<0.01 ***=P<0.001. 
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Figure 6.9 IL-4 differentially modulates components of the MAPK signalling cascade in WT 
and RELMα deficient DCs. WT or Retnla-/- GMDCs were cultured for 6h with 20ng/ml IL-4, 
RNA was extracted and an illumina microarray carried out (same experiment as Fig. 4.12). 
Heat map of transcripts significantly altered following IL-4 treatment, limited to genes 
involved in signalling pathways. Data is from one microarray experiment, 3 biological 
replicates per genotype, following normalisation comparisons were performed using linear 
modelling. p= Adj. p significance values  assessed using Bayesian analysis, corrected using 
Benjamini & Hochberg method for multiple testing (Al Ivens, CIIE Bioinformatics support).  
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Figure 6.10 ERK signalling inhibits IL-4 driven RELMα in GMDC. GMDC were 
cultured for 1 hour with an inhibitor of ERK1/2 signalling (10μM U0126) or 
media, prior to addition of 20ng/ml IL-4 or media to the culture well for a further 
18 hours (A). Alternative activation was determined by secretion and 
expression of RELMα (B), Ym1/2 (C) and CCL24 (D). Data is representative of 
2 independent experiments, error bars represent triplicate culture wells, *= P< 
0.05 **= P<0.01. 
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Figure 6.11. Model of how TLR2, IL-4 and RA signalling integrate in DCs. IL-4 promotes DC 
RELMα, and limits pERK, pERK restrains IL-4 induced RELMα, and IL-4 can limit TLR2 
induced pERK, which may be via RELMα. RALDH activity is promoted by TLR2 signalling 
and IL-4, RALDH activity results in RA production, RA signalling enhances IL-4 driven 
RALDH and RELMα. ERK signalling is known to promote DC secretion of IL-10 and inhibit 
IL-12p70, IL-4 limits  TLR2 stimulated DCs secretion of IL-10 and promotes IL-12p70, which 
based on data in chapter 4, we propose will polarise naïve T-cells to secrete IFNγ. Blue 
lines represent TLR2/ERK, yellow lines represent IL-4R and green lines represent RA 






















Chapter 7. Concluding Remarks and Future Directions 
 
Work in this thesis has shown that DCs can be alternatively activated by IL-
4, both in vivo following provision of exogenous IL-4c, or in response to a potent Th2 
inducing parasite. Ex vivo following isolation of splenic DC populations, and in vitro 
in the presence of the Th2 cytokines IL-4 and IL-13. We confirmed that DCs are 
more superior at activating naïve T-cells than macrophages in vivo, and that AADCs 
are different flavours to AAMs, showing differential expression of the alternative 
activation products RELMα, Ym1/2 and arginase-1. The lack of IL-4 driven arginase 
in DCs highlights what we believe may be different biological roles for alternative 
activation in DCs as compared to macrophages, with AADCs fine tuning the priming 
of T-cells in the context of a type-2 immune setting.  
 
A functional role for DC RELMα in the promotion of T-cell cytokine 
responses was highlighted, with RELMα being required for the optimal induction of 
T-cell IL-10 and IL-13 and modulation of IL-4 and IFNγ. In future work it will be 
necessary to determine if DC responsiveness to IL-4 is important for health and as 
such whether AADCs are required for animals to survive disease. CD11cCreIl4rafl/fl 
animals should be infected with Th2 driving pathogens such as S. mansoni, to 
confirm whether alternative activation of CD11c+ cells is required for survival, as is 
the case with IL-4Rα positive macrophages (Herbert, Holscher et al. 2004). In 
addition, the data presented in chapter 4 of this thesis would suggest that the ability 
of animals deficient in IL-4Rα expression within their CD11c compartment to survive 
bacterial and viral infections should also be investigated further. The expectation 
being that such animals would be less capable of mounting a Th2 supported Th1 
response and thus less competent to clear a Th1 infection.  
 
The notion that a Th2 immune response characterised by alternative 
activation can support survival following a severe actue infection such as bacterial 
sepsis, is supported by the theory that Th2 immunity evolved to repair damage. For 
example, the Th2 immune response may serve to promote a Th1 response following 
wounding, such as the damage caused as a pathogen breaches a mucosal barrier 
(Allen and Wynn 2011). To address whether this theory holds true, it would be 
informative to investigate whether animals unable to be alternatively activated, for 
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example those genetically deficient in STAT6 or IL-4Rα, are worse at surviving 
bacterial or viral infections.  
 
RA was revealed as a factor able to promote IL-4 driven RALDH2 and 
RELMα in GMDCs. In contrast, RA was not shown to promote IL-4 dependent 
macrophage RELMα. In chapter 4 we highlighted that in the absence of IL-4R 
signalling to bacterially stimulated DCs there is an enhanced level of IFNγ and IL-17 
induced in vivo. It would be interesting to determine whether following in vivo 
transfer bacterially stimulated WT and Il4ra-/- DCs produce different levels of 
Aldh1a2 and thus potentially produce enhanced levels of local RA.  
 
Through the use of panRAR inhibitors, addition of exogenous RA and 
GMDCs deficient in RARα, regulated signalling between RARα, and all other RARs 
was highlighted as a mechanism via which RA controlled the alternative activation of 
DCs. To confirm whether RARα expression by DCs is required for surviving chronic 
Th2 infections, CD11cCreRARafl/fl animals should be infected with a Th2 polarising 
parasite such as S. mansoni.  To address the importance of our TLR2/IL-4 
interaction story, a pathogen that signals via TLR2, such as the fungus Aspergillus 
fumigatus should be used to infect IL-4, IL-4Rα or STAT6 deficient animals.   
 
Excitingly, we have highlighted for the first time a role for pERK signalling in 
the inhibition of DC responses to IL-4, specifically limiting RELMα but promoting 
CCL24, whether ERK signalling regulates the IL-4 dependent production of RELMα 
by other cells such as macrophages and eosinophils should also be investigated.   
 
Data within this thesis would suggest that secretion of RELMα from DCs 
does not following a standard secretion pathway, as the use of golgistop did not 
enhance intracellular levels and we were unable to detect enhanced RELMα 
secretion in the presence of RA and IL-4 in spite of an increase intracellularly. The 
secretory pathway of RELMα will be investigated further, by initially determining 
whether RELMα may be released contained within exosomes.  
 
 Multiple avenues for future work were revealed through the use of a 
microarray assessment following IL-4 treatment of GMDCs. Further assessment of 
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the function of these novel targets of IL-4 in DC, will help in the search for the 
elusive signal 3, in DC Th2 induction. 
 
The results in this thesis would suggest that alternative activation of DCs, 
primarily determined via the IL-4 dependent induction of RELMα expression is an 
endogenous biological process with functional relevance to DC APC function, 
further studies will be required to address whether DCs express RELMα at sites 
other than the spleen. Based on the data presented here it may be expected that 
DC populations within intestinal sites at which vitamin A uptake occurs may in fact 
become alternatively activated at steady state, it will be interesting to determine 
which pre-defined DC subsets (Merad and Manz 2009) are responsible for RELMα 
production, and whether there is a role for RA in alternative activation in vivo.  
 
We believe that with further work it will be possible to more closely interlink 
all strands of this thesis, determining how signalling pathways downstream of GM-
CSF, RA, IL-4 and TLR2 ligands integrate in their regulation of DC function, 
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Interleukin-4 is a cytokine widely known for its role in CD4+ T cell
polarization and its ability to alternatively activate macrophage
populations. In contrast, the impact of IL-4 on the activation and
function of dendritic cells (DCs) is poorly understood. We report
here that DCs respond to IL-4 both in vitro and in vivo by expres-
sion of multiple alternative activation markers with a different
expression pattern to that of macrophages. We further demon-
strate a central role for DC IL-4Rα expression in the optimal in-
duction of IFNγ responses in vivo in both Th1 and Th2 settings,
through a feedback loop in which IL-4 promotes DC secretion of
IL-12. Finally, we reveal a central role for RELMα during T-cell
priming, establishing that its expression by DCs is critical for opti-
mal IL-10 and IL-13 promotion in vitro and in vivo. Together, these
data highlight the significant impact that IL-4 and RELMα can have
on DC activation and function in the context of either bacterial or
helminth pathogens.
antigen presenting cells | T lymphocytes | innate immunity |
adaptive immunity
Activation of dendritic cells (DCs) with bacterial or viral an-tigen (Ag) results in production of proinflammatory cyto-
kines and enhanced ability to stimulate Th1/Th17 responses (1).
In addition, a range of cytokines influence DC activation, with
IL-12 and IL-10 playing critical roles in either promotion or
regulation of DC maturation and function (2, 3). The hallmark
of allergic disease and helminth infection is induction of a CD4+
Th2 response, characterized by secretion of cytokines such as IL-
4 and IL-13 (4). Although DCs themselves are not thought to
produce IL-4 (5), this canonical Th2 cytokine can be secreted
rapidly in direct response to pathogen stimulation by a variety of
other innate cells (4). As such, DCs encountering Ag or patho-
gen stimulation in Th2 infection or disease settings will likely be
simultaneously exposed to IL-4. However, the impact of IL-4 on
the functional capability of DCs remains relatively unexplored.
In comparison with DCs, the effect of IL-4 on activation of
macrophage (MΦ) populations has been much more thoroughly
addressed, with IL-4/IL-13 treatment resulting in “alternatively”
activated macrophages (aaMΦs) (6) characterized by the ex-
pression of Arginase-1, chitinase-like molecule Ym1, resistin-like
molecule α (RELMα, also known as FIZZ1), and C-type lectin
receptors such as mannose receptor (MR) and Dectin-1 (6, 7).
Although the individual and cumulative function of these IL-4–
induced products is not clear, aaMΦs are thought to play vital
roles in helminth infection and tissue remodeling, and are capable
of suppressing T-cell responses (8–10). However, only a limited
number of studies have addressed whether DCs express markers
associated with aaMΦs (11–14), and it remains unclear how ex-
pression of IL-4–induced molecules may influence DC function in
Th2 settings. Somewhat surprisingly, previous work has indicated
that IL-4 can enhance production of IL-12p70 by DCs stimulated
with bacterial LPS in vitro via inhibition of IL-10 (15–18). This
suggests that IL-4 may facilitate DC priming of Th1 responses in
ongoing, counterregulatory, Th2 settings (15, 16, 19).
We set out to delineate the role of IL-4 in influencing DC
activation and function, both in vitro and in vivo. We show that
treatment of DCs with IL-4 in vitro resulted in robust expression
of a wide range of alternative activation markers at both the
transcript and protein level, with a more selective expression
of alternative activation markers RELMα and Ym1 in vivo.
We further demonstrate a key role for DC-derived RELMα in
promotion of optimal Th2 responses that contrasts with the
previously suggested regulatory function of this alternative acti-
vation product (20–22). Together, these data reveal that the
ability to respond to IL-4 is critical for optimal Th1 or Th2
priming by DCs through modulation of IL-12/IL-10 or RELMα
production, respectively.
Results
IL-4 Induces DC Expression of RELMα in Vivo. The phenotypes of
aaMΦ populations, isolated from a variety of tissues in Th2 in-
flammatory settings, have been well characterized, with one hall-
mark being the abundant expression of markers RELMα and Ym1
(6). RELMα has also previously been identified in cells other than
aaMΦs, including eosinophils and epithelial cells (10, 20, 22). To
investigate whether DCs respond to Th2 environments in a manner
similar to MΦs, mice were injected i.p. with rIL-4 complexed with
anti–IL-4 mAb (IL-4c), which ensures slow release of cytokine for
2–3 d (23). Peritoneal exudate cells (PEC) were isolated 4 d after
mice received a single dose of IL-4c or PBS. For flow-cytometric
analysis, granulocytes, monocytes, and B cells were excluded (based
on cell size, Gr1, and CD19 staining), MΦs were defined as F4/
80+FSCint/hiMHC-IIlo/int and DCs as F4/80−FSCloCD11chiMHC-
IIhi (Fig. 1A). IL-4c did not significantly alter the number of DCs in
the PEC but, as recently reported (23), significantly increased ac-
cumulation of MΦs (P < 0.05; Fig. 1A), suggesting that, in contrast
to MΦs, DCs do not proliferate in response to IL-4c injection. To
assess whether IL-4 administration caused alternative activation of
these populations, we performed intracellular staining for RELMα
and Ym1/2. As expected, MΦs isolated from IL-4c–injected mice
displayed striking levels of RELMα and Ym1/2 expression com-
pared with MΦs isolated from PBS control animals (Fig. 1B).
Furthermore, the expression of these proteins was not uniform,
with RELMα+Ym1/2−, RELMα+Ym1/2+, and RELMα−Ym1/2+
MΦ populations all being identified. In contrast to the effect on
MΦs, predominantly single positive RELMα−expressing DCs were
observed at a low dose of IL-4c (0.6 μg) with little change in Ym1/2
evident. However, at a higher dose of IL-4c (4 μg), a significant
proportion of RELMα-positive DCs expressed Ym1/2. In addition,
the ability to respond to IL-4 in vivo was not restricted to peri-
Author contributions: P.C.C., L.H.J., J.E.A., and A.S.M. designed research; P.C.C., L.H.J., and
S.J.J. performed research; T.A.W. contributed new reagents/analytic tools; P.C.C., L.H.J.,
and S.J.J. analyzed data; and P.C.C., L.H.J., S.J.J., T.A.W., J.E.A., and A.S.M. wrote
the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
Freely available online through the PNAS open access option.
1P.C.C. and L.H.J. contributed equally to this work.
2To whom correspondence should be addressed. E-mail: Andrew.MacDonald@ed.ac.uk.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1121231109/-/DCSupplemental.









toneal cavity DCs, as splenic MHCIIhiCD11chi DCs also signifi-
cantly up-regulated RELMα and Ym1/2 expression following IL-4c
injection (Fig. S1).
To determine the general capacity of DCs to alternatively
activate in vivo in response to stimuli other than IL-4c, we
assessed RELMα and Ym1/2 production by DCs from mice
infected with Litomosoides sigmodontis or Schistosoma mansoni
(Fig. S2), parasitic helminths that promote strong Th2 responses.
Pleural cavity (Fig. S2A) or splenic (Fig. S2B) MHCIIhiCD11chi
DCs from infected mice displayed significantly increased ex-
pression of RELMα in comparison with naive control animals.
Ym1/2 expression was less dramatically influenced by infection
(Fig. S2). Thus, DCs from diverse tissue sites can express
markers associated with aaMΦs in vivo, in response to injection
with IL-4c or in the more complex setting of helminth infection.
IL-4 Up-Regulates DC Expression of Multiple Markers of Alternative
Activation. To carefully dissect the influence of IL-4 on a well-
characterized population of cells, we generated DCs from murine
bone marrow (BM) using GM-CSF, then exposed the DCs to
recombinant IL-4 in vitro. As shown previously, DCs expressed IL-
4Rα (Fig. 2A) (18), and IL-4 did not substantially alter MHC-II or
the costimulatory molecules CD40, CD80 and CD86 (Fig. S3).
However, IL-4 significantly increased DC mRNA levels and pro-
tein secretion of both RELMα (Retnla) and Ym1/2 (Chi3l3) (Fig.
2 B and C). Intracellular staining showed that production of these
Fig. 1. IL-4c induces MΦ and DC expression of RELMα in vivo. MΦs and DCs in PEC from PBS- or IL-4c–treated mice were assessed by flow cytometry (A). MΦs
and DCs as defined in (A) stained for intracellular expression of RELMα and Ym1/2 (B). Data are representative of five experiments. Graphs show percent
expression for individual mice, three to five per group. FMO, fluorescence minus one control.
Fig. 2. IL-4 stimulates RELMα and Ym1 expression by BMDCs. IL-4Rα expression by BMDCs (A) (shaded portion = isotype control; black line = media; gray line= +IL-
4). WT or Il4ra−/− BMDCs were cultured overnight with or without IL-4 and were assessed for markers of alternative activation (B–F) (black = without IL-4; gray = 20
ng/mL IL-4). Data are representative of more than three experiments. Error bars indicate SEM of triplicate wells. a.u., Arbitrary units.
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proteins was not limited to a single population, with both RELMα
and Ym1/2 single and double-positive DCs clearly distinguishable
(Fig. 2D: WT). Verifying that DC up-regulation of RELMα and
Ym1/2 was a consequence of IL-4 responsiveness, Il4ra−/− DCs did
not up-regulate RELMα and Ym1/2 in response to IL-4 (Fig. 2D:
Il4ra−/−). In addition, in WT DCs, IL-4 increased transcripts for
Dectin-1 (Clec7a), Mrc1 (MR) and Ccl24 (Fig. 2E), markers
previously associated with aaMΦs (6, 7). However, Arginase-1,
another signature molecule of aaMΦs (6), was not significantly
increased in terms of either transcription or enzymatic activity in
IL-4–treated DCs (Fig. 2F). Increased transcript expression of
Retnla, Clec7a, and Ccl24 was also seen following in vitro exposure
of FACS-purified splenic cDCs from naive mice to IL-4 (Fig. S4).
Together, these data reveal that murine DCs can respond to IL-4
in a manner similar to that previously described for aaMΦs by
significantly up-regulating RELMα and Ym1/2 and other aaMΦ
markers, with the notable exception of Arginase-1.
Signaling to DCs via IL-4Rα Alters Their Response to Inflammatory
Stimuli and Is Important for Their Ability to Induce IFNγ and IL-17.
Previous studies have shown that IL-4 can boost DC proin-
flammatory cytokine production upon engagement of specific
pattern recognition receptors, and suggested that this may rep-
resent a mechanism to enable DC induction of adaptive Th1
responses in IL-4–rich environments (15, 19). We assessed the
influence of IL-4 on DCs exposed to IL-4 concurrently with
complex Ag from pathogens and individual toll like receptor
(TLR) ligands. We found that DC exposure to ligands of TLR4
(LPS), TLR9 (CpG), or a heat-killed preparation of the Gram-
positive bacterium Propionibacterium acnes (Pa) boosted IL-12p70
secretion, and inhibited production of IL-10, RELMα, and Ym1/
2, in response to IL-4 (Fig. S5 A–D). Production of proin-
flammatory cytokines IL-1β and IL-6 was not significantly altered
by IL-4 treatment (Fig. S5E). In contrast to Pa and TLR ligands,
DCs exposed to soluble extracts from the egg stage of S. mansoni
[soluble egg Ag (SEA)] in the presence or absence of IL-4 did not
alter secretion of either RELMα or Ym1/2, indicating that SEA
has no potential to drive or block alternative activation of DCs
(Fig. S5 C and D). Similarly, unlike Pa- and TLR-pulsed DCs,
IL-4 treatment did not alter production of proinflammatory or
regulatory cytokines by SEA-exposed DCs. Thus, the influence of
IL-4 over DC activation is context dependent: IL-4 can enhance
TLR-driven IL-12p70 production, but engagement of these pat-
tern recognition receptors by defined TLR ligands or bacteria can
also dramatically inhibit alternative activation markers ordinarily
induced by IL-4. In contrast, the helminth Ag SEA did not impede
this process.
Having demonstrated that DCs can express molecules asso-
ciated with aaMΦs in an IL-4Rα–dependent manner, and that
IL-4 can boost TLR-mediated proinflammatory cytokine pro-
duction, we next addressed the relevance of DC responsiveness
to IL-4 for T cell priming, one major characteristic used to dis-
tinguish DCs from MΦs. We have previously shown that Pa-ac-
tivated DCs generate a strong mixed Th1/Th17 response
following transfer into naive recipient mice (24). In contrast, we
have established that DCs pulsed with SEA are capable inducers
of Th2 responses both in vitro and in vivo, despite failing to up-
regulate traditional markers of activation (5). Although it has
been debated recently whether DCs are needed to prime Th2
responses (4), we have definitively shown that Th2 priming to
schistosomes is dependent on CD11c+ DCs (25).
To investigate whether DC responsiveness to IL-4 alters prim-
ing of naive T cells, we generated WT or Il4ra−/− DCs, exposed
them to Pa or SEA in vitro, then adoptively transferred them into
WT naive recipient mice, and compared Ag-specific immune
responses in the draining LN (dLN). Transfer of Pa pulsed Il4ra−/−
DCs resulted in significantly lower amounts of Ag-specific IL-17
and IFNγ in recipient mice, in comparison with WT Pa DCs (Fig.
3A). This demonstrates that DC IL-4Rα signaling is required to
promote optimal T-cell responses even in a Th1/Th17 polarizing
environment with low levels of available Th2 cytokine. The de-
ficiency in IL-17 priming is unlikely to be due to alteration in DC
production of Th17-promoting cytokines IL-1β and IL-6, as IL-4
did not significantly influence secretion of either of these cytokines
by DCs responding to Pa in vitro (Fig. S5E).
In the context of helminth- rather than bacterial Ag–condi-
tioned DCs, Il4ra−/− SEA DCs induced similar levels of Ag-
specific IL-4 and IL-13, but significantly lower amounts of IL-10
and IFNγ in comparison with WT SEA DCs (Fig. 3B). This
indicates that DC expression of IL-4Rα is not an absolute re-
quirement for Th2 priming, but is needed for the induction of
IFNγ and IL-10 responses against SEA. In keeping with previous
work (26), the level of IL-17 induced by SEA-activated C57BL/6
DCs was negligible, and was not influenced by the presence or
absence of IL-4Rα on the transferred DCs.
The reduced ability of Il4ra−/− DCs to promote Pa-specific IL-
17 and IFNγ, and SEA-specific IL-10 and IFNγ, was not due to
a fundamental defect in Ag uptake, processing, or presentation
by these cells. Il4ra−/− DCs capably took up Ag in the form of
FITC-labeled dextran (Fig. S6), and displayed enhanced ability
to stimulate proliferation of OTII TCR Tg T cells in vitro, fol-
lowing exposure to ovalbumin (OVA) peptide or protein, com-
pared with WT DCs (Fig. S7).
IL-4 Alters the Response of DCs to CD40 Ligation. CD40 expressed by
DCs binds CD154 on the surface of activated T cells, this in-
teraction enhancing DC activation and cytokine production
which is often crucial for their ability to prime Th1, Th2 and
Th17 responses (24, 27). To address whether the IL-4 induced
alteration in the balance of IL-12, IL-10, RELMα, and Ym1/2
production by DCs might be influenced by interaction with T
cells we examined the impact of CD40 ligation on DC cytokine
production following IL-4 exposure. To mimic DC–T-cell in-
teraction in vitro, we analyzed cytokine secretion by DCs that
had previously been exposed to Pa or SEA in the presence of
absence of IL-4, after stimulation with agonistic αCD40 mAb.
IL-4 treatment of Pa-pulsed DCs significantly enhanced pro-
Fig. 3. Il4ra−/− DCs are less able to induce IFNγ and IL-17 responses. WT or
Il4ra−/− BMDCs were cultured overnight in medium alone (M), with Pa (A) or
SEA (B), harvested, and injected s.c. into WT mice. Seven days later, the
draining pLN were harvested, cells were restimulated for 72 h with Pa (A) or
SEA (B), and cytokine secretion was assessed by ELISA. Data are representative
of five experiments. Error bars indicate SEM of three to five mice per group.









duction of IL-12p40, IL-6, and IL-12p70, and reduced secretion
of IL-10, following addition of αCD40 mAb (Fig. S8A). How-
ever, in keeping with previously published data (28), control
(medium) DCs or SEA DCs did not produce significant amounts
of IL-12p70 or IL-10 following stimulation with anti-CD40, and
this was not influenced by IL-4 exposure (Fig. S8A). Therefore,
the influence of IL-4 on cytokine secretion by DCs responding to
bacterial stimulation was not transient, and extended to sec-
ondary activation via CD40 ligation.
Previous studies have suggested that RELMα and Ym1/2 may
have a role in regulating or promoting T-cell responses, respec-
tively (14, 21, 22), and it is conceivable that during T-cell priming,
CD154 expressed by T cells could engage DC CD40 and influence
secretion of these molecules. However, IL-4–treated DCs stimu-
lated with αCD40 mAb produced similar levels of RELMα and
Ym1/2 compared with isotype controls (Fig. S8B), indicating that
CD40 stimulation does not regulate IL-4–driven expression of
these alternative activation products either in control or SEA
DCs. Furthermore, in the case of Pa stimulated DCs, bacterial
inhibition of RELMα and Ym1/2 was maintained throughout
culture, and was not overcome by CD40 ligation (Fig. S8B). These
CD40 ligation experiments also illustrate that DCs previously
exposed to IL-4 still produced substantial amounts of RELMα and
Ym1/2 up to 36 h after initial cytokine treatment (Fig. S8B). Thus,
production of RELMα and Ym1/2 by DCs is not transient and
requires neither the continued presence of IL-4 nor subsequent
CD40 ligation.
DC Secretion of RELMα During Th2 Priming Regulates IFNγ and
Promotes Th2 Responses. Although our data demonstrate that DC
sensitivity to IL-4 plays an important role in priming of T-cell IL-
10, IL-17, and IFNγ (Fig. 3 A and B), it is not clear whether this is
a consequence of alternative activation marker expression or some
other facet of the diverse influence of IL-4 on DCs (Fig. 2 and Fig.
S5). To specifically address the role of a defined alternative acti-
vation product in T-cell, priming we generatedDCs fromRetnla−/−
mice (20), which were similar to WT in terms of numbers and
phenotype. We adoptively transferred SEA- or Pa-pulsed WT or
Retnla−/− DCs into WT-naive recipient mice and assessed the
resulting Ag-specific immune response.
Retnla−/− Pa DCs induced similar IFNγ and IL-17 responses to
WT DCs in the draining LN following transfer (Fig. 4A), dem-
onstrating that DC-derived RELMα neither promotes nor reg-
ulates T-cell differentiation in a bacterial Th1/Th17 setting.
Thus, impaired priming by Il4ra−/− DCs exposed to bacteria (Fig.
3A) is RELMα independent. The lack of a major role for
RELMα in Th1/17 priming also fits with the observed inhibition
of IL-4–induced RELMα expression by DCs following bacterial
or TLR ligand exposure (Fig. S5).
To directly assess the importance of DC RELMα secretion in
a Th2 setting, we transferred Retnla−/− DCs pulsed with SEA
into naive recipients. In repeated experiments, both WT and
Retnla−/− SEA DCs stimulated similar levels of Ag-specific IL-4,
but mice that received Retnla−/− DCs displayed significantly re-
duced levels of IL-10 and IL-13 compared with WT SEA DCs
(Fig. 4B). Furthermore, Retnla−/− SEA DCs induced significantly
greater amounts of IFNγ compared with WT SEA DCs (Fig. 4B).
This suggests that DC production of RELMα is required for
optimal Th2 cell priming by helminth-activated DCs, promoting
some components of the Th2 response while regulating the level
of the Th1 response.
To further dissect requirements for DC RELMα production in
promoting optimal T-cell Th2 cytokine secretion, we examined
the ability of WT or Retnla−/− DCs to induce CD4+ T-cell IL-4,
IL-10, and IL-13 in vitro. In this assay, the addition of exogenous
IL-4 to WT DCs cocultured with CD4+IL-10eGFP− T cells
purified from IL-10eGFP reporter mice (29), or CD4+ T cells
from KN2 mice in which IL-4–producing cells express huCD2
(30), resulted in induction of T-cell expression of eGFP or huCD2,
and secretion of IL-10 and IL-13 (Fig. 4 C andD). In keeping with
the lack of a significant impact of RELMα deficiency on IL-4 in-
duction in vivo (Fig. 4B), Retnla−/− DCs capably provoked huCD2
expression on responding KN2 T cells in vitro (Fig. 4C). However,
Retnla−/− DCs were incapable of promoting T-cell expression of
IL-10 mRNA as detected by GFP expression (Fig. 4C). Further-
more, analysis of secreted cytokine by ELISA showed that cocul-
tures of CD4+ T cells and WT DCs produced more IL-10 and IL-
13 protein in the presence of IL-4 compared with cocultures with
Retnla−/− DCs (Fig. 4D). Interestingly, T cells cultured with WT
DCs secreted lower levels of IFNγ protein than their Retnla−/−
counterparts, supporting observations following in vivo DC
transfer of SEA activated DCs (Fig. 4B).
Fig. 4. DC expression of RELMα during Th2 priming regulates IFNγ and
promotes IL-10 and IL-13 production. WT or Retnla−/− BMDCs were cultured
overnight in medium alone (M), Pa (A), or SEA (B) and injected s.c. into WT
mice. Next, 5–7d later, pLN were harvested, cells were restimulated for 72 h
with Pa (A) or SEA (B), and cytokine secretion was assessed by ELISA. CD4+
cells sorted from KN2 IL-4 reporter mice, or IL-10eGFP−-CD4+ cells, were
cultured for 4 d with WT or Retnla−/− BMDCs and anti-CD3 mAb with or
without IL-4 and assessed for IL-4 protein production or IL-10 mRNA ex-
pression by flow cytometry (C) and cytokine secretion by ELISA (D). Data are
representative of two (A and C) or four (B and D) experiments. Error bars
indicate SEM of three to five mice (A and B) or four to five replicate wells (C
and D) per group.
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Mechanistically, the altered ability of Retnla−/− DCs to po-
larize SEA-specific cytokine responses was not due to defective
Ag uptake, processing, or presentation by these cells. Similar to
Il4ra−/− DCs, Retnla−/− DCs competently took up Ag (Fig. S6),
and showed enhanced ability to induce proliferation of OTII
TCR Tg T cells in vitro (Fig. S7), with either OVA peptide or
protein. This increased proliferation is consistent with expecta-
tion, given the reduced IL-10 production evident following
transfer of Retnla−/− DCs in vivo (Fig. 4B) or coculture of
Retnla−/− DCs with T cells in vitro (Fig. 4 C and D).
These data strongly suggest that DC production of RELMα is an
important process both for directing priming of Th2 responses and
for control of Th1 responses, and provide mechanistic insight into
the function of RELMα during the early stages of T-cell
activation.
Discussion
A substantial body of literature documents the ability of IL-4 to
generate aaMΦs in multiple settings. However, comparatively
few studies have addressed how DCs respond to IL-4, whether
they can express markers associated with aaMΦs (11–14), and
what the functional relevance of this expression may be. The data
that we present here reveal that murine DCs can respond to IL-4
both in vitro and in vivo in a manner similar to that previously
described for aaMΦs, by significantly up-regulating RELMα,
Ym1/2, and other aaMΦ markers, with the notable exception of
Arginase-1. Furthermore, we have identified that DC expression
of RELMα plays a critical role in their instruction of T cells to
produce IL-10 and IL-13. This demonstrates a previously unde-
scribed role for RELMα, and reveals that DC responsiveness to
IL-4 is vital for priming optimal Th2 responses.
Exposure of DCs to IL-4 triggered expression of numerous
markers associated with aaMΦ, but one notable difference was
the lack of Arginase-1 up-regulation at both the mRNA and
protein activity level. Arginase-1 competes with iNOS for L-ar-
ginine (6), and one consequence of increased Arginase-1 activity
is L-arginine depletion from the local environment. In murine
Leishmania major infection, increased arginase activity in para-
site-infected MΦs depletes the skin of L-arginine, impairing
proliferation of T cells in the lesion (31). Furthermore, MΦ-
derived Arginase-1 is required to suppress T-cell proliferation
during Th2 infection, where it limits pathology (8). The function
of DCs is instead mainly to prime naive T cells in the early phase
of immune response development. In this context, a high level of
Arginase-1 expression by immunogenic DCs that could deplete
L-arginine from the local environment might be undesirable.
In addition to RELMα and Ym1/2, we have found that IL-4–
treated DCs significantly increased expression of Mrc1, Clec7a,
and Ccl24, all of which have previously been associated with
aaMΦs (6, 7). MR and Dectin-1 are both C-type lectin recep-
tors that can bind carbohydrates and trigger distinct signaling
pathways in DCs (32). MR has been linked mainly to in-
ternalization of Ags containing mannose motifs; however, in the
absence of an additional stimulus (such as TLR ligation), en-
gagement of the receptor is thought to be unable to mediate
proinflammatory responses in DCs (32). In contrast, Dectin-1
recognition of β glucans, which are mainly found in fungal cell
walls, initiates proinflammatory responses in DCs even in the
absence of TLR ligation (33). Our finding that IL-4 increases DC
expression of both these C-type lectin receptors suggests that they
will have an enhanced ability to internalize and respond to a wide
range of glycosylated pathogen motifs that could further modulate
their activation and function. Increased DC expression of CCL24
could also influence this process, as this chemokine can enhance
recruitment of CCR3-expressing cells such as eosinophils and
basophils, as has been reported for CCL24-producing aaMΦs in
the lung (34). These recruited granulocytes could, in turn, assist
Th2 priming in certain situations through provision of cytokines
such as IL-4.
As well as identifying that DCs can display hallmarks of al-
ternative activation following IL-4 exposure in vitro and in vivo,
we have revealed DC expression of alternative activation markers
in the context of chronic helminth infection, a subject that has so
far barely been addressed in the literature (11). There was some
heterogeneity in the levels of specific markers expressed when
comparing in vitro and in vivo settings, in particular with Ym1/2.
This could reflect basic differences between BMDCs and their
in vivo counterparts, or differential regulation of aspects of DC
alternative activation in vivo, in line with the well-documented
diversity of aaMΦs (6).
Our results also support and extend previously published work
addressing how IL-4 might alter the IL-12/IL-10 balance (15, 19),
but are unique in showing the impact of IL-4 on T-cell polariza-
tion by DCs in vivo. Our data highlight an important feedback
loop in DC-mediated priming in vivo, where sources of IL-4/IL-13
will not only promote Th2 responses (4), but will also facilitate
DC-mediated priming of Th1 responses through enhancement of
IL-12p70 and inhibition of IL-10 production by DCs. Extending
our understanding of the cross-talk between microbes, DCs, and
their environment, we have demonstrated the ability of defined
TLR ligands and heat-killed bacteria to inhibit the ability of IL-4
to prompt RELMα and Ym1/2 production by DCs. In light of our
identification of a pro-Th2 role for DC-derived RELMα, in-
hibition of such by bacteria or their products may be important in
some settings to allow optimal Th1/17 immunity to develop.
In peripheral environments, DCs migrate away from the site of
Ag exposure toward draining LNs (35). In order for RELMα and
Ym1/2 to play a relevant role in T-cell priming in the draining
LNs, DC expression of such molecules would have to be pro-
longed, or responsive to subsequent interaction with T cells. We
have shown that production of RELMα and Ym1/2 by DCs is not
transient and requires neither the continued presence of IL-4 nor
subsequent CD40 ligation. Furthermore, by adoptive transfer of
Retnla−/− DCs in vivo, we have identified a previously unreported
requirement for DC production of RELMα in the initiation of
Th2 responses in the LN draining the site of DC introduction.
A Th2-promoting role for RELMα contrasts with the down-reg-
ulatory role that has previously been described using global
Retnla−/− mice, which identified RELMα as a negative regulator
of ongoing Th2 inflammation against helminth Ag, with Retnla−/−
mice displaying elevated Th2 responses and greater pathology
(21, 22). These reports would suggest that the ultimate role for
RELMα produced by multiple cellular sources in vivo (including
eosinophils, epithelial cells, and MΦs) is to regulate chronic Th2
pathology by influencing T-cell differentiation and cellular re-
cruitment while regulating wound repair. In the present study, we
focused on the early events in Th2 priming by DCs in vitro and
in vivo. By restricting RELMα deficiency to DCs alone, our results
extend our fundamental understanding of the cellular, temporal,
and spatial diversity of RELMα function, demonstrating an al-
ternative function of DC expression of this molecule early in
immune response development. Our identification of a critical
role for DC-derived RELMα in promotion of T-cell production of
IL-10 reveals a mechanism that may, in part, explain the dysre-
gulated immune pathology previously observed in Th2 infection
models using global Retnla−/− mice (21, 22).
It is clear from our results that RELMα production does not
solely account for Th2 induction by DCs, but helps promote
specific facets of this response (IL-10 and IL-13). Because we
have shown that IL-4 stimulates production or expression of
a wide range of alternative activation-related molecules in DCs,
and that Il4ra−/− and Retnla−/− DCs do not display identical
functional ability, it is likely that a combination of IL-4–induced
products will work together and in balance to ultimately dictate
the character of the resultant Th2 response. For example, as
Ym1/2 has previously been suggested to promote some Th2
cytokines, at least in vitro, its production by DCs responding to
IL-4 may act in concert with RELMα and other alternative ac-
tivation products to generate optimal Th2 immunity.
In summary, we have shown that the canonical Th2 cytokine
IL-4 can have a profound impact on DC activation and function,
triggering both in vivo and in vitro expression of a range of









molecules ordinarily associated with aaMΦs, altering responsive-
ness to challenge with bacteria and TLR ligands, and dramatically
influencing T-cell response induction and polarization. Although
the cumulative impact of IL-4 on DC activation and function is
complex, in the context of pathogenic stimulation, the over-riding
effect of IL-4 appears to be to enable IFNγ induction through
enhanced DC IL-12p70 production. Furthermore, DC production
of the IL-4 induced protein, RELMα, is important in priming of
T-cell IL-10 and IL-13. Together these findings indicate that IL-4
has a more influential and diverse role in directly regulating DC-
mediated T-cell priming than has been previously appreciated.
Materials and Methods
Mice and IL-4c Injections. C57BL/6, BALB/c, Retnla−/−, IL-10eGFPxDOG, KN2
(C57BL/6), Il4ra−/−, and OTII mice (20, 23, 25, 29, 30) were maintained under
specific pathogen-free conditions at the University of Edinburgh. Experi-
ments were conducted under a Project License granted by the Home Office
(United Kingdom) in accordance with local guidelines. IL-4/anti-IL-4 mAb
complexes (IL-4c) were prepared as described previously (23). Mice were
injected i.p. with 50 μL PBS or 0.625–10μg IL-4 complexed to 11B11, and
peritoneal exudate cells (PEC) and spleens harvested 4 d later.
Cell Culture and DC Transfer. BM-derived DCs were generated with GM-CSF as
previously described (36). Following 10 d of culture, BMDCs were harvested
and replated at 2 × 106/mL for 18 h in the presence or absence of rIL-4 (20
ng/mL; Peprotech). In coculture experiments, CD4+GFP− T cells were sorted
from IL-10eGFPxDOG or KN2B6xB6 mice using BD FACs Aria-II and cultured
with WT or Retnla−/− DCs. For DC transfer, WT, Il4ra−/−, or Retnla−/− BMDCs
were cultured as above, with SEA, Pa, or medium alone. BMDCs were
injected s.c. into recipient WT mice (2.5 × 105 per foot) and 5–7d later the
draining popliteal LNs and restimulated as previously described (24, 36).
Supernatants were harvested after 72 h, and cytokine production was
assessed by ELISA. Further details are provided in SI Materials and Methods.
Flow Cytometry and ELISA. Details of mAb used are given in SI Materials and
Methods. Samples were acquired using FACS LSR II or FACS Canto II using BD
FACSDiva software and analyzed with FlowJo v.9 software (Tree Star). ELISAs
were performed on culture supernatants using paired mAb, and recombi-
nant cytokine standards, or DuoSets (eBioscience, BD Pharmingen, R&D
Systems, and Peprotech). Arginase assay details are provided in SI Materials
and Methods.
RNA Isolation and Quantitative PCR. RNAwas recovered from cells using TRIzol
(Invitrogen), cDNA was generated using SuperScript-III (Invitrogen). Relative
quantification of the gene of interest was performed by quantitative PCR.
Primer details are given in SI Materials and Methods.
Statistical Analysis. Statistical analyses were carried out using GraphPad Prism
5. The Student’s t test or one-way analysis of variance was used to determine
significant differences between sample groups (in figures, *P < 0.05 **P <
0.01 ***P < 0.001 ****P < 0.0001).
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SI Materials and Methods
Infections.Mice were infected with L. sigmodontis for 10 d or with
S. mansoni for 8 wk, as previously described (1, 2).
BMDC Stimulation and DC: T-Cell Coculture. In selected experiments,
DCs were exposed to endotoxin-free soluble egg Ag [SEA, 25 μg/
mL, prepared as described elsewhere (3)], heat-killed Propioni-
bacterium acnes (Pa, 10 μg/mL), lipopolysaccharide (LPS, 250ng/
mL, Sigma) or CpG oligodeoxynucleotide 1826 (ODN 1826,
5 μg/mL, InvivoGen). To assess further activation, CD40 ligation
with αCD40 mAb was carried out as previously described (4). In
vitro coculture polarization experiments were performed with
50,000 IL10-eGFP−CD4+ or KN2 CD4+. T cells were cultured
in 96-well plates for 3–4 d with 2,500 RELMα sufficient or
Retnla−/− BMDCs, 1 μg/mL anti-CD3, with or without IL-4
(20 ng/mL). For CFSE dilution assays, CD4+ OT-II TCR
Transgenic T cells were purified from spleen and LN using
CD4+ Dynabeads (Invitrogen) following the manufacturer’s
protocol. T cells were labeled with 5 μM CFSE (Invitrogen) for
15 min at 37 °C. Excess CFSE was allowed to leach from the cells
before culture with 5 × 104 WT, Retnla−/−, or Il4ra−/− BMDCs in
the presence of 0.01 μg/mL OVA323–339 or 5 μg/mL OVA protein
(Sigma), which had been endotoxin depleted in-house. Cultures
were incubated at 37 °C for 4 d before assessment of CFSE di-
lution by flow cytometry.
Flow Cytometry. In some experiments, cells were first stained with
LiveDead aqua (Invitrogen). Following FcR-Block (2.4G2), cells
were surface stained using the following mAb: CD4-PE, CD11c-
APC/eFluor780, MHCII-PerCP/Cy5.5, CD11b-eFluor450, CD80-
APC, CD40-PE, CD19-AlexaFluor700, CD86-FITC, Dectin1-
APC, IL-4Rα-biotin, SiglecF-PE, F4/80-PE/Cy7, Gr1-PerCP/
Cy5.5, and HuCD2-APC. For intracellular staining, cells were
fixed in 1% PFA, permeabilized using Cytoperm (BD PharMin-
gen), and stained with anti-RELMα, and anti-Ym1 biotin followed
by AlexaFluor 488–conjugated anti-rabbit Ab and streptavidin-
APC. To assess Ag uptake, 2 × 105 BMDCs were incubated with
200 μg FITC-conjugated dextran (Sigma) for 30 min at 37 °C or on
ice before acquisition.
Splenic DC Purification. Splenic DCs were enriched from five to six
naive C57BL/6 mice using NycoDenz density gradient separation
and CD11chiB220− cDCs were sorted from B220+CD11cmid
pDCs using a BD FACs Aria II. After sorting, 5 × 104 DCs were
cultured overnight with 20 ng/mL IL-4, before RNA extraction,
reverse transcription, and quantification of transcript levels using
quantitative PCR.
Arginase Activity Assay. Arginase activity was measured as de-
scribed previously (5). One unit of arginase enzyme activity is
defined as the amount of enzyme that catalyzed the formation of
1 μmol urea per minute at 37 °C.
Quantitative PCR. Relative quantification of the gene of interest
was performed by qPCR analysis using Roche Light Cycler 480,
with LightCycler SYBR Green I Master mix, compared with
a serially diluted standard of pooled cDNA. Expression was
normalized to hypoxanthine-guanine phosphoribosyltransferase
(Hprt).
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Fig. S1. IL-4c injection induces alternative activation of splenic DCs. Splenic DCs (MHC-II+ CD11chi) from PBS- or IL-4c–treated mice (2 × 5 μg, d 0 and d 2) were
harvested at d 4 and stained for intracellular expression of RELMα and Ym1/2 (A and B). Data are representative of at least three experiments. Graphs show
percent expression for individual mice, three per group.
Fig. S2. Parasitic helminth infection induces alternative activation of DCs at multiple tissue sites. Pleural cavity (A) or splenic (B) DCs (MHC-II+ CD11chi) from
naive mice infected with L. sigmodontis (L.s.) (A) or S. mansoni (S.m.) (B) were stained for intracellular expression of RELMα and Ym1/2. Data are representative
of three to six experiments. Graphs show percent expression for individual mice, four to eight per group.
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Fig. S3. IL-4–stimulated BMDCs do not dramatically alter their activation phenotype. WT BMDCs were stimulated overnight with 20 ng/mL IL-4, and their
expression of costimulatory molecules was assessed by flow cytometry (A). Shaded area indicates isotype control; black line indicates media; gray line indicates
+IL-4. Geometric mean fluorescence intensity (MFI) of marker expression by CD11c+ cells (B). Data are representative of more than five experiments. Error bars
represent SEM of triplicate wells.
Fig. S4. IL-4 alternatively activates splenic ex vivo DCs in vitro. Following enrichment for DC populations, splenic cDCs (CD11chiB220−) from naive mice were
separated from pDCs (B220+CD11cmid) (A) and cultured overnight in the presence of 20 ng/mL IL-4. IL-4 increased mRNA expression of alternative activation
markers (B). Data are representative of two experiments, with three to four replicate wells per group. a.u., Arbitrary units; N.D., not detected.
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Fig. S5. Defined TLR ligands and pathogen products modulate IL-4–driven RELMα and Ym1 expression by BMDCs. BMDCs were cultured overnight in the
presence or absence of IL-4 and TLR agonists CpG 1826 (TLR9) or LPS (TLR4) (A and B) or Pa or SEA (C–E). IL-12p70, IL-10, RELMα, Ym1/2, IL-1β, and IL-6 secretion
was assessed by ELISA. Error bars represent SEM of triplicate wells. Data are representative of four (A–D) or two (E) experiments.
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Fig. S6. WT, Il4ra−/−, and Retnla−/− DCs are equally capable at antigen uptake. WT, Il4ra−/− or Retnla−/− BMDCs were incubated with FITC-conjugated dextran
at 37 °C, and Ag uptake was assessed by flow cytometry (A and B). Shaded area indicates 0 °C; black line indicates 37 °C. Data are representative of two
experiments, five to six replicate wells per group.
Fig. S7. Ag processing and presentation is unimpaired in Il4ra−/− and Retnla−/− DCs. WT, Il4ra−/−, or Retnla−/− BMDCs were cultured for 4 d with CFSE-labeled
OT-II TCR Tg T-cells in the presence of OVA peptide (A) or protein (B), and the ability to stimulate proliferation was assessed by flow-cytometric analysis of CFSE
dilution. Shaded area indicates no peptide/protein; black line indicates 0.01 μg/mL OVA peptide (A) or 5 μg/mL OVA protein (B). Data are representative of two
experiments, five replicate wells per group.
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Fig. S8. IL-4 alters the response of DCs following CD40 ligation. BMDCs cultured overnight with IL-4 and Pa or SEA were washed and recultured with agonistic
anti-CD40 (■) or control antibody (☐) for another 24 h, and cytokine (A), RELMα, and Ym1/2 (B) secretion was assessed by ELISA. Data are representative of
three experiments. Error bars represent SEM of triplicate culture wells.
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